0001144204-15-063377.txt : 20151110 0001144204-15-063377.hdr.sgml : 20151110 20151106163055 ACCESSION NUMBER: 0001144204-15-063377 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151106 DATE AS OF CHANGE: 20151106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 151212076 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 v422632_10q.htm 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-32587

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2726770
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Park Place, Suite 450, Annapolis, Maryland		21401
(Address of principal executive offices)		(Zip Code)

(410) 269-2600
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer x

Non-Accelerated Filer ¨		Smaller Reporting Company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: The number of shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding as of November 4, 2015 was 64,451,334.

PHARMATHENE, INC.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION		1

Item 1. Unaudited Condensed Consolidated Financial Statements		1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3. Quantitative and Qualitative Disclosures about Market Risk		27

Item 4. Controls and Procedures		27

PART II — OTHER INFORMATION		28

Item 1. Legal Proceedings		28

Item 1A. Risk Factors		29

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		29

Item 3. Defaults Upon Senior Securities		29

Item 4. Mine Safety Disclosures		29

Item 5. Other Information		29

Item 6. Exhibits		29

Item 1. Financial Statements

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30			December 31,
	2015			2014

ASSETS
Current assets:
Cash and cash equivalents	$	17,389,409		$	18,643,351
Billed accounts receivable		-			110,656
Unbilled accounts receivable		659,663			297,431
Prepaid expenses and other current assets		196,478			199,194
Total current assets		18,245,550			19,250,632

Property and equipment, net		248,270			325,772
Other long-term assets and deferred costs		53,384			53,384
Goodwill		2,348,453			2,348,453
Total assets	$	20,895,657		$	21,978,241

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	306,172		$	391,396
Accrued expenses and other liabilities		1,453,123			1,195,412
Accrued restructuring expenses		619,119			-
Short-term debt		-			746,146
Other short-term liabilities		-			70,326
Current portion of derivative instruments		2,355			178,509
Total current liabilities		2,380,769			2,581,789

Accrued restructuring expenses - long term		184,018			-
Other long-term liabilities		431,015			493,137
Derivative instruments, less current portion		227,898			629,170
Total liabilities		3,223,700			3,704,096

Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		6,436			6,360
Additional paid-in-capital		240,151,146			238,780,633
Accumulated other comprehensive loss		-			(229,528	)
Accumulated deficit		(222,485,625	)		(220,283,320	)
Total stockholders' equity		17,671,957			18,274,145
Total liabilities and stockholders' equity	$	20,895,657		$	21,978,241

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014

Contract revenue	$	1,155,839		$	962,451		$	9,374,155		$	8,363,909

Operating expenses:
Research and development		1,125,865			1,728,929			3,962,019			7,528,616
General and administrative		1,231,035			3,192,427			5,246,396			8,289,788
Restructuring expense		422,482			-			2,519,273			-
Depreciation		35,005			37,125			108,798			113,272
Total operating expenses		2,814,387			4,958,481			11,836,486			15,931,676

Loss from operations	$	(1,658,548	)	$	(3,996,030	)	$	(2,462,331	)	$	(7,567,767	)
Other income (expense):
Interest expense, net		(9,888	)		(46,930	)		(48,492	)		(173,356	)
Realization of cumulative translation adjustment		-			-			(229,192	)		-
Change in fair value of derivative instruments		359,796			(560,487	)		577,426			464,703
Other income (expense)		(691	)		80			6,594			(1,470	)
Total other income (expense)		349,217			(607,337	)		306,336			289,877

Net loss before income taxes		(1,309,331	)		(4,603,367	)		(2,155,995	)		(7,277,890	)
Income tax provision		(15,437	)		(25,068	)		(46,310	)		(48,105	)
Net loss	$	(1,324,768	)	$	(4,628,435	)	$	(2,202,305	)	$	(7,325,995	)

Basic and diluted net loss per share	$	(0.02	)	$	(0.08	)	$	(0.03	)	$	(0.13	)
Weighted average shares used in calculation of basic and diluted net loss per share		64,187,618			58,952,731			63,858,500			55,577,550

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014

Net loss	$	(1,324,768	)	$	(4,628,435	)	$	(2,202,305	)	$	(7,325,995	)
Other comprehensive income (loss):
Foreign currency translation adjustments		-			(5,869	)		336			(7,162	)
Realization of cumulative translation adjustment included in net loss		-			-			229,192			-
Comprehensive loss	$	(1,324,768	)	$	(4,634,304	)	$	(1,972,777	)	$	(7,333,157	)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

		Nine months ended September 30,
		2015			2014

Operating activities
Net loss	$	(2,202,305	)	$	(7,325,995	)
Adjustments to reconcile net loss to net cash used in operating activities:
Realization of cumulative translation adjustment		229,192			-
Share-based compensation expense		426,988			1,172,703
Change in fair value of derivative instruments		(577,426	)		(464,703	)
Depreciation expense		108,798			113,272
Deferred income taxes		46,310			48,105
Non-cash interest expense		(51,820	)		68,130
Impairment of property and equipment		36,981			-
Gain on the disposal of property and equipment		(7,600	)		(5,393	)
Changes in operating assets and liabilities:
Billed accounts receivable		110,656			1,427,113
Unbilled accounts receivable		(362,232	)		1,895,858
Prepaid expenses and other current assets		(9,602	)		23,869
Accounts payable		(85,175	)		(846,090	)
Accrued restructuring expenses		800,769			-
Accrued expenses and other liabilities		149,438			(773,517	)
Deferred revenue		-			(284,937	)
Net cash used in operating activities		(1,387,028	)		(4,951,585	)
Investing activities
Purchases of property and equipment		(68,277	)		(92,269	)
Proceeds from the sale of property and equipment		7,600			8,000
Net cash used in investing activities		(60,677	)		(84,269	)
Financing activities
Repayment of debt		(750,007	)		(749,997	)
Net repayment of revolving credit agreement		-			(1,091,740	)
Net proceeds from exercise of warrants		-			683,325
Proceeds from issuance of common stock, including exercise of
stock options, net of offering costs		943,601			15,341,264
Net cash provided by financing activities		193,594			14,182,852
Effects of exchange rates on cash		169			(7,585	)
(Decrease) increase in cash and cash equivalents		(1,253,942	)		9,139,413
Cash and cash equivalents, at beginning of period		18,643,351			10,480,979
Cash and cash equivalents, at end of period	$	17,389,409		$	19,620,392

Supplemental disclosure of cash flow information
Cash paid for interest	$	108,134		$	105,916

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

Notes to Unaudited Condensed Consolidated Financial Statements
September 30, 2015

Note 1 – Business, Liquidity and Organization

Since 2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning.

On March 9, 2015, our Board of Directors approved our realignment plan (the “Realignment Plan”) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (“SIGA”) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA’s appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (“NIAID”). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2 million (all of which was expensed as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company’s product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5 million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.

As of September 30, 2015, our cash balance was $17.4 million, our unbilled accounts receivable balance was $0.7 million, and our current liabilities were $2.4 million. As of September 30, 2015, we had approximately $3.0 million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 – Financing Transactions – Controlled Equity Offering). We believe, based on the operating cash requirements and capital expenditures expected for 2015, the Company’s cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016. On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (“GE Capital”), as discussed further in Note 6- Financing Transactions.

On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVax^TMvaccine platform, to develop an anthrax vaccine utilizing PharmAthene’s recombinant protective antigen (“rPA”). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax^TM.

On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 - Commitments and Contingencies - Leases.

On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016.

We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, in connection with the Realignment Plan, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman’s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA’s appeal has been adjudicated and we have received SIGA’s payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA’s appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.

In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in one business segment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).

In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.

Significant Customers and Accounts Receivable

Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (“BARDA”). As of September 30, 2015, the Company’s unbilled accounts receivable balance was comprised of receivables from NIAID. The Company’s receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.

Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.

Restructuring Expense

As a result of the Realignment Plan, we recorded approximately $2.1 million of restructuring expense during the nine months ended September 30, 2015, including approximately $2.0 million of related severance expense, and the remainder being legal and other employee related expenses. Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $0.4 million of additional restructuring expense (see Note 4 - Commitments and Contingencies - Leases).

Financial Instruments

Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 – Fair Value Measurements for further details.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

A milestone is considered substantive if all of the following conditions are met:

it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

it relates solely to past performance, and

the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee’s requisite service period.

The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.

Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:

	Three months ended September 30,
	2015		2014

Research and development	$	12,034	$	52,434
General and administrative		81,723		228,286
Total share-based compensation expense	$	93,757	$	280,720

During the three months ended September 30, 2015, we granted options to purchase 100,000 shares of common stock to non-employee directors and made no grants of options or shares of restricted stock to employees and consultants.

Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:

	Nine months ended September 30,
	2015			2014

Research and development	$	85,259		$	329,655
General and administrative		395,470			843,048
Restructuring benefit		(53,741	)		-
Total share-based compensation expense	$	426,988		$	1,172,703

As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $75,000 of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $129,000 of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $53,741 net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.

During the nine months ended September 30, 2015, we granted options to purchase 112,000 shares of common stock to employees and non-employee directors and granted 117,500 shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase 1,357,755 shares of common stock to employees, non-employee directors and consultants and made no restricted stock grants.

At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $0.8 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.2 years.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.

Our income tax expense was $0.02 million and $0.03 million during the three months ended September 30, 2015 and 2014, respectively, and $0.05 million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.

A total of approximately 6.0 million and 10.9 million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 – Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.

Note 3 - Fair Value Measurements

The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable approximate their fair values due to their short-term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.

The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of September 30, 2015
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,430,038	$	-	$	-	$	6,430,038
Total investment in money market funds	$	6,430,038	$	-	$	-	$	6,430,038

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	2,355	$	2,355
Non-current portion of derivative instruments related to stock purchase warrants		-		-		227,898		227,898
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	230,253	$	230,253

	As of December 31, 2014
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,429,104	$	-	$	-	$	6,429,104
Total investment in money market funds	$	6,429,104	$	-	$	-	$	6,429,104

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	178,509	$	178,509
Non-current portion of derivative instruments related to stock purchase warrants		-		-		629,170		629,170
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	807,679	$	807,679

⁽¹⁾

Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2015 and 2014:

						Exercised
	Balance as of		Unrealized			Stock Purchase		Balance as of
	December 31,		(Gains)			Warrants		September 30,
Description	2014		2015			2015		2015
Derivative liabilities related to stock purchase warrants	$	807,679	$	(577,426	)	$	-	$	230,253

						Exercised
	Balance as of		Unrealized			Stock Purchase			Balance as of
	December 31,		(Gains)			Warrants			September 30,
Description	2013		2014			2014			2014
Derivative liabilities related to stock purchase warrants	$	1,740,235	$	(464,703	)	$	(423,739	)	$	851,793

At September 30, 2015 and 2014, derivative liabilities are comprised of warrants to purchase 1,775,419 shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.

Assets Measured at Fair Value on a Nonrecurring Basis

The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the Company recorded an impairment charge for property and equipment in the amount of $36,981. These assets were written down to their fair value of $0 in conjunction with the sublease of the Company's leased office space (see Note 4 - Commitments and Contingencies - Leases). As of September 30, 2015, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to license, development and marketing rights for SIGA’s drug candidate, Arestvyr^™ (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.

In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery’s finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court’s opinion.

On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company’s lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company’s reasonable attorneys’ and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.

On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with BARDA. SIGA’s petition for bankruptcy initiated a process whereby its assets are protected from creditors, including us.

On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015.

On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company’s lost profits for Tecovirimat, also known as ST-246^® (formerly referred to as “Arestvyr^™” and referred to by SIGA in its recent SEC filings as “Tecovirimat”), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene’s entitlement to interest from and after SIGA’s bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.

SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply brief on cross-appeal on May 11, 2015.

On October 7, 2015, oral arguments in SIGA’s appeal and PharmAthene’s cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene’s favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.

While we believe that we may have a right to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future.

PharmAthene’s ability to collect the Judgment depends upon a number of factors, including SIGA’s financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA’s filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company’s ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. The Company has not recognized any potential proceeds from these actions in its financial statements to date.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (“DCAA”) and other government agencies such as BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies.

We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA in the amount of $5.8 million in connection with these costs, all of which was collected in April 2015.

BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax^® contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.

Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company’s financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company’s financial condition and/or results of operations.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $0.2 million for each month until the failure, if it occurs, is cured.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

License Agreements

Leases

The Company leases its office under a 10-year operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized a loss of $0.4 million in restructuring expense our condensed consolidated statements of operations for the nine months ended September 30, 2015.

The present value of the Company’s remaining lease liability (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses as follows:

Description	Present Value at September 30, 2015
Accrued restructuring expenses	$	244,769
Accrued restructuring expenses - long term	$	184,018

Note 5 - Stockholders’ Equity

Long-Term Incentive Plan

In 2007, the Company’s stockholders approved the 2007 Long-Term Incentive Compensation Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

In 2008, our stockholders approved amendments to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January 1, 2015. At September 30, 2015, there are approximately 10.3 million shares approved for issuance under the 2007 Plan, of which approximately 4.4 million shares are available for grant. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.

Warrants

At September 30, 2015, there were warrants outstanding to purchase 1,922,781 shares of our common stock.

Warrants to purchase 2,572,775 shares of common stock expired on January 28, 2015 without being exercised. The warrants were classified as equity.

The warrants outstanding as of September 30, 2015, all of which are exercisable, were as follows:

Number of Common Shares Underlying Warrants As of September 30, 2015			Issue Date	Exercise Price		Expiration Date
	100,778	⁽¹⁾	March 2007	$	3.97	March 2017
	500,000	^{(2) (3)}	April 2010	$	1.89	October 2015
	903,996	⁽²⁾	July 2010	$	1.63	January 2017
	371,423	⁽²⁾	June 2011	$	3.50	June 2016
	46,584	⁽¹⁾	March 2012	$	1.61	March 2022
	1,922,781

⁽¹⁾

These warrants to purchase common stock are classified as equity.

⁽²⁾

Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 – Fair Value Measurements) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).

⁽³⁾

Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.

Note 6 – Financing Transactions

Controlled Equity Offering

On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $15.0 million.

On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.

Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.

As of September 30, 2015, shares having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement. The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.

Termination of Loan Agreement with GE Capital

On September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5.0 million based on our outstanding qualified accounts receivable.

The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method.

The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets.

In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult to predict and may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risks associated with the following:

our interest in the judgment relating to SIGA’s Tecovirimat, also known as ST-246^® (formerly referred to as “Arestvyr^™” and referred to by SIGA in its recent SEC filings as “Tecovirimat”), including the risk that we will not be able to collect any amounts related thereto,

the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of our product candidates,

funding delays, reductions in or elimination of U.S. Government funding and/or non-renewal of expiring funding under our September 2014 contract with NIAID after we receive funding of approximately $7.5 million over the base period and the first option,

our common stock,

the continuation of availability of our net operating loss carryforwards, or NOLs,

delays caused by third parties challenging government contracts awarded to us,

unforeseen safety and efficacy issues,

our Realignment Plan,

accomplishing any future strategic partnerships or business combinations,

continuing funding requirements and dilution relating thereto,

our ability to continue to satisfy the listing requirements of the NYSE MKT,

as well as risks detailed under the caption “Risk Factors” in our annual report on Form 10-K and in our other reports filed with the U.S. Securities and Exchange Commission, or the SEC, from time to time hereafter.

In particular, in its August 2014 decision, the Delaware Court of Chancery awarded to us lump sum expectation damages for the value of lost profits for Tecovirimat. On January 15, 2015, the Delaware Court of Chancery issued its Final Order and Judgment, finding that we are entitled to receive the Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company’s lost profits for Tecovirimat, plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene’s entitlement to interest from and after SIGA’s bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.

On October 7, 2015 oral arguments in SIGA’s appeal and PharmAthene’s cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene’s favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.

There can be no assurances if or when we will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the potential award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene’s ability to collect the Judgment depends upon a number of factors, including SIGA’s financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA’s filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, we are automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. Our ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court.

Moreover, at this point, future government funding to support the development of Valortim^®, recombinant butyrylcholinesterase (“rBChE”) bioscavenger and liquid SparVax^®is unlikely. Even if we received such funding, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for our product candidates. It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans.

Forward-looking statements describe management’s current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential” or “plan” or the negative of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to, statements relating to:

anticipated results of pending legal proceedings,

potential payments under government contracts or grants,

potential future government contracts or grant awards,

potential regulatory approvals,

future product advancements, and

anticipated financial or operational results.

Finally, PharmAthene can offer no assurances that it has correctly estimated the resources necessary to execute under its NIAID contract and seek partners, co-developers or acquirers for its other programs under its realignment plan. If a larger workforce or one with a different skillset is ultimately required to implement the realignment plan successfully, or if PharmAthene inaccurately estimated the cash and cash equivalents necessary to finance its operations until SIGA’s appeal has been adjudicated and it has received SIGA’s payment, if PharmAthene prevails on appeal, its business, results of operations, financial condition and cash flows may be materially and adversely affected.

Forward-looking statements are based on assumptions that may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.

All forward-looking statements included herein are expressly qualified in their entirety by the cautionary statements contained or referred to above. Unless otherwise indicated, the information in this quarterly report is as of September 30, 2015.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three and nine months ended September 30, 2015 and 2014, as well as our financial positions at September 30, 2015 and December 31, 2014, contained elsewhere in this quarterly report on Form 10-Q. The following discussion should also be read in conjunction with the annual report on Form 10-K for the year ended December 31, 2014, including the consolidated financial statements contained therein.

Overview

Since 2001, we have been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. Our efforts are focused on the development of the improved anthrax vaccines utilizing our base recombinant PA technology platform. We currently have one active program funded by NIAID under a contract awarded in September 2014 for up to $28.1 million assuming all options are exercised.

Realignment Plan

On March 9, 2015, our Board of Directors approved a plan to preserve and maximize, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time expected to extend beyond the adjudication of SIGA’s appeal of the decision of the Delaware Chancery Court awarding us $194.6 million plus post-judgment interest. We refer to the plan as the “Realignment Plan.” Under the Realignment Plan, we intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our anthrax government contract with NIAID.

As part of the Realignment Plan, our Board terminated Eric Richman as President and Chief Executive Officer and Linda Chang as Chief Financial Officer, Treasurer and Secretary, as well as our executive officers Francesca Cook and Wayne Morges. Mr. Richman remains a member of our Board of Directors, and, as such, will continue to play a key role in managing the ongoing litigation, other legal matters and any strategic transactions. In addition, Messrs. Joel McCleary and Brian Markison resigned from our Board of Directors effective March 11, 2015, and our Board has reduced the number of directors from eight to six.

John Gill, a member of our Board of Directors, began serving as President and Chief Executive Officer effective March 12, 2015, and Vice President and Controller Philip MacNeill began serving as Chief Financial Officer, Treasurer and Secretary effective May 1, 2015. Mr. Gill is expected to devote the necessary time to carry out his duties as President and Chief Executive Officer, and although he does not have other employment, he is not expected to devote his full time to the business of the Company, which is reflected in his compensation.

The terminations of the departing executive officers were without “cause” as defined under their respective employment agreements and the departing officers will therefore receive cash payments in accordance with the terms of such agreements. The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2.0 million, with substantially all such severance expenses expected to be paid in 2015. Mr. Richman, Ms. Chang, Ms. Cook and Dr. Morges furthermore entered into separation agreements with the Company. These agreements extend exercise periods of options and health benefits. In light of his continuing service as director, Mr. Richman’s options will continue vesting for as long as he serves on our Board of Directors, with his then-vested options terminating 90 days after Mr. Richman leaves our Board. Ms. Chang’s, Dr. Morges’ and Ms. Cook’s options will remain exercisable for the duration of their respective severance periods under their employment agreements. Changes to the exercise period of these options were made in accordance with the terms of the Company’s 2007 Long-Term Incentive Compensation Plan, as amended. We recognized approximately $75,000 of share-based compensation expense resulting from our agreement to extend the exercise period. In addition, to the extent that the executive officers elect COBRA coverage, the premiums payable by the officers during their respective severance periods will equal those payable by active employees of the Company for the same level of group health coverage, and will be deducted from the officers’ severance pay. The separation agreements contain releases by the executive officers and the Company. The agreements with Ms. Chang, Dr. Morges and Ms. Cook furthermore obligate them to cooperate with the Company in connection with the SIGA litigation. The agreement with Dr. Morges also provides that for six months following termination, Dr. Morges may be called upon from time to time to assist the Company with matters relating to his duties and responsibilities prior to termination at an hourly rate of $169.

We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman’s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA’s appeal has been adjudicated and we have received SIGA’s payment, if we prevail on appeal. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA’s appeal, or enforce payment of or collect any damages award from SIGA, if we do prevail, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.

License Agreements

Leases

On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space.

Other Recent Developments

On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive the Total Judgment, comprised of (1) expectation damages of $113.1 million, for the value of the Company’s lost profits for Tecovirimat, plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene’s entitlement to interest from and after SIGA’s bankruptcy filing may be negatively impacted by the Bankruptcy Code. SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. Subsequently, both SIGA and PharmAthene have filed appeals and reply briefs. As a result, the decision could be reversed, remanded or otherwise changed.

There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the potential award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene’s ability to collect the Judgment depends upon a number of factors, including SIGA’s financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA’s filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, PharmAthene is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company’s ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court, and the Company therefore has not recorded any potential proceeds to date.

Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the U.S. Securities and Exchange Commission.

There were no significant changes in critical accounting policies from those at December 31, 2014.

Results of Operations

Revenue

We recognized revenue of $1.2 million and $1.0 million during the three months ended September 30, 2015 and 2014, respectively. We recognized revenue of $9.4 million and $8.4 million during the nine months ended September 30, 2015 and 2014, respectively.

	Three months ended September 30,
Revenue ($ in millions)	2015		2014		% Change
SparVax^®and next generation anthrax vaccine	$	1.2	$	1.0		20.0	%
rBChE bioscavenger		-		-		-	%
Total revenue	$	1.2	$	1.0		20.0	%

	Nine months ended September 30,
Revenue ($ in millions)	2015		2014		% Change
SparVax^®and next generation anthrax vaccine	$	9.4	$	7.9		19.0	%
rBChE bioscavenger		-		0.5		(100.0	)%
Total revenue	$	9.4	$	8.4		11.9	%

During the three and nine months ended September 30, 2015, our revenue was derived primarily from contracts with the U.S. Government for the development of anthrax vaccine programs. During the three and nine months ended September 30, 2014, our revenue was derived primarily from contracts with the U.S. Government for the development of anthrax vaccine programs. Our revenue in the three and nine months ended September 30, 2015 changed from the comparable period of 2014 primarily due to the following:

Under our contract for the development of SparVax^® (the liquid second generation rPA) with BARDA, we did not recognize any revenue for the three months ended September 30, 2015, and recognized $1.0 million for the three months ended September 30, 2014. We recognized approximately $6.1 million and $7.9 million for the nine months ended September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, revenue was primarily attributable to the receipt of a one-time payment as a result of an audit completed by BARDA and contract wind-up activity. On April 4, 2014, we received notification from BARDA, advising us of its decision to de-scope the SparVax^® anthrax vaccine contract through a partial termination for convenience. The contract formally expired on February 28, 2015. We do not expect that we will receive additional funding from BARDA for the further development of SparVax^® as a liquid product. Therefore, we anticipate that revenues for this program in 2015 will be significantly less than in 2014.

In 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. We billed and recognized revenue using the provisional rates as defined in the contract. As a result of the audit, we recognized revenue of $5.8 million in the first quarter of 2015, representing the difference between actual rates (i.e., actual cost to us) and the provisional rates used to calculate previously billed and recognized revenue. We received payment of this amount in the second quarter of 2015.

BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax^® contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014 which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.

On September 9, 2014, we entered into a contract with NIAID for the development of a next generation lyophilized anthrax vaccine based on the Company’s proprietary technology platform which contributes the rPA bulk drug substance that is used in the liquid SparVax^® formulation. On September 10, 2015, NIAID exercised the first option under this agreement. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016. During the three and nine months ended September 30, 2015, we recognized approximately $1.2 million and $3.3 million in revenue, respectively. We recognized milestone revenue of approximately $0.2 million in fixed fee during the three months ended September 30, 2015, relating to the successful completion of the manufacturing of two lyophilized anthrax vaccine candidates which utilize the same rPA bulk drug substance that is used in the liquid SparVax^® product.

Our contract with Chemical Biological Medical Systems (“CBMS’), for our second generation rBChE bioscavenger ended on September 8, 2014. We do not foresee any additional funding for this program and expect that revenues from this program in the future will be minimal. Revenue in support of contract activities for the nine months ended September 30, 2014 was $0.5 million.

Research and Development Expenses

Our research and development expenses were $1.1 million and $1.7 million for the three months ended September 30, 2015 and 2014, respectively. In 2015, these expenses related to the lyophilized anthrax vaccine candidates as well as the stability program for the liquid product. In 2014, these expenses resulted from research and development activities in all periods relating primarily to our SparVax^® and rBChE bioscavenger programs.

Research and development expenses for the three and nine months ended September 30, 2015 and 2014 were attributable to research programs as follows:

	Three months ended September 30,
Expenses ($ in millions)	2015		2014		% Change
SparVax^®and next generation anthrax vaccine	$	1.1	$	1.7		(35.3	)%
rBChE bioscavenger		-		-		-	%
Total research and development expenses	$	1.1	$	1.7		(35.3	)%

	Nine months ended September 30,
Expenses ($ in millions)	2015		2014		% Change
SparVax^®and next generation anthrax vaccine	$	4.0	$	7.1		(43.7	)%
rBChE bioscavenger		-		0.4		(100.0	)%
Total research and development expenses	$	4.0	$	7.5		(46.7	)%

For the three and nine months ended September 30, 2015, research and development expenses decreased $0.6 million and $3.5 million, respectively, from the same period in the prior year, primarily due to decreased costs relating to our BARDA sponsored SparVax^® program, as a result of BARDA’s de-scoping of the contract, and the expiration of the period of performance under our rBChE bioscavenger contract on September 8, 2014. Costs were incurred in 2015 to further the NIAID (lyophilized) program and internal research and development funds were expensed for release and stability testing for the liquid product.

General and Administrative Expenses

General and administrative functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal, and compliance.

Expenses associated with general and administrative functions were $1.2 million and $3.2 million for the three months ended September 30, 2015 and 2014, respectively. The $2.0 million decrease when comparing the three months ended September 30, 2015 to the three months ended September 30, 2014 was primarily due to a reduction in employee costs resulting from our implementation of the Realignment Plan, which eliminated approximately two-thirds of our workforce and a reduction in legal expenses. We expect general and administrative expenses for the last quarter of 2015 to be consistent with the third quarter of 2015. Expenses associated with general and administrative functions were $5.2 million and $8.3 million for the nine months ended September 30, 2015 and 2014, respectively. Similarly, the reduction in expenses of $3.1 million was attributable to a reduction in workforce, and legal expenses.

Restructuring Expense

Restructuring expense was $0.4 million and $2.5 million for the three and nine months ended September 30, 2015, respectively. Pursuant to the Realignment Plan, we recorded severance expense of $2.0 million. An additional $0.1 million was related to legal and other employee related Realignment Plan expenses. Twenty-four employees were terminated with some payments extending into 2016, although the majority of the payments are expected to be made during 2015. The remaining restructuring expense consisted of $0.4 million resulting from the sublease and related impairment.

Other Income (Expense)

Other income (expense) primarily consists of the realization of cumulative translation adjustment on substantially completing the liquidation of our wholly-owned United Kingdom subsidiary, PharmAthene UK Limited, changes in the fair value of our derivative financial instruments and interest expense on our debt and other financial obligations. For the three months ended September 30, 2015, other income was $0.3 million compared to other expense of $0.6 million for the three months ended September 30, 2014. For the nine months ended September 30, 2015 and 2014, other income was $0.3 million.

In June 2015, we substantially completed the liquidation of our United Kingdom subsidiary, PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed consolidated statement of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.

Other income related to the change in the fair value of our derivative instruments was $0.4 million for the three months ended September 30, 2015, compared to other expense of $0.6 million for the three months ended September 30, 2014. For the nine months ended September 30, 2015 and 2014, other income related to the change in the fair value of our derivative instruments was $0.6 million and $0.5 million, respectively. The fair value of our derivative instruments is estimated using the Black-Scholes option pricing model.

Income Taxes

The provision for income taxes was $0.02 million and $0.03 million for the three months ended September 30, 2015 and 2014, respectively. The provision for income taxes was $0.05 million during the nine months ended September 30, 2015 and 2014. Our provision for income taxes results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.

Liquidity and Capital Resources

Overview

Our primary sources of cash during the three and nine months ended September 30, 2015 were the receipt of a $5.8 million one-time payment as the result of an audit completed by BARDA, and proceeds paid under our contract with NIAID. Our primary sources of cash during the three and nine months ended September 30, 2014 were amounts paid under our development contract for SparVax^® and proceeds from sales of shares of our common stock under the controlled equity offering arrangement. Our cash and cash equivalents were $17.4 million and $18.6 million at September 30, 2015 and December 31, 2014, respectively. We believe, based on the operating cash requirements and capital expenditures expected for 2015, the Company’s cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016.

In 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. We had billed and recognized revenue using the provisional rates as defined in the contract. As a result of that audit, we were able to record revenue of $5.8 million in the first quarter of 2015, representing the difference between actual rates (i.e., actual cost to us) and the provisional rates used to calculate previously billed and recognized revenue. BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax^® contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect; furthermore, in 2014, our actual rates exceeded our provisional rates. We also do not control the timing of the audit.

Our sole sources of revenue consist of (1) revenues related to the audit of the BARDA contract and (2) revenues under our September 2014 agreement with NIAID for the development of a next generation lyophilized anthrax vaccine based on the Company’s proprietary technology platform which contributes the rPA bulk drug substance that is used in the liquid SparVax^® formulation.

The NIAID agreement is incrementally funded. Over the base period of the agreement, we were awarded initial funding of approximately $5.2 million, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestones. On September 10, 2015, NIAID exercised the first option under this agreement. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016. The contract has a total value of up to approximately $28.1 million, if all technical milestones are met and all eight contract options are exercised by NIAID. NIAID may exercise the options in its sole discretion. If NIAID exercises all options, the contract would continue approximately five years. If NIAID does not exercise any additional options, the contract would expire by its terms on September 30, 2016. Due to the current economic environment, the U.S. Government may be forced or choose to reduce or delay spending in the biodefense field, which would decrease the likelihood that the government will exercise its right to extend its existing contract with us, the likelihood of future government contract awards, and/or the likelihood that the government would procure products from us.

We have incurred significant losses since we commenced operations. As of September 30, 2015, we had accumulated losses of $222.5 million since our inception. While we have undertaken efforts to reduce expenses, if we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.

Historically, we have not generated positive cash flows from operations. To bridge the gap between payments made to us under our U.S. Government contracts and grants and our operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity and equity-linked securities and proceeds from loans and other borrowings. On March 25, 2013, we entered into a controlled equity offering arrangement pursuant to which we could offer and sell, from time to time, through a sales agent, shares of our common stock having an aggregate offering price of up to $15.0 million, which we later amended on May 23, 2014 to increase the offering amount by $15.0 million. During the three and nine months ended September 30, 2014, we generated net proceeds of approximately $10.4 million and $15.5 million, respectively, under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement. Aggregate gross proceeds of up to $3.0 million remain available under this arrangement. We have no current plans to sell any shares under the controlled equity agreement.

On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with GE Capital.

On March 9, 2015, our Board of Directors approved our Realignment Plan with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from the SIGA litigation and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time expected to extend beyond the adjudication of SIGA’s appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with NIAID. The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2.0 million, with substantially all such severance expenses expected to be paid in 2015.

We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman’s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA’s appeal has been adjudicated and we have received SIGA’s payment, if we prevail on appeal. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA’s appeal, or enforce payment of or collect the damages award from SIGA, if we do prevail, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.

In addition, we may voluntarily elect to raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2015 and 2014:

	Nine months ended September 30,
	2015			2014
Net cash provided by (used in):
Operating activities	$	(1,387,028	)	$	(4,951,585	)
Investing activities		(60,677	)		(84,269	)
Financing activities		193,594			14,182,852
Effects of exchange rates on cash		169			(7,585	)
Total (decrease) increase in cash and cash equivalents	$	(1,253,942	)	$	9,139,413

Operating Activities

Net cash used by operating activities was $1.4 million and $5.0 million for the nine months ended September 30, 2015 and 2014, respectively.

Net cash used by operating activities during the nine months ended September 30, 2015 reflects our net loss of $2.2 million, adjusted for the realization of a cumulative translation adjustment of $0.2 million, non-cash share-based compensation expense of $0.4 million, the decrease in the fair value of our derivative instruments of $0.6 million, and other non-cash expenses of $0.1 million. Receivables (billed and unbilled) and prepaid expenses increased by $0.3 million. Accounts payable decreased $0.1 million, and accrued expenses and other liabilities increased by $0.2 million. Accrued restructuring expenses were $0.8 million.

Net cash used in operating activities during the nine months ended September 30, 2014 reflects our net loss of $7.3 million, adjusted for non-cash share-based compensation expense of $1.2 million and the decrease in the fair value of our derivative instruments of $0.5 million. A decrease in receivables (billed and unbilled) of approximately $3.3 million was offset by a decrease in liabilities and deferred revenue of $1.6 million and $0.3 million, respectively.

Investing Activities

There were no significant investing activities during the nine months ended September 30, 2015 and September 30, 2014.

Financing Activities

Net cash provided by financing activities was $0.2 million and $14.2 million for the nine months ended September 30, 2015 and 2014, respectively.

Net cash provided by financing activities during the nine months ended September 30, 2015 was primarily due to $0.9 million in proceeds received from the issuance of common stock due to stock options exercised, partially offset by a $0.8 million repayment of the term loan. Net cash provided by financing activities during the nine months ended September 30, 2014 was primarily due to net proceeds received of $15.3 million from the sale of our common stock under the controlled equity offering arrangement and stock options exercised, and net proceeds received of $0.7 million from the exercise of warrants. This was partially offset by a $1.1 million repayment of the revolving credit agreement and $0.8 million repayment of the term loan.

On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013, to our prospectus, dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $15.0 million. On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended.

On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, have been effected under the 2014 Prospectus.

During the first, second and third quarters of 2015, we did not generate any net proceeds under the controlled equity offering sales agreement, as amended. Aggregate gross proceeds of up to $3.0 million remain available under this arrangement. We have no current plans to sell any shares under the controlled equity agreement.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

The following are contractual obligations at September 30, 2015:

Contractual Obligations⁽¹⁾	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 Years
Operating facility leases	$	1,413,095	$	842,037	$	571,058	$	-	$	-
Research and development agreements		756,652		756,652		-		-		-
Total contractual obligations	$	2,169,747	$	1,598,689	$	571,058	$	-	$	-

⁽¹⁾

This table does not include any royalty payments relating to future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology, as the timing and likelihood of such payments are not known. The table also excludes any obligations related to registration rights agreements, as a result of a maintenance failure (as defined in such agreements), as the likelihood of any such payment is not probable.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

The Company’s current operations in foreign countries are minimal. We had maintained only nominal operations in the United Kingdom, but those operations were substantially liquidated in the second quarter of 2015. A 10% change in exchange rates (against the U.S. dollar) would not have a material impact on earnings, fair values or cash flow.

Because of the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market interest rates would have a significant impact on their realized value.

The change in fair value of our derivative instruments is calculated utilizing the Black-Scholes option pricing model; therefore, a 10% increase/decrease in the closing price of the Company’s common stock at September 30, 2015, would result in a change in fair value of derivative instruments and our earnings of approximately $0.07 million and $0.06 million, respectively.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2015. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2015, and has concluded that there was no change that occurred during the quarterly period ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Except as noted below, we are not a party to any material legal proceedings.

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively the development and marketing rights for SIGA’s drug candidate, Tecovirimat, pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with us.

In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us, upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery’s finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court’s opinion.

In August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company’s lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company’s reasonable attorneys’ and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.

On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million, for the value of the Company’s lost profits for Tecovirimat, also known as ST-246^® (formerly referred to as “Arestvyr™” and referred to by SIGA in its recent SEC filings as “Tecovirimat”), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene’s entitlement to interest from and after SIGA’s bankruptcy filing may be negatively impacted by the Bankruptcy Code. SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. Subsequently, both SIGA and PharmAthene have filed appeals and reply briefs.

There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene’s ability to collect the Judgment depends upon a number of factors, including SIGA’s financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA’s filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company’s ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court.

Item 1A. Risk Factors

Investing in our securities involves risks. In addition to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in the section titled “Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014. There have been no material changes to the risk factors included in the section titled “Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

In connection with his services to the Company as its President and Chief Executive Officer, the Company entered into an employment agreement with John M. Gill (the "Employment Agreement"), dated as of November 5, 2015, for the period commencing on September 17, 2015 and initially ending on the first anniversary thereof. On each anniversary of the Employment Agreement, the term of the agreement automatically extends for an additional one-year period, unless either party provides the other party with 90 days’ prior written notice of non-extension.

Pursuant to the Employment Agreement, among other customary terms, Mr. Gill: (i) will continue to be employed by the Company in the position of President and Chief Executive Officer; (ii) will receive a base salary of $200,000 and a special lump sum bonus of $50,000, for the period between September 17, 2015 to December 31, 2015; (iii) will receive a base salary of $300,000 per year, subject to annual review and increase at the option of the Compensation Committee of the Board of Directors (the "Compensation Committee"), beginning in 2016 and for each year thereafter; (iv) will be eligible to receive, at the sole discretion of the Compensation Committee and the Board of Directors, an annual cash bonus of up to 50% of his base salary based on the achievement of certain pre-determined performance milestones established by the Compensation Committee and the Board of Directors, beginning in 2016; (v) will be granted an award (the "Incentive Compensation") of restricted stock award under the Company’s 2007 Long-Term Incentive Plan for 612,244 shares of the Company’s common stock (valued in the aggregate at $900,000 based on the closing price of the Company’s common stock on the NYSE MKT on September 17, 2015), which will vest upon the earliest to occur of (a) a "change in control," (b) each of three pre-determined milestones, or (c) the termination of Mr. Gill’s employment for any reason other than (1) a termination for "cause" or (2) a "voluntary resignation."; (vi) will receive, if terminated without cause or for "good reason" or upon a written notice of non-extension, (a) unpaid salary, housing allowance and expenses, (b) payment of a pro-rata portion of the $50,000 bonus for services rendered in 2015, (c) payment of a pro-rata portion of the annual cash bonus and (d) if, upon the occurrence of a "change of in control," the Incentive Compensation; (vii) will continue to be provided with corporate housing in the Annapolis, Maryland area comparable to that previously provided; (viii) will be required to devote an average of three days per week to the business of the Company; (ix) will be entitled to receive reimbursements for certain expenses, in accordance with the practices of the Company in effect from time to time; and (x) will be subject to certain work-for-hire, confidentiality, non-disparagement and non-competition covenants.

Item 6. Exhibits

No.		Description

31.1		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

31.2		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350

32.2		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350

(101)		The following condensed consolidated financial statements from the PharmAthene, Inc. Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, formatted in Extensive Business Reporting Language (“XBRL”): (i) Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, and (v) Notes to consolidated financial statements.

101.INS		Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMATHENE, INC.

Dated: November 6, 2015	By:	/s/ John M. Gill
		Name: John M. Gill
		Title: President and Chief Executive Officer

Dated: November 6, 2015	By:	/s/ Philip MacNeill
		Name: Philip MacNeill
		Title: Vice President, Chief Financial Officer, Treasurer and Secretary

EX-31.1 2 v422632_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, John M. Gill, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended September 30, 2015;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2015	/s/ John M. Gill
	Name: John M. Gill
	Title: President and Chief Executive Officer

EX-31.2 3 v422632_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Philip MacNeill, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended September 30, 2015;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 6, 2015	/s/ Philip MacNeill
	Name: Philip MacNeill
	Title: Vice President, Chief Financial Officer, Treasurer and Secretary

EX-32.1 4 v422632_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended September 30, 2015, as filed with the Securities and Exchange Commission (the “Report”), I, John M. Gill, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ John M. Gill
Name: John M. Gill
Title: President and Chief Executive Officer
November 6, 2015

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-32.2 5 v422632_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended September 30, 2015, as filed with the Securities and Exchange Commission (the “Report”), I, Philip MacNeill, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Philip MacNeill
Name: Philip MacNeill
Title: Vice President, Chief Financial Officer, Treasurer and Secretary
November 6, 2015

EX-101.INS 6 pip-20150930.xml XBRL INSTANCE DOCUMENT 0001326190 2015-09-30 0001326190 2014-12-31 0001326190 2015-01-01 2015-09-30 0001326190 2014-01-01 2014-09-30 0001326190 2013-12-31 0001326190 2014-09-30 0001326190 2015-03-09 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2014-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-01-01 2015-09-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-09-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2013-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2014-01-01 2014-09-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2014-09-30 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember 2015-09-30 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember 2014-09-30 0001326190 2015-01-07 0001326190 2015-01-11 2015-01-15 0001326190 2015-01-15 0001326190 pip:GroupThreeMember 2015-01-01 2015-09-30 0001326190 pip:GroupFourMember 2015-01-01 2015-09-30 0001326190 pip:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2015-04-01 2015-04-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2007-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2015-09-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2015-01-01 2015-09-30 0001326190 us-gaap:WarrantMember 2015-01-21 2015-01-28 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeOneMember us-gaap:WarrantMember 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeFourMember 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeFiveMember 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeSixMember 2015-09-30 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeSevenMember us-gaap:WarrantMember 2015-09-30 0001326190 2009-07-01 2009-07-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeOneMember us-gaap:WarrantMember 2015-01-01 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeFourMember 2015-01-01 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeFiveMember 2015-01-01 2015-09-30 0001326190 pip:DerivativeInstrumentWarrantsMember pip:ShareBasedCompensationWarrantsPriceRangeSixMember 2015-01-01 2015-09-30 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeSevenMember us-gaap:WarrantMember 2015-01-01 2015-09-30 0001326190 us-gaap:LoansPayableMember 2015-09-30 0001326190 us-gaap:LoansPayableMember 2015-01-01 2015-09-30 0001326190 us-gaap:LoansPayableMember 2012-03-30 0001326190 us-gaap:LineOfCreditMember 2012-03-30 0001326190 pip:EquityOfferingMember 2013-03-25 0001326190 pip:AmendmentToControlledEquityOfferingMember 2014-05-23 0001326190 pip:EquityOfferingMember 2015-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0001326190 us-gaap:RestructuringChargesMember 2015-01-01 2015-09-30 0001326190 us-gaap:RestructuringChargesMember 2014-01-01 2014-09-30 0001326190 2015-07-01 2015-09-30 0001326190 2014-07-01 2014-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0001326190 2015-11-04 0001326190 us-gaap:LineOfCreditMember 2015-09-03 0001326190 us-gaap:LineOfCreditMember 2015-09-02 2015-09-03 0001326190 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2015-10-12 2015-10-13 0001326190 us-gaap:EmployeeSeveranceMember 2015-01-01 2015-09-30 0001326190 us-gaap:FacilityClosingMember 2015-01-01 2015-09-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

196478

199194

18245550

19250632

248270

325772

53384

2348453

20895657

21978241

306172

391396

1453123 1195412

619119

746146

70326

2355

178509

2380769

2581789

431015

493137

227898

629170

17389409

3223700

3704096

0.0001

100000000

64358834

63603303

6436

6360

240151146

238780633

18643351

-229528

-222485625

-220283320

17671957

18274145

20895657

21978241

110656

659663

297431

63603303

64358834

100000000

0.0001

-0.03

-0.13

63858500

55577550

9374155

8363909

3962019

7528616

5246396

8289788

2519273

108798

113272

11836486

15931676

-2462331

-7567767

48492

173356

577426

464703

6594

-1470

306336

289877

-2155995

-7277890

46310

48105

-2202305

-7325995

1155839

962451

1125865

1728929

1231035

3192427

422482

35005

37125

2814387

4958481

-1658548

-3996030

9888

46930

359796

-560487

-691

349217

-607337

-1309331

-4603367

15437

25068

-1324768

-4628435

-0.02

-0.08

64187618

58952731

229192

336

-7162

-1972777

-7333157

-5869

-1324768

-4634304

-229192

426988

1172703

46310

48105

-51820

68130

7600

5393

-110656

-1427113

362232

-1895858

9602

-23869

-85175

-846090

800769

149438

-773517

-284937

-1387028

-4951585

68277

92269

7600

8000

-60677

-84269

-750007

-749997

-1091740

943601

15341264

193594

14182852

169

-7585

-1253942

9139413

10480979

19620392

108134

105916

395470

843048

426988

1172703

112000

117500

1357755

800000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <b style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Note 1 Business, Liquidity and Organization Since <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning.    On March 9, 2015, our Board of Directors approved our realignment plan (the Realignment Plan) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (SIGA) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA's appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (NIAID). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2 million (all of which was expensed as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company's product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5 million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.   As of September 30, 2015, our cash balance was $17.4 million, our unbilled accounts receivable balance was $0.7 million, and our current liabilities were $2.4 million. As of September 30, 2015, we had approximately $3.0 million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 Financing Transactions Controlled Equity Offering). We believe, based on the operating cash requirements and capital expenditures expected for 2015, the Company's cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016. On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (GE Capital), as discussed further in Note 6- Financing Transactions.   On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (rPA). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 - Commitments and Contingencies - Leases. On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016.   We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, in connection with the Realignment Plan, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman's continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA's appeal has been adjudicated and we have received SIGA's payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA's appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.   In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders. </div>

700000 3000000

2000000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap">Nine months ended September 30,</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> </tr> <tr style="vertical-align: bottom;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"> 2015</td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"> 2014</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;">Research and development</td> <td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"> 85,259 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"> </td> <td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"> 329,655 </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">General and administrative</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 395,470 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 843,048 </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;">Restructuring benefit</td> <td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"> (53,741 </td> <td>) </td> <td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;">-</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Total share-based compensation expense</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 426,988 </td> <td> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,172,703 </td> <td> </td> </tr> </table> </div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">Three months ended September 30,</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">2015</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;">2014</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;">Research and development</td> <td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"> 12,034 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"> </td> <td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"> 52,434 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">General and administrative</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> 81,723 </td> <td> </td> <td></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> 228,286 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;">Total share-based compensation expense</td> <td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"> 93,757 </td> <td> </td> <td></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"> 280,720 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"> </td> </tr> </table> </div>   </div>

85259

329655

P2Y2M12D

6000000

10900000

683325

36981

2300000

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Goodwill   Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. </div>

200000

75000 129000 53741

-53741

12034

81723

93757

52434

228286

280720

100000

6430038

2355

227898

230253

6429104

178509

629170

807679

-577426

230253

1740235

-464703

851793

1775419

230253

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap">As of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 1</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 2</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 3</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Balance</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';">Assets</td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Investment in money market funds(1)</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total investment in money market funds</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';" width="100%">Liabilities</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 2,355 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 2,355 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Non-current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 227,898 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 227,898 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 230,253 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 230,253 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap">As of December 31, 2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 1</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 2</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 3</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Balance</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';">Assets</td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Investment in money market funds(1)</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total investment in money market funds</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';" width="100%">Liabilities</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">178,509</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">178,509</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Non-current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">629,170</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">629,170</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 3%; font-family: 'times new roman';"> </td> <td style="width: 3%; font-family: 'times new roman';">(1)</td> <td style="width: 94%; font-family: 'times new roman';"> <div>Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</div> </td> </tr> </table> </div> </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Exercised Stock</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Unrealized</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Purchase</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">December 31,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">(Gains)</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Warrants </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">September 30,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Description</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap">2015 </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Derivative liabilities related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(577,426</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">230,253</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Unrealized</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap">Exercised Stock Purchase</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">December 31,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">(Gains)</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap">Warrants</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">September 30,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Description</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2013</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Derivative liabilities related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,740,235</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(464,703</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;">(423,739</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">851,793</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div> </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Note 3 - Fair Value Measurements   The carrying amounts of our short term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable approximate their fair values due to their short term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows:   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 2%; font-family: 'times new roman';"> </td> <td style="width: 2%; font-family: 'times new roman';"></td> <td style="width: 96%; font-family: 'times new roman';">Level 1 Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table> </div>   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 2%; font-family: 'times new roman';"> </td> <td style="width: 2%; font-family: 'times new roman';"></td> <td style="width: 96%; font-family: 'times new roman';">Level 2 Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td> </tr> </table> </div>   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 2%; font-family: 'times new roman';"> </td> <td style="width: 2%; font-family: 'times new roman';"></td> <td style="width: 96%; font-family: 'times new roman';">Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</td> </tr> </table> </div>   An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.   We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis. The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis: <div> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap">As of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 1</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 2</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 3</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Balance</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';">Assets</td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Investment in money market funds(1)</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total investment in money market funds</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 6,430,038 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';" width="100%">Liabilities</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 2,355 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 2,355 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Non-current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 227,898 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 227,898 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 230,253 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 230,253 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap">As of December 31, 2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 1</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 2</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Level 3</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Balance</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';">Assets</td> <td style="font-family: 'Times New Roman';"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Investment in money market funds(1)</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total investment in money market funds</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">6,429,104</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font-family: 'Times New Roman';" width="100%">Liabilities</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">178,509</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">178,509</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Non-current portion of derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">629,170</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">629,170</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Total derivative instruments related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 3%; font-family: 'times new roman';"> </td> <td style="width: 3%; font-family: 'times new roman';">(1)</td> <td style="width: 94%; font-family: 'times new roman';"> <div>Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</div> </td> </tr> </table> </div> </div> <p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0px; text-align: left;">The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2015 and 2014: <div>   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Exercised Stock</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Unrealized</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Purchase</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">December 31,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">(Gains)</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap">Warrants </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">September 30,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Description</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap">2015 </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Derivative liabilities related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">807,679</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(577,426</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;">-</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">230,253</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Unrealized</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap">Exercised Stock Purchase</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">Balance as of</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">December 31,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">(Gains)</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap">Warrants</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap">September 30,</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Description</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2013</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">2014</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%">Derivative liabilities related to stock purchase warrants</td> <td style="font-family: 'times new roman'; padding: 0px;"></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">1,740,235</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">(464,703</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;">(423,739</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">)</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">851,793</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> </tr> </table> </div> </div> At September 30, 2015 and 2014, derivative liabilities are comprised of warrants to purchase 1,775,419 shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.   <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap">Quantitative Information about Level 3 Fair Value Measurements</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Fair Value at September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Valuation Technique</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">230,253</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> Black-Scholes option pricing model</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Expected term</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Expected dividends</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Anticipated volatility</td> </tr> </table> </div>   Assets Measured at Fair Value on a Nonrecurring Basis   The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the Company recorded an impairment charge for property and equipment in the amount of $36,981. These assets were written down to their fair value of $0 in conjunction with the sublease of the Company's leased office space (see Note 4 - Commitments and Contingencies - Leases). As of September 30, 2015, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis. </div>

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap">Quantitative Information about Level 3 Fair Value Measurements</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Fair Value at September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Valuation Technique</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;">230,253</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> Black-Scholes option pricing model</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Expected term</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Expected dividends</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;">Anticipated volatility</td> </tr> </table> </div>

3500000

4600000

10300000

4400000

P10Y

1922781

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Note 4 - Commitments and Contingencies   SIGA Litigation   In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to license, development and marketing rights for SIGA's drug candidate, Arestvyr (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.   In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery's finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court's opinion.   On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company's lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company's reasonable attorneys' and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.   On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with BARDA. SIGA's petition for bankruptcy initiated a process whereby its assets are protected from creditors, including us.   On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015. On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company's lost profits for Tecovirimat, also known as ST-246® (formerly referred to as Arestvyr and referred to by SIGA in its recent SEC filings as Tecovirimat), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company's reasonable attorneys' and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene's entitlement to interest from and after SIGA's bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code. SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply brief on cross-appeal on May 11, 2015. On October 7, 2015, oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene's favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.   While we believe that we may have a right to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future.   PharmAthene's ability to collect the Judgment depends upon a number of factors, including SIGA's financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA's filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company's ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The Company has not <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">recognized any potential proceeds from these actions in its financial statements to date.   Government Contracting   Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (DCAA) and other government agencies such as BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies.   We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax® contract for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA in the amount of $5.8 million in connection with these costs, all of which was collected in April 2015.   BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax® contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.   Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company's financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company's financial condition and/or results of operations.   Registration Rights Agreements   We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.   Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a Maintenance Failure), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment, would be approximately $0.2 million.   Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $0.2 million for each month until the failure, if it occurs, is cured.   We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or piggy-back basis or both.   License Agreements    On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (rPA). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM.   Leases   The Company leases its office under a 10-year operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized a loss of $0.4 million in restructuring expense our condensed consolidated statements of operations for the nine months ended September 30, 2015.   The present value of the Company's remaining lease liability (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses as follows:   <div align="center"> <div> <div style="display: block;"> <table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;"> <tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"> <td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"> Description </td> <td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">   </td> <td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"> Present Value at September 30, 2015 </td> <td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">   </td> </tr> <tr style="mso-yfti-irow: 1;"> <td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> Accrued restructuring expenses </td> <td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">   </td> <td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> $ </td> <td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> 244,769 </td> <td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">   </td> </tr> <tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;"> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> Accrued restructuring expenses - long term </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">   </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> $ </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> 184,018 </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">   </td> </tr> </table> </div> </div> </div> <div align="center"> </div> </div>

113000000

194600000

113100000

81500000

0.010 200000 0.010 200000 5800000 2572775

100778

3.97

500000

1.89

903996

1.63

371423

3.50

46584

1.61

2010-04-01 2017-01-01 2015-01-28 2011-06-01

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">   <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"> <tr style="vertical-align: bottom;"> <td style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Number of Common Shares Underlying Warrants As of September 30, 2015</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Issue Date</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap">Exercise Price</td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"> </td> <td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap">Expiration Date</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 100,778 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">(1)</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> March 2007 </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 3.97 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> March 2017 </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 500,000 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">(2) (3)</td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> April 2010 </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 1.89 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> October 2015 </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 903,996 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">(2)</td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> July 2010 </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 1.63 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> January 2017 </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 371,423 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">(2)</td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> June 2011 </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 3.50 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> June 2016 </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 46,584 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;">(1)</td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> March 2012 </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 1.61 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"> March 2022 </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"> </td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"> 1,922,781 </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"> </td> <td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">  </td> </tr> </table> </div> <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="width: 3%; font-family: 'times new roman';"> </td> <td style="width: 5%; font-family: 'times new roman';">(1)</td> <td style="width: 92%; font-family: 'times new roman';"> <div>These warrants to purchase common stock are classified as equity.</div> </td> </tr> </table> </div>   <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 1722px;"> <tr style="vertical-align: top;"> <td style="width: 3%; font-family: 'times new roman';"> </td> <td style="width: 5%; font-family: 'times new roman';">(2)</td> <td style="width: 92%; font-family: 'times new roman';"> <div>Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).</div> </td> </tr> </table>   <table border="0" cellspacing="0" cellpadding="0" width="100%" style="width: 100.0%; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;"> <tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;"> <td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;">   _______ </td> <td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;"> (3)___________ </td> <td valign="top" style="padding: 0in 0in 0in 0in;"> <div>Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</div> </td> </tr> </table> </div> </div>

2016-06-01 2017-03-01 2010-07-01 2015-10-01 2022-03-01 2012-03-01 2007-03-01 15000000 15000000 0.030 3000000

2500000

5000000

46584

1.61

423739

1775419

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> Note 6 Financing Transactions   Controlled Equity Offering   On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $15.0 million.   On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.   Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an at-the-market offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.   As of September 30, 2015, shares having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement. The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.   Termination of Loan Agreement with GE Capital   On September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5.0 million based on our outstanding qualified accounts receivable.   The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method. The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets. In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase 46,584 shares of the Company's common stock at an exercise price of $1.61 per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method. </div>

false --12-31 2015-09-30 PIP Accelerated Filer PHARMATHENE, INC 0001326190 64451334 2015 Q3 10-Q

<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="display: block;"> <table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;"> <tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"> <td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"> Description </td> <td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">   </td> <td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"> Present Value at September 30, 2015 </td> <td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">   </td> </tr> <tr style="mso-yfti-irow: 1;"> <td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> Accrued restructuring expenses </td> <td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">   </td> <td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> $ </td> <td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"> 244,769 </td> <td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">   </td> </tr> <tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;"> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> Accrued restructuring expenses - long term </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">   </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> $ </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"> 184,018 </td> <td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">   </td> </tr> </table> </div> </div>

244769

184018

400000

2355

184018

500000 210000

36981

81347

75000

208

6129

2100000

178509

807679

Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. These warrants to purchase common stock are classified as equity. Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 – Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense). Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.

EX-101.SCH 7 pip-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 101 - Disclosure - Business, Liquidity and Organization link:presentationLink link:calculationLink link:definitionLink 102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 103 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 104 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 105 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 106 - Disclosure - Financing Transactions link:presentationLink link:calculationLink link:definitionLink 107 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 202 - Disclosure - Summary of Significant Accounting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink 302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 305 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 306 - Disclosure - Financing Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Business, Liquidity and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Fair Value Measurements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Financing Transactions (Controlled Equity Offering) (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Financing Transactions (Loan Agreement with GE Capital) (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Financing Transactions (Principal Payments on the Term Loan) (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 304 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Commitments and Contingencies (Leases) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pip-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pip-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pip-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Expenses And Other Current Liabilities Accrued expenses and other liabilities Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement Additional Common Stock Aggregate Gross Sales Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement Adjustable interest rate reference rate, based up 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%. Adjustable Debt Instrument Reference Interest Rate Floor Percentage Adjustable interest rate, reference rate, floor percentage 1.5% Amendment to the Controlled Equity Offering [Member]. Amendment to the Controlled Equity Offering [Member] Accounts receivable, billed and unbilled Billed And Unbilled Accounts Receivable Net Accounts receivable (billed and unbilled) Breach of contractual commitment award period - number of years following initial commercial sale of ArestvyrTM. Breach Of Contractual Commitment Award Period SIGA breach of contractual obligation award period following initial commercial sale Cash Equivalents, Maturity Period Cash Equivalents Maturity Period Cash liquidity maturity period Class Of Warrant Or Right, Issuance Date. Class Of Warrant Or Right Issuance Date Issue Date Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares. Commission Owed To Sales Agent Expressed As Percentage Of Aggregate Gross Proceeds From Each Sale Of Shares Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies [Line Items] Amendment Flag Amendment Flag Court awarded fees. Court Awarded Fees Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest. The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time, however, with a floor of 1.5%. Debt Instrument Interest Rate Floor Percentage Variable interest rate, with floor of 1.5% Debt Instruments Maturity Date Month and Year Debt Instruments Maturity Date Month And Year Term loan and line of credit, maturity date Derivative Instrument Warrants [Member] Derivative Instrument Warrants [Member] Derivative Liabilities [Member] Derivative Liabilities [Member] Derivative Liabilities [Member] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Equity Offering [Axis] Equity Offering [Axis] Equity Offering [Domain] Equity Offering [Domain] Equity Offering [Line Items] Equity Offering [Line Items] Equity Offering [Member] Equity Offering [Member] Equity Offering [Table] Equity Offering [Table] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Table] Final payment fee payable on term loan balance, percent. Final Payment Fee Of Term Loan Balance Percent Final payment fee payable on term loan balance, percent Future Value Settled Future Value Settled Proceeds later settled Group Four [Member] Group Four [Member] Every 30 days until failure is cured [Member] Current Fiscal Year End Date Current Fiscal Year End Date Group One [Member] Group One [Member] Expiration 2015 Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Group Three [Member] Initial Maximum Maintenance Failure Obligation [Member] Group Two [Member] Group Two [Member] Expiration 2017 [Member] Line Of Credit Facility Borrowing Capacity Percent Of Qualified Billed Accounts Receivable. Line Of Credit Facility Borrowing Capacity Percent Of Qualified Billed Accounts Receivable Line of credit facility borrowing capacity, qualified billed accounts receivable, percent Line Of Credit Facility Borrowing Capacity Percent Of Qualified Unbilled Accounts Receivable. Line Of Credit Facility Borrowing Capacity Percent Of Qualified Unbilled Accounts Receivabl Line of credit facility borrowing capacity, qualified unbilled accounts receivable, percent Liquidity Arrangements [Member] Liquidity Arrangements [Member] Long Term Debt Excluding Discount Long Term Debt Excluding Discount Total Prepayment premium, if we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date. Long Term Debt Prepayment Premium Percent Of Principal Prepayment premium, if we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, percent Prepayment premium, if paid after the first two years of the term loan, percent. Long Term Debt Prepayment Premium Percent Of Principal Period Two Prepayment premium, if paid after the first two years of the term loan, percent The maximum value of common stock issuable under the controlled equity offering arrangement. Maximum Value Of Stock Issuable Under Stock Offering The maximum value of common stock issuable under the controlled equity offering arrangement Net profit on ArestvyrTM (as defined in court's final judgement) before distribution for breach of contract. Net Profit Retention From Sales Before Distribution For Breach Of Contract SIGA net profits (as defined in courts final judgement) before distribution for breach of contract Document Period End Date Document Period End Date Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Notes Payable Aggregate Principal Repayment Amount Aggregate principal amount of obligation Percentage of aggregate principal amount of convertible notes relating to the affected shares. Percentage Of Aggregate Principal Amount Redemption Percentage of aggregate principal amount of convertible Notes Percentage of net profits awarded on the sales of ST-246 and related products. Percentage Of Net Profit Awarded SIGA breach of contractual obligation awarded, percentage of net profits PharmAthene [Member] Pharm Athene [Member] PharmAthene Previous Proceeds From Issuance Of Common Stock Received Previous Proceeds From Issuance Of Common Stock Received Proceeds from issuance of common stock, net of issuance costs received Award Type [Axis] The remaining value of common stock issuable under the controlled equity offering arrangement. Remaining Value Of Stock Issuable Under Stock Offering Amount remaining available under controlled equity offering sale arrangement Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Annual Forfeiture Rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate Share-based compensation expense, forfeitures rate Entity [Domain] Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Granted in Period Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period Restricted stock granted Share Based Compensation Warrants Price Range Five Member. Share Based Compensation Warrants Price Range Five [Member] 1.63 [Member] Share Based Compensation Warrants Price Range Four Member. Share Based Compensation Warrants Price Range Four [Member] 1.89 [Member] Share Based Compensation Warrants Price Range One Member. Share Based Compensation Warrants Price Range One [Member] 3.97 [Member] Share Based Compensation Warrants Price Range Seven Member. Share Based Compensation Warrants Price Range Seven [Member] 1.61 [Member] Share Based Compensation Warrants Price Range Six Member. Share Based Compensation Warrants Price Range Six [Member] 3.50 [Member] Share Based Compensation Warrants Price Range Three Member. Share Based Compensation Warrants Price Range Three [Member] 2.50 [Member] Share Based Compensation Warrants Price Range Two Member. Share Based Compensation Warrants Price Range Two [Member] 3.00 [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' Equity [Table] Stockholders Equity [Table] Stockholders' Equity [Table] Stock Incentive Plan 2007 [Member] Stock Incentive Plan Twenty Zero Seven [Member] 2007 Long Term Incentive Plan [Member] Stock Issued Value Convertible Notes And Stock Purchase Warrants. Stock Issued Value Convertible Notes And Stock Purchase Warrants Stock issued of convertible notes and stock purchase warrants, Value Stock Options Contractual Term Stock Options Contractual Term Options award term Value of warrants issued to lender in connection with loan Value Of Warrant Issued To Lender In Connection With Loan Value of warrants issued to lender in connection with loan Warrant, Expiration Date Warrant Expiration Date Expiration Date Warrant expiration date Warrants Issued To Purchase Common Stock In Connection With Loan Agreement. Warrants Issued To Purchase Common Stock In Connection To Loan Agreement Warrants issued to purchase common stock, in connection with loan agreement Represents information pertaining to National Institute of Allergy and Infectious Diseases ("NIAID"). National Institute of Allergy and Infectious Diseases [Member] NIAID Represents information pertaining to Biomedical Advanced Research and Development Authority. Biomedical Advanced Research and Development Authority [Member] BARDA [Member] Represents the amount of cash inflow from initial funding as per the agreement. Proceeds from Initial Funding Amount received from initial funding as per agreement, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestone events Represents the value of the agreement. Value of Agreement Total value of the agreement, assuming all development milestones are met and all contract options are exercised Represents the number of options that can be exercised. Number of Options Exercised Number of options elected to be exercised Represents the aggregate funding amounts to be received upon the exercise of each option. Aggregate Funding Amounts to be Received Upon Exercise of Each Option Aggregate funding amounts to be received upon the exercise of each option Disclosure of information about organization, consolidation and basis of presentation of financial statements disclosure. Organization Consolidation and Presentation of Financial Statements Disclosure [Table] Organization Consolidation and Presentation of Financial Statements [Line Items] Organization and Business Represents the number of common shares exercised underlying stock purchase warrants. Class of Warrant or Right Outstanding Number of Shares Exercised Number of common shares exercised underlying stock purchase warrants Represents the number of common shares expired underlying stock purchase warrants. Class of Warrant or Right Outstanding Number of Shares Expired Number of common shares expired underlying stock purchase warrants Trading Symbol Trading Symbol Initial carrying value of derivative instruments issued during the reporting period. Initial Derivative Fair Value New Liabilities Biologic License Application Approval Member. Biologic License Application Approval [Member] Milestone Payments Member. Milestone Payments [Member] Studies Or Trails Member. Studies Or Trails [Member] Sublicense Fee Percent. Sublicense Fee Percent Upfront Payment Member. Upfront Payment [Member] Upfront Payment [Member] The percent of interest to be paid as part of a litigation settlement. Litigation Settlement Interest Percentage Post-judgment simple interest rate Amount of share based compensation expense incurred during the period due to the extension of the exercise period of vested stock options. Share Based Compensation Extension Of Exercise Period Share-based compensation expense, extension of exercise period Reversal of share based compensation expense due to unvested stock options forfeited during the period. Share Based Compensation, Reversal From Stock Option Forfeitures Share-based compensation, reversal from stock option forfeitures The net reversal amount of share based compensation due to adjustments during the period. Share Based Compensation, Reversal, Net Net reversal of share-based compensation expense Government Contract [Member]. Government Contract [Member] Government Contract A [Member] Entity Filer Category Entity Filer Category Revenue recognized during the period based on auditing of a contract. Revenue Recognized From Contract Audit Audited BARDA revenue Audited BARDA revenue Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity. Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation Realization of cumulative translation adjustment Realization of cumulative translation adjustment Entity Registrant Name Entity Registrant Name Annual payment due under the licensing agreement. Annual License Payment Entity Central Index Key Entity Central Index Key Immunovaccine [Member]. Immunovaccine [Member] Represents the amount of cash inflow from additional funding as per the agreement. Proceeds from Additional Funding Additional funding received Monthly rent amount under the operating lease. Monthly Rent Amount Monthly rent amount Monthly rent amount by the end of the operating lease. Final Monthly Rent Amount Final monthly rent amount Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Income (loss) from operating lease cessation. Income (Loss) From Operating Lease Cessation Gross loss from operating lease cessation Loss from lease cessation Estimated lease payments from sublessee. Estimated Lease Payments From Sublessee Estimated lease payments Expected sublet cash income. Expected Sublet Cash Income EX-101.PRE 11 pip-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(``*(9D?U42*BIP$``&<4```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CT]*'@$WIMD5J?\!-)L3"CBW;!/C[V@&J-J(5 MM$2:31[<\=R;C',6C-^V!EQOHV3E)DGIO7D@Q&4E*.Y2;:`*2J&MXC[_[V".9CE]JL%;DT'O<";'W).'&2)%Q+W1%ZBIO=>WK MHA`9Y#I;J;`D]<$:KH*>].;<^F>N0@NRD:01=D>:1IU76I!-C2N%V5L];4(7%WZ;)$%U)SFT%_Z63*@X M-%,MOJV(]W]\EM9+K)6<6;X6+8.ZLS'%< M:W/]T]`;T9'FU"$DSLK!D.08(LEQC23'#9(<(R0Y;I'DN$.2XQY)#CK`$@0+ M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$KPT)6 MAH6L#`M9&1:R,BQD'7Z2E33_+TX_`%!+`P04````"``"B&9'2'4%[L4````K M`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\ ME,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4 MX$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@` M`HAF1Z^6X@AN`0``-Q,``!H```!X;"]?1O@T( M+(W_JQ\6^]:GNR>I;:BZUI=5[V?O3=WZW?#^D)0A]#MC?%Y*8_V\ZZ4=5J^= M:VP8'EUA>IO?;"&&TW1EW'1.%^=H@,?$@C@!-&;U;T9HS>K.C-H+.V M=MC&Z,V*WHS1FQ6]&:,W*WHS1F]6]&:,WJSHS1B]6=&;,7JSHC=C],X4O3., MWME$;U]:)Y?GX*JV$^N^39<+9K@[<.]EL>GC%/5AHG68=A)S'A]^-=LG/H9 M8G[](SM^`%!+`P04````"``"B&9'%J/V&4OCC>ZU*E!;@88]YYDT(U)>.RMKBY'K M&K["',P9F4C:393.P=)2IZY*$L%QIGB9H[3NT/.N7'RV*&.,/Q<[IXX_KJ), MBB(3'*Q0TK\37"NC$LN"9X[9V'UK4"/(0 M&6RL_BIKFZG*"Y`;MUG-A7PR/XM(SGY\,RCWXZ"K;[QC1`+F=Z#T,8?K^UHC=PJ_=JF MM3VU2['B5=/-0T3Y&8<]@L%*O';6H`5(ZS`C7F@Y=)JPC;:6L$8[?]2^LFL M$*T9NSME+;9MV[*X]"^\VH*D?4MW5YG_2MM>W94F$C9#LTSN0=O_1$5=TY:( M"\]I5;]UP4#&+)"6QI'=RB84-:]-R4Z:+A>S8!$&,T92N)S?SB81+6XF\\EB M&K`3,!=],&%$?W?!X@3,EQ,P5YV8F]((B<9\8G/QNQ1QQ5M%X5*G(,5+)R8L M\QSTAJF$A2*5@EI(0\,FG*N2F._$?*?!80^0EJ6Z:Y#Y;FP]7Z= MRU215SJJDM/=U9V15?QII;*8CNH'%E`A=M.=AI!`;F3*(@W2`*^&XX#/8U6> M=W?Z..:R#S-L$,%C=J#>HPRQP3]SM`WRL?]LG'\]@8%O_3%#KQ]K(5TV<=D3 M4R?0#[,`K<'VSVW8/05'.SH\<-Z/8KK/>_<4-,6(-?;`-$1GV'U/=A\T-JAR MU"KKA9DKD&R2OGO6VN_3F]?(W?^*\O\`4$L#!!0````(``*(9D=-5VRM/@$` M`&D#```1````9&]C4')O<',O8V]R92YX;6S-D\%.PS`,AE\%]=XEV<20HJX' M0)R8A,00B%M(O"VL3:+$4]>W)\NZE@&7WKC5M?_/O^.DD(Y+Z^')6P<>-82K M0UV9P*5;9%M$QPD)<@NU")-886)R;7TM,(9^0YR0.[$!,J5T3FI`H00*<@3F MKB=F9:$DEQX$6M_AE>SQ;N^K!%.20`4U&`R$31C)RA>S,[8Q!1GT91$=5R+@ MTBJ]UJ!NVZ'L=RIV1O!U.,E!]>W3WS\]I`S)NLI#T'U5TS239I;JXL",O"T? MG]/9Y-H$%$9"5`7-L76PR,Z=7V=W]ZN'K)Q2=ITSEM/YBMUP2CEE[\?)+OP- MANMNB'_K^&PP;1&UL[5I;<]HX%'[OK]!X M9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/`0L MZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#0 M5%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@ M?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSV MQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^ MQL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>" M(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RC MEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZ< MTT#PE"\D^DJ1CVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-& M(81IN_`>KR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@ MR.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z& MU3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@* M-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y M/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?! M4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D M8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2 M.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S M&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL M6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R M0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@ MF_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS M#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O M#;#"Q([A[8N_`5!+`P04````"``"B&9'4+S5)U4"``#6"@``#0```'AL+W-T M>6QE9A;T6V94>@#T^6 M,Z>_?OIP[,20IDG34K_HZNC>54J,LLH$,>I-?'_J,40XC$->LQE3%4A%S54$OW80 M33R'R]NAOBY7;B`P''\S"(83"^A]W+2L:^? MG=PB2A))#)@C1NC*P1,#V+)H_1CA0MK<+L,PS]CO,\DB MB:#?/B]/E_3L=C#;(Y1N;T\#<5@BI;#D,ST!K3U?E7IS7'#L1%J_/=Z%1*M@ M=-Q$RP[++',`U%(<4YTH'2%(LS*A$::0+I0331D90(3BBAG(=T1J: M-L64/IB7\$^^Q=WDP/F8._8A,"K6ICZ(UNS+P!ZJM\GFN#=IC^,%3=XET-&H M+.GJ!R4%9]B)==!,M+-]],$.^CA$:U:P$)(\:7]3"*D&L(1@B:4BZ2;R3Z)R MCAO55K#7Y+L4'KOEM]1T^E/KU>@2?._C.3JYA>YJEF`YLY_%PR5]N=I_9?;M MA`.9[ULU1T@XP>&8GOEAI4T_KK2WJ:F32+M^I32O[0P;[6>K^70H2&I"%>%K M#[(4RBY&L+=_&?G! MM/.:=Q01[.W?.",U^V85]'^R\7]02P,$%`````@``HAF1_+=S=5.`P``$`L` M``\```!X;"]W;W)K8F]O:RYX;6R5EFUOVC`0@/^*E2_KI&DD+M`6E4H4Z%:) MTFF@[K-)#)SJV,QVUI=?OW-2UF,UJ/V4V$D>V^?'ESMWO0=C[Q?&W+/'4FG7 ML_UD[?VFUVJY?"U+X;Z:C=3X;&EL*3PV[:IEEDO(Y\T-Q[:&YCI2C<6DI?J@96"M#)Q;GK+4').VD=@IG8;*:BE/WD425, M">?'!7A9]),V-LV#W.FPU>:R`A4:G;23M`)LN]0?EN6FD`ULO@;WZ^5!P@JY M%)7RP[RQY=;FX;NQ\&RT%VJ66Z-4_55X4'^$ M([A_/3A'#_G.BUXL?H:=Z"?=%(%_P,$"%/BG?E+?*QE6TOIO*77X7^^8KH.S MW6(F=,'&VB.%7>MF\S`T80[X\G51#VQ[@#?VNLB:4%'0\'8Z&D]GXQ'#N]GM MY'HTF&/C9XN1E/":A-0.V/@CH$U"&@ MSD=!70+J$E#W+>BR#SQ/4N<@*29+J8=I9$G>Y/=KHPH\W)_8&,/CG^CW.QY'1+X" M+7!0O6)S*[0+AQYS'B50@;.(P0>#FE&#,ZIP%G'X,*I-453B+&+QGAUB1YAN MU&Z(J<99S.-#>\6.*(J*G$5,CNW6=DJ?*8B*G$5,/G@DLE.*HBIG$9TJQ(O>81K_?NWPQ_O$5%451Q'E-\+ZJ>+D7M).N(ZWM14V&M M\!1%7><1UP\ND%/7.76=QS+V(4$YS=B2QO1U&-"4KN_&VI[3R6N:/YCAV%A6+)05'4=AZQ?1]J8H1F@Q7]=5/;C].7 M>N6U1,$J#4]S$0HX5P^#%5`>JCJ\-#FXW0F'+[1OL-+K)Z$,N_@)02P,$%`````@``HAF1\#D4A9.`@``]`<``!@```!X;"]W M;W)K^/_S>3TN>LH^>(6Q"#X;TO)=6`G1;:.( MGRK<(/Y".]S*/Q?*&B1DDUTCWC&,SMK4D`C&<1XUJ&[#LM!];ZPLZ$V0NL5O M+."WID'LSQX3VN]"$#XZWNMK)51'5!;1Z#O7#6YY3=N`X@3Z8RVO5']*]Z MNG+X1\3Q@9)?]5E4*?]-SS,(5,!3Y1P_0U.-RYH\["$08,^ M35FWNNS-GS09;'X#'`QP-(#U?PW)8$B>!KUTD1F9GM<7)%!9,-H'O$-JM\%6 MRID*(B,'SMM3QYYJ>ZKMF726RDFR#V54_ M/CPXT5LK3#8=>\<'[A7J)/V4ET6'KO@'8M>ZY<&1"IGJ=9:_4"JP'$K\(C-# M)9_@L4'P1:CJ2M:9>91,0]#N\<:.#WWY%U!+`P04````"``"B&9',^J@\R($ M``!'$@``&````'AL+W=OU>3# MD7:WIOW:G;SO-]_JZM+=;T]]?[W+LN[QY.NR^]1<_27\YZEIZ[(/M^USUEU; M7Q['H+K*4`B3U>7YLMWOQF>?V_VN>>FK\\5_;C?=2UV7[7\'7S6W^RULWQY\ M.3^?^N%!MM]E[W''<^TOW;FY;%K_=+_]%>X**0;)J/C[[&\=N=X,YA^:YNMP M\^?Q?BL&#[[RC_W01!E^7GWAJVIH*?3\[]SH]SZ'0'K]UOKOXW"#_8>R\T53 M_7,^]J?@5FPW1_]4OE3]E^;VAY_'H(<&'YNJ&_]N'E^ZOJG?0K:;NOPV_9XO MX^]M^D\NYC`^`.<`?`\`]=,`.0?()"";G(WC^JWLR_VN;6Z;[EH.V8:[(&^' M1D++FS"8;KP=IVMZ^KI'MAW8BR6&2X"3A%$6DT.^2+/3/FL#$!([Q7*D MRI7FU_)/A?J`G4$^&]P2T*Y$[;33+J")6@K-AO:W88Y#B%"A/I5W10@I4 MH$25[`8\S)IYA0D#EMU!1:QS(-T*BD$*5*"XE"PN#Q#Q,F04<"'[BD(>G%:P M8G=`BE:@;%4\6R&"*[C0&W^$:OXX6':3HA4H6Q5PO1PBS<*A,VLFQU894&OR ME:(5*%O5PLJ@S+1"KCGZ(24F4&0J'IFSQLZ[7;/P*(`B$VRNQ9HTI,P$"DW% M0Q-<1)]<6+.0"T>-ZSRX6N$)4W0B1:?BT8F4B)`K`6S94D1MK5FHF$(3*305 M#TVD*`R5A@`^9[-NFB#E)*S!'?Y0?R)UQ!>0LV;.&89$\'5)I#/H@)S/RXY2 M`",%L.(!C!%8$:45?"D0"ZT(I>^*G88I@E&18T6MR7P*3*20X^NH`](R,Y3? M[/HH8I4T:^8X!292&&J^&$4*0PR;0@/P2[9`$V]JFX<2<$51@2DZD:)3LV]< MATBS`'*D>/T%T6GR)K)L)P4L4L#RY=0!*6!#5Z$NU087MFP>VQ*82XEK$IBB M%BEJ-8]:=!'4C0VG/5]]QA_:$Y_"QCGY\OA^4_FG?KBTX;J=OG-, M-WUS??ML\_[M:/\_4$L#!!0````(``*(9D=EBR'IX`$``&H%```8````>&PO M=V]R:W-H965T&ULC93=CILP$(5?Q>(!8H/!22."U%!5[46E MU5ZTUTXP`:V-J>V$[=O7/R0EB$W*!?;8Y\Q\`[+S0:HWW3!FP+O@G=Y%C3'] M%D)];)B@>B5[UMF=6BI!C0W5">I>,5IYD^`P08A`0=LN*G*_]J**7)X-;SOV MHH`^"T'5GSWC&U/C7$+L,CAS5>U@G6ZE1U0K-Y%G^-M29S""WZV M;-"3.7#L!RG?7/"]VD7((3#.CL9EH':XL))Q[A+9PK_'G/]*.N-T?LW^U7=K MZ0]4LU+R7VUE&@N+(E"QFIZY>97#-S:VD+F$1\FU?X/C61LIKI8("/H>QK;S MXQ!VR'JT+1N2T9#<#''ZT(!'`YX98"#S?7VAAA:YD@/0/74_.]Y:N7));&9@ MF]$^])\KK%Z*C.3PXO+<2?9!DGA)LJ0H[Q3930)M_46(9`:1>#\.$.OG?CSS M8^]/@W]SC]B%)H)DXR5HA1"*EV3E`]F'-.F,)IW2?%JD"9+,2V(T/HM`CY4? M,F4SIFS"1!8K[;-))9+B;+/!Z2+2G1`3A#'"SXG(C(A,B19_QI[\+Q%Y3@0G MQZ*G)_:#JE/;:7"0QIXP?[AJ*0VSZ=#*=MC8B^\6<%8;-UW;N0IW00B,[*\W MV^UZ+?X"4$L#!!0````(``*(9D>Y5W'@K`0``!$4```8````>&PO=V]R:W-H M965T&ULC5A+<]LX#/XK'M\3$WPSXWBFDM79/>Q,IX?M68F5 MV%/+MT69-_?5L3CX7UZJNLQ;_UF_+IIC7>2;7JC<+SAC>E'FN\-\M>S7OM6K M9?76[G>'XEL]:][*,J__2XI]=7J07K$O[OBU*#W66?\4U7][#[^WCS.66=#L2^>VTY%[A_O15KL M]YTFO_.O4>G'GIT@?C]K_]K3]>8_Y4V15OL?NTV[]=:R^6Q3O.1O^_9[=?JK M&#FH3N%SM6_ZO[/GMZ:MRK/(?%;FOX?G[M`_3\,OEHUBM``?!?A%X+(/+2!& M`?$A(/\H($>L.:A10T0Z+@7OON77>YJME79UFS3'O\@D>/+SNE'C-,^^N MIO_L`S*LOJ\T7R[>.ST!)!D@?(`("K+&$+@@%GY_T@@>&I%P)$[:D&*$EJ0- M5Y5D$THFS121KT0O+P9Y=5U>1O*REY>#O`Y-/`R>&"!F<"0H986C<"G&.`EP7')# M\L/Z%)<^L&3:95B?]>XRUE[G9R-^%O$SC.1GD3V2@E562='T:(H5SF@DRV=``YH_)1.P" MA4P+,1$[C/.C@36W5*9X-@#GA+,)98#?\ M%\/CN8'CN2&>X$:&(^9M;(0:00/HC[- M-)X<.)X<+#TYC!@W[,7N&>F0]!.,CN0G&+EI%L/@AGK*XVF!<\R.K&_)B!FK MH`1K-$S$$2.5=ONT,R>JK:M MROZ"YJ6JVL*;SNZ]T[=%OKE\[(N7MGLU732&&ZOAHZV.YPNXRRW@ZG]02P,$ M%`````@``HAF1ZI2(\QZ`@``0P@``!@```!X;"]W;W)KQ>P`4-$D#8?57NHM-I#>W82)Z`%3+$3MO^^_B#$ M("?92\#FO3?SAL&3K*?=!RL(X4;/O"H;\M8Y[%S7N/NW(A7MEV[@ M7C?>RU/!Y8:79][(.Y0U:5A)&ZGZ,@52D3V7"EA<+F1-JDH*BV M`&L3$8?6')Z*;.^(W$T3SFH%%1_J6L7/^>&,'RI^J/FS%!M="0U!"O(M@"!$ M<6(#KB?`,`9)"",;<#,!`N`#Z%N!VPD001"E:?3<8S3S&)DU0L_Y\8P?FS5* MK/UH0D!JK4YL>HF2V(K::%2D4!#&UJI,E%`0@^>6T,P2,BVE5DOH@:7A"W@$ M&?P@PP\`:9#:/X,[2G?])#,_B<%/?6L;)U]MXV3:QC"$?FCU-E5,$4`(65]8 M,FUC"(-HWH:><436I#NIX<2 M;O)YUN(3^86[4]DP9T>Y.-C5F7ZDE!.1N?\BREV(B3XN*G+D\A;)]Z"'G%YP MVEY']OB_(?\/4$L#!!0````(``*(9D>]+]\[SP0``!86```8````>&PO=V]R M:W-H965T&ULE9A-;^,V$(;_BN&[UYP9BA^!8V"MHF@/!19[ M:,]*K,3&6I8K*>OMOR_U88?DCA#N)9:4=\B70_+1B)MKW7QK#V79+7Y4IW/[ MN#QTW>5AO6Z?#V55M)_J2WEV_WFIFZKHW&WSNFXO35GLAZ#JM$8AU+HJCN?E M=C,\^])L-_5;=SJ>RR_-HGVKJJ+Y;U>>ZNOC$I:W!U^/KX>N?[#>;M;WN/VQ M*L_ML3XOFO+EC-/]7UM_[FS_WC4O0>RE/YW/5- M%.[G>YF7IU/?DNOYWZG1]S[[0/_ZUOKOPW"=_:>B+?/Z],]QWQV<6[%<[,N7 MXNW4?:VO?Y33&+*^P>?ZU`Y_%\]O;5=7MY#EHBI^C+_'\_!['?]CQ!3&!^`4 M@/>`>S]\`$T!]!X@AY&.SH9Q_59TQ7;3U-=%>RGZV88')V_Z1ES+"S>8=K@= MTC4^_;ZUL%E_[]L))+M1@H/D7;%VC;,]8-C##KUPY#K(?862'_=`T1AHB*=Q M#/AQO(SBY1`OAW@363R/@Q@E>I"L$`62R#AA'@@U869M]K&C+'*4^2.BC^-5 M%*^\$6G%CFB49..TH`7+SXW?$MJ/G>C(B?;BK62=:,^)1&6-83.KO'75$[Z_4#PFC+IR>0`:%. MV`@@8AH(WP^_<";--%^*0+!^0ID!D;`-X"^'GZ])D&_&\F;(SXY68B8YY',KHQ3H M0,Q1D!ZV0*3D-P8?9'Y29O*;!4M=J(S?H*%.HG;;(L%2S%+P$4AL^G;@TW1% M"I'8]T@>",'8S&0FP5-,5?"Q2L![\KFZLDK,./)E2$:EK,08J^!SE6:F+0"F MR4#S;]!)-RU%(Y6P*2LI)BOX:)4ST^9#TPBAE>6WJOW%K8HQ6-$'*_%;==), M;SAI)9_(/-"MM":7R@1+,5O19RL(OO8+1,CZSC$`,!II*<5/C%;$P`]?ATVB M:>Q`1@N>$CGZ%%Y)FX';:PFV8L@B!5!+(`C&7$09C(RO@B;1Y%<9Y,N3/-19 MQ)0-BS%G,0LL\94'^@"=?74$*K>)$C8KQHQ%%=CA"P\,(*N$FLM0H#,R+4,Q M8E$'\YZRHF,JH@E&Q6,1`]SIS"5P9E@!/[6TUJ:8BKF(-C#%`F^',\`+_/CP M7+F60,N$N:<8C>2C$>)J:B3KF`V6<+'`OWTV4V!*>)- M^?4GQ._7FZ.P2$T"-<64I8"RP%.6`GH"NDI7\G51H+3@="G5(\6@I0"TP(.6 M@DK5*$GNGN!04JYJ,E3$O;K8"I54H*.4@AF+H M4@#=E+*&8NA2`%W@H4L^=!V9@6:V2JC+K)>IT=+:.VZKRN9U.(9L%\_UV[D; MS[3N3^]'G9^Q/ZZ+GN_@(1\/+-^;V6XNQ6OY5]&\'L_MXJGNNKH:S@%?ZKHK MG4'QR:V'0UGL[S>G\J7K+[6[;L9CR_&FJR^W4]C[4?#V?U!+`P04````"``" MB&9'J`!``"Q`P``&````'AL+W=O?,&5_*&5=2VPWMG1O7C-FZ!R7L%8Z@_9\6C1+.IZ9C=C0@FDA2 MDO$LNV%*#)I69:P]F:K$R>AZUTHL*ID"Z\9 M%&@[H"8&V@V]R]?;(B`BX&6`V9[$)'C?(;Z&Y'>SH5FP`!)J%Q2$7_9P#U(& M(=_X[:#YV3(03^.C^D.N]V8R2!EHQ2?>,\R,<1K@.@C5* M&[^DGJQ#=:10HL1[6@<=USG]*6X/M*\)_$#@"^$VB\93HVCSEW"B*@W.Q(XB MG%V^]G`31+PR\=YL3./TJ;JO\OQGR?9!Z`RS31B>,`N">?4O6_#S%EM^0N?? MTU<7#E>1ODK=>?:]0'$A4$2!XK\CGF'XY9#L9$\5F"Y>'4MJG+1+F[=4E]MY MQ^.9?,*K:?4!4$L#!!0````(``*(9D=6W\X5GP$``+$#```8````>&PO=V]R M:W-H965T&ULA5/;;J,P$/T5BP^HB4.ZJX@@-5U5[4.EJ@^[ MSPX,8-7V4-N$[M^O+X0F4;5]P3/#.6?.^%).:-YL#^#(AY+:[K+>N6%+J:U[ M4-S>X`#:_VG1*.Y\:CIJ!P.\B20E*0/#6[+`\60$+M@@+WRQ'N0&7BO=F8QNE3]5BM&"OI,0A= M8/8)PQ)F05"O_F4+=MEBS\[H['OZ^LKA.M+7L\/U]P+%E4`1!8K_CGB)*:Z: MT+,]56"Z>'4LJ7'4+FW>4EUNYQV+9_()K\J!=_#,32>T)0=T_F3CH;:(#KR) M_&:3D=Z_GR61T+H0_O"Q256C MG-"^NA[`DS>MC-O3WOMAQYBK>]#"W>$`)OQIT6KA0VH[Y@8+HDDDK1@OBGNF MA32T*E/MV58ECEY)`\^6N%%K8?\>0.&TIRLZ%UYDU_M88%7)%EXC-1@GT1`+ M[9X^KG:'340DP"\)D[N(2?1^1'R-R8]F3XMH`134/BJ(L)S@"92*0J'QG[/F M>\M(O(QG]6]IVN#^*!P\H?HM&]\'LP4E#;1B5/X%I^]P'F$;!6M4+GU)/3J/ M>J90HL5;7J5)ZY3_K&?:QP1^)O"%\*5(QG.C9/.K\*(J+4[$#2*>W6H7X#:* M!&42O+F4INES]52M^+9DIRATA3ED#,^8!<&"^H?RZPN1'8)('-?T>\QCS<-&$7>ZK!=NGJ.%+C:'S>O*6ZW,Y'GL[D'5Z5 M@^C@I["=-(X338?:(GH()HJ[+25]>#]+HJ#U,7P(LA_F!+*^T M^@=02P,$%`````@``HAF1R`,EP:A`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\02K32IH8L($X1M(<"00[MF996$A&2 MJY"4E?Y]24I6;"-H+N+N:F9VEH]R0OOB>@!/WK0R;D=[[XV8&RR()I&T8CS+OC`MI*%5F6I/MBIQ]$H:>++$C5H+^WFI\"R[WL<"JTJV\AJIP3B)AEAH=_0^W^Z+B$B`WQ(F=Q:3Z/V`^!*3G\V. M9M$"**A]5!!A.<(#*!6%0N/71?.]922>QR?UQS1M<'\0#AY0_9&-[X/9C)(& M6C$J_XS3#UA&N(V"-2J7OJ0>G4=]HE"BQ=N\2I/6:?Y3Y`OM8P)?"'PEW&7) M^-PHV?PNO*A*BQ-Q@XAGEV\#W$:1H$R"-Y?2-/U\W0F[_"J'$0'OX3MI''D@#Z<;#K4%M%#,)'=W%+2 MA_>S)@I:'\.O(;;SE9H3C\/I@:ROM/H'4$L#!!0````(``*(9D>"@KP8GP$` M`+$#```9````>&PO=V]R:W-H965TZ:EE42$Y*HD9:5_7SYDQ3:"MA=Q=S4S.\M'-:-Y MLP.`(^]*:KNC@W/CEC';#*"XO<$1M/_3H5'<^=3TS(X&>!M)2K(BR^Z8XD+3 MNHJU%U-7.#DI-+P88B>EN/F]!XGSCN;T5'@5_>!"@=456WFM4*"M0$T,=#MZ MGV_WFX"(@!\"9GL6D^#]@/@6DJ=V1[-@`20T+BAPOQSA`:0,0K[QKT7SHV4@ MGL]Q6N_^P"T\H/PI6C=XLQDE+71\DNX5YT=81K@-@@U*&[^DF:Q#=:)0 MHOA[6H6.ZYS^E,5"^YQ0+(1B)7S-HO'4*-K\QAVO*X,SL2,/9Y=O/=P$$:], MO#<;TSA]JA[KO,PK=@Q"%YA]PA0)LR*85_^T17'98E^8LJK)NQL3Q68/EX=2QJ*@=H@-O(KNYI63P[V=-)'0NA%]\;-*52HG#\?1`UE=:_P%0 M2P,$%`````@``HAF1T2K#,B@`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RI*<%H8L($Y1M(<"00[MF996$A&2JY*4 ME?Y]^9`5VPB2B[B[FIF=Y:.:T;S8`<"15R6UW=/!N7''F&T&4-S>X0C:_^G0 M*.Y\:GIF1P.\C20E69YE]TQQH6E=Q=J3J2N!;]X$*!U15;>:U0H*U`30QT>_JPV1W*@(B`WP)F>Q&3X/V(^!*2G^V>9L$" M2&A<4.!^.<$C2!F$?.._B^9;RT"\C,_JW^.TWOV16WA$^4>T;O!F,TI:Z/@D MW3/./V`981L$&Y0V?DDS68?J3*%$\=>T"AW7.?TIRH7V/B%?"/E*^)I%XZE1 MM/F-.UY7!F=B1Q[.;K/SJHW15FQ4Q"ZPAP2)D^8%<&\ M^KLM\NL6A_R"GG].+VX<%I%>+`ZWGPN4-P)E%"@_'/$:"9O\+H:>0^_N.F%MN2(SI]L/-0.T8$WD=UM*1G\^UD3 M"9T+X1&ULC9;;CILP$(9?!?$`"S:' M'$20-EM5[46EU5ZTUPYQ`EK`U';"]NUKFX1EO([@)MCFG_\;$P]#UC/^+DI* MI??1U*W8^:64W38(1%'2AH@GUM%6W3DQWA"IIOPG->MW/O+O"V_5N91Z(T%Y.QIY,_,/:N)S^/.S_4.=":%E);$'6YTA=:U]I) MD?_>3#^9.G`ZOKM_-]M5Z1^(H"^L_E,=9:FR#7WO2$_D4LLWUO^@MSTDVK!@ MM3"_7G$1DC7W$-]KR,=PK5IS[8<[27P+`]:A27P`F32_$4GRC+/> M$QW1?Q[:*CG7)LK94[D),S6['U:O.8I667#51D"S'S1XT(R*0+D[$1@B]G@2 MCN?#(RO#R(1'`QU'\P:Q91`;@_BVQ;5SBU"SF8J$0,UJ'K*Q()N)090X&1O`6,\S M4&@74`@L-NX*`J(D7,#Y4J@(6"`W!XH65!O"-@<#B\C-@:)X`<3!&PZ*EIP#^P6`0'4G#\X!$*5+SH']#D"@P-,'YP"*[',0 M3'I$0_G9M$+A%>S2RJ$9C*MCNWW&IL=\RO.L(V?ZB_!SU0KOP*3J5*9)G1B3 M5&41/JG=ENJ#8)S4]"3U<*7&?&B1PT2R[M[QQ\^._#]02P,$%`````@``HAF M1Q?YYWNC`0``L0,``!D```!X;"]W;W)K&ULA5/+ M;MLP$/P5@A\0RI*<%H8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5VS"0B[B[ MFIF=Y:.:T;S9`<"1=R6UW=/!N7''F&T&4-P^X`C:_^G0*.Y\:GIF1P.\C20E M69YECTQQH6E=Q=J+J2N!7]X$*!U15;>:U0 MH*U`30QT>_JTV1W*@(B`WP)F>Q&3X/V(^!:2G^V>9L$"2&A<4.!^.<$S2!F$ M?.._B^9'RT"\C,_JW^.TWOV16WA&^4>T;O!F,TI:Z/@DW2O./V`981L$&Y0V M?DDS68?J3*%$\?>T"AW7.?W9E@OM/B%?"/E*^)I%XZE1M/F-.UY7!F=B1Q[. M;K/SJHWCT7%3D'H"G-(F#QA5@3SZG=;Y-*@=H@-O(GO84C+X][,F$CH7PB\^-NE* MI<3A>'X@ZRNM_P-02P,$%`````@``HAF1_0[6&N]`0``>P0``!D```!X;"]W M;W)K&ULA53-;J,P$'X5BP>HP4E(-R)(3:MJ][!2 MUI&F& M+TYHACD%#`F8"8&M^JH%F5NVUQ?UJ MBW/,XWV3W<)D-Q/XL6HRP^SC^R;IPB2="22K)G/,\GOCF^D0H&I_"#0J9-^: M,`93=CIG3\1/US<\SSI:PV^J:M9J=);&SJ@?STI*`[:(^,&VVMB;8`HX5,9M M[6@C%0Y'"(SLQJ,^W3?Y?U!+`P04````"``"B&9'OM*1I*(!``"Q`P``&0`` M`'AL+W=OP6 M]\X-&T)LW8-D]D8/H/R?5AO)G$]-1^Q@@#61)`6A679+).,*5V6LO9BJU*,3 M7,&+07:4DIG/'0@];7&.CX57WO4N%$A5DH77<`G*]UJ_A>1/L\59L``":A<4F%\.\`!"!"'?^'W6_&X9B*?Q4?TI3NO= M[YF%!RW^\\;UWFR&40,M&X5[U=,SS".L@V"MA8U?5(_6:7FD8"391UJYBNN4 M_A3Y3+M.H#.!+H1?632>&D6;C\RQJC1Z0G9@X>SRC8>;(.*5D?=F8QJG3]5# ME=^M2G((0F>87<+0A%D0Q*M?;4'/6^SH"9W^3%]=.%Q%^BIUI[]_%B@N!(HH M4,PC%E='/,>L+YJ0DSV58+IX=2RJ]:AQK/Y!M>E0/KX"\S'5<6 M[;7S)QL/M=7:@3>1W:PQZOW[61(!K0OAG8]-NE(I<7HX/I#EE59?4$L#!!0` M```(``*(9D=PIPZ'HP$``+$#```9````>&PO=V]R:W-H965T&+"!.4+2'`D$.[9F65A(1DJN0E)7^??F0 M%=LPT%[$W=7,["P?Y83FW?8`CGPJJ>V.]LX-6\9LW8/B]@X'T/Y/BT9QYU/3 M,3L8X$TD*#XCO(?G1[&@6+("$V@4% M[I.7U*-UJ$X42A3_3*O0<9W2GR*?:;<)^4S(%\)C%HVG1M'F"W>\ M*@U.Q`X\G-UJZ^$FB'AEXKW9F,;I4_58K38/)3L&H0O,/F'RA%D0S*O?;)%? MMMCG9_3\W_3BRF$1Z47J7OR'P/I*8!T%UO.(FYLC7F(>KYJPLSU58+IX=2RI M<=0N;=Y276[G4SQ$]@6ORH%W\).;3FA+#NC\R<9#;1$=>!/9W3TEO7\_2R*A M=2'<^-BD*Y42A\/I@2ROM/H+4$L#!!0````(``*(9D?M]B_Q3`,``(0.```9 M````>&PO=V]R:W-H965T[,3H@T^ MRZ)JIN&N;??W4=2L=J+,FCNY%U7WRT;69=9VE_4V:O:UR-8#J2PB!`"+RBRO MPMEDN/=GZ(_#FE>6)$@9E]CD>\VHX'L=?.%`T-P$I`CH3(+E*P(J`?0E$ M$8@O@2H"]24P16"^A%@18E\"5P1N$:)Q.X;-7&1M-IO4\A@T^ZQO<7C?P>L^ M2!H0&9*<]4L5B&JN M[)9T!7=9DCTFH#$G$F>J%!J#`OOFLB<%)$8NIXTM(#%\C$/L-*$'"T<3Z--G MMO=#:DCR&-30=DS(_KM5;9>#ALTESB$Z5Z!QP7U9?#+9M@0-7TJFBO0Z:_"/?+8;H(,-TF^\XOG["]02P,$%`````@``HAF1YR5?JU2`P``/`X``!D` M``!X;"]W;W)K&ULE5==ZIN1BV>VC_MC1%VU]*D+^E/3E-W?!:W9>19">-EXKO8'/FQ$\VETM=M6#6W[ MBK5!1W>S\`$FCP@-$(GX5=%SK]T'@_@7QEZ'Q8_M+(P'#;2F&SY0E.+R1I>T MK@LZ:BTD8-.7[>*U:>3V/O^2Q,G,;(&6`K@:(W#5(E$'R80!W M#5)ED/IZP,H`^QIDRB"S)$5CLF2J5R4OY]..G8/^6`X-"!,![P82P1R(_/9R M*2LX[K[-H2#3Z&T@,C"+$8,D)DM#PE906+>/$Z>6$8-].RFS7&2:B]S9)(OL M3D)4SNY!E,Y,SQDJ1-*<*;O!=#,>8L5#-'O(G2E[)+J46'X^=Y1;CG*C-JDS MYERK#<%>;@K+36&XP4XWA=X"J/#R`[$]V&+#4^;TI$!CZG!"4H^.@_]&*!B> MB/-A52`5E%DC0Y&!`W0#MS9Q"28$8P_MR-:.#.VY6Q,R-`V5=_:Z2>;1[&"/ M34@,.BLB8BN!1262/ M.P1?#1C94P>ASP-6&-5UKG@C[4VWH=U>'DKZ8,-.+1_U77>O!Y\'>>ZQ]A
?Q./RT$;L8%9\?+6>UZ8)S_`U!+`P04````"``"B&9'-0G4S)P"``!- M"0``&0```'AL+W=O=J?Y!Z(2J+:.!MJX:U MHN)MT+'=/'P$LS5`&F(0/RMV%LYSH)-_X?Q53[YOYV&L[/Y02GWFV^'H?%*,;9'17^'C(`W?9YU8-LP5\(2C'PGGACL>E_,G)Z1<.ZO>G2(MCP4RMM$N%0=SC2W'>>2J:3C!^7, M0=UMADG-=E(_IMHRV^WM1/+CY?(RW*#*OU!+`P04````"``"B&9'P#<%H,T# M``#H%```&0```'AL+W=OZW;I3DOJE043LGW3XLO]'$#<2UI%#]3?JD&VTX-_R;$>[WS??>T(#4# MS_A6UBT2]??!USS+ZD[JRK^[IO^N61<.M_ON7YO;5?AO2<77(ON5[N11T9*% ML^/[Y)S)5W'YQKM[\.N&6Y%5S:^S/5=2Y'W)PLF3S_8_+9K_2WLF(EW9>`'K M"IAM`70%<"V@WF2!UQ5XJ,!M;Z49B$TBD]6R%!>G.B7UZT$?E;RLFZC.CKK[ MJMEMQK<]^K%BC"W=C[J1IEFW&M9JQA0;3>%?):X"&*5@B((U]=!1P'P#0`V@ M:>!U#3P=LFAOH]6$K09\?TRT&8IH&/DDGH?Q$(RGP8Q>9]UJ_$X31G$TBC.4 M!2RF(9G'\1&.K^$$HSC^$`<(\V$49RB+2!B$%J,3()Q`PPGG&X2H0:B]+-%\ M@P@UB#2">.R-?M8T0$8'+1H^'`$@?&'J.O44R3>/'2,H&,-B(X"Q99`\?\` M48*C@]SK6GJ3/M3"MYW(GS:NIK)U+L5!1)F%=SO1K'DUG:U[*8XV"A;^[42S M!M9TM@ZF.."HEG#`+%K@4*+^O2ZF.$AH8.%C760P:-PX2VCH')Q@-+X#,<'\RR,JXNPD@*,"F(5)=9'!I+IH M?-1,&C/OS1<@6)A4%QE0#!HS"LXW\.[^G,61`_Z42?L/6M_JBW:HLIT8`PX> M"*:LV@,-IT<3$V--9SLQ!AQD$$Y9MD<*M3$R3HPUG>W$&*Z!5G1(]8'I$AP\ M$,];Z!F)\`J+.UCSR7EY:!;/*FL"W7.SG(:/0_2X5C=Q>T8A MJ#/-FI[[[Q*KY2DY\!])>4B+RGD34HJ\6:C:"R&Y(B*4[^N>%W<7/T%4$L#!!0````(``*(9D&PO=V]R:W-H965TFP=V?%:GI=>F'_FWB1W4\<3D1E$70\_950UI6T=;K MR&'I/X6+;0@E1"%^5N3*K'=/FG^A]%4.ONV7/I`>2$UV7$I@\7@C:U+74DE$ M_FU$/V)*HOU^4_^BTA7V7S`C:UK_JO;$-P"W]N3`[[4_`>]?B4FAT0*[FC- MU*^WNS!.FQO%]QK\KI]5JYY7_24#AN8F0$.`/:&/XR9$AA!]$.)/";$AQ',C M)(:0C"($.G>UT?DKLUHM%B1 MXD=FL="T0#P2B)5`;`2RH56'&B)$=Y MZH*M;=A#DH(X0T[;&IS7I M'`(``)T&```9````>&PO=V]R:W-H965T&$M-.K-B7&*I5KRLR]:#OAH2)3X41!D M/L5UXY6%B;WQLF`72>H&WC@2%THQ_[T!PKJU%WJWP'M]KJ0.^&7A#[QC3:$1 M-6L0A]/:>PU7NX5&&,"/&CHQFB/M?<_8AUY\.ZZ]0%L``@>I%;`:KK`%0K20 MVOA7KWG?4A/'\YOZ%Y.M"^0S@?Q_O]IB)K"8.,B=9;"8U)[N/$^3<.DLQI.XW;]PUK@_ M^HLI\+-IAP(=V*61]I`/T:'COD:Z"\SB6]6);>.\RY1%B\_P'?-SW0BT9U+U M&-->3HQ)4`:#%_59*W57#`L")ZFGN9ISVS[M0K+V=AD,-U+Y!U!+`P04```` M"``"B&9'6,?#)*`!``"U`P``&0```'AL+W=O^;YSH4"J MDDR\ADM0EFN%#+0;_"-?UT5`1,!?#H.]B%'POM7Z$)(_S09GP0((V+F@P/QR M@AJ$"$+^X'^CYN>1@7@9G]5_Q6Z]^RVS4&OQQAO7>;,91@VT["C$H0ES#U%? M(>83A'@#=UW0&QX'B1J"(`K.QC<=KDRJUD3#+A"DR.B_NP>I+ MV"I;+I:/-W;(Q0WW;`_/S.RYLFBKG7^L^$ZMU@Z\6/8PQZCS,S0E`EH7PJ6/ M3?JM4N)T?QZ2:5*K_U!+`P04````"``"B&9'OFEP?(0"``!H"@``&0```'AL M+W=O]'6K/++(3PNO!2[0]"+43S,KKQME5#6UZQ-NCH;A9^ M@>D*)@JB$3\J>N&#<:""7S/VJB;?MK,P5C'0FFZ$DB#ROU.2`E."&U5S_!YL3 M%ZRY4L*@(6_]M6KU]=+?P8FA^0F)(20W`F0?$E)#2,<2,D/(W@GX0P(R!#36 M`1L"=@A17RQ=ZB0)A*>*=$I'(@Z\OU5#_!?O4\3U!<1F>TQB,.##+&Q,XL,\V9C4AUE:&!]B9:MD-TPDL_6FG#@I)UH@-0+HLQ^0:`Y!"K'X^Y,I!QC;RGT%E3E"9%53N#:K'H-YJDN&1 M5LBQ0I95X;5"@ZP*0".=L..$+:>)]ZVR,'B$2>Z8Y`,!*+SI+/-!.@F,2Z9P M?`K+9^+U*88^(XLV<7PF5D'@4Q6W22&[N[!N\P$:4UAT=V'=U@,\IK#X?PKK-B#D MEA4>(>'V%A1W%]9M&[#[QKN#+@RH3Q@5OHRCP0?X2/;T.^GV5YVN)S_`5!+`P04```` M"``"B&9'6^>O4%0"``"Y!P``&0```'AL+W=OB@2$WM`=^/O095K5OD*O9&BYR<>5VU^(TZ[-PTB/Y=X9KT2S=PKX'W MZE1R&?"*W!MYAZK!+:M(ZU!\7+JOP6(;^!*B$+\JW#-C[TCS.T(^Y.''8>GZ MT@.N\9Y+"226"U[CNI9*(O.?0?264Q+-_57]FRI7V-\AAM>D_ET=>"G<^JYS MP$=TKOD[Z;_CH89("NY)S=2WLS\S3IHKQ74:]*G7JE5KKY]$V4"S$\!``"-A MS&,GA`,AO!'@0P(<"/"K&:*!$$TR>+IVU;D-XJC(*>D=UB'Y/@4+`:=21"@[ MHEU,'=4/HJ.7`L1I[EVDT!UFI3%`8>+0!MF8D&!$>,*`U06X=[$"!AW8$JQ- M1`RM'IZ*;&=$9FV&DV:%BA_J*D'V7`!.!*`2@$H`^O<>6]T*#4ET%1`F<6:# M;1[`9MU$$S>1Z2:RNM&02%><0C](K6X>P&;=Q!,WL=%<\)5RDHE`8I23V)N; M&%V#`,#4_K*92L#>_\2H&$1!!A+K'V,[(S5;5#HI*C7Y0?1<()L(9/_;UL"? M7A'^T\9N!LS065]^)ID\XUYJ,#VIB<"07R7IO$5\%B'5CB M&SFEU#UXDR_R#IWP3T1/5'B-E47Z9$0CH5Q_T4478HY.AYJ?.1RF\AN MZ,FB#YQTUT$Y3NOB'U!+`P04````"``"B&9'"3@[&2D"``!Z!P``&0```'AL M+W=O\8>U.#;X=E&*D:""5[H22P;"YD32A52M+YW8C^\53$:?^J M_D7'E>7O,"=K1G_6!U'):J,P.)`C/E/QRH:OQ&1(E>">4:Z?P?[,!6NNE#!H M\,?8UJUNA_%-EAN:GX`,`=T(,/DO(3:$^%%"8@C)HX34$%*'`,;L>N4V6."R MZ-D0\`ZK[PDN)+Q7(E(YD,O%]5#_(>/LI41Y5("+$K(PJQ&##`;Z,&L+XT-L M;!4O9FMCXAL&R"3>.,B)@[1`;`22^P*Q(Q!K@<0(I':5[9AUQ*0:`^<(Y3-X MWRAQC!++*+LOD#H"Z6>C9HY`9E60^Z*NLDE4E.82EMXWRAVCW#*:W1>8.0*S MST:=.P)SJX*Y+^IF/HF:9)'Z^7#;*2Y.;=P_"X*1N^^B:4DSK]7:@,R7%L6/ MFOVUR:%E!OUF<+H`R:->[@Z$R/+R[O.U`W(W.IB<81T^D>^X/]4M#W9,R.-0 MGX1'Q@214M&3K*.2%^%M0,E1J&ZN"AROAG$@6'>]Z6[7;?D;4$L#!!0````( M``*(9D>64)Y!O`,``/D2```9````>&PO=V]R:W-H965TI;#^T;3AUH3@'"(NC:7]V.ZUM]*NNFNYQMK-V/X_C;K73==$]F+UN^IZ- M:>O"]I_M-N[VK2[6SJBN8L%8&M=%VO,X^X//7Z6#.,3W4A^[B_=H M2/[-F)_#Q]_KQQD;/E^\OZG&VZ? M_EO1Z6=3_2C7=M=GRV;16F^*0V6_F>-?VH\A&1RN3-6Y_]'JT%E3GTQF45W\ M&I]EXY['L2=GWFS:0'@#034`;P!G`RZO&DAO(#\,TJL&B3=(/@SW@Y.>L]17Z[.?;H)&5O?ER*7B_A],\)AD M"O,28!*8PKP&F#,B[K.<3%6@5(4S!Y]&>ML!(`?@'$CO(`MS;,8<1TSB,%P) MD>7\=B")`LD@4#Y9L`"3LMM!$A0D"8*HVPY2Y""]MYX9_C*,(#A1RH.X=*6=8)NP:=T;04P@"-DDP#_(,8RS+*PJ=`I`BZ%#@=4$$DE>$5`66LN#WTDE\VAD%@4X!"-CTZN1!(YT4`Z4H M^6`Q"R#0*0`!(VRS`HM92`*=/.A$IQ0(@;#D14*@4P`"1CGAX'5!I($+2JI8 MRB*[FTY8I2*GT"FGT"F_H!-D7`K*D+"8A:+0207Y$/8&P&(&1J"3!YTV.\(& M`ECQP`EL"D#`*''PL@"AXBDGYD]'9KC[T(U%"I+`IA#T'T,@H;,J"`1&V.CBO"HV/,S1<-\'" M!75M5D]3'PJ7L(5*+%S)KJU%/DX(XH1CDL3"E8$F^21WGA`(;P/QQ>_S6K=; M=S/212MS:.S([7/K^?;ER=V5X';(YR_]I'SNZ4O:]ZBI'LGF+Y)-]O"^9[R3 M^4AKN=@76_VE:+=ETT5OQEI3NXN(C3%6]Z-E#WVI=KI8GS\JO;'#:S;4<+R9 M&3^LV9\NFLZW7&PO M=V]R:W-H965T=\,V/'3ELNWF0)H-`'H[7<.Z52 MS0YC>2F!$?G$&ZCUEX(+1I0.Q17+1@#)K8E1[+MNA!FI:B=+[=J+R%)^4[2J MX44@>6.,B#\'H+S=.Y[S6'BMKJ4R"SA+\>#+*P:UK'B-!!1[YYNW.R5&806_ M*FCE:(Y,[6?.WTSP(]\[KBD!*%R4(1`]W.$(E!J03OS>,_^E-,;Q_$%_MMWJ MZL]$PI'3WU6N2EVLZZ`<"G*CZI6WWZ%O86.`%TZE_467FU2OVMF6#WQO\P>"%GQJ"WA!\U1#VAG!FP%TK=B-.1)$L%;Q%LB'FW^'M MM%P8B"8CW;VTH=W?;O6>!5Z0XKL!332'3N-;C;^D.(X5@1$*T#@AD@L("@!\3K@'`&""<5;*=MUEV;G2:VFJ]TN9GEV$QR M)(M;.='X[GJ2:)8DF@"\I48.T:B18#U%/$L13U+XZX#M#+#]W]-*9H!D_;2. MR6>GA4=7J2%7^$G$M:HE.G.E;Z6]D`7G"C3(?=)G4NK7=0@H%,I,8ST7W8/3 M!8HWC^=S>,.SOU!+`P04````"``"B&9'U!_!2`P"``#^!0``&0```'AL+W=O M?L@10Z(O16FZ]4JEFX_NR M*($1N>`-U/K/B0M&E%Z*LR\;`>1H28SZ.`A2GY&J]O+,[KV+/.,71:L:W@62 M%\:(^+<#RMNM%WJWC8_J7"JSX>>9W_..%8-:5KQ&`DY;[R7<[,/`0"SB=P6M M',R1"?[`^:=9_#QNO<#$`!0*922('JZP!TJ-DG;^VXG>/0UQ.+^IO]IT=?@' M(F'/Z9_JJ$H=;>"A(YS(A:H/WKY!ET-B!`M.I?VBXB(59S>*AQCYT+O,T^(.D)T)\0V4Q>9S>L'423/!&^1;(BY[7"CX<*(:&6D MDY%V:8_+[5[S"$>9?S5"(\S.8;#%A#W"U^JS%GALL<,#.IXSV`\1$8X?6T23 M+"(K$'<"R6.!>"(06X&H$T@?"R03@604P7*<9NW2=)@P<">Q>"+,=.*2CEQ6 M&UL[7WI;AOIM>#O\"D*#0]:`DIL+EK=20.R+'>4>(LEIW$17%P4 MR2)5<;&*7564S&!^S#MTY@[F)>8A_"CS)'/6;ZF%I-U.!AE,@K8DLNI;SG>^ MLR^_+^^&8^'WP0?EVE6_NZ;^ZI:/?WNNW)Z'R^CLI^O MX@R^F>?%,JK@SV+Q7;DJXFA6WL=QM4R_&PT&I]\MHR3[YH??ELD/OZU^>)Y/ MU\LXJX(HFP776954F^`FXQ&2/`N.@O(^*N+RM]]5/_SV.WR'W[L(7N59=5_" M.[-X5O_V-E[U@_$@#$:#X4G]R]?Y0S\8'+=_N6L]?[F;WZS M=9,ODG(:I<&_Q5$1O(`/&V"N/RGSMC[[IW']D[LBFB79(KC=+"=Y6O_V[7=[Z]?7X?!S>NKCE&N8-T%K/D&,.1C M\,=X4W_N:ET4=2AT0?3H:#@Z&@\[IGJ1I'$17,%[B[QHS',YG<;P/7P[XR>[ M%IPOEX!BMU4^_1`&MX3WP9MU55:`C`#'QOK?O'Y^_?KV^GD`O]V^>7GS_/(. M_GAV^?+R]=5UHA2>;R#%LR1-8=O1=(K4HPR*>!K#LY.T#F$D*4_+532- M?_<-T(PR+A[B;WX(ZN.]SR;[COC#VR)>1G!I4D$D$JJ)&Z>WJ7";A5MV@`'WQ?KN!5PSK!= M;\'A5<5Z6JT+O/LZ1H-$W>=%Q?"8Q9,.F)7VH2T3ZY97\##2Z'P.0Q:`$U7R M$`=)ALM9MB&G?\Y?O#6X8GBX`:YSU]EOF>1YZYK#((W+TBQ2]MB^DRV#$U&Y MSU,`3/DMX6NU:=YJ)D`E$Z`G@_Y@,!@"DA0!W.YU_'TP'`S"`?\G?#F(UA4< M4O*W>/9]<'HPBJ<(IK1):6>S!,$#L,";?Y1D1]-HE0!L6DYTO5RG M1).%).1+H#OW<*)X`FE>MF&!>0SW.&+37H_EG<\[;._CQ MZOHU;/;-B^#-V^MWEWQGKF$;^#/Z`J[&0YPUX?YFA<*' M2[$:-_\=,-RHF-X+4X*[E1,_:W"D.(M1IL+'HMDRR4A.P\O8,F*35#9)'ERY M:1)UD[2\L?;Z(:I<)+!'8^#`QGIL`&%FPQH-*Q;YVKE MYN_B*$W^%BFG$9*`-`,EUC+E;Z+97]=EU0;"J_LH6R")#^91(C=E?Y;5OI,. MV.WU[.NX(FH73&)0W6TC"EP[8?;_?M/`G/57<7!.17\!!)HM,I(;II@,U M&V?TN;B-RTC7,SZ,K./@KW8RUOU`=GG[^^#%RS<_;8&]I7012@CMLIS=?E#E MJ#[DV12T,HLK\"G^3JJ-8EK>,G(#[*2R'0$6DD"_Q/O&$-N#_'4_(QK"MGOY M.D=!!Y:;U"A8XP(O02XJZ.C@?%>M.DR#YD>X_RP`+(1[5:[R$FG+OF\SN2MK M,+0:T#8]Q>R]@[&]WN>4FC3L`0"T_9FW:^"%$8KV>^\3],%I',^$%2&L`$SQ M_N\W]I+LLE+.&EB],2A M\=-\#JA"2VY3I`UPB6LAO9IL@OD>P+N&8:<5H4'\<`#%J7EVOWJY7JY3. M&2XXW/0I4,-UP0>#@\W3_!$V8XRAK5.3Q04>,:2H(0>LRR0#E38,7B:PNEDB M-^--L8@R83Y?\LX6!OHZK^)@&'SZSV"O@6X31,<1Z+YA\!9(^O(2KG,&TB"( M/_W@X)O'^)N0;O@WR-JB;//-80#4`DXG!N883`"T0+B`^A(3@.\![`N07NA: M$Q6U`C8"-XL_5L&")&N:?PF7#@V29*0!SK\$+%J3KK2(4#3$&=)\0<_02=_' M2_JCN@>$J\I^\)RE[NH^`6Z6+&'ICS$L\8&FSE$P*M<35(ZJ!%Z+YW!>;/&& M67*@?3$QP9:EXDEC8,OJ8+)._P9\AX2P^ M.H&#F"=,5&`Z5R/G4S<2.YZL3_WP!>1E"SY(FO[VYL?+X"Z>WF=T:'&I>/3I M%_P*E\GVD`)(3,(4WT$A9I7]X`XAC]N-4UAR1D8(@@OL`/Y(0<9[S(_@Q(M9 MJ6M_S(L/L"U`9M+7`!%F>*YJ7@4DF*,5`R'62:#P!::4,8T)TA(L$:TX5MU" MQ,O7"QA`*`NA2H+2RCT0'4!"%$>F%4\/V(YD:!)O"W?!G`*]8^#99*F,"L_ ML]YBW???#0;]LV#<'P16!+I#%26:,D8"K2>S2$[#79,A+7BC0@))Z"+26IF1 M5EC$A`0,.;X09$!DB1H8!E%B@\^(*;S'\V$X/CX+SD[(.CHYP]1<#O-@77U/8BAIP16EBPGZP(VOU[AY@`OAVRO'HG= M&FV%267/]XKN,BQ[FI`I_R5?N%%_C(0'Z0;)EG!GD!:OZ6Z5AJX04YWF!;*J MU-Y&IFN6+L'Q6+($%PU$D*C8X`*_#E'*BQ8Z1`3#D"`XBSFB4U0L8I(9E!\`GL![\-#6::477>X'T>)D*?(B3=<@%^5ZBAN=K]-T0Q+( M,MH`V8<5TGTF8D[\-_;Y*OY!7--AI?NPR!LT3;`#(-R7IH66-.(YPUT#2#_> MYWRPQ";Y+)7>XBDL\9=-',&C]!@)?NC>8;X)=-[ M&`,NDN6F));@<3!5(BDH9)P&S$,'$IP:`"]ZB))4X;<`$39VET?,,DJ!\0'B M9GG%*!L'FWSMHRQ0KH5I M/'PH[PGC@C,D&8L05RP`CISE8W<0P2[)4P;;S'!H)$;39`6ST4!-0S*=2ZQH MA?1<-I$7"KU)+,8N84D%:J.(S*C?S,T&Z,KY8"3I)ZGX`*OH`Y/H=2GR%QXB MHJ@'*1HVSOA:.OHXK@?Y&.X2$&\6+2.TJ$2/*"@3/'`89U&S/,#5ZSQX?60" MI)1,1(PB!`N'Z\TRHSG(4+5C4D,ROE06+5`3+'EO$[S6@/OP9+H1OP!(("5B M5D3:4F/DQ!4,'V&);03Y\=\ MG:*@Z5`B!#I.3%*`G7H.1T@Z/9PRW%6^7W"AF00#W%.00QWO(MIVRKK%0NG; M,H)+&2'\$[,:1$\R2I,Q-;=TS-4O^DV-?+G$"X=B%5"M!.@3LESQWQ-?SE,4 M@IO^WKW?W*4WCX`G[C]:#\W\!)FWJ&5D?*>"-R3<17#]*[*-PH7)V$J:E?#F MC.Z-/660#"H1P<3"S'J"2H4X?$,Q1]Q+*J+>@(I'^6,F>BZH^;#X/LK8)%;I M\LE"H:)&Y4IF.)2(FRZ)=U0O9B^R=L+'+]^BG6"%=C@V]@J]88D7.0D;".B2 M$8Y:*1GA#[@&XZY2EN816.\S6LAM1"2P_R1C#?K!B%#Z+@V-I"E'GF]4!13+8#D4^H:R M3#^XB@O2K!T3'P%JGN=5AJ3`L0GRD=&\U@-$P[9M&[1T[H$]"I1.05Q' MT*U`K%]'K'RRAW0JO*I8IZ+8%O%"_($T:3DMD@E;>^E*X%2WB&4VXN):S;JD M%Y3HT233S/4579.?<$5I$C^(+4.<(`*&TAJ4D1OA[@ID:2`VP=Y9POW`M,L% MJJ`N^B?A%&'6-.9`R4=D>/!T&7_AA!6Z--?UUE-_KURAWAAAKAUA@"@ M(.$OO:/%ZW6996MX]EV,04C(+%_`CD#3/?JC02I$)#0RQZVA._,$E7&S%H`Q M`5ABF_`2$XZ3Q1QTDMY[UF&OC8GCCLV/@$O&5M1!=W#W"'!4^VMH)AI,Z1`\ M&L.EX(%,\0%'*9 MV[89LOVU8S%&8B:WD\J\,[4,ZTO$/,AH]VM8F!)ZE[U:6*KF6G;Y1W4?1@7T MJ;D7#@=;1*Y!/O'J'I8/Y/M9/(T<@X?\:A>09/>LU#:(E`,$M.2B0`Q"P)J^ M8?(Y)2&2]6)W?X"NXNK+2P=Q^CUUOE^I\_W.\9W?$>7E6VEB#Z<;8[%U99>Y M#&1E&-]$]/Z/P4L02$CC!)D+91\TF-A10>1I1S"%<&,"(B#JZZ>;#S?#ER1F ML$+4?">N$#$UT1N=I[`\<[1$!V2KN]%TK9D`N M*=P[/A_SA'698!:K<42(-CIMO0@6DD?_L,YBL80^QC4XX]K26+5KA;H,UW4I M6'(D+7VFAC1:U&@P..^#AI(@V\H[CE21"$9T;Z`!^3S%\#81-AYCXKPHVB"2 MEN9N[3JAQH&WG07#"J\S/,V$26]6%Y@<$!$XR6WV-[*\N*9[/F88"RWJHY[Q M'M,OUX[UI].O3"=.K(`N*_K?562WTR"S+3[`J3.%)U5-6`;'.1B^#=0]WNC3 MK)83__:Y`3I.&.Y&.;!+<*?RG27J/"H];\3V&9*,#$4,)?AF71!T`<5*?_!9 M#B.1SN_/W.^Y^O05(`6<<\$$VT3IO[,^$.30H.J1,CZU M3\/VR1QF)8)G2:YNY,O9`\XU"[P@S^>.N?V28W!!5`+)]]GEN^=LN^_VYS@6 MQV_+_;TVA-0)4T7G&3'JT0X\D'[;-A+HLA.X(X'."7O1!1SBQ4//<4-#H^NY MQ_0T'$&@W]/LB\#\4L0BN9?&KLMHL9)X(3;Y!.C_8SG#B_`DJC=#U_D\H1VI M^%>6.4:!J6Q,E(KUUY($9.!M2?PH'&V*HS,K)[%AH:N+2#Q'^X#'?EF4,FH> M6UZ15.(BR9//%D\;IS5-"F`-2%6F]`';;,672_Z`)0:*ILD'0'Y$ET4*U#4C+*7 MK0D%"`(VU4"CSDNEGXZ0@N`YU,`'/*Q)GG_P95+EOS?SYA+9G%S2%_[;(=HG MY^N"*#LH'>D&;62T>>9)K`89VHTC\&FZ\$1L*4LU"AL8`EUIXCN'<3/7)9[) M.%'P/G[H]K5(9RV\I^E,>7298-U!W!_"?P/'C(J6]*@YK*4X M(TD%`2:74B@5RBUNGH]/B.B9F?AQ`DHFV[ZD0?]X3W]@S^K*-U8;(7K'<\SABWS'J?Q$="XE'>5G+]\GG5<(''340'DM]A%,UY#"?/K'AP5D+6W]TW49O]I7DOZYG"WJZ']RB0.?&S5C" MJ+&`O"^T_J'+A+R(D[AK:S..L)"@(R"\4T-'@7!6XGLT"Q2(8W`#W7=TCR`O M/F+#.QE>)&B]_+Z%/I,"INM,2O<">,A1SDPU MN,T\.4O05@4B%5K!8K+R!&,,E7B!$5$UDZ4:`$9$,@$@YB"JT<*)7$ MJL42C\7/$!.U[N-JLU(/"7OHD)H1<-GD4CXE4?%HE:[+HWDAZ@PG[7+FYBQX<#S0A1F.6`>3@?!W>D1&;791FZ\IY@._,P`5?=C+7UZ M&*SRV0=-'-B!#:AN^18M((@7ASZ#*CHRP[R[7+]S46D6A6CQ%*8^])=?BE'D M'DWKL^_A`7C"D9+8(<\+4J,PQ\&0C M,1$P*6[I('DXM$HT,"")AB4YR?4WR5K]&4%)UN8-B)$.:&F,NK"Q_ MY&AU\:TS/.!,G_8^_7>1LM&W'*/"B7>`-AXG!!PDNRZ`T'J-SBD?&!H2EMWC M0VX$KQ=I`_P'5DB&$9"Z*(B`[7"^8!8I?DY1GB;3C8O<$I116U4KS$+9(=.) MDDQ3*;OTHK)RAR`A"I]N+-J#N3E:H3WB8D>`.QMD58\"1"6T@LFFL*@\;KSONO.'Z2+5;Y8+@``\$T-*[$TU`'3VL<2_A?K"$ M*08M+.*C?'[D\$*&BH1A;W_(/4DQFQ545\DZ!YH@J>_ MV4P(G[*'`W.L&M945YAU6"F@O@3*Z-[0V"0>(]$F?):I8?*$FZ&&@TFL@UKM M=!0&B;B73.Z8?5Z1"?^4U<'*Q9`SV)9VQ'=1V+6\Y25`CGH M6IB#Q-,Q"U0?DA M<09SV9Q7190K8G5)S2SM:247S9?E[E*.0R7:O1TV0K[/IC^,,((-TA_->VM= MFO[:.7".[SNI->BK9<.TD`F:++2GTBZC*P%N%8Q8:U/AJ=_CM-9G)#A?N6[; MGPR@O!LYJ^G5KMN7@A;+8(%*-B-&#!0HW\3H)Z>T!/D3KH2D_X2:2%QS34[F\Z#[ MIH9G46D0`[U=&,X9H?_V*,5(_PF'"*J17(']K7`RX`R&N5F_;?,XMV*5BRY? M\^A$MCDRMFA,JD0E^>=U5,`$XC?1*<,ZG1O8%(8Y@80D"J M]92C/UR*FA?SF)./]MBEO;:PM/>W8YW>O0./M_KJAH3/`F&HW`P/H9? M3D;A\?BXUUTX!A.GSD;C8#0Z#T?GISTIH;1KBT^"BW%X=G*&CH7S`8PPL%FO M>VZGPV"\^-Q.#@^KWE[-/OUX`2@>SP,#H.C_4_D>'0:7IR?X_&'P[-1 M>#88M[F-_"IJQ*1\^X>)1XUAX]FYP&8\*=LDLU<+5!0'1\U MQJ!BT?/Y%ZQH*Y+A5<$U#<_"$_P9CD_.`+-/T!QVV589+=20%K8AHNIC-KSS ME!PE M'KBEAN9X?@]7YT+?U!JI'=4:DN/@,",WC$VE\"5P7#33J?L!-\ M'^$=#JYU/LCKVAHOAU8^9(02O$-"/"HK"?G"`"T24%M$NO9LADS+K2J%\\D4 MHBBHHN3RA(F-UK'Y7.:,X3HY,&$%9PVKX=AM*LTDP>\(((S0GHL]\=,O;7[[ M3W^W.K6^B4^7H+#!B!)Z(U9K([>A%1%L$4B[MC4[JJ!LJ-<4D#1\"WG6M)!2"J>X%5K:.UG,I;9,EDD:%6RHYT)KM>N;Y_72D38F9Z#5YUVL>D^_Y%#Z/E:KEI19[E:_&!E!AI M^BK:"%W`\6UHA_/2K400E%*0Y.#3+R\N;Y]AN0ZI8MKZ\/L5J3'P].7M>WSX M==ZGJ8X&%Z$Q)M%Q7QGS-?EV;/#?P5V^`O">#DX/92!W%`[-\S_#2)'"NG>= M9#!DT"TF1,[[AUDJP9@H*^=\]P"H2PJ2PP@C8KG&T%RW,EJ_.G$0,>H96[?U MF)!'0DVP0/9Q1HCD'#E$BB'G&28'6[C\%GDF<42B5"77TYC%R@JFO0M]CXA;)Y\SI70V%RD?96"E+B/"F MM&W8B%.2%*]B4"<,>N^,ZYM<:\Z` M?74'J..O[2KDV=ZH;XA0LM0"`XW\^(ZXM3T?VY7Y/@8BW?7J71.UC!))5>O) MIM$5&\J\T,JCF@O167PC;(VM/VB+@>=CBVHE_KV'NI(6XFW_B6&5HH. M_%,LL6>N9=@$(PK'9ELO%V#0Z@NFO@?B(,H,9!E`:11K!;KL-W)N_@$&WGU, MI(S"H5Y^D6U0!"R`3J-FB?D-Z-#&@EF:."(&.3.5'9?E%@R5)6'62652BX&, M@45Y**32I&C'WHWG._J39IEU)7,:,[[K,G`@J(%K9+(\2M&NYWY]GX`,!?+_ MA@N/%9NNXVNL_ON6,>QF]AI0X6!0@_@"S?*]22/4?9J' M'+!SA1J\6QCUDT]R;BZ#`IY]2-`8T#1RH#E&:+YOB2TV\X"P*]G$$TR&PSCK M@,*J=40IE[H1G5Q?:UW$/'7760;(@>70IZ^]1;)R04(/B?RJ_62)K7$6%@B"F/\ M'X/31&DR^QGI:*YFW)'H*A:$8P,=\05)-MEHW=U$H+IS2 M\:X77-.Q<`\H.TZ`X@^=#`09NX@H4U"CA5+%/1!HJ6@])>IZN"J,",D[AO!B M!F8SI4*N!%%Q*?BU*.)%I$DXEGU_(7$GS9,M@,BID`?#PBCO@>O,GY.-NEBQ+7=>)93X,.OWC"I3[:0BVA,=U[0:R6AFEXRGMKKLB+WE)DI!U+:^8Q5CQ[GU?=N3.YJ1^KJP?`P>!*#*XL+_]8Q#@%'=T-M"?7Q$!S@=GX>G9A?VM!P>$GDTC+7;7/M1` M%;7O3^ MA-6Y,*P;!W*;ID83C,U7C.U*-G0^;V\(]V?CJKU3T=[79&Y(0.I96K]'/-^U MFT;9NVZD2O8NVQ,KI;+.*T?<<#9`X@;01RMQ<%W$.R?VUI3UY\(]V>(H)2L) M"S9.^XNPHX4(_:5YX&&;P).Y*["RF*F9V\C;\H90CS!+SI+)PA9TTE"/4/D^ MTN@+LF-15CF&+7Q^+)8;EFQSF3,W4QT0KA"O4`=$-&#'V'J?!&.,21H&^Q9^ M;FLMU_G69SV\R]QX#&O8/@`517YIBR+?.*G_V%J9]$`NLL8A%"G6.S%M(^AU M@=!SH#*/>*Q7H.<0I*XH30SK9))MT[Z=IO&"$C<;A;?"P*LI+(9`*4!>H'H67$;^3`GM3Z:4N[MD-XT@GC77;WI(D"O(*8TP&`[# M'4=I^VV:.I^:6AJ1]3Z39"+=%H;(3`JT,:!4(V88-X';3<7$"#)T1F`(BT9Y M@'J=+$OK1B[S@@I,YZM5G(IE&H/-J*1HJ:6,^SP[%RDF"KC2KCNXV%D\Y=0@ M`9?9\.UZA=)L53JUWTZWY9?Y00XUZ,H94TZY+8CP+0^HL,&%2;`)QO@;>*3 M]DLCS[X$[0%3V-B#101+Z>;G\RU01/,:8R2YO"_7BS40J'.-UMH3K8'[+H'U M9+/U,G@C"!Y1-Q]8'KLY>6`2NN13#^:/XD;3X`/>8$R2T'JY0MGO<0L:O* MIO^5S64[R7U15>4%J*'EMZ:$1$'$"(N&4YXX'=R;:963S_#,/3I=);Y)6$U6 M2V9,#S(II7?'C\P1^TX$A;-5FVD]GBL+K)!B+0\BTY M'9[J!I@491PQI,DOE6&K(`*":('ZVBJNV!7,,39I$L\E,PE.;X4NU>%0I_=+ M*#Z+L@_%>E5-L>?[S!CFJ$2I]QUB@Z+:+5'V=3N M->/K'Z)LC6=WYDJ=^U":-*[P1%NH#(<>*+E7U.>J@DMLGH>!/J1!8N74F&=GXOLQ4Q"O`#YH'1T%)9NB& M<32G;7W/W:$9QRS&(?CF`N649E(LUH8D^]T_:I-CSQ-O#CZY.CZWGHZ6:@9@ M@'0^C1NZ3$T>O-O1(6(+XG&YOS6YI6K+GT(`8^U&N727X/[O%@]S-Y?UP[749"$]PK0FKYY7>:,I]MJ'#["3D2L;3`J9I]/!#"K%F)Y/T8 MVXJ]&^IJ:LP(&]WH3,-O51OFDB&J75#0T#O94SB7"#(\0)`1RQ))":W,O M8!?$VRVHV0]J*I6J*9JRZ63#$)JBX5.0'^)H/9X'(M8:FVZSR`FN4"C%G58K8F, M.N2\IGY9&E,:"UI("7E>&LH_ZN6I5>,_QV+\=#4E:E0"B:W01EJ!5/;62->I MN0$=XIKE3'9`[,(@'6XY,$NJ8:"[)B\QH0-@ZR@^HDAP(\=[4Y<'[C`JN^M4 M`AZ]%:&1QCUEBGR&"21VLB['FI+/D4T&MRL_4S[V@HM,859.)V43(V,E`K4M MT3"/9Y1:ZE%D-0#36H0-@-%3NE1:IDU%3I.Y]CC$QZB&N%95X=0. M<6KMM!IP''XDKDVCHE(01\X#^1:ZW/9\9D$%:7R:4F@Q&0OKA8);2%%C.J=7 M%K<6"Z7"D8=DI@09MW:EVR^'4@>?7P#Z/F+J[!K4D0V8'*55O41@A]M(1#-'J$$%Z?3IXN%.XHD.C=68HVI*=QT8[,,.%@EDZHN M',C,5G@Z.&ZJT6QW*D7!+4QM7Y90:I90/J`1-I+29M_)W7XNW?UTHZ#"XWN7 M"XKE.?CTR_.K2]L]ET[,J9,2J.U5=V%X=&")RJDR(ILS`W=85:M$*^=F&NNII229%?[HU_N9>!X":E11KMB1YN[+>2OB3H'2^AO' M1H%5:J01NP.Q@D0\O5P\)&,?DGM[C`H1D5J3C!+.N(F@]T:U$3549,V`YO(5BR7.NAZ56Q::,_<1U`$\PH&ODC$4J[4H<% MJ'QW>S3V1%$AKIBYH@9Y[$VH=\UD5Y9KKC2U(IZ`J]1B:Q4GZ[6LVW!@4[?! MWX=*6[9O%ZBR*=5+-7DI)EM*_!:QW\2;AVW?LLUMX:ZB)#-2*4S4O(BFRO8. MB%\APR,V4-H.7V+VPN!!!4&]@B@%G/HIA\[8A\[NL/\+]8-$PQCL)M%J+PC*0.O67%F`G)/#`;]MHC#@ MXE'9O]S:`T?G*N/:DK'&"]EZTK9+RCXK8,%IKL@VDL)<2D2UJRB<$[!H)T)_ MIK4^G!)H$PS.0'AQ$/,A[H/78KIK.C53G4-U6Q!/G&XS^39\D0=8ITNK\/^`%NPP#57L3H*6B:VLY(F7YN:V\UMF9O",%+'-N',;(.@J<%: M#2;BHX\LG:6;9&AF**CNZ[LU=^6'.%X)'A9L]9QQ5O+^)$"?Y3@Z@Q0'7+)0 MM7<"@%EK_1:'8A'PUFML9F;_M<63N;5KJ9Z=!%%1:O5B./Z21-0",&F5+!:; M(_2V?OJ[UN,"N1-N2C]X*=$!#B=[\\_M$!_/I".ZJ^JD_!'59.%N M"VI`'`ZHJ\+=O4G<['*2VN*RW-O!2?W"C'^]]]KZ`:T=%"J+-20.N>-9[>:W M)(;66UX5R`[\8C]&?J&N37CYRJ=N\%Y/.MENBTWK76X=NO>D-SH^#L].+W8\ M&!Q1)!@'HSWI#<^/P\'PO-'++U2-1#8H;4:HY8\Y]3/FI%/Z3`!ZPOQOX[ELJ%7BUB]+=PH^Q:91`N MF\25;>SCDSQ;4V5?K:&)N>6P$7X<=P&TQ*CHVG.>!"ZM>]6O-4DQD"/`1-RN M2?/RW,UOV:Z(HNU[<%9D2UZ*=0942C+CBH*O915%!1V`Q&$*23:.W,E>%CYK MMA&J^=#4/QGW3P)R(@[Z8_CE.,`^*":XMJ,4%KL0'KFUC3SJUHWQ0U4O1J/P M['QH1W6_'H4G6+3L[,07L[PJ-)TML414L;9DD9Z13X6\/I>^O#;6ZBNN@W++ MHBR);5S*Q>Z\J];1#4JWP7-D51J_C$WMIO@GB(:,T?AU#RO9G9V=4TJ"."WQ M')X`S"_.S"?#L]Z)D/V#T6%P,#ZTM0<&Z./MGU\8#R"1O8O!.+RX.*7'13>2 M)T_'5BC%@<=GP_!X-)8GN='?D!9P,C`?G/:.3\.3\V-OG<,1#S@TGXQ&/7.4 M%,1_1Z:TUO!DK]YD,P-,&CKU8%F]6A?1+2UGK*DF%#/>E\S='G;=5GR3YW!C MLP_*O1JX_`?_KX='^1_V?[U6_)>S;V3/LWX.&.GT?6SFV+<^M8OCG-+BVU^] M8N<(:L;"AMY@=3=\SKK>V5\\YGXAOM(_M>_S*2.QY?=9P:C)2Y'YV$0!-!L6 M85?HSO"CLDAJ&V:J`K\=8\Z\>V&CF5 MS3&T%XEOP.AO-BFC3H&$E@P_:B`C$S]O2@MKM=1B!=%75;2%)$%:@)D2KNL5 MC@_W\024AC<2,CEVJJSYAY!9#N#N\CBXM!^['6\^X[A(.'0/K!58U/?\_R:H M(AOL!]*K`.Z]7_![KUUSJ[0EV?U"NU#:(>Y+%XS5P"B[@,KY._5VR$\EQ4.= M4'Y8(,@FU1&,>,01V:":F$7X6A69,8Z!\V!HZ3IE>XYUC3FMU2\Y/FUX,1[[ M"[<.7]X?*>,L&2]TL'!!%!R&YFR65@& M=:8,9<74;(50DZ"Q(I?.5-NZV>91I&DR31+_(QQF2"$J*MFIA\4V*N!O,4S0 MP)3"H"RR-*Z"9!R3G3!?:R[VU/:BU'(%GCV/AJ1P#![6HH37'J7-%$C&$@-6 M4M@P:%F,DV/L%]@I<\EL^UW')S38G5]I]F4.;]4LP3]>!U?1*D%E$PC<"(12 MO++$E"DH26TVZ%!#1[-JE1HG2RF!ID0UE5$1B<*?+72*I5I#AXG:-67[#'=L M-@1Q(CZ%)B8>G22IDS(8EIB?^;>NA=E7]EJ2"&DHDS743IO,Z':V=:OQ:3N- M`_IMB2%29P&G5;AM$ M<[4$-P2%P#?5N%!7PJ%0*.UJ:RU4,0:2F*P4NW:.EO_B+=H)0++EMF8M`=2V M'0U\@W?.U!*2VZ25!35HV8ML/OCT"_NB+B_?4J'"FTP"%SEN%B`*2G*T<.FI MFU/[ZPX/=3"OM;93_).48Z*Z-B/.>]9J;EX)7S5BH4">;FI5(;1J;=CNJ;*Y MQ%BJI#3&_YUIPZU]UVU& M/SA>(7Z7AB9Q"Z,(C&F&BNPZ=<+ZP95$7B5NAB@RMCROT"6AL4YKFAZ/S%;( M,HZXU@UNPVN#ELX]L$>!0H3(2:X8Z7*_+F:+"*)=#!UOK",+X1O7ZE^ZLOP- M+@MH%'1-?JJ%<)*ORX"A5(O7+$!K1\+=84%P^GE-Y;S4[D\G:H%J"^=1,>*D M3&.6-S1TL8R_\,)QVFBD].FOZ\QC0A2T88>P]55OG2$`**_)]^4>+5ZO2R[T M6`ML&PXPLDV0BAI9LP>\I=9S4VOC_LHF:))QG&)[\RRNLQ9IW7JM_:5V?:^V M;G(::/'R=C*%P,+S03F_AI6F%+JEC^9@_?9:&(FZU$+R)*!:KSI7!B+#FV%A M[8520O>:L>N:,TT["YDI6D:VNVG;-FT/^K;%%-K`U9&62K?*?[VVT:_A>,H7 M7&YL8:F:0V?)?-V'UR"XJ]MS(T_&MG`28,FO=@%)=L^]CB-"8A45;)> M-4OX,LL,5D@%,=U:2R8>@`B%MIS+9I;KU=%42JX[>*V--/T5R%B-ZN?>C,16 M'B**/=Y^.]RS<.09B6,0,)BD9Q,>[[A"3<]$8K1I\O-:[I07Q`/4@I.7P,-R.2`2+J\2.D6U/N=XJ9TS*3O#_JC1H$&K?!# MOUS;"C][/QA<=18)HL#02B\Y:NNJ5-CEF0JE4JJ-*NPRE[)%H,J.*E`D,O@, M**G6C$-R MH?+,22_1F1L,RK4>V-+X"*]+5<_?F4JXO^IE;E]"M7@WM3#?US>7-\^M0/,L M@:]F5.?S$HO.8GZPUY7IN5/AXI*]M!7%*E-H+5?N[[1F^2[T;?TOC;+X*#W* M384>^XS8]F@']5CYYDB@N6,0BL9">P6%Q>G9U$\J($%,UUCEW@U5AMBSS*><3L[-GRIWCC%T3^\_& MC\)DISDUC#:=$K7(3L!%Z-$XXDD$+!@:'5?R?H!ZXR)1XJTT.E;#G?VNN'YW M6^[6T]$S!K^W%7'(*DX1L9U+IFYZN#=64+FEO=;K\(@1AE"9\HF33;T_9+#$ M9B5<.5\T79MSY3K)Q2P;F:!#1VY"\!RZC3TFF,[I2=@J$MS,FTM$=,`$"NTH M8]\.W>[QIO!I8J,%606:K*WAQJIG M>SU$;*!+N^-P=-S\#-<[CR-JQ>CW?6:=RWLQGV,,R[ZN?U;O/;F+4,HOUBY= MA^HB:%O$@%LKD7U'LFYC;?!-"YHIA15Y4);-O2:QC3IT7"".J\$8?V+'UIQ^ M/EL"*\P"!>(8SU1**Y7`:1"49TX,QOMT^SWO=6A]^CH)S7 MTZZ[9KI)3&(NYQ2A"QVYR2LYIZJE7Z`.38U[A((TB4FC^\P>CR`-90\!&H&< MANG$[;7]'B#M9A67:E;2TD6.+[!\VIV91G$7'V,IL&Z_,;VXRUV);7YO5]NE M".VEJ8TW\+QICI+-JG6`@^/+>D6,L\QZ97%J[(,62\O8KB]^X$XXQEK<$@D.QK?C[G.8L=:)BE&96=:$AV0QK:'PNH]VG6)5T3N M7IZ'^*.0%`JB-D.1A)K9F=L[BVN2B+N"0BF;MYEB+^GMK;.!`$H6E M3JC0PTSR!9"73`^*L>Y<;521+LRA$BZCL]-3]T#!#=]#$RV2QQ8"=8!,NJ5X]Q48-+/]38`EJV93R1*VT M.*.``LH<`%';#VTT:5:CX?X996&[F>)>.+XDX>-I@VQ'R5!LM/3%OTCQ3S$DE/N M;I!U4@K5EO`-)IO.K6`[E4WGM;-XO>P.W:+]7GC+#<+)6YL$6I'FEG,!$X,5 MS8JG='VD@Y\O2C`WU ML)VB:,IKTK[4?5`@S'?**W9CF'8O7@BU:TM(652!'I'/7^$D.=?-T");% MM0F8;^?`\``FJPG%LVD_#[)0:,R7')4L)05'SHH[" M(!$WGNE99Y]O:=T)*Q=W:I(]Y,F44<;KRVF-9K4=T7TD9DTEY^+NS"ESFQNS MME]M;U;U]XHUT5O>?M-OLWZ"0(3BJBT\55.$(WO3#$1M=0'.U#"7S7G5MNG3 M*#Y+>UK)1?-EN;M4Y*82>X`=UJ:^4N"7%IMHWEOK.O;73LBBG17=V@R&3$AO MQJ)UV8V*5:V"$6MM*CPU[?+D+7]&XV\\`H=)*+2K!E-SR#`YI,K?:ZB-;66;^(XX%PK<'(1OF M5?D]OF@8;6^%,J+8]=P>]^CJJJ%G5!K$H&IAF#>"/O(C+,FER;)J]5=@?RL, M$!B*X8G6-]X\SJU8Y:++USPZ$8F.W-Y$I%O_O,8Z*P5Q?W7LX-W'9%`IFQ/,,2\0"WN0%1@L_IO<(./-MDW4!"3G/;(>(8)B*42MUPA(U+ M4?-B#DHC&E3WV)Q*3GOU:_"V\+1WM^.=GG9X.>Z]ZS(I/`F&HW`PQ@9')Z/P M>'S<^Y&%8S:OS+`;)6?>@WA_/@S/1N-@-#H/1^>GTB6H,Y)+M_@DN!B'9R>8 M^#@Z'\`(@R]H5/$8V]IR&H;G)IE*!N7>\/YLC'G:>[W]E?V@?7X2CDZP6\YX M=!&>GIQL`_?XXB0\/AL$Y\?C<'!\WO-=41-X<0Z2R,$)0/=X&!P&1_N?R/$( M&W2<4U.;(>;?#L9M/BT_7YZ8E"_V.2*!8\W;![C&%Z7$H^:-.CNA`QT"F/"G M;)*M8RU04-,`*IK<[\EKA[+WBK8B&5X57-/P+#S!G^'XY`PP^P2M:!V9TA(V MQ*9'U)C,AG>>DJ.;KBE*Q;+/O%FC>M`_#T;-V!L)D+N+/C;==NYWE";$8C^W M_>/O*OK.LEUN[>L&`FYX)6N*($H4B?`\/@?NV8BP%*(P47$0!.I0LA"]6[F*])@>` MK%&J)]>UYF99$(M@BO#=83H2YM.(.9?+Y5(13GUH.]`V3OL0@N[=8-QA)QY>\H_&R'"Z)(AB3H:<8"FJZS?NAE4:!Y=PTFZ'B M>(;1L#J36=%C1$86,[H8UE=KR8@E+ZH&PS@S27Q+(TC7*3(LZ<%N<0C1G)RF M]VGJ&)1U@4:X:6\C:+>&2S+A^]!`OHS'9I9*_7I:6;CL75 MK?S-BB)=L0$-)R?ZQS9&U"I(%=K(ZR;7L7GT'$.L)TK!G?YI6NE9&C^S-V%" M.%A[WJD[WG5*W:#`U$H7S]R0!ETITW)FL0W.>-H?8&V3BZ:??1K7)5(8@P%*\_YZG)?I)A[YQ'3-\;TNB75Q@[XK3K$ M6F>]0K;H`'O=*A1'G`8I$Z>71KW<(-L)&XN1MN@+C'JF#I1"]&@<$]%/]18X MK:%63M1N!)%4]]^8ABUEY7I%+0<.@RQ:(@JW8L256[%;3Q9K M2;4$D/1-3;,+-^X5$2]XR"MQ']F243ES/X?JT\V3&(LZDF#08A9+GJ'7:*'^ MI-;MLV.2!]S&<**`MT@R3&$[(]28L2)4R5(1<=E`C9@4^.!F/,PA:1 M[]-_!C?(RHW`I-]PZR__/;A-.7((@,M\HZF1YLU9/.'.;G33Q(K.\K,I8$5Z M'5HTF0"J'9Z#.IOONTI3Y`J&]*S562:QDZB9=!:RD[+.,ZUI;'T;4V"YQ%AM MUTN[)C-/LQ`%?8])@*0AL*#@ZDAX$=T>\H80X4UIV["1Q@BS8Q,EW`E#J3K> M"6+RQ=0N:%N:'R/*9U]@:8VC2=!Z[XQ[G]R'SH!]]5VH<[/M*B`^[8GZA@@E M2RTWW72W?$8]A3L*UZ9]I#CX.,R?4KQNK_[AI"T>(B_ M^>'_<>O3O[`QLQ'HW!X+NA>J.)F63G?YCH;']8&ZU.<>-X$>2C/HD6D*+6VV M>SQK[\;D0G6D0F&!N"?!*4!V`&`^=]J\F\\$CLFNH78-X^R^=_4UV]W;R4;A M^.1$?_9>Y]G1]&M.=`3_'XW.PO.+<_TIP/DJBY=FV[;+^F5[PM#7/WP@'MR<( M*VD][S.3B_I6P>0]T?.NPL&/F'AY:.M[^LS%J3S,'A_E-OP/?-^:7['7B=F3 M.C@Y.P,D/PT._5OYND9CKR2U/F\D?LI1O<4%EJS:U_BB7@FT`4+'+RC."NH92:)28W%PF"FG MY0F-2-'L4/P:8]!K/%^D`8?V#K7>'*7Z-M][#V3/MHWJ7L&FW' M!O]")WJ#R4K-TN*V+`%7,\2B!/&B[2!W16F%',QM#GT-Z/L?@?+@/AWZ6G:4T!C=;LE# M#&K`>@6["=MJ[6(U>Q8`MI&]9\99^JQ=2'5,@6+6:Y!I%G<[WJ\?(9RJT1:[ MCK73YOA3Q[WJ/)LM;@&%8^KT+%T=@&G5LUVS MP!=Q@U]GF]P+LG:?3?:PW3JX>^P_1%G?^/8;]'156%VG\>8Z54/`H!&>1\,. MSMK?W+[H;?AR:71FDZ[*HBF#?!8MHT432/8M$F?;C!8%Q7=0&U94*3M0A[O' MZEQ5X[K2KD?G8>\WOVG;]PT&B0"540M`2Z?2X(W)XN_$X[7=OB M3NJ=K%U*6?-3$J_XF;>!JY_M=>5\L1$%8!KP'3NWMN)HNZ6Z@Y:V*R.*1[L, M<(.&F=S]\FS;RDQWRRT[^G;11T)[.R5@<_;EC;-*^M"7Y/ M*=$TRPS:>F]VK>/*M0Z+"[/=4N$T:IQKB^P6SJW/&OLB/DRV@8;52P/#.048 M%MVXHP/6H_?#-)!>&\PCW[881;N5B!ELY?:8U/K:K``PALD M^)=AW3GRCB)Z]S-,[?3.M%!VU_/21=4=D>+6=)@/KA^VJ:+DJVF*9=W"MG$/ MM1KVALPSFG=6QG7@1DF^VP89-@8A7U&[X&2+.>Z6+/\R^O?P+^,F:5XYVO]M@U]:)_3>?=__YOOW0)ZH&4/W++$7#6`F6AQ23YU#L-F.PF M25P`K=99#HTGW3Z2%BU[9_\.)RHV]YL0E5*_0LOKBP'NL'%2+==YFSNR@^T; M=@T?J$M:N4B@A:8F,7O]13OM^PV#N2[V/J?:YE9JZ81ZT-T*M54"!*X(A_`* M2PRU=&I]%6WZIF=GZ^W2]J4-'E1KP]JIMM>?VV9NQ?1%42(,:GL'0F+)UW!K M.JV7\DMN@KK);;N M6MVENZ-;Z+;-FX:KFHBRI;UNITFY`SVW=U'L0M'O3&)=1AU9@&SNP%NKP3?H M/BZA1(\R06NK>]=A>]L0DYZU5MZPGF?Q.1J&BPEA6^/&-*?NE0+!;I5]F]RD M+NXIN[CGXMH)S?6:Y$4AA2>C%7SK!FA]5Y;5#_\'4$L!`A0#%`````@``HAF M1_51(J*G`0``9Q0``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S M72YX;6Q02P$"%`,4````"``"B&9'2'4%[L4````K`@``"P`````````````` M@`'8`0``7W)E;',O+G)E;'-02P$"%`,4````"``"B&9'KY;B"&X!```W$P`` M&@``````````````@`'&`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"%`,4````"``"B&9'%J/97)PC$`8``)PG```3``````````````"``8T(``!X;"]T:&5M92]T M:&5M93$N>&UL4$L!`A0#%`````@``HAF1U"\U2=5`@``U@H```T````````` M`````(`!S@X``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0# M%`````@``HAF1\#D4A9.`@``]`<``!@``````````````(`!R10``'AL+W=O M`!``!J!0``&```````````````@`&E&P`` M>&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1[E7<>"L M!```$10``!@``````````````(`!NQT``'AL+W=OJ4B/,>@(``$,(```8``````````````"` M`9TB``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1W*(.GJ@`0``L0,``!@````````` M`````(`!4BH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0# M%`````@``HAF1R`,EP:A`0``L0,``!D``````````````(`!TB\``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1TCO MP2!+`@``@@@``!D``````````````(`!5S4``'AL+W=OZ,!``"Q`P``&0`````````` M````@`'9-P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1[[2D:2B`0``L0,``!D` M`````````````(`!ISL``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1YR5?JU2`P``/`X``!D``````````````(`! MW4(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@``HAF1R]$'!"B`@``B@D``!D``````````````(`!/4T``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1[YI<'R$ M`@``:`H``!D``````````````(`!0%0``'AL+W=OO4%0"``"Y!P``&0`````````````` M@`'[5@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@``HAF1Y90GD&\`P``^1(``!D````` M`````````(`!YEL``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@``HAF1P$=(ZJ,3```[1T!`!0``````````````(`!-F0` K`'AL+W-H87)E9%-T&UL4$L%!@`````G`"<`@PH``/2P```````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Details) - USD ($)
1 Months Ended 9 Months Ended

Jan. 15, 2015

Apr. 30, 2015

Jul. 31, 2009

Sep. 30, 2015

Jan. 07, 2015

Commitments and Contingencies [Line Items]

Amount of contract expectation damages $ 113,100,000 $ 113,000,000

Amount of award 194,600,000

Expert witness fees $ 81,500,000

Warrant expiration date Jan. 28, 2015

Maximum amount of reimbursement $ 210,000

Annual License Payment $ 200,000

Initial Maximum Maintenance Failure Obligation [Member]

Commitments and Contingencies [Line Items]

Percentage of aggregate principal amount of convertible Notes 1.00%

Aggregate principal amount of obligation $ 200,000

Every 30 days until failure is cured [Member]

Commitments and Contingencies [Line Items]

Percentage of aggregate principal amount of convertible Notes 1.00%

Aggregate principal amount of obligation $ 200,000

BARDA [Member]

Commitments and Contingencies [Line Items]

Audited BARDA revenue $ 5,800,000

X

- Definition
Annual payment due under the licensing agreement.
+ References
No definition available.
+ Details

Name: pip_AnnualLicensePayment

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Commitments and Contingencies [Line Items]
+ References
No definition available.
+ Details

Name: pip_CommitmentsAndContingenciesLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum amount of reimbursement to be paid.
+ References
No definition available.
+ Details

Name: pip_MaximumAmountOfReimbursement

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure.
+ References
No definition available.
+ Details

Name: pip_NotesPayableAggregatePrincipalRepaymentAmount

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of aggregate principal amount of convertible notes relating to the affected shares.
+ References
No definition available.
+ Details

Name: pip_PercentageOfAggregatePrincipalAmountRedemption

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue recognized during the period based on auditing of a contract.
+ References
No definition available.
+ Details

Name: pip_RevenueRecognizedFromContractAudit

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrant, Expiration Date
+ References
No definition available.
+ Details

Name: pip_WarrantExpirationDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
No definition available.
+ Details

Name: us-gaap_LitigationSettlementExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of damages awarded to the plaintiff in the legal matter.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyDamagesAwardedValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyEstimateOfPossibleLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Fair Value Measurements [Abstract]

Fair Value Measurements

Note 3 - Fair Value Measurements

The carrying amounts of our short term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable approximate their fair values due to their short term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

• Level 1 — Quoted prices in active markets for identical assets or liabilities.

• Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

• Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

As of September 30, 2015

Level 1 Level 2 Level 3 Balance

Assets

Investment in money market funds⁽¹⁾ $ 6,430,038 $ - $ - $ 6,430,038

Total investment in money market funds $ 6,430,038 $ - $ - $ 6,430,038

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ - $ - $ 2,355 $ 2,355

Non-current portion of derivative instruments related to stock purchase warrants - - 227,898 227,898

Total derivative instruments related to stock purchase warrants $ - $ - $ 230,253 $ 230,253

As of December 31, 2014

Level 1 Level 2 Level 3 Balance

Assets

Investment in money market funds⁽¹⁾ $ 6,429,104 $ - $ - $ 6,429,104

Total investment in money market funds $ 6,429,104 $ - $ - $ 6,429,104

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ - $ - $ 178,509 $ 178,509

Non-current portion of derivative instruments related to stock purchase warrants - - 629,170 629,170

Total derivative instruments related to stock purchase warrants $ - $ - $ 807,679 $ 807,679

⁽¹⁾
Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2015 and 2014:

Exercised Stock

Balance as of Unrealized Purchase
Balance as of

December 31, (Gains) Warrants September 30,

Description 2014 2015 2015 2015

Derivative liabilities related to stock purchase warrants $ 807,679 $ (577,426 ) $ - $ 230,253

Balance as of Unrealized Exercised Stock Purchase
Balance as of

December 31, (Gains) Warrants September 30,

Description 2013 2014 2014 2014

Derivative liabilities related to stock purchase warrants $ 1,740,235 $ (464,703 ) $ (423,739 ) $ 851,793

At September 30, 2015 and 2014, derivative liabilities are comprised of warrants to purchase 1,775,419 shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at September 30, 2015 Valuation Technique Unobservable Inputs

$ 230,253 Black-Scholes option pricing model Expected term

Expected dividends

Anticipated volatility

Assets Measured at Fair Value on a Nonrecurring Basis

The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the Company recorded an impairment charge for property and equipment in the amount of $36,981. These assets were written down to their fair value of $0 in conjunction with the sublease of the Company's leased office space (see Note 4 - Commitments and Contingencies - Leases). As of September 30, 2015, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Financing Transactions (Controlled Equity Offering) (Details) - USD ($)
$ in Millions

Sep. 30, 2015

May. 23, 2014

Mar. 25, 2013

Equity Offering [Member]

Equity Offering [Line Items]

The maximum value of common stock issuable under the controlled equity offering arrangement $ 15.0

Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock 3.00%

Amount remaining available under controlled equity offering sale arrangement $ 3.0

Amendment to the Controlled Equity Offering [Member]

Equity Offering [Line Items]

The maximum value of common stock issuable under the controlled equity offering arrangement $ 15.0

X

- Definition
Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares.
+ References
No definition available.
+ Details

Name: pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Equity Offering [Line Items]
+ References
No definition available.
+ Details

Name: pip_EquityOfferingLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum value of common stock issuable under the controlled equity offering arrangement.
+ References
No definition available.
+ Details

Name: pip_MaximumValueOfStockIssuableUnderStockOffering

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The remaining value of common stock issuable under the controlled equity offering arrangement.
+ References
No definition available.
+ Details

Name: pip_RemainingValueOfStockIssuableUnderStockOffering

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: pip_EquityOfferingAxis=pip_EquityOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: pip_EquityOfferingAxis=pip_AmendmentToControlledEquityOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Schedule of Warrants) (Details) - $ / shares
1 Months Ended 9 Months Ended

Oct. 13, 2015

Jul. 31, 2009

Sep. 30, 2015

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants 1,922,781

Expiration Date Jan. 28, 2015

Warrant [Member] | Subsequent Event [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of common shares expired underlying stock purchase warrants 500,000

3.97 [Member] | Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants ^[1] 100,778

Issue Date Mar. 01, 2007

Warrant, Exercise price $ 3.97

Expiration Date Mar. 01, 2017

1.89 [Member] | Derivative Instrument Warrants [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants ^[2],[3] 500,000

Issue Date Apr. 01, 2010

Warrant, Exercise price $ 1.89

Expiration Date Oct. 01, 2015

1.63 [Member] | Derivative Instrument Warrants [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants ^[2] 903,996

Issue Date Jul. 01, 2010

Warrant, Exercise price $ 1.63

Expiration Date Jan. 01, 2017

3.50 [Member] | Derivative Instrument Warrants [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants ^[2] 371,423

Issue Date Jun. 01, 2011

Warrant, Exercise price $ 3.50

Expiration Date Jun. 01, 2016

1.61 [Member] | Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants ^[1] 46,584

Issue Date Mar. 01, 2012

Warrant, Exercise price $ 1.61

Expiration Date Mar. 01, 2022

[1] These warrants to purchase common stock are classified as equity.

[2] Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 – Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).

[3] Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.

X

- Definition
Class Of Warrant Or Right, Issuance Date.
+ References
No definition available.
+ Details

Name: pip_ClassOfWarrantOrRightIssuanceDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of common shares expired underlying stock purchase warrants.
+ References
No definition available.
+ Details

Name: pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired

Namespace Prefix: pip_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrant, Expiration Date
+ References
No definition available.
+ Details

Name: pip_WarrantExpirationDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pip_DerivativeInstrumentWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Financing Transactions (Loan Agreement with GE Capital) (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended

Sep. 30, 2015

Mar. 30, 2012

Loans Payable [Member]

Debt Instrument [Line Items]

Debt instrument, carrying amount $ 2.5

Warrants issued to purchase common stock, in connection with loan agreement 46,584

Warrant exercise price $ 1.61

Line of Credit [Member]

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity $ 5.0

X

- Definition
Warrants Issued To Purchase Common Stock In Connection With Loan Agreement.
+ References
No definition available.
+ Details

Name: pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement

Namespace Prefix: pip_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in one business segment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.



Foreign Currency Translation

The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).

In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.

Significant Customers and Accounts Receivable

Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (“BARDA”). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.

Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.

Restructuring Expense

As a result of the Realignment Plan, we recorded approximately $2.1 million of restructuring expense during the nine months ended September 30, 2015, including approximately $2.0 million of related severance expense, and the remainder being legal and other employee related expenses. Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $0.4 million of additional restructuring expense (see Note 4 - Commitments and Contingencies - Leases).

Financial Instruments

Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 – Fair Value Measurements for further details.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

A milestone is considered substantive if all of the following conditions are met:

• it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

• it relates solely to past performance, and

• the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.

Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:

Three months ended September 30,

2015 2014

Research and development $ 12,034
$ 52,434

General and administrative 81,723 228,286

Total share-based compensation expense $ 93,757 $ 280,720

During the three months ended September 30, 2015, we granted options to purchase 100,000 shares of common stock to non-employee directors and made no grants of options or shares of restricted stock to employees and consultants.

Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:

Nine months ended September 30,

2015 2014

Research and development $ 85,259 $ 329,655

General and administrative 395,470 843,048

Restructuring benefit (53,741 ) -

Total share-based compensation expense $ 426,988 $ 1,172,703

As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $75,000 of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $129,000 of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $53,741 net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.

During the nine months ended September 30, 2015, we granted options to purchase 112,000 shares of common stock to employees and non-employee directors and granted 117,500 shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase 1,357,755 shares of common stock to employees, non-employee directors and consultants and made no restricted stock grants.

At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $0.8 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.2 years.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.

Our income tax expense was $0.02 million and $0.03 million during the three months ended September 30, 2015 and 2014, respectively, and $0.05 million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.

A total of approximately 6.0 million and 10.9 million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 17,389,409 $ 18,643,351

Billed accounts receivable 110,656

Unbilled accounts receivable $ 659,663 297,431

Prepaid expenses and other current assets 196,478 199,194

Total current assets 18,245,550 19,250,632

Property and equipment, net 248,270 325,772

Other long-term assets and deferred costs 53,384 53,384

Goodwill 2,348,453 2,348,453

Total assets 20,895,657 21,978,241

Current liabilities:

Accounts payable 306,172 391,396

Accrued expenses and other liabilities 1,453,123 $ 1,195,412

Accrued restructuring expenses $ 619,119

Short-term debt $ 746,146

Other short-term liabilities 70,326

Current portion of derivative instruments $ 2,355 178,509

Total current liabilities 2,380,769 $ 2,581,789

Accrued restructuring expenses - long term 184,018

Other long-term liabilities 431,015 $ 493,137

Derivative instruments, less current portion 227,898 629,170

Total liabilities 3,223,700 3,704,096

Stockholders' equity:

Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 6,436 6,360

Additional paid-in-capital $ 240,151,146 238,780,633

Accumulated other comprehensive loss (229,528)

Accumulated deficit $ (222,485,625) (220,283,320)

Total stockholders' equity 17,671,957 18,274,145

Total liabilities and stockholders' equity $ 20,895,657 $ 21,978,241

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: pip_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_BilledContractReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgesLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 4

+ Details

Name: us-gaap_RestructuringReserveCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Paragraph Question 4

+ Details

Name: us-gaap_RestructuringReserveNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 912

-SubTopic 310

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51666815&loc=d3e55302-109406

+ Details

Name: us-gaap_UnbilledContractsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Operating activities

Net loss $ (2,202,305) $ (7,325,995)

Adjustments to reconcile net loss to net cash used in operating activities:

Realization of cumulative translation adjustment 229,192

Share-based compensation expense 426,988 $ 1,172,703

Change in fair value of derivative instruments (577,426) (464,703)

Depreciation expense 108,798 113,272

Deferred income taxes 46,310 48,105

Non-cash interest expense (51,820) $ 68,130

Impairment of property and equipment 36,981

Gain on the disposal of property and equipment (7,600) $ (5,393)

Changes in operating assets and liabilities:

Billed accounts receivable 110,656 1,427,113

Unbilled accounts receivable (362,232) 1,895,858

Prepaid expenses and other current assets (9,602) 23,869

Accounts payable (85,175) $ (846,090)

Accrued restructuring expenses 800,769

Accrued expenses and other liabilities $ 149,438 $ (773,517)

Deferred revenue (284,937)

Net cash used in operating activities $ (1,387,028) (4,951,585)

Investing activities

Purchases of property and equipment (68,277) (92,269)

Proceeds from the sale of property and equipment 7,600 8,000

Net cash used in investing activities (60,677) (84,269)

Financing activities

Repayment of debt $ (750,007) (749,997)

Net repayment of revolving credit agreement (1,091,740)

Net proceeds from exercise of warrants 683,325

Proceeds from issuance of common stock, including exercise of stock options, net of offering costs $ 943,601 15,341,264

Net cash provided by financing activities 193,594 14,182,852

Effects of exchange rates on cash 169 (7,585)

(Decrease) increase in cash and cash equivalents (1,253,942) 9,139,413

Cash and cash equivalents, at beginning of period 18,643,351 10,480,979

Cash and cash equivalents, at end of period 17,389,409 19,620,392

Supplemental disclosure of cash flow information

Cash paid for interest $ 108,134 $ 105,916

X

- Definition
Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity.
+ References
No definition available.
+ Details

Name: pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 958

-SubTopic 225

-Section 45

-Paragraph 11

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=51659069&loc=d3e92212-112881

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Impairment

-URI http://asc.fasb.org/extlink&oid=6515133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2420-110228

+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInUnbilledReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-Subparagraph c

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from other long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net total Increase or Decrease in the accrual for restructuring costs during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringReservePeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 22 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Beginning Balance $ 807,679

Unrealized (Gains) $ 359,796 $ (560,487) 577,426 $ 464,703

Ending Balance 230,253 230,253

Level 3 [Member] | Warrants [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Beginning Balance 807,679 1,740,235

Unrealized (Gains) $ (577,426) (464,703)

Exercised Stock Purchase Warrants (423,739)

Ending Balance $ 230,253 $ 851,793 $ 230,253 $ 851,793

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Fair Value Measurements [Abstract]

Derivatives $ 230,253 $ 807,679

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 25 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business, Liquidity and Organization
9 Months Ended

Sep. 30, 2015

Business, Liquidity and Organization [Abstract]

Business, Liquidity and Organization

Note 1 – Business, Liquidity and Organization

Since 2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning.

On March 9, 2015, our Board of Directors approved our realignment plan (the “Realignment Plan”) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (“SIGA”) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA's appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (“NIAID”). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2 million (all of which was expensed as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company's product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5 million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.

As of September 30, 2015, our cash balance was $17.4 million, our unbilled accounts receivable balance was $0.7 million, and our current liabilities were $2.4 million. As of September 30, 2015, we had approximately $3.0 million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 – Financing Transactions – Controlled Equity Offering). We believe, based on the operating cash requirements and capital expenditures expected for 2015, the Company's cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016. On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (“GE Capital”), as discussed further in Note 6- Financing Transactions.

On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (“rPA”). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM.

On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 - Commitments and Contingencies - Leases.

On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016.

We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, in connection with the Realignment Plan, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman's continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA's appeal has been adjudicated and we have received SIGA's payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA's appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.

In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 64,358,834 63,603,303

Common stock, shares outstanding 64,358,834 63,603,303

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Tables)
9 Months Ended

Sep. 30, 2015

Stockholders' Equity [Abstract]

Summary of Warrants Outstanding

Number of Common Shares
Underlying Warrants As of
September 30, 2015 Issue Date Exercise Price Expiration Date

100,778 ⁽¹⁾ March 2007 $ 3.97 March 2017

500,000 ^{(2) (3)} April 2010 $ 1.89 October 2015

903,996 ⁽²⁾ July 2010 $ 1.63 January 2017

371,423 ⁽²⁾ June 2011 $ 3.50 June 2016

46,584 ⁽¹⁾ March 2012 $ 1.61 March 2022

1,922,781

⁽¹⁾
These warrants to purchase common stock are classified as equity.

⁽²⁾
Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 – Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).

_______

^{(3)___________}

Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 04, 2015

Document and Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Trading Symbol PIP

Entity Registrant Name PHARMATHENE, INC

Entity Central Index Key 0001326190

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 64,451,334

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: pip_DocumentAndEntityInformationAbstract

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Business, Liquidity and Organization (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 03, 2015

Sep. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Mar. 09, 2015

Dec. 31, 2014

Dec. 31, 2013

Business, Liquidity and Organization [Abstract]

Expected severance cost $ 2,000,000

Accumulated deficit $ (222,485,625) $ (222,485,625) $ (220,283,320)

Cash and cash equivalents 17,389,409 17,389,409 $ 19,620,392 18,643,351 $ 10,480,979

Accounts receivable (billed and unbilled) 700,000 700,000

Liabilities current 2,380,769 2,380,769 2,581,789

Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement $ 3,000,000 $ 3,000,000

Short-term debt $ 746,146

Organization and Business

Maximum amount of reimbursement $ 210,000 $ 210,000

Annual License Payment 200,000 200,000

Proceeds from Additional Funding $ 2,300,000

Accrued interest paid $ 108,134 $ 105,916

Line of Credit [Member]

Organization and Business

Debt termination payment $ 81,347

Final payment fee 75,000

Outstanding principal balance 10

Accrued interest paid 208

Legal fees of the lender $ 6,129

X

- Definition
Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement
+ References
No definition available.
+ Details

Name: pip_AdditionalCommonStockAggregateGrossSales

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Annual payment due under the licensing agreement.
+ References
No definition available.
+ Details

Name: pip_AnnualLicensePayment

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accounts receivable, billed and unbilled
+ References
No definition available.
+ Details

Name: pip_BilledAndUnbilledAccountsReceivableNet

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Maximum amount of reimbursement to be paid.
+ References
No definition available.
+ Details

Name: pip_MaximumAmountOfReimbursement

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of cash inflow from additional funding as per the agreement.
+ References
No definition available.
+ Details

Name: pip_ProceedsFromAdditionalFunding

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Expenses paid for obtaining loans which includes expenses such as application and origination fees.
+ References
No definition available.
+ Details

Name: us-gaap_LoanProcessingFee

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount expected to be recognized in earnings for the specified restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB Topic 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringAndRelatedCostExpectedCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]

Contract revenue $ 1,155,839 $ 962,451 $ 9,374,155 $ 8,363,909

Operating expenses:

Research and development 1,125,865 1,728,929 3,962,019 7,528,616

General and administrative 1,231,035 $ 3,192,427 5,246,396 $ 8,289,788

Restructuring expense 422,482 2,519,273

Depreciation 35,005 $ 37,125 108,798 $ 113,272

Total operating expenses 2,814,387 4,958,481 11,836,486 15,931,676

Loss from operations (1,658,548) (3,996,030) (2,462,331) (7,567,767)

Other income (expense):

Interest expense, net $ (9,888) $ (46,930) (48,492) $ (173,356)

Realization of cumulative translation adjustment (229,192)

Change in fair value of derivative instruments $ 359,796 $ (560,487) 577,426 $ 464,703

Other income (expense) (691) 80 6,594 (1,470)

Total other income (expense) 349,217 (607,337) 306,336 289,877

Net loss before income taxes (1,309,331) (4,603,367) (2,155,995) (7,277,890)

Income tax provision (15,437) (25,068) (46,310) (48,105)

Net loss $ (1,324,768) $ (4,628,435) $ (2,202,305) $ (7,325,995)

Basic and diluted net loss per share $ (0.02) $ (0.08) $ (0.03) $ (0.13)

Weighted average shares used in calculation of basic and diluted net loss per share 64,187,618 58,952,731 63,858,500 55,577,550

X

- Definition
Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity.
+ References
No definition available.
+ Details

Name: pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_ContractsRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Financing Transactions
9 Months Ended

Sep. 30, 2015

Financing Transactions [Abstract]

Financing Transactions

Note 6 – Financing Transactions

Controlled Equity Offering

On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $15.0 million.

On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.

Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.

As of September 30, 2015, shares having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement. The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.

Termination of Loan Agreement with GE Capital

On September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5.0 million based on our outstanding qualified accounts receivable.

The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method.

The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets.

In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase 46,584 shares of the Company's common stock at an exercise price of $1.61 per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method.

X

- Definition
The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.
+ References
No definition available.
+ Details

Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity
9 Months Ended

Sep. 30, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 5 - Stockholders' Equity

Long-Term Incentive Plan

In 2007, the Company's stockholders approved the 2007 Long-Term Incentive Compensation Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

In 2008, our stockholders approved amendments to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January 1, 2015. At September 30, 2015, there are approximately 10.3 million shares approved for issuance under the 2007 Plan, of which approximately 4.4 million shares are available for grant. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.

Warrants

At September 30, 2015, there were warrants outstanding to purchase 1,922,781 shares of our common stock.

Warrants to purchase 2,572,775 shares of common stock expired on January 28, 2015 without being exercised. The warrants were classified as equity.

The warrants outstanding as of September 30, 2015, all of which are exercisable, were as follows:

Number of Common Shares
Underlying Warrants As of
September 30, 2015 Issue Date Exercise Price Expiration Date

100,778 ⁽¹⁾ March 2007 $ 3.97 March 2017

500,000 ^{(2) (3)} April 2010 $ 1.89 October 2015

903,996 ⁽²⁾ July 2010 $ 1.63 January 2017

371,423 ⁽²⁾ June 2011 $ 3.50 June 2016

46,584 ⁽¹⁾ March 2012 $ 1.61 March 2022

1,922,781

⁽¹⁾
These warrants to purchase common stock are classified as equity.

⁽²⁾
Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 – Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).

_______

^{(3)___________}

Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Fair Value Measurements [Line Items]

Impairment of property and equipment $ 36,981 $ 36,981

Fair value of leased assets $ 0 $ 0

Level 3 [Member] | Derivative Liabilities [Member]

Fair Value Measurements [Line Items]

Warrants to purchase common stock 1,775,419 1,775,419 1,775,419

X

- Definition
Fair Value Measurements [Line Items]
+ References
No definition available.
+ Details

Name: pip_FairValueMeasurementsLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 958

-SubTopic 225

-Section 45

-Paragraph 11

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=51659069&loc=d3e92212-112881

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Impairment

-URI http://asc.fasb.org/extlink&oid=6515133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2420-110228

+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of property, by major property class, net of accumulated depreciation, subject to or available for lease as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6454179&loc=d3e41551-112718

+ Details

Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=pip_DerivativeLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Narrative) (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2015

USD ($)

shares

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

shares

Sep. 30, 2014

USD ($)

shares

Mar. 09, 2015

USD ($)

Significant Accounting Policies [Line Items]

Restructuring expense $ 422,482 $ 2,519,273

Number of operating segment 1

Realization of cumulative translation adjustment included in net loss $ 229,192

Expected severance cost $ 2,000,000

Share-based compensation expense, extension of exercise period 75,000

Share-based compensation, reversal from stock option forfeitures 129,000

Net reversal of share-based compensation expense $ 53,741

Stock options granted | shares 100,000 112,000 1,357,755

Restricted stock granted | shares 117,500

Unrecognized share-based compensation expense related to unvested awards, net of forfeitures $ 800,000 $ 800,000

Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period 2 years 2 months 12 days

Income tax expense $ 15,437 $ 25,068 $ 46,310 $ 48,105

Anti-dilutive securities excluded from computation of earnings per share | shares 6,000,000 10,900,000

Employee Severance [Member]

Significant Accounting Policies [Line Items]

Restructuring expense $ 2,100,000

Facility Closing [Member]

Significant Accounting Policies [Line Items]

Restructuring expense $ 400,000

X

- Definition
Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Granted in Period
+ References
No definition available.
+ Details

Name: pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod

Namespace Prefix: pip_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of share based compensation expense incurred during the period due to the extension of the exercise period of vested stock options.
+ References
No definition available.
+ Details

Name: pip_ShareBasedCompensationExtensionOfExercisePeriod

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reversal of share based compensation expense due to unvested stock options forfeited during the period.
+ References
No definition available.
+ Details

Name: pip_ShareBasedCompensationReversalFromStockOptionForfeitures

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net reversal amount of share based compensation due to adjustments during the period.
+ References
No definition available.
+ Details

Name: pip_ShareBasedCompensationReversalNet

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: pip_SignificantAccountingPoliciesLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount expected to be recognized in earnings for the specified restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB Topic 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringAndRelatedCostExpectedCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Measurements [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value

As of September 30, 2015

Level 1 Level 2 Level 3 Balance

Assets

Investment in money market funds⁽¹⁾ $ 6,430,038 $ - $ - $ 6,430,038

Total investment in money market funds $ 6,430,038 $ - $ - $ 6,430,038

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ - $ - $ 2,355 $ 2,355

Non-current portion of derivative instruments related to stock purchase warrants - - 227,898 227,898

Total derivative instruments related to stock purchase warrants $ - $ - $ 230,253 $ 230,253

As of December 31, 2014

Level 1 Level 2 Level 3 Balance

Assets

Investment in money market funds⁽¹⁾ $ 6,429,104 $ - $ - $ 6,429,104

Total investment in money market funds $ 6,429,104 $ - $ - $ 6,429,104

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ - $ - $ 178,509 $ 178,509

Non-current portion of derivative instruments related to stock purchase warrants - - 629,170 629,170

Total derivative instruments related to stock purchase warrants $ - $ - $ 807,679 $ 807,679

⁽¹⁾
Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

Summary of Changes in Fair Value of Level 3 Liabilities

Exercised Stock

Balance as of Unrealized Purchase
Balance as of

December 31, (Gains) Warrants September 30,

Description 2014 2015 2015 2015

Derivative liabilities related to stock purchase warrants $ 807,679 $ (577,426 ) $ - $ 230,253

Balance as of Unrealized Exercised Stock Purchase
Balance as of

December 31, (Gains) Warrants September 30,

Description 2013 2014 2014 2014

Derivative liabilities related to stock purchase warrants $ 1,740,235 $ (464,703 ) $ (423,739 ) $ 851,793

Schedule of Quantitative Information about Level 3 Fair Value Measurements

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at September 30, 2015 Valuation Technique Unobservable Inputs

$ 230,253 Black-Scholes option pricing model Expected term

Expected dividends

Anticipated volatility

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Policy)
9 Months Ended

Sep. 30, 2015

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in one business segment.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

Foreign Currency Translation

The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).

In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.

Significant Customers and Accounts Receivable

Significant Customers and Accounts Receivable

Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (“BARDA”). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.

Goodwill

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.

Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.

Restructuring Expense

Restructuring Expense

As a result of the Realignment Plan, we recorded approximately $2.1 million of restructuring expense during the nine months ended September 30, 2015, including approximately $2.0 million of related severance expense, and the remainder being legal and other employee related expenses. Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $0.4 million of additional restructuring expense (see Note 4 - Commitments and Contingencies - Leases).

Financial Instruments

Financial Instruments

Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 – Fair Value Measurements for further details.

Revenue Recognition

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

A milestone is considered substantive if all of the following conditions are met:

• it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

• it relates solely to past performance, and

• the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.

Share-Based Compensation

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.

The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.

Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:

Three months ended September 30,

2015 2014

Research and development $ 12,034
$ 52,434

General and administrative 81,723 228,286

Total share-based compensation expense $ 93,757 $ 280,720

During the three months ended September 30, 2015, we granted options to purchase 100,000 shares of common stock to non-employee directors and made no grants of options or shares of restricted stock to employees and consultants.

Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:

Nine months ended September 30,

2015 2014

Research and development $ 85,259 $ 329,655

General and administrative 395,470 843,048

Restructuring benefit (53,741 ) -

Total share-based compensation expense $ 426,988 $ 1,172,703

As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $75,000 of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $129,000 of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $53,741 net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.

During the nine months ended September 30, 2015, we granted options to purchase 112,000 shares of common stock to employees and non-employee directors and granted 117,500 shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase 1,357,755 shares of common stock to employees, non-employee directors and consultants and made no restricted stock grants.

At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $0.8 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.2 years.

Income Taxes

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.

Our income tax expense was $0.02 million and $0.03 million during the three months ended September 30, 2015 and 2014, respectively, and $0.05 million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.

A total of approximately 6.0 million and 10.9 million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3,4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6327-108592

+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2015

Summary of Significant Accounting Policies [Abstract]

Schedule of Share-based Compensation Expense

Nine months ended September 30,

2015 2014

Research and development $ 85,259 $ 329,655

General and administrative 395,470 843,048

Restructuring benefit (53,741 ) -

Total share-based compensation expense $ 426,988 $ 1,172,703

Three months ended September 30,

2015 2014

Research and development $ 12,034
$ 52,434

General and administrative 81,723 228,286

Total share-based compensation expense $ 93,757 $ 280,720

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Tables)
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies [Abstract]

Other Liabilities [Table Text Block]

Description

Present Value at September 30, 2015

Accrued restructuring expenses

$

244,769

Accrued restructuring expenses - long term

$

184,018

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 39 0001144204-15-063377-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-063377-xbrl.zip M4$L#!!0````(`.*#9D=Y<#;XMK@```E,"``0`!P`<&EP+3(P,34P.3,P+GAM M;%54"0`#%QP]5A<`L``00E#@``!#D!``#L7>MSHSJR_[Y5^S^PWJIS M=JO&$X1X9AY;>U,DDHRNWOOERD"LJT]&+R`D_C^]5?"&`0&&V21V`GS MX9R8A_K7K5:KNR4U'__V-/6D!Q1&./`_#2`AWPE<[(\_#>;1T(X??BYN)6.K/#^\`?#NG+3_>AAX_I?R4"P8^.<12H"C`^#29Q/#L^ M.GI\?'Q/;[\/PO&1(LOP*'UBD+[@8?_W#4_3V_=VA%:/S^.P]FGKB-Q=/4AO MN#A[EGU./UK>9!_%FQ#[5'!.AN%I#?,C3)X&EF4=)7>S1R-<]2!I%AS]^_NW M6V>"IO:P3,!%)>`1&JA?=/D3N0CI;M+-7%"?P8/<42=C\-+I;8K.&* M5O84\F,<+])KV57LTNLCC$(IP8,*;*SD=';QC\%GF0@9*CJPY(]'Y9=7I(XJ M:*649BC$@;M&/^FJ^',..VL\O5-LF6EE=2EE?Y-$U"%0:&\=F$12V*(E MJ&HW0J5C%Q[FV(7=C-V+`U.L@C7KS+Z3,0U)ZX=V1'\Y"(PH^C&^3,PY`XNLN'7D"DN5%"8PHI MNYS><`F,IYF''1PO,4HN)L\M??7413O.>#M=9'_^G="P0V>R2*1P\H2CP>>U MY]?E]/&HDNJNL!BA?PW1?^O6S%X%:M,BO9/8.XFBM;:CU-4VK>V=Q-Y)/#RM M[9W$WDD\$*U]W9K9JP"?X?J7'8:$WJO1@[VR4-BW?0?;W@7IU'!.V2OB*`C_ M]>A>[2IEKXF])K*"WL_UX*:)P5YAWYK"/D]N!_;3=J][+[!!H78?3*^)O2;6 M3=O[M>.H5]A>85]P)]-6W3LG+3_8,7Y`W[!]CST<8Q3UFMAM=G`EZL699T?1 M$LT,SXXW=,;K,WO-?!&;2;P'XP!W?U+8G>7-`),W([^T@Y#/>C8' MM,WF4%X[RN8H'SG;O7K0IM6">JA4/4YQ,$4N=FSO MQ'V@QSC=&Q0AZF^=$-K4GPIF24PXCR=!2*1PF&KD(GS\#8UM[TN"--<33OY? M2I_4]OJD=I.XD8TTYWT;!\[O%T1R/O5^KSW;OWLD?R_^%X7!+1&@?Y@:LS(\ ME*%+>XIRE6G(\/.[_:LNZ<#ME\V^M_>MM\WNMJ&LG(>^M_>EM[M*-M4[CGW? MOVS?[[.AF*]DE68OET/6=4%IGZA1S"ZWW=Q.[!"=VA%RSX+IC(C5 MCHE@4VE%UR%VT(U-HK0K'[VF5;UJMI.K41HS_!]R?_@N"A/[/=NC>+69H#W3_>0_HY7G\W`"LA)[J;=.>.?RD M2RZ,5;:E:L&C3E`B%?+%A]GSIY(.5^])([W>OQ:]SSJSU_LMHKK%3[W:OQ*U MS_KR=6I]8S'D86_OKHM1K.:)A-YAWY"#(.W*1I:T6OXZD+IU;#"_8J-%,+_B M]?F6D/O0O@_MWV2*?88=X*O0N5F:R_L0^/=(2(AO+97>?J,WY?GFA$>^!N MU(7O!%-T&Q-'D[;Q+7"2$+TX^S;@_XW[V/65U7K=V4_=V9^R9AL.XR,?A;9' M1'?B3K&/HSA,\M5O1WL:2:"W/36VI]>?_=6?0[`_Q';'X=R)Y]3=.YO8X?C0 M*X8UG;)JV.XM3;V7TVO*BVO*WMD48\VF'-R6VQ4;^S/\C+7A=WA"5=L+];DU MM8_<]C1R.X`!V>O.GNK.(=B=/FK;WZCM$&Q/KS_[JS_[8W^6ZU:`Q`OJ0;B/ MA?6?!'9G*WDR[/=5//MZGBQ\9?8\:UIA9]B^=U]@TJ2=T'K2S%5"K-,%Y"'( M58+^@L5]W#]OY_=1\HG1^,L#.O3=W2)V0;>A5Q+>.N5*Z;Z09B:ZT$XS$X5Y MOB3\E^G,"Q8HV2,?TI+#AZV-Q91I$,7$2Z/18OA0TI(:OOL4?.V75YWT2R-! M=+"[CUIK2277;U!'YCY>*LB/V_-2IT^77\/^C*-`58!Q3)Y8-;2ZQ39.6ZIK M^1J%R9&>$@47/Q`U*#-*7[R<3\G@C8.UF:0Q+%84U2TRY,Z1'Y"`;S/!M'^2 MTTU-**XWNKK+\+U5>LO35#5=LPW2UM:OYVN=4FQ[1OYLUG)6\39$,QN[:?`:6KAKFQZ,6%+DA*NL0TV]C;X%H`4O=`6(E&,@I+U-1-4V3MR)L<6H( M5$U5@SGI5;N;J0&9C\^&Y):L9\0XS:4BFY:F:T9Y%&ZDQ6GW%&`9Q-J`+;0< M)YC3@[S+@U;E68'3S$%9!^R`JJ;2"@FGW8,6@);>#$ER_,%QPCE:S0[1:GI( MGV.^])IP%I$PVDHR(MFN.[2W-\91K-S20W#873-AJJ#E1F M\%20J)B(&"THXZ@PFXUPR"1@+H*;$578V2;"42T(H-$>4>5G,C+C,SL,%V3& M2KY.G$6C%0:^D1-B0--267O0B&SM0,SPJPP0R.F_2HQEDENP7431G,'5R*FNP:6K4#--J&Z`M:36 M#E(C][D.$M1E"&7(#ZDXW'E]917JE1`J1G4M;^&?V3,5\.O>H35N&E,%T%J()756BOBG=,D:_"/PU"!$>^TMWS%G9 MC-A)X+DHC):5&3)4G($#,'0#6&R&<9U&8PRXCD."YN#6PRAME]A`4!BU+2#5FAKS[@+2 MU:RXNGMJ1]BAQXNP-X\9:9:,?.U^J>VX%3)-$]B,4F[!P`?86@=<><:Z*6#` M"_A?Q*>;D*LG=+_=&%W.Z9ZIJU'R(J/@-7SH`/R,]C,EWA&@PES!8D#AF[3%$FUQ`,Y%+T$A@3 MZM`JY!PW@MEX#C%#IHH0$[1T\F1Q,;&>-@],380`#1+PZ4#G@KGE7%4&5!HDCY#M@N*852K"`]DTBNL\.:4&&#B,?U6(`A5V5TL]AJL9W>!* MQ+[:*)$!$6+.`2`V5#79)?$RP:9XA%ATH%D0Z`8'GCPAE2$28LF'Q/(HD(V4 M*D@VQR3$;`\-33<,W6B!Z8+0)!Y(>1HQA%AGU50M1IM+M)H!$6)[@0$A&_IO M1/+##Y'MT5#H-QO[5&17?KZPFG>9$*M+/#V5W7FRA3@?4EY37.Q,735DR(DT M211?!GY0U,=29YM"#+FN6>5MI;64N5`*,?5#H+(K]VU@;D0*79H0*4XQC?@J$NA6-63:$65OHIL+25%,W6MNW2.53U7MI0?,,ALJ?!EG1KF2*SJ M2:ZM/!5BL*#6;3K'JIY+6LH4`DM1%:.#=(Y5;?M;BE*E.QR4-MF14@5]CY]G)1 M+PD-@:Z9FFJ*2:P`N<+0MQ?3$%J6+D-Y]\P*L6\BI&29 M;"J9)[,"Y`J3S:%`N@5EL9D5XAN*L3J6876<6@%RA;'F4"]-EU76*G207`&R M$%L^U"W0978%R$+LO=E5;@7(0N8!J%H*:)^^V`ZO?$J94R%UV8#P(-(KH'Q4 MFG?:@;)5R.>_I?P**)\!YU0;E6[18A<@]C7!`LH'SSD#%DV%:]SNEF$!Y8/H M?%U!BW&8(E(LH'S^G'M\*:K!0FJ;8P'E\^7<.JJ8*FR69&FX/PN4SY8WE-&& M'65,Z-;%CC)0/GG>4)@;$)N!N4QX#E`_C-QZOU5M`:'6(Q)7;?,;$=I(S)K[+G#BY M08YG1Q$>8:=T`N4F=;-_S`+_UO;05?@-D^G%+:0@0/GD?F,3N'^<\"84]X\3 M(=?4-N_0:GLFK(JU^E-LH%SO@'-M&Y:K?0A'_+Q2 M$;(L-S2`KCRO7"J:7V=.S"(?L.CRK\$N(]72Y@`I:@60Q*`:#\B.-:Q<`&+' M*?"Y4`M9?QQJ)ELW9E_&1;DIX`[:H`IE]87&1?U42_,1)U=G M%QNGW'6A\*Z6=C^8A+/*N]IZ@*P*<4V&*Y=T#UD]@#[@=80VJ]LJBT'/P4YI M`JWH2I=+EG!NUU)TBUW5JR;:#I@0KP0`XCFQ>W^;(#M'(T0ZW]V6[BS7+A&R MU6T+<4ZD0C;^EO:^M4*Z+,GR#TPSXLOD>`Y.R)[?H09,MMS$.L'F@(1L\]5- M`%O@R5=+$U,Q*M19SHHLYQB%Y!`,G3V(V@S";K"%[(;5H`5W@TUT-D3$"IRC MY?\O_%7QV_5Z!*!<;X0WBBM5<6B"81?48@)K,CP-P!ZZ%@%[59JAHD8&*-Z4`Q;$D4Z+IV3;#RL+P0J94 M8G15N-%6MH/7%;."4MP&U(#Q?-RN+%CI8`3@K$'37K=J`8B9:A53M>!&>98` MK.WTH#4NX\8>!@Y";[):K".>J&>@@%FZ!0P`#0J)B4Q;"0,UH6FY7;#'8 MQ03-NJP7SDKO!*X;1L7,[J9:&#\B&655X88$)\N1>35:?J:`^6Y)SI.8=6M# M(RII5.OD1B`[XQ>TI*U:EM4=?OK]ZFCU`>L,.W=-H,WN54L0@BI%R!8PU!JK M5(NB'C@M!$^_E4N>7"\E#L04$"(AA7(FMC]&-W:, MKOSJRO,Y8V)B"`NU"=,'/0_4S6S(W8HHS#8&B04MEU*L-&!%L M")F!Z0<*57;Q0307-5][`.5Z3K0B,&Q2J5M63=DR=OMH4$NHE47%FYA:79&A MM55%-D)=K672UWW+:5;M4+%KF90=V.OZ20I@#V3;J\SGY<],46.2KMF MG@.XF**$Y5TU/,BK'ST)0SK)TK#@=)$_DJ:33A[MT+V:)1[/;^3!.+KPE\8_ MYY!C_JRK/@^40DI%+.+\%`5WN\G"$':HW*E?_X/PLR1"'<>R7*H/F_')Q4@* MF'>-_5GTI:KH5/O:YTNYP*3Z>;<*D[FETYD7+!"Z1>$#=E`UJ`<@6L1M\&&6K+1"0[;CJ#6MK4&8YM M:6:])?1+C)SZM1&E/97O)9AB0%<8XCQPNB>8CN"+^G'ANH MUU3)]Y-^O4A0O//1I,"+M#4?V M%'L+Z5CZ]0Y/421=HD?I)IC:_J\?!K^,XP]__`-M;T;_I'_YC\(RRH*K!F3ZO;E-"QY`.P?$Z[L,$XO8=]%E(9,H2178KKE=D1:H6WYZ(/T.,$Q2J@R"!^Q&SR2 MU@'Y,PC='%32T/`1W?^.25NT06)W@M_1D+P13Y;W$V$3Y4(2D'ZQI[,/?P8: M$>OI/*)I*2*YY;Y=^C$CVWOO5J(;DXFCFV42BV*?@I3_A MZ2P(8R("PKH7V'%*.^DQXB^`=](U,7#3DWA"/-MW$HE*WTM_&3RBP3N)7)(& MU*C9_F+P5VEB1](]0KYD2_?$OJ-1XJHYR_L2\L?VF)IC/WG/S:O=2<%(\@E< M:9SXSLFVZ2ERL6-[4K(/!H7DMTV-62398QO[44PI>,$X>8;JL#-!T^1'/"'! MF`GNR.YO?T:'5,#*>$1D3N<=(4H1+, M0X?0BH,JJ/32+*1+Z`E2^DI,::[NDQ8G(=T([]-$R^H1G^YR(>CI0[,`1P$] MEO^^.!J.J.YU,_9*A(2V?>5+WVD-0\EZ)]')XYU$Y">=!F3>H_(XQR&10Q"2 MOIO-PN"!2)[>3\HJC?U$:D0C?>DO5+`I3M7X<,/P=SS$)*(\(-1V1/ M[1_NU/TW?&P`/X?TZ%#FD,/3.'VDM5EC2KZC,`1MX`,,R$%G:QP&4WH!DTPF M3)PT_WS##XA]""CO#"F.P(06,Z')3%S^L$IY*#X2,( M9\OF$WSX@+2!B]7V`3`]">TI3Z&0P,L13@(J-0&QS6]-@)9#)E!\$.N@9I3Y MT>;>K4`4L-L=Z^E@$@BX)$(0WR13CT?KR^OWVGDP[1QI<0I MC(H$@1L'IB4L&HM'X.ZI4Z@,:*J31D(H\$^UKP"[#F+0R:@:02]R'@YD3U$0 MTU\Y8OR'TN*D+O)"+!4YH,(]G.&%[1&W@EH#:7%O,[T`UD?9LS:AZ4;,8HJ4 M6-T6"Y67#090$]HP/0X8)3!8MGRARC/JM#A$M+BD?'"PIO6?P(%!B!K#>V#V M5XA%+0:4@FH8WN7=+MEI1NB$/!I6&S;LX<@:PQM2:KCD`:#@>P&6CY=0BSL[ M[>H+>F7(&D?(QI*R"37#2+^@N_82%Q`E$7$#TEW&D'F20,BC&0*I:S8&2&K= M4):;;>A*#5@$3(%4E6(]3O4YYM-Y?%W\`,:CS0DY?0S%)@(V0_M!1R&P-)#( M*'%0W/@C]%HD_1%?A]\%+SL2L'O@)JNG(Q(!I*(!7WA?;62!#Q,QI0H;MOD! MH+`5NVL#2NLD;N_`LS_Z'0ZS?X<23:MZS&)#8W1:6XU M,0G44`#G`,R8"PP/T$[#1L*VP302P?"]@U0"B`C@5WZ=;(ZI_8#T%PJ2.H0$ MA\X6M'T\+(5_6<&CK/A)LPQMC[@1F?P?[4&S-X=Z?CB1R?^X;Y3R#'A*KW[( M0;)7:31=XK2:@\4RIY$J72(HX`U/RVB]%["U_^B40->TJA=)=F11*^?`ZC9; M.;`L)0&)>U"UD2BXLUV/@7G0U`I)F("0(@5#,!X+,F;M+-0""_.`U%`;`SS` M9$2BQ%(H"R(*Z>!\#AV4L[TC9R&).0:O@68>*4-9D/',1H2/O@&\%]^"((67 M1B68L%Z`IK7(SSS3_4QW6::0_>I6M57;7_2372OBC45Z26!B" M/01RIV$-=41CU,4*6+:E51&9`B6_L2IDBX?ZI[."`"%,[D2J)-`4H.VM,,GS M\HUF@'EO23[$9<@!:R@5$6A;)7ZY*044"=*`!2C:/K!E\/Z9YAJ`?:V-KZAP M#&@+[HDJE,HG0:>CY[S=Z/;R'-(`Q,PX>L3OYEX8]!O@>^=I%ZU"+YUB#%L^ M2T),PXB5@\36OUQYQ_H]`#E\.0%28D+-S=`NC!YH[5]GL/&..X/9).<7WNVT MSO,OVYP@3F8C'F,QM^?>.6NT.Q?YMSPQ0;THF#]P`1Z2>$B!6$H#QY-,WR^^V] M>D(S_V!M$7KO3A*QG1%BEA9"R1QX2GPGIM6,1UC@!PY,X0`'_%<"0O9,$;\6 MD@!S8.*C`@')[K`KE?+G+&?!QNE26JFG0+'3$0ZMQZ?4-$6>7Z%Y/&?8,V/[1\-H),[ MV[IQ`C`+FSD,WH-V`DC=Z1`8&]8RP\7F.:_=FA<,\%`I;MU0AE/(;I/0I;$8 M"34LT$^-X49A(`D0&@*(*S_)!%`T)^0ZK7G86!!HMG;ZMMI_L"91GRBQZ8B0 M[&M0U&BS^P*WSF-U0J8=6_WX,?63OC5OFM9OF6M@HT&!^C>2HY,ND@.KO?LE M%!,T3X/P0;J8TZD(,7BOS2W!SX,8V7@_,\;*?F@J7Z:+0P]F$?ZL,'@`8^$! M%18/0DMC4Q07(CD@I7Z2#L/P%]IE[>^<(NHH7M2=)T&"F`0R>(KHAWADZA98 MTK8H@$%.^@-_!>(;-3%YF!9Z%-)<0O^`QD#-".8\\#N&0Y&R+GW?G@6>"^@" M`?P`&F/4!`"E2=*S3O,BB24?Y@VZ<685*%'W^R6&[)$GS['>"*Y51083>-"THQ;4\@7ZVT#7Y&5O):05A"51+"9817SD$(,J12FC!Q9Q5!(LQ+TC%Q=+ MD8;O0!"1H.!?XL6*B'1GUYW./"G$8+JYX!(X([A0-+4>='\Y\96_+:.Y(A^E MQ0\4@]4"LRL$6#-*R.F?%4-AC2RB)L41H/S^-N`=IFCK*"<0<3N`A!ZR:3&$ M$?'S=%@"`E/&>4GJ-[+),>(R4W+PC[!I?7&=6SS[BK3H;,2'T,H)HJA[@Q4` MT*(7^+B/@$[I;#)&)PF(`QU.8-6\(/'_7R\>#M>,D%38F,3=*89$*;J3>DSH>-I-B^$3**E:5Q?'S M]$[!'0\#6[!,'X=&TPR=D%C00)E7J046\6A`$AHJ+;F((%38&W*L.XIE8"-$ M48OD#8^XXW0!Q(1Y-%(TW8UY`V/[.QM5223C^;B)2*LY3-&PPF=&U5Q!A`=] M:UPED.+(GMI8%-C&A`3&!PZC`34**(B@YD&&DA.@GAJ-`M]T'BX2F+)DB10G#B0KR9 M`Y4!Q4A!L+`P`.G#&B3&8+IN5DI;L1A"DN)Y:H,$L9%8W!0:Y*41%J=&\4BG M#U(,ZX=MG;RBE# M`YDRM/J<&8S9#FAW7"XG8$&#EA._A4$4W=AZJ99BQ[>5H>RV-#!7G79!+0=8 MXQ?V+#"[Z;T,K>'?[0S8?BFPW5/LYE()[-G)KYU6(0UKU:D+MV9DE>1^E;='>++H/:B3U? MX:8"&KG;P?(_5D6GOLP0/:!U:>+)EZ8?M%GG_4:G?V'-KW;-I6^PPWU<_>Y6 MN;:E\G3`&XXY8([I=BX:9_W^>BRS>SOND:II=62HK#(^.]%K#>PV!+`#CM^5 M`'LJF'?./9NRR$6_T1NTZJ55ZJ(Z*N24?.0TY"@J+4-]AVC@KW:L0@Q%5YE) MO6ZCU3O?H]`_(%=E_AZT&&(K M."LGJE[TNXU!K[V^J'JYTLG"H7M)ALL,ESV>RTZ?J_?WE6]]8U[(Z9#2XQV] M[:!,5GP&GF#%"7VG>8[)):,`KR!4G])7,E#!#6A7.@SU",SL"`M;M-Q[G;/& MQ?EV+?>C3"O<\4N$6Y*3M*4UN+6:D#+>O5*7@^'+AZD4@G<,AB#2S[*DW?9?<>4#( M[ST5\K?F<)A\K4IN/XIU'0OV=N!AUQ7"HSV%,0EC)OUE!^DO[4ZCU>W5ZVA_ ME57*\AE;HO,ZGFP8!G@2!NAW&KU#9(`Z&;$F6:VVV05/=+'FB1#UU(>;M<.> M+KG.VXU!I[OEDQ!#M89J=TJUG%6V\$&N=W__D*-6(OXE%Y M/IWF^2KL4W(D>\S>RP&C-"?%+[J-07]P4+:'X03#"=OEA&WD<.1MH_,6F/1+ M+]K4QU"JU;Y5A017SF'!3ULH'"O1CH4;W?'#@FJR!9BW6[YV92AR$KD"GOGB M>CNK,?:H1KX7J[:Y_4N=HESZHW?9&RT2OK65A2F^]SYW\X?[1EMC M+.YX5JR7N!5`=[KVDKZTZ[[7SP0F!M]&NL%28%O;T!XNV.PIOQ8 MUOF$<3X''K:PFZ_'V&EUGT4]1D]V!"*<84E9'6NDI]QR(VGWE>$?Z_QOMSSQ M*M!\HKY9=C)R8PJCX*(XH*)*Y6)_F+2:<)26QK6X#9V0#3!DPRWY]V3`5N,@.'YK8R)`ZKTA:YQ8\JOM(K+=[PJ%D/Q^][KG6 MWY*+KV=E?IO6YDO,)IB%8F9S,PI9A)L[DF%Y=6ZB0)6GJ19RUH!,ZT/DB;1O M'K9SQS33F%K9:5U;N`?(Y>5G]17W;E$=J5Q?EF^'K;=5XRZ%?<(5SO>XS<0> MB%QMG+YOT*NR\#)VUJ7<9RR6GH3<1$Q_EELQ4H<[O4R[[!!EC6TW!"25EZ>N MJ`%>*/?-G2@J%J;:Q$6W`IL"QM8[@(+S>-L-;HN1EH$';X.JO5/E<@UA2]!D MQUR<&A]A6(A4W6D5]++;G\('2E&0&]2V]"[M/*#>I:&Q)':`A?'3UAW4.&KL M1MA#$0O^-ZTKV0?&]:DK1EH7?1P$L8_]2D9IW6JY930OZR=%AJ4+7$3G*7EJ M?)%M!39UF+HQHDYOZ87]E?%^.!=T#Q/D`VZ,3)UK"$M(($[H#G$/'[)N.)EJ MI3=`O]YBPSJ+NJY$4:'/U&*_4!"5%2Z3ZF(PLK(J.JPU%KL?: M%.OEQ[3#&9(E*0MND`=0>,*FSB?W6'@=GH[$A@R(TX(*WV( MM%2Y=:,-`4C";C51;JN1W2ZYZ]$70=TU850P0J>@!$[_.R4R:H;)^>]S;(.% M^+&K7@H+X)H0+-L@(E,3S5,G'3V6$?CY*'Q:\M^*N&9URJ!LM;,E.T21O:;T5CJTU!91_ M9@"X_BTW/YK3RAHVL'\\MDD!*SBA7]A><*A;!_=/TM<'8H;L&NX>G,ZUKJS- M2\B\]/PL6]JCL_LG=9*-W\LV99HL[:_O@\_'H<[.N]V.%H=:-'4>R&LPBMT0 M-^?3^'?8FM_1Y+LD"O]/X6$DYEL66>NT-FC54!(U.[LXUWHUK`3"HZ`NZ<&P M$HY_1.XKW_7>G`#]BA/KEZQGB([@K)''!]GC+9VX/,@Z6`-=&%WI=+6V(0MG MSF,)T""`XJ_(`G$>]-:D8!#01VE>DAWP4!(M*8FD'K&FEPBS%,8L#4=/H?4/ M6<./I36.+9<4^J0JR,4TQA+'66PCWUWVVW];O[M3E]JSN1&WHPP<;53L%%ZJ M@)7BF9N`'(=8;J5JEIF/,(SPMG0(CJ_>X%HH;XK,=CO7,KI4%V,H)Y@*77G# M`L0T*D(@Q^*KUOCY#ER#26'&2#4&PQD6F0`ZF>K1!M+<*1I(L#4=09;Z3:6=+:.JW6>=/Z M#)054M.T4LI0M`@CZHR<[MS8PWIW,G9Q+\AQQT@)TGJ4LNBRC9ZCF[(M992C M5,#.NV3V*0:M0I.&(D)GB%TGN:FKWIR5J:78_KC5[.3]==6B5082*@QOS=PN M=/#CG4B[Q$<BO]ZGW6MK+)`VJL?4QZ#!7*ENGK2'QI^3-`AQ>A59>=3%-/$9Z1AG2"* M5;P]8VJ,((3?052SMTKG+M+]=>F\.@U&@*Y0I)VT64!/@V_S,*[2)7(ES\\S^A_VO(+P"<00B.I2/5K+ZRD?Q1\'J M6D#62C%$]*CZ55I9PTK#_NL?V$G/&SRK,O1 M'7+"R,K=&]?R@JS+)+X-0HQ.:HQ/L&`W8M?9&>4K'-163BCY5Q`8M0FM*`06+?),]^%"=&T11`+H]5H>%Y'OQ`7]$)X9H[\."V-5W<'2. M<5`\9:*@L^F\$A,J>A@5\J0;9C>3:^!";$C(H MJH%`YZRR%R"/IL)F"V?(^1#<#9M1#BY^[,X\-SL-]ZGA+V,@QL50():.+"(I MW0K1&T3/2W2,Z'68>A@$W_-G&"HP<3V>!Y&;TD?T0_[M!C8.'R:E--AMZ"VZ12XF#]3"G!O(Z\0D492VHE<',`B`/(/382'D MI-D.A)V4[F7V)T5U?/TMF"[$6-G?";=USS,G?G+L,*1$'[F;2/L82%3'/".- M5=?55RNKGX+7BZG;ERGK_PF<__Z'&W\*WU%,S?8NP9.^HT#FIS#7,*#:-7Y> MJ8SY+@KOM?N+M5$=];*!2P)B7P1==B`V^NS9*OJE(G.9EPS;GPMZ=9KM\J`7 M683ZQJBXMQ:P]A>W4I:V,7OAE#"W"([6`C@XUA6AKB/;6<*B'[FCWSV">8<" M9LKVRQ,362R#0XQ")KBG@ZJS^*:U$/?-56XUR7*GTRB`AT)0<_#PPC?RSP*` M4W'*M`,"/PC5+_R8[4?N*>SM)+$G`-/[CZ??;O(#E/XX=$?Z:Y=?3F\N)1VE MIXS>0P/U1Y&JLMWL\&9BD-$3-I_CVQ8=5_`>Y1T@>@85\AB5.MV?6IDB6\U> M)278*<05Q/DB@JW%/#"K9YU:6?0-L^;B+%/L2B5]8(X4//@[PJN%XE[FE4?) M;;3%\92MZ83"N2\HM_]!W?9IG";!76=)&$7OZ'EE0EF76;;R;#HW$E=WE'CE%0-%LX35G"GF6?Y-+-_)2/*SH0Y M;O#(3[H,TDM1'N(])]]PZ(GRQ&$Y?!XS%%5+&R5"V;7L@3JI0PEF9NQQ]EL* MH,2X'_BGY/C8X8@"OZ=\_X92N/P;>69SX1#IUP`=T,+>H^LNP"/I,@358?R]"1(,?3-1[A[2A5T+0ETOU5@ M-Q8Z\M/_"*8/:A;E*AZ$DU^R( M);U$C*5AY@#D?-W#8W\*>9D'TUQ!8^S#@E!PDNE$F9)&0X M>3=Z1>=SIS,/Z'@L1/J])?%S+3%36N?-?NKEC"HH7;^HI*( M`[\:R6$:9?FWO,KBJZ2#7&0%!Z`,83SV'^EN'6:5'BZH(TQ^(N!R1P<;+>66YX]P7\.(8XU6L[03=N<"1.,?: MC;[+-&806P!+X$N='H%V0+LC?2^2BEI"E,RD*I3!.VE."!MT43H4G?+XV5F9)DDO_@@ON'^=Y6.1KY3B4DVHL`?;:4W`M/#51@$& M,8HW08\L#*13AM?+1$BW=Q"Q4P&6F:;WE^Z^/)VRI5$34]6I+,X&$_T+D^]Y M'++9>*]UAY"]21QX',H$++G!/)P:!%>GMBA-PU);OD/A<*ARX!M%.A!)*96I M#$*+MNND'`P]=Z(RT/"@!6":T460H(`3.KJ@P=R7 MU#=',!$2Z]H1,,D0SUDB.HYX34MZX=Z]S-++P'X7XS'>&Z-XNWZQ4\*:G]'0 MZGRP4ML/-])=)1W+(.;Q]JVZ7@-;%=PC86KG#4@@0.2O#MU66*M!E-X0JM@P M*@<+5PVJ=1>H!9VL-F@0A=T62FLTRK&Z/RTM^+3+FH42BK-5H9!I)A[3"O\6'U-EF[NH8 M9U9[P.R4CAR+*;XED^CSH6=;&0,.GOE2WK5N28`[4@)5J3QN+-ZN)RN+1?_I M=I&1AY!AORBBJQT>E\:PHUCG8@HQ&X8U#&L8=N\,.Z>Z9UZK`DZS),3[R_29KVO!MWP]'/`Q,LRW46*A?@JH M)^[.9'&IE`+PLHFLU2+3$?)!8WE[ECF8%4:,-0NIK)ZZQ:-&8<*1A5UD*1?] M><5R^%%"U[0N9:4=U[\+7(<9*[L>E+M?5U@1R78*5X\]3B&0[%"HJ*=IAKE9 MR]5$;E95"DA>TLF!M]KTBRX5F;CS_!D)'NF!.'$YQZ:0*&1G`CHEL0FFD_M< M6=*F:R)21FNORN.N,$U!'>'%"+G?95IF_N4TL3TFDYCRI;)A;8Q\\ZT2K/8) M.TX?YL5]5ETI#SMQCTJYQZ-?+!O%]TJE=J')&AF9EI]C*NNF]*R$S__5>3#E1:@_S63]NVL?E1Q8`9CW/)<#N7)=HZ/(C"%4G1*N+!U93Y%I M91@U+XTLSS$7"F$P>AK!B' MGBXH7$K28S;/T@USU=AF2-]LY!7`H&<#61JO#`*:J!R(0C:&M+AH$"YYEWE; M*^0)$G0K9`,J][Y0.`Y-24),+OO/<\=91LD]9T&.\H]HZ8#Y?$WT'ABJ7#B# MA^&K;H!V+U:IZ%G*86!AT8"">`0]K`@#"W+0K2F,?IUB)`RS*[`HM[HVJ)#] ML[3;P0Y.3?FTRE\-J+U>O%="WPO93.>?;=*R#`"S1&=E)X2X"!ZC#S:C2;I^XCI<``@ES61IFC46 M'95%T9TT/QL/7K%L!XMP7Q-.(R[N,:K>^-".R2A+!8[9Y4?M\LV2GHJ%O$HR M[V]#D5Z!(R6[PI4X>I"K,&"6G>TYLK!92BY2+BP2!SA&6M$=Q%/BZX(AQR;%B1B9D-@<6B@-8]+'>T M=X;;]7H>'P"!=`Z'(%#T[V73=\F=!X3\WE,A?VO9(%O@UK*LEUS+R[)^IVLS M]8YG*>'VHUC7L6!O!^E/=85P/993K_F+Q77=G8B,U>!N'X- MSH^XT?@6&W[CWU:[TVAU>\MZ=#]U6^[-VV-O1N>/@\4PP`$S0+_3Z!TB`]3) MB'VD6EQ]3;]QUAU?4AY-7=^E6H?NG5AUR_;L,3P%[>ANVZF*/H'3IKMK^8=D M&&W>J\L_IDA1.H+:@T^%J">0+_7&GBZYSMN-0:>[GN0JV8*2!PS5&JK=%=5V M.N>-SOE9W11NO1%HG%]U>D_%1BJ[7`JMXNP^7.'ZV0F/\2)6I.-RYNDTSU=A MGU&`94CSSQVQ]W+`*,U)\8MN8]`?')3M83C!<,)V.:'JH66UI65F0(EM=-X" MD[ZUC*WJ8RC5:M^J0H)/?7=8HAT;_+GCA\5I=;M(FUH3BIQ$KH!GUSC:"5OM M/#]M\5*>?L9M(>]=5D%PI7PYJG&HTKC5W06L"B(K+.=)3.U*N]5J@-#([U3Z MI.P*0Y>3M+1:&+7B[@.&!*?V2)O,#U0F+S7S9+"PVVXZ]%SF[]Q%"RTC?>>9 MMZ7;.H>ZG7!'G5,VUT[#79RQN3U)]K3IFR9[\FBR)_>3D[4H:7,MTY\W^CT+^IV2K^7$]BG`]YPS`%S3+=ST3CK][=Z)FIR,X\J-_-H$LXV M99&+?J,W6'J^>3R;LMX.E,HI^MU&JW>^ M1Z%_0*Y*M]FE?UKM?J_7OE!DFV\:/P0U,G;WY[4.P[ME) M3X_8"L[*B:H7_6YCT&NO+ZI>KG2R<.A>DN$RPV6/Y[+3Y^K][3$QOUZJN^*$ MOM,\Q^22DLS&U1BHX`:T*QV&>@1F=H2%+5KNO)S1276N7Z@]B04W'H4 M$W*QNX*J$2Y"QXW2QN:J,2FL/TWA58F^F#X:B3L*2FMGH@!>Z75HWFT@]#H%\7@BI.FMAY=&MS]H#/K]S3&3 M;_21O9K'C]ZP0%U`R4'B!WGT5-2:;Y;86L^^J/=E7,4?MS863\>``S:06UW3 M:JWZ4ATKZ[-C!X=JC=]JGE>0TA0[G6%[*A'K/?!R%=L;LI'=O>IR@@"D<.?Z M/V#Y?]MB?21&IS;:+Q/=WM&AZC0[%5`]"#M<1 MX'X*V%62FP@16]O.K>)"V5`MDF9SU@L1N&N<(,/BL,KRH1N#:C!LE)@V@T,S MR@Y5>T-!?3*'(KX7LNO:&(QOW\%6R%EO&;++<7`[8OU#W@X"'>6@=E%#7E*+ M$I9@W$L.FPB"=0U"!BPP-[I53=ZX-2<"0X(%&TAD+0YQ/CF%[%>G&ACJC2B& MU"340SG:M!#97I2343I.V%%+`)H0&T/23[,@ M!H!9S_U.+>/!8L:.?NK7\]=9AU`U$KX=@?$',]"EM[2C!FY*+)Q;'P,LUA1H M#!7HIR3D;I;4YRXG8.D2G6JT`8+-]M1.5JV!'"Q4(6`9^ZKEGB0X):QA@V@+ M*VXCOH,]X6_;F@6#FDMWIX'B/*]TGX&F'6Y91CAS;P-6`+Q+J5N'!(1`9;V. M>:O3%JQ3[#E)+9)+\$_W>Z/;P#-]95:#!JELGA3(A2\8#*TJW:PL!B22XCO= M)>^,UKR9G=Z+Q1Z1$7([Z&_OH5$Z>96U7#+Y6G=R&[*S/+PK?C@>2.L[HD$6 M1MQ(.6OFF9-;FA2/H@"$*4HK[!K-*$#)-D71FO'#!-CD'@!6TMZE7LQ>,E)A MDQQ7QV1-U!R=C'XT39WT?KZ2IC*B6$P4&:*.M,FFF+ MG+*(@:WCJ81*K:&@Z51K9%85^-NWYDW3^NWR\O.ZIEZ5I<;VW,R=O;KT_<3V M?G<=7,9GU5-=V7'G>3ON6K/<0*:Z_.VWFWA/>2?^U0K.>?OU1- MD#TI&SPC4]'R)&@WAK62/*FD$)L!<)`;:/-M)P0 M2BA`=5-UIS-LB(T:%?3(+,`&U>B**`#S1-3@)JX1ZFAM(]*_9B'(\!!E8;%% M;:.:K`@6V;I5!>GN[9#C7=G87TDI2J@RL`,RYR78WD,%X,7#H_R!R0(`BLT= MR4WT'E+C*J1.H0_R]:F(;['U8@EJK!)204;.*``_%78_:Q,8N:!B[)#-H2') MD\+S0ZTU>,6N5J/'C?)T"1)"*,-+0?H$'07SO+V'2**,%LX%^70+^*Q9%4C7 M+?91<(!04U&YBUP-?=]9$&=M:-41"+M6D5-:M=TBJ(7M`.[ M=8USW3'0R,T-V72.$(3[(/%&&"7(T=.Z=N<2DRYO_P$)7'+(!U[Y'`9^@.XZ MVHDR^EAE$'9:S\H@_"(P,&MEN++RR'H*8S`K#K/DR&![Q[Y9DLL>#WKWJU;_UA/TC^1V'S(8U5:E1T@T8%'8Z\#;"+\8LLEO?A M\N9M%KM["7HF2D#.E+[\;4;MC[6W+V^^Z2]_#)H$"O!DP_HB[H0/2HK4^16L M,[31RB*?_PK6`)91&%DOO@8S4)5GK;.7A8'UT;1)FE;A-RRT!23ERC@P6#BP M_ADV$$?'6H7H<"6AA`C4YDC`K+&T$'";V0X#C3)U,4*`CCN7F..>S12'=%*H M750A,OK*\4Z9)\$PD`TV4L$0>),C&&1L`E)CU3DXDO%:^M)CC0':`VASHJJF M!2#!YX#!(`48!),$?`^,/]C2@J5Q&!'8%QV#I1@RI7;L.OJSA:`%H=8_-PT' MEZ)D1@DM,"S@%G[&,$4Z=\/R[2DJX%**N0I&L#,.XT'M=-\Z38GC2Q:U;UJ? M?.N_$ACJ0AT0$D$#@5IW`=G-ODQ;NN-(-P68-!.>S"+J^3Z>(Q*P"X&'+3Q. MHW"ORKIIS#U)\9JA/B;NQ-B-,$9-QW'P*["G3U;Z&'&<1H@1:!AGT&`\"[(' M[9'J9(]&:DS.0A*3J\$(E69<$+HP+$PROQJ;0BRI=;IL_K-Y)G$5K:%U[)*1 M#])(MQ<`$&I:/Z4]*S[!W>OY0`$L%3![0J`O[($M0][2WM8,6UHV?%T$)0O' M9=YS=L0"#E#,VJYI5$^=5<\*OH#9IQKL$Y@(ER!GO*),59H^XTZPI;L-ZUJ= ML-`"#ACPI`?I]!.J#CFKY?$$_K*9L M(PI2<*)LJM51[90M.(U3D9K@F,="'/*H\Z2BWH%Z6E%/9)J='>*P0(0%=Z<:IEW<-?U6?,> M[PWP(5D^?JR-@F^`>5;BY[:?BY]+E40_@CEG=<`,O$E@2T(*1FH8RSG`$F>T M2<,C.`?92]5B_<2)@IN?-<%LCIC6SQQ(?#L9409_Q:ERN03E\VN6UDSCO!NW M=CB]A&]]@?K7:;+`C.EV@^<]G`;W&-N.DB&XE2XP#-CW(-(BC65(NN)AA.T_ ML$MG.UGL7"JZ7)32<^5U"50'&>SLB6V\Q&P"T+8S.^3A<;$A:S72B9PJ@*%4 M^`5#FB.%#^1YS867BOJ;3X#=IC-A,#^/8(32[Z7C^!H6,$,MA0XX/+1$I2?Y8#`Z31]*E@'MI<*R2^V"!JIW+=8(-C7@_1\`Q MZ'B30:0A;`F:;*G$,T-$&0(5T$OK1N$#U1?(#0HBW`GMD@R]2T-/;4"1XR"2 M9*5YRL72;(JF=26SPUP?S74[M;S&01#[J([00O,"M,+DEM&\^4A^Z0(7T7E* MGAI?9%N!'K<,",R2$&T\RB=V?;ZWP:=R8>+)/)%03.0Q`DT:.:$[S*P_FNHF M.X_`-]ZK6-)5,)V"^8:+UICGYOU5CFW^1`@]5]R)S.[*T(*3!G#*'H%]CD8D`#ZUO\O3+0W)F=%-.6QNY`F;#CC5^2M8?YLQ($X?PF!2?OT+ M[#.:,OI&4Z`:T)P%CAAFJ=#'_TH"MS(_$6#(2;%`BN`6SQ!J%<[J:GC MD?]>39]O$0F/]S*MWZ1QKXG(KQ1;1U&7>O,5:A&9$?D?O>Z"%$PSMC-]G`H. M=>&"N=(&9W.J+@>A,&)O5PI_9$JT&::I"56>>MW0Q3HEW)"%@=.6OV`IL2<# MKU52OY'F9Y0!(P\:>'290!CI.3U9'CE[PUI"PN.M2]TLS)"*4@L%6^75&K4@ MC.<*E;B13<1:22U^&J!U0SF7Z,5/P,QX*\^;)=;DGQD`KH]JPX_GE:F&C3!` MK0\3.'%"O[":=^C,FC,N]?6!&)7Q&0PBI',]F8C<&H,?@``%!2@`\]85:3#G MP?J*7H;W9"[D(0O.L;1-@*0=A3[)83D/;RQQG'EZ#=TYM+[]M_4[N&T@`AJ4 M#PVLX06.-BJ>;97*-<7/QM\!5_:EF3$ M2+&)U_M3"[T@XBR9D:G)1%B`F$9%".18<^ERN1G)!+ZS87GY;,GY:34RU7TO M+BN@T)`>FI*=CI8JV>H@<0'3^!3>#.7D'\_].Y%B&$4JRL![K&2`U[,#0M"X MP:8QN"331&%52DL4N:&`S<3<>9E?5DAEITPUO,DAPNAG"S5F#/NJV"^EG[AB M781-P`3`+O(#ZP!505/J!$HDI*.?,XLREO*>D,O)26V$N/;99 MR#'1TTUTCEW*7]=X:@R\D=XIS6\7+M$3=$!`-W!X\R145;R5WO+$6SZV0T8+ MK:W3:ITWK<_JV+:<,A0MPH@Z(Z<[-_;P5K[TY*AV!9X'A/)BPWC%C9ZCF[(M M993G3KP5@U:A24.1K!G"E\DHXR'+N6-J@;$*ET_REV4LE3[G+KR#H5DQN6A` M=M-/NI&1=NVMI%`'X7!5!.HG1PA;;KL.SX2HK>%PA;$HE/KTQWN@+C`QGRJ= M[4!Q\-TZD<$K#DQD(^E0K=I0N M*<]0F4>Q5Z[5S^.R=#TDK4MU-!2\9#/OMX?7G] M+HLNO'7AIQ%=C[XZ!W67L@ZS(!/SC$L(L6Y'U[^>7=93Y_LN*R M8VUMLRM MA%8!E;6)2"@$%@W93/6E]YJ`E!U9/H:B9+8;9B$Y\J(01R"9B7E4%+-PIYI< M%ED"@8X=T$R&!:E"&>A1R[PH_98RIYGBJ6S.G>=`8'J81LR$IS=82L["4"?7 MUF#OG"/`;@BN)KH7#GU!QW?R5(FK2534,,#?04:X(0DT\<.-T`[X4@TRE:C# MM?%)&)WJANH.7LXJ>@%"1.99T:,4#.4[983R*5X_X]Q8>:26W<_3+^;)"UDL MD@I!#T3/2_U:UC`(ON\^E]^K4@6#((A^@R8V; M9D(CL$95/U(E)H@A=1UG4@\/!,B5,98]!=.%&&+Z&S$F]R]CSESZG]Q-I'V,OVEUHE)6K:.2 MV5A$[A7:?$>1]UKM\=K(]GI9EB6!GB^"TH*)SK'B5UH)EB-.U;72.LU\)=$T MF*-J`J8;H^*Y:]>D93>5TF(6P=%:`(>\?DL%8M$BE;#H)W3HF(Y@WJ'(78OV MQ$1V.>/065HZ40VJCNZ:UD+<-U>ITBR3VJ=1``_AI61X>.$;^6SQ4AV+W MIXEI..@Z.U@V883UPPA5)_3^Z)<`1=I0C"@H+FRJ8$DI$#:9=&GR?>[%8!P+ M3NUR/+`7^2J8'7'Z'^?@Y?(E,%TJ%"^Y<3,*+7I?X=G087%'40C]X?>O9SO?3&^8MO66K&\A'RI15E*D?B!T.\&DJ.I^O/P"?BF*NM MG%E5A!#@;FAQVI%U%^#Q"Y?_DL>_]"153`'K`'=/">>N=O$HSVXL.!!I_T-( M^R.[-:.)#KZ@(ETE0*+M>D^7$')<0KKDENX!B.BZ!X/^3$OE"6+Z4+\HKZK* M@11]F*G*UGQY&UU3D@^<.!>]HM.@TYF71*=C(;1+WB0XW1^85TRAC?27)ZL- MV3YK]M<[$JF58OVB$O@"OQK)8:Z?1JXD0"Z.P+?VP--)J!KB7&DO"P?'EY5F M4W*:KFH[)&YQ:BQ`A8$>U*4K/3I?&BD4JF1A"ALOYQ76>=6_P,OU&)UA126X M-@V,Q/F-;O1=IA""`0ZP!+Y4QWA=/*O%,!8B+7'`$"4SJ<5DJ$JUM+!!C:1# MT4&$G\T'PO7Q*>$?$X3K&V51)9CH7YCX M*N]^<@D$3]54R%V'X.)9,DM';C`/IP;!U:DMRNH3R2TWU>/FH/E&80-$4DIE M:H.S-%\]LMC0'IQQ*I%%.4I^)7,%&.5EWC0/]5.^D7;*IZN`HA"2_6<0 M*.235S#URSSXD4Q-N\5K'J/7\``\H<66=5(.AIX[46E*>*P@"TPIVLH60X%Z M&LS%97A8"D46?L;H0X!UGZGR*P;?7].27KAW+[,CDZEEVN.*=2VP.L4BUK6:KH.A(($/FK0[<5\)8T^;!O M3JZ2,`K"SP%=/=,N/E/_&\L1GB=K,F!Q6_HLF\#1YQPL&Y>?D*\7ZC@4%UA> MC2(?*8P)SUF/.]"7N<(9LN,=\J$]B\0K2_U%I2BHXVJK]9.Z`+ZL*6D4L>75,^'?VK(:0=HZ38NC@+[P@-DI9S464WQ+9EKG MX[BV,@8QSL44'38,:QC6,.S>&79.=>>,^-1YDN$.M.!1!8,%KZEY MSG:DECBRO0-':C2_DP^XL^KAV2RY6I4OLZI,0GF[F],NJI_G3]KDP@QX9H#PM)PB5HL#ZI$'X':@*JRD\ M*$V!T;JT'=>2<-=K+=&"[MXM`X?6JOH<^:.*&(8\6%)K5NEM?/&Q(E)A0MQK MA;@Q1%EZ5&"]0%$`;D$N?*#'D2(ML$KM9%\60K4RU`L;A66M[8DX#<:G6N!7 M%N.G@/:2AW1ZE]<([2@7O402G8#W@JE_+[+Z0MH=KY)8O"L/94>*SM-RORJO MTDK2$*":Z25#K-UU7P;\2,SPD%,A1.6QJLH'FI3G)^G/_#DWGQ>KBGCY_%JL M?\,A,Q=OZ8#G!L`CEV%F;*1"[.EPZ4V:?%YN?)N;,Q34DM/C/&-5\T0V+J+/ M:5%COD,,^'BZWF,'SGR%+#W]%%!/4YW)XG!]"%DG0682Y(/&\HHE7"]>\"UV'&RM7%SK)F"RLB MV4[A:ME17+'#7!7.5#/,S5JN)G*SJC(<\AY)#KS5IE]T[\7$G>?/2/!(#\2) MR^DQA1P?.Q/0*8E-,'G:YV)L-EV*D#):>S4K=2K3]T;-M&AXJ9:9?SE-XZ9: MK)SJE`W+_1GI#@46R(,=IP_SXCZK;)*'G;A')9CCT2^6;)$-)EF[R/JV82G8 MZ3FFLFY*STKX_%^=I^SI4O(.7?&GYQU/W6^D.CC4)-G2NR03D/5.<*D5^_^9 M!B^F@5H]V*5F:TW'<9+Y@4!IS=#QTP*O.6# M\:M3C&5Q.X'LFIM"]L_2\@9+-C7&TQI9-:#V>O%>"7TO9#.=?[9)R]*%/TVO MUV'W$4SI^3NQ0YB#_#!5EX=+J\F-=\/J_Y)B6[3G<[+C20M5M,R47*A47B`,=(RQB'V-F!JP3IQDH0 MCH5+B?SUT#-%&)9U8]OS=JOXT'J]S'%3=YAF]+1GA\5=RGDWCWISP\-+_;"R M>)@ID;'@3/!@SC4W.+P%>_M4#@;; M`+OEOSDY.P&LW(?V[,T)_SO=.KW?CT.MWI:>2JHC8%Y^VI?):@-342TVZ_]S MIVBFP?960;J2Y!JR(;!8%-"ZA^6.]LYPFYY4'@N!=`Z'(%#T[V73=\F=!X3\ MWE,A?VOY'%O@UK*\E5RO-$^,EU[>7TI7.YZEA-N/8EW'@KT=)##5%<+U6!+< M-.?[)`P2?W2JFD$ZCA#C<3FW+EO@$@FT;+J5,/&EXN+-3F3F*A!7S/,X7.&" M?UCR?Z^MJOTK]+-$"W0[6/['JNC4EQFBG[`N33SYTM1#^+?5[C1:W5Y)D9`U ME[[!#O=Q]9NN4O=''T_GCX/%,,`!,T"_T^@=(@/4R8A]I%I M35W?I=I\[IU8=WH;IOJU(Q.F^ZNY1^28;1YKR[_6+Y=MO[@4R'J M">1+O;&G2Z[S=F/0Z:XGN4JVH.0!0[6&:G=%M9W.>:-S?E8WA5MO!!KG5YW> M4[F0RAYQ0BO`N@]7N'YVPF.\B!7IN)QY.LWS5=AG%&!5SOQS1^R]'#!*?<5O(>Y?5`%PI M7XZJ%*HT;G5W`>MZR/+&>1)3N])NM1H@-/([E3XINYC0]2(MK19&K;C[@"'! MJ3W2)O,#ED[S[PMW=8YU.V$.^JA6 M&:'N)6"JITIM*'Q!:`7^!+]/TSVSKU:EU;HF/QT\A,^6$GMK4N(2AJ^9)'PR M.MWM+&6;?@SKVA_VMBA7MLH1AW@T9O)"35K<]@YXSON-3O^B;J?T>SF!?3K@ M#<<<,,=T.Q>-LWY_JV>B)C?SJ'(SCR;A;%,6N>@W>H.EYYO'LRGK[4"IG)*/ MG(8<1:5EJ.\0#?S5CE6(H>@J,ZG7;;1ZYWL4^@?DJG2;7?JGU>[W>NT+1;;Y M'NI#4"-C=W]>RP&IDTG?3TB*W@K)RH>M'O-@:]]OJBZN5* M)PN'[B49+C-<]G@N.WVNWM\>$_/KI;HK3N@[S7-,+BG);%R-@0IN0+O28:A' M8&9'6-BBY=[KG#4NSK=KN1^%XV<(^"`(>-D+Z^0#MAOM0:4[(?I45VGQ%::,TANVMK#C05U,XW.=#*EVO]O5=)K*347KUD[6P6!C]4 M)=-_Z`0YZ,^E\Q8K/E=48IWKZ&E/0L'-0S$A%_LCJ!KA(G3<*&U-KEJ+POK3 M%%Z5Z(OIHY&XHY"T?`Y>=Q(,2$?`AP&L+,S:,F#_AFO?0B;F/MD+5MKN7)0N M=8;];((D\AYTE"U%P+UL%1)&LNQKXE>M"&O`89Z:LS1J M$4OP&)-+UT-%CF43D^K\Y;RYOUQ_+\EF# M<'9K^]$KRT[B8"5Y@Q#2-W$(+V*3,!S-%W/J@2<`?R>XA_';K[$/VB@#BP8" MX(??71@+!\0$HN]">4CT^\B-9IX-.'5]JB>NZZRQ%]BQG)N$"_=UGX_&J1K) MU$;+BG?<:6;S6PY/)I]7A^;=!@)WP5T**R>(L'K3!E7WGIX:73[@\:@W]\<,_E&']FK>?SH#0O4!90<)'Z01T]% MK?EFB:WU[(MZ7\95_'%K8_%T##A@"[C5-:W6;"_5L;(^.W9PJ-;XK>9Y!2E- ML5<9-I@2L=[%+E>QO2%;T=VK+B<(0`IWKO\#EO^W+=9'8G1JH_TRT>T=':I. MLU,!U8.PPR47EK9H8R^[\K;7/DK7W(WQJ_U#1`38L^^=5(!P#>C^%*KG'-FI MLM%EC*C5^K'8422XJ0$V9^1./L1;MG.K6$'V)8ND[9JU%`02'R?(-3BL,C_H MVIX:#/L-ICW5T):Q0]4E4%"[R:&([X5L7C8&"]AWL*-PUN"%C&,$Q0BW9,->?&#B`J>#&>1&MZI7&G>X1&"(N[&+0]8I$.>3 M4\BV;ZH/H-X-8DB]-CT49DT+D>U%.4&AXX2]I02@";&_(OTT"R)77G/T082Y M8\NE9C.2JGJ#U],`,.NYWZGS.IBMV!A/_7K^.FNTJ4;"MR.PP&`&NGF6MK7` M38F%<^MCE,.:`HVA%ON4A-P4DMK%Y:0VLFJ-9"7@W(XST+3#?<,(9^YMP%*8 M=RGUK9"`$*BL93!O==K)=(JM&ZG3<`G^Z9)M=!MXIKG+:M`@ECT15)FO)Y&M=C&W(!NWP MKOCA>""M[X@&61AQ/^*L)V9.;FE2/(H"$*8HK;#Y,J,`)=L416O&#Q-@DWL` M6$E[EUH:>\E(Q2YR7,W]XKS`GYQBS*(HZ&7/V!$UV22+&\_T9),=K36J#&R4 M$`9'2J*LP6>F+7+*(@:VCJ<2*K6&@J93'8995>!OWYHW3>NWR\O/>^I^N2-> MWJO1]M:.7(Z.&V/N<1;Q"P_0^1)="W:<7F4( MM3+(>2?<\E>0L9&5:8>&:(7)5N4Y+D77*#_`\('X3;DYEG)S_(2$E^:72T<] MB;&7.`VM"4#VBAHLT.C'U*LK^MGU:)I5*WKX`+*+,4@6E+9+:>M?`6+2D?V( MT5"Q_=@]'2%'@O9H6"/)F^!L^M2O>SEAH##79EI.""44H#J&NM,9MFU&A05B M>A9@&V6T]!6`>2)J<*/2"%6@MA'I7[,0'/?0]1[FVK`VJLF*8)'M254@ZMX. M.::3C?V5=(Z$*@,[(&M9@NT]5`!>/"#)'PHL`*#8P)"\,.\AM5U"ZH;Y(%^? MBO@6VPN6H,8J(15DY(P"\%-A][-6>)$+QHL=LK4Q)'E2>'ZH-;"NV-5J]+A1 MGBY!0@AEURA(GZ!K7IZW]Q`MDQ&QN4"6;F">-:N"Q;I!G`NEMIH72UXIW:-( M.""HR8:[!:[FWH8LJ+.6BXI(I-FHJ$GMFDY1]()V*+6N[:O;W1JYN2%;IA&" M$4*Y\#@,_0'\>K>@G";,.[G,%&NNE#W)]T-V+@,GK+SNVO?^L-^D$R)$N!#&I_3J.@&-3U% MY=\&V#[W11:_^G!Y\S:+5[T$X1\EP/RE+W^;4=]=[>W+FV_ZRQ^#)H%RVKIH M6%_$G?!!@*1<&?L$LP/6/\/.U>A,JK`4KB24$($N&PF8-99J&[>9C2,0\U,7O6)T M5KFV&3<+IMB;DT+MHER7$4>.\H9!=7!G00QOLM=.%B`@-58M:R,9HZ0O M/1;C(-*!-B>J7!=XQO/`H&,.6GJ2@$.`/KH%4LIYBH8PUTWWK M-"6.+UFDNFE]\JW_2F"H"W4R100-!&K=!63,^C)?YHZCNQ14T>QJLE6HV?AX MCDC`6`,>MO`/IG.8\1Q&A5% MH&&<08/Q+,A(LT>JA3I:CC%9\$E,]C\C5-I60>C"L##)_&ILWT_@!V4R+IO_ M;)Y)7$5K:+*Z9'F#--*5.`!"W=*GM&?%)[AM.@?1P7P`6R0$^L+FRS+,*XU@ MS=JD9@Z"K9]"T;-9J'TH M%#29NY0+=W,@G=-1X.51XA#4:8S;L<.0?'VI]BE/4,&4SI-&1="0)R5`OX]` M?=#Q),?4]0-:2G.AR`%G:*9:'=5.V8+3X!&I"0Y$+,0ASUF-8ARPJ.WFQ;$B MF+6U89_M"#JO=*>I$D/D$"!HXN@#DI)1>1WJ_+2H5Y">5M0CJ49WI^C!@ZCP MYE1+>;KT/W])HM.);<]>W0!?D27CQYFA\QD/9L'<^@JL]]8+G.^__M__8UG_ MG+GP/#K9;_%L]TK+FWF/F;?H&7\:OY>9MY\Y$<4=O3GY:D\ZG>^7;S[@0(Q7%!,$18KO3701_$[3]_ MV0"092OX(O-6/P!7W&"8ZQ/MQ8T]+?+/5UV;+%,#2[O,%:E9?77G[4&G^[2KNUAQ=0OA MON@.^H,GA1L!*F&)02E+/(KB^IW>$U-G?.SIUU>B68O7=YB MP,];@T[K<8"7/WJ)9UP3LIC>/F2/?+8?\*M+3.IEQ1K]1H=AUW[!=.F6Z_N% M/$7S1/H:KS]^`'%'_J)F?6T5XF7FP`KC?DF/+N??#PHM]15+29 M@;+?_LB\D^@+'D.AFEV!R\YZW5:K>Y[MXV*`-UO`:/=D>2_Y/30%.2+NE!\$<05%]!KU86JJT%LUX6.JT'L/"7E MKKK5OV?9F%<<1<\`[CX=W:Z*TT7@]NI'I8O`75,//H9B\T9;M]\OHY-Y6#=9 MU2H*L!:0?PQ\IPC\FLKPB0F^#.)5M.'^:+X,XC65X?;(OC,XOR@5D*4`;[:Z M_BJ:LCXKR.!>4WT^,>5G<*ZB0_='[QF<:ZK.+0KW%DR^A$;66LDJ6O4)H5W1 M3>B7:-?>:;MSVFWOVN;N7+1;O9UZF?T2);MH<7OW,OLEBG41P'OW,OLE>G4. MX+V02*5[T2]1K/NA^`V]S+,2W;D?JJX&L41-[H>.JT$LT9"[H]PM>)EG):IR M5W2[!;?MK$0?[IM*%X&[IA[K:,OZK""#>TT5NB]/<["*'JV!ISE8 M4WUNCW`W(WWQ57^8WV_7Q/OTG/WM- M`[XDEZD\/VL[2SGM#P:]CI;AL`30M39BPQ/,U:'?>DQE4*)+NUNEG?:@U^IT MEP7+-R2>DFRE\D2X+1%/[ZPW:'5W0CSGI5ITF]"?]]N#B_6(Y\JS84EC.<>G M\`O>!?BDW9!/H=_PT+,4AKFU5&7##`;]7EN32\O`76L_JN.[VV;1&^=6C!)/ M?!JGJ&(?]M(?Y=!""F?TR4_5#=;,B+YBO:PTU3I;P,IIQK_*^[WXZL_O1Q,[ MO+F\;'>ZO?[@').,6S^7%)NW*AO\/DV=/[S=&`'*P?F)@O!S0%GT>F<*JB+F M",^3]=)Q=^BSO&5"GR6,L@:[$WB>/8O$*TO]]>B[->675.9N\)1>MY6D&I6TFK]I/9A6_T\-FG0Y5@KJ\SD)%O;GY*^Y/AM$M]XDQ=+4I774V)RO2OU9[CU1D M-F?)YG2>=G,>54[JP``[7*+H'CSN:PO8(1+%6[ZB>Z"XWW_#N;G&27&@-4BJ MP&+9.]8R0,J]I!7)<6LKTXFN%JL\,ESN0"QM&4,&PLTA-#O^W"!\YCN^V];P MVUL.Q@@Y6((!4X)\6%X'Y0"3]:.^.E;7S]3M!EB M,L1DB,D04UW0]F@+B4KB[22V<<*'@6].\#!P]95GR?]8"&T:^.(!SV2_B]@: M`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`C#+4[6>;Z7":<8$H#[`4+1^J`'$A!`&.I&-XVO&UXV_"VX>W] MN2+=5J/3[];*%3$\;GC<\+CA\1JP1QIR4!]M`%?[>>3>99]F^I0\FU5(`6KP M%PWK!GS^\6LLPSUQ`;,M^,]Y)X]BP`B]9>D"WH,]RVYKZ,XE#$SFWQVVSMEN?ZXO2V[-U*DFQ8,2,]8J13J`;':_VD M@D$KQI26AHXVZM,GJ?S-"?_[9)O:9MW!]<4X`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`U)*M:4=#VKM0J:ZMZ6X8YCFH M91GFJ=-N&.8YJ&49YJG3;ACF.8!E'=\-[*N]-^4^*.%Q),D8SR-OJE:BX]GK M7<,ZAG4,ZQC6>3K6:0_.&_W6A6$@PT"&@0P#U?9\;C^>W\?`/W7V[OT=PRU; MTQ&^-L4!:G5!YP"*`IC+.8:E#4L;ECX,/F\-&F># M_9Q<&@ZOT2(,AQL.-QQ>'FY0'VT`5_MYY-YEGV;ZE#R;54C]:?`7#>L&_/WQ M:RR]/7$!LRU96L#U1P+?;37[KK^E] M#L$56H[PL+^N`_A]<](ZH<\2W_0Y!PO^C5L53FU/DL>=';HV+B3W[;W@[BF"E%(L?KGW'2T9B MA$7K'3NZM6Q_Q'^(OQ/WSO8H6A;X5GPK+-MQ@NG,]A^`6F&CD:4B>!7^HN`F M!=2&MF?[CK"B6R'BJ#G/S)N+`?7IG[\DT>G$MF>O;IQ;,4H\\6G\P7;#_[&] M1'!'Y$M_I%4$^$/841**T2?_B\!L(P#_K1VYT5><[2N(A[=>X'S_]?_^'\OZ MIQHZ'7"%<;[YP1#XX0Z'N_9G20P_![X#;]F8T93.8+FC-R=?[4GGO(>-MGV4 M3%_$^,W)NTZKW3]MM>&_?WT-_N)/%Z?=ULFO2KK`JS^_'TWL\.;RLMWI]OJ# M\PL4^#^76$I696KD%N3I?F6G+BN+LE3"LD`D'8Q8W4!V2NNF5'SF)R\IOL'F MP)L3_G?9[FUVBVKC@77KR!%(#FL?&A2F?J+.]O5"]>[]F>/?G.<.BA)&'7([ M2O9^'.\.5AX##]A@&/800=FA&OTL(\W>0?4Q4Y)*GI#V[5L"'2>J9[:<3.T8J=8RR%\RZ[J.9E M*2=[OZAFBF'5J1C6/A-.:Y4_^NPSQ`T[;8&=7O0'@T:O<[87?GK"/5LY,'E` M:UJ9#G='=-412:;WS8AR/U<"GW#GC(RO^PX=DXSO=%N-3K]K3*;-KMQH%VF6 MK'T[$)O$\-HGAJ\JIX_EQ-VDK=5Q5YYEVMHV3L[S*FJ7^=R624RK+_^8Q#23 MF&82TXZ=RY]?8EK-5>2?6^Y39SC$)(F9)#&3))8[UR^)=IDDL8/?U2=._=MW M''^GY+8TF7POR5^'1!Z'1GN&Z4V*EDG1,N>-.^]7V!CT6HU.MR2W&P% M26A%MT$8PSK"J35V?1MHT?;TGET-Y%7GUIJ%+HR*=.!R\>+JPL4-*EF<<,,O M1[A$[=8+X`T/_'5$_'YP\L&?4P?G]D/]*P]FX7!#Y@0MCB^%;"_8]SD.]SD MR!K!3H/7SS]H\,/C24CLU[3^%-9(P(*$]B:FDF%!9?'#N;7]B<`U.3B!'5OW M0>*-K*&0$`.$8VD83"(B(7@N%`*$\IWP])]O71':H7/[P`/!\@/78$YF)EF_1\HF1EBZ,<`KD-PX\+[B/7AV>%#*U]I^DUGZG M%K7V5X:")^A=K##FQ=DVE_8[B9ZV)2'HMU];_R$,!Y,$C@BR>E0T)@E9$1B MUD4>P?U0`E"3MJ@WMF@H;I&EV\U^T8`W+&U8^BA9NJ.S]*'5;907/2XW7)&)DP66E`)8=2&\L/ M8CG+:QR!ER;7F3ZDV2_PC&.CY0?T&H8!4#'W_GC0'Y+V(-A[MI%F1IH9:;97 M:=;5I=FW>6(9!*),;"N?7=OQ/E7Z)OIL-=Y:353W35-L*S$C27,IKQ ME/CV0QM!&%U9GA\,75J M\8E28KR,+6&#`N>0!1+@#!8?C!K6O<`_00=/+=L:"2!2CBS9WD/DIJ&MS6(< M&BB7GEG!P5@CAPP1 M3;PW(`U#$9&0P`V[XMZ`(,1+:83\%`Q^+-NR-7;JU3([?-MXJM@$4ZE@YY4* M]GM'\UBNE;1[FV?^7I(YD[LN93U]#P$6R]ZQE@%2GCJW M(CEN;65EO47WNLHCP^4.Q-*6,60@W!Q"L^//#<)GON.[O4Z\O>5X,B?\DF*; M!'E%YO=FA65VJU[6&7ZC8,E^P=^C%-C6RG8,VJ,V]7FAS1"3(29#3(:8ZH*V M1UM(=!-R)[&-#P+]I\45E^W$T4 MJE;4M'F\[UAN*>\``]N[TFR=-7K=5J/5/;?F4;![\;(>R;#SS59A.%GP\^&GPT_&WZN*3\;R[N>9RS[B2%\#6*J(K,\DO`\XP6= MYCEFPH^"!-/3GZOD>BP6CEYZ52.H5A+,V":&RP^!RVOE-KQM>-OP=BW8 MPO"VX>WZ\K:QSO<:7UB0H5#7O-5#@G`7=Q/J18%FK<>^UA6Y[!'0&PXU5&O6 M:CC4[*19ZW&NU7#HL>RD6>LQK76_=R`W.W_'AX;XA]:2B-8R7"=NPKB/:KF>J:VNZ&X9Y#FI9AGGJM!N&>0YJ689YZK0;AGD.8%G'=Q/[ M*@E#3)ZF[@>!CW6`1R)T[VQJ3*1W"PB%1V7IXP`&Q)ZPLR1T;NU(6/=V&-JJ M&^IQ^WQ'DH[Q/#*G:B4ZGKW>-:QC6,>PCF&=)\SIZS2Z_?Y^\OD,`QD&,@QT M+`QTC/=G/P;^J;-W[^\8;MJN-OPMN%MP]O['45O3JZ2,`K"SX'KQR+4@R"X)LL1GB"]S'T9Q:&(G=OBM]G:+<_UQ>EM MV;N5)-FP8D9ZQ$BG4`V.U_I)!8-6C"DM#1UMU*=/4OF;$_[WR3:US;J#ZXMQ M!%+*+H.M6E_G=J\2U*6\U]TA%9G.6;$[G:3=GWZ[#4P)VN$31/7CGH[H7+`5\^,=E>AJ_KS->URM(V_&SXV?"SX6?#SX:?#3\;N[NVYRO[ MO/;MKA!%>)ZQ`G.#I%XW2&HINP[D!HFQ2PR/'P*/U\K?,+QM>-OPMN'M6K"% MX6W#V_7E;6.;US,SH:[YJH<$X?$W-3=K/?:UKLAEINE,[7?2K/4XUVHX]%AV MTJSU.-=J./18=M*L]9C6NM^[CYN=O>-#0_SC=]<>NIX;NV*'MR%K2%:UHJ#M M7:DYA'4=T78]4UU;T]TPS'-0RS+,4Z?=,,QS4,LRS%.GW3#,5*U$Q[/7NX9U#.L8UC&L\W2LTQZ<-_JM"\-`AH$,`QD& MJNWYW'X\OX^!?^KLW?L[AENVIB-\;8H#U.J"S@$4!3"7U^\?=X:-,X&^SFY-!Q>HT48#C<<;CB\/-R@/MH`KO;SR+W+ M/LWT*7DVJY#ZT^`O&M8-^/OCUUAZ>^("9ENRM(#KCP2^VVKV77]+ZYEE$`*X MEN/94?3FY"H)HR#\'+A^+$(]'((KM!SA87]=!_#[YJ1U0I\EONES#A;\&[)(\[.W1M7$CNVWO!VY?[,HI#$3NWQ6^S!5J>ZXO3V[)W*ZFP8<6,YXCQ M+*G0"3S/GD4PLOKK-0=M<*K63RHLM"RZE#:CGTL9X[&Z/RWEDITFKNT""N^Q MW>4D5!>]%<%**18_7/N.EXS$"(O6.W9T:]G^B/\0?R?NG>U1M"SPK?A66+;C M!-.9[3\`M<)&(TM%\"K\1<%-"J@-;<_V'6%%MT+$47.>F3<7`UL7"I+J'(&L MNN:>Y79F&/Y2)A5FM6/G8L)DBJ&H@"'4`W,::HW8*U#+&"1!<(^DPJ(/.U7# MEV$,1&9%R13F>L!D+^?6]B<`EDIWQ8/?9=B&\C2_A(TC=B%HOI4(16M]6P.JUVGZ@;_NB]6B;-MT1G M^U4TNF(I*AX)RP+Y71NB7::#-E`TTA0LU36+.>;UB;2=WISPO\MV;[,K9QL/ M7"+,UCUA*4R-9`#4XK\YZ3R==[=O5._>^3O^S7GNH"AAU)G3H,K*V!C6]S]$ MZ+AH<-W@B>7QXUIV.VC9'>DH9'"QOOQ5CI2-KA?XUU31UV) MK7:[\LT/!4#Q;S$Z&(8]1%!VJ$8_RT2?72--CPG4?CMJPEU2YF7PVU'V]^ZE M8)UTY&-O9AHEB@^]$XZ,`+4;1H?69%->_&:[?O3R8+CY$$'9H0+]4R7('C'Z MGB%7YJ+E!X/&K7NCV[SL\!B]%3FA.\/[\)MMQ9:M@TUH]#%XVP9!XSE/+9"W MG<%K(GEJL*O]I]W5G6N?0P4L;V/D".-4G@$D7]('B[.TTW^,56^1)*: M_N!6#1LBK6>ZET;L'*W8.<:Z0>^R6WUZ+LB^;_69RF%UJARVS^S<6B7;/OMT M>L-.6V"G%_W!H-'KG.V%GYYPSU8.3![0FE:FP]T1775$DNE],Z+9MK:-D_.\BMIE/K=E$M/JRS\F,7F%9S%?GGEIOZ&0XQ M26(F27.]4NB729)[.!W]8E3__8=Q]\IN2U-)M]+\MAT9YA>I.B M95*TS'GCSIL[-@:]5J/3+'&#(`N%@\$+^"76Z\_")V$[M_F:QA;6.6Z`HHQO]=*UVFOI M:&Y)V>3$MY.1&W/9Y+("RK"&6'"3,EAT,!.AC8N(&*'YZKA!$F8H=@%S(A;A MU/6I#C/M+T/PUK.=[Z$WK6Y06W%W^.*SQ[\1% M[./S";^:^,$P$N$=I1FZ_BP!H*($\&?S8^+'3#CD^P.0#=HCQYW1HN\"#U8) M^_]`&Y0^"5P+%../8/57&:X!E0I4.XJ2*0&8"RT05"7@X&"Q.W9QJX9J,MNC?R51S/0I2R]'HJK+'G$] M)J4RRF'B`)X/<8W!5%@O$"7``2\5A&TNKCIP5U5P?[#LS7BZ(><92BD8I=9F8>T>%930[`-MTI MW"1F]J_"N?7=OY,-\X?W?@9V>+C_IEM>UV1Y'?(QW[.,II@+;R8X^2AFR$!; M[C6;'=C%#KS7/?`="^`=-KE_HJW82`X?)XG5=5F/`&M)NR\#]M&`_?3B-0U; M/@LCUTA9(V7KR/<&[*.4LI>EYT8K2MJU:I1L-J*!IX)>@LS3P!/[&1@,\N#T[\2=T9D_?IH$P>C> M];Q&X;">-LS7-VR(&T;'YI&0DZ2G_1.?#CSS0]S?"CI1?*#'1D),TU0%.K<\ MC6]M_S06&$FT0Y``E@LKD]3JW M@')!YZP5&%%'H%.PH&(\T/R''MWJGC4NSMLY.BC@XU[`2N]#-XYAZ:/@WI>G MYX"3_!%L;MQ6;DCJ'1WX_TI\AV(>E!I!I^G8@]Z.2AKYTM>8?C)V,:\"U8+U M(@*L?0QB8?6L4\I`$5,<'MZ:NO+$&1=_!=,"JH7O8++(J?4[G6H31/S"RZ9U M28>[R[!^:X^`8N29M$0(H%K/18$=CQE)4TU.K$!V"YE/B>9__I)$IQ/;GKU" MR4."YYT;.5Y`?/(5Q,!;+W"^__I__X]E_7/N40XY_YY!JQ\$:N>`7U$OI(-9 M[NC-R5=[TCD_P\,B'X7-%S%^<_(.$73::L-___H:_,6?+DZ[K9-?$68L,`6O M_OQ^-+'#F\O+=J?;ZP_.+S#._G-)Y,JJU-7FV-H<6T_,L;4YMC;'UN;8VAQ; MFV-K^=.3*[JC3!77K^P9O.O=T/WE+P)C(F+T(0@_ M)'BQ^#J*$KKUFYZ7#/+G)=>=5FMPVNZ<=MM_T7C7/H9]`)3/GNU_O8>_'_Y_ M(@QNQ)WP_Z!(Y(F5^"Z_S;.>X+5,=VI[T9N3T_[)K]T^!8"RM:\-[M96>SZ_ MVO,MK[9WMMW5TL-O\6013_B$'Q$U7.(=W@F=&KQ]R![Y;#_@5Y?W=CCZF""\ MG\8\VV42WP8AG0^GV+B8PX8Z'=L:-MJM;@$=6U_/;M!U9[L>KJZ,B%\_ MMUO_^\]?E@!08'^\>_UI+,MH?PJ_H,9*UXDGUB1&KVS/$Z.W#ZKYW(#L*'W^\/NBN]?#[RT5 M(,$_THR)A7D2I%F'J3[>?:I2WF;9>N(1I6#=7/]V:?T.Q#*QTR+8[M;7N//U M7/M6V@X"M.Q9P[H7UMCU,->$:K5XMHO)3U2=(;9HU3+OYYWP['M,5KH*DI#R M?[!,AB/"!RX7HKT-S#01HP:F"OD3F?,2WP*!1`V5Y6+=VG="ENIPO"3"@WDR MJH0`:=I3>R*B)L]NPT,V M<5R$<:-(I:RA+L/*06IOTP7?)#/,1.&%-RW`#Y#V+"`.`4YRPB"*3M-158I9 MZ=CT]A_V`^*UVU@PC<(IYD^&B4<+E_E_-!$LH(G,$N22TC1PXB8T4.VL4A@'HDKB>!R M+/X<*8H\,![\Y%N7R20!%7#>D$6^5N1!"VS(`(RH43*U/DEN1+1]PNR#!N8\ MRH%Q5/5MCD"`I'$*-%)C*2IA-P25[DJFL#88F0L<<5J'Y"Y5(BC+(RWD@08P M*=#*V)5Z0U,&Q!88EL`!ERYUC+%8AE5/\72C4IB!'$[_E8PF,H<6)#90*:'D MS@ZICM!,A&B2TR+FP,9"2H%/"11V'`>A+QZBG],B3R&)>5]$L"2!$@8V[I,3 M!R@ZVP-]ZQ24^":Q()4;8]4O:312=;Y0O`!Z$7K8&5BU"QS)T[&]]RZTQS%O M'G_Q7W*!7#/+P0QC3$:AK\;HX0#H]),D75/E/89B'O^T`ECE+] M;IQ:67>!E\!F`QW-P)0A"D9J#(7G"BQLAB('2`W&A4';"E???"HT=8,5I2+K MK>U_#Y-9[#S`OHZ$4G??FC?-_&](NHHO;H($50-8@"[LA>L04>-:_S<(OQ,' M@,CS!2=6XY,"=T^NAZ%/MW-N$M"]J!!&]IV+5#YR'3NF]/I*&Q">8RXF`>^0 M!\'5^(#.,+XF<8'LJC0#`_#V\LN[RZ:R^W)8'&9P`4F3=84X![9WD$?N<57# M!QI3R]*'GV,^P1F#+@&%*D`2!*%^3P`TT.%1YW_9?H*$-M`STE>1X9Z(D?Q* MY/?(#9%"I-970@4K["=#<`GAW2_BCNH]?@Z#68!_*-G`VQZ*L4>;;F?2G%4J M0`*V11C\0(DLP+'-W0-H%YKG6.#[>M+42\FC1"V`F0_N1844)D('H.2=!MI] MM.7Q7D603)C6T9U(37%*HF-UL:*41G,N&+2')$HK48:,T$DT";*=O2" M=W07).GML-JH1I-(CNL1Y0=011[384[GK&X^E)%LVS_)%"RJ&2WLB$ M09"_!C&`DP&1JW3ZHOVRU$:9F[#=;;873_@8NZ;!7NAW'V_;@-=Z\_6TTZ,% M1LE,FVW0X\V6WUHO4/Z*D(HZCD4HRZC"`/+YWN!UZE[/#0:>MCZ8>N7\M33* MLP%!$JL(`_D9`LT@Z^;]%:H;5!7Y*;6%98.^E`S^HO-R72;?C0T&!(V4@8/F MMOJ\W>POWFFLCZD,87:'+2!NO$#O(CSK`0N=,9%>MD9#3U MUW].#586ST&&,T(2>3MC5`12U6K:E3>(:IH.!88RZ&!,7E,C50J;RV5U0?6* M$>UFDBZO8,`-,'52YUCZ>^(,R<>G:G><)JC:+EXB" M)'5M-3HLBD3ZA*ZP4]:L"^#6H\?D`/QAQT";(@S^V[X)0:F(81"<#?DLI?#"V9GSN%K%,HW@HWMG,JG+G M8F]@K7DCA%5%FQI9&`FF(S_F'K2\K!\\.C"GX$\J[`QB8(CN)D7@V61"04XA M>3L+PV=F4^1.?'<,/IV?JE&6Y3:JF\A%S:A,'+*L&C"!8V.Q;AGNBS87ETAZ M:K2XBIRTV")1`,R"CX#-CH[?./%4,6\.J,L8ICJ'P*.BUYO`/0F-&I=63&=_, MIF-EW*4Q6$"%\($4R%DX#:DZK0@.GR6E-I1I@/7LA_^B.8/"+8HM(`[<\`#:;\KFI0"X`5@0J%'=T*T](&A[Q\3F#AJ[`%=,K M^,5H&J#._H`1H?/3_Y9RA`V*CO2#LX@2&;`X#)_I!2-"E6+7BEA29J%D`P9I M=7QEQG)?!]BJ41"!I$/<:AZ)=`=BX8^D1L&*$Z!.(SSC`"W&YX,YB/`@4=]E MC'X`8I3I7`RR*=K`UR:8I\!=%R3D`V5Q?9W)'A\3F">G,,F@\TSK7"8 M_/9!.\24,D^>OTHK5A%KBC#53&(.8?24`I7`)"0,\5S7<\>Q1`55D`@\.E_% M^`MI)\\+[IE2I=%`A0/OL>F";18T(ALS=>3\,KDI1?0UT]XL2K#F.^0N MRSM-A:VL2J"G=7:;7?H'*+;7:U^D2:R;5U?@F.6IK.B@?5]63B$(9[!_T2LB MCGS-(2"2,"YFFZ0MRD!T^!%&1W`L7\SE;O/P]^XHN(?1V_`G&!094#00@#[\ M[L)8.&`$(O*[4'V,Z7>0AF!;`T9='X'/7X$=R[GGJMX@::.VGTN*W M4K4*LVM:(K->[@?M.1"PH)!!0$ENDY8=-S*Q99Q8JKS,--#:A@##8OAYAPU# M]IM6]5L`.M(G\:6R"P'C.\JNVLM2/RN;7J8=*%XE7S.*3S%X>3H6(K5+TB,I M96^P+K`=L.%M1^8@H.(#M0^D07%':H@5H7%#59Q([=!AH(;?_/B:1@C%)&&/ M!M0K-K2A*3*_SHU(@Y&7)2V3=V),Z4AJSZQ+>N\2,P`?K!=9R/;=U>6E%JME MJY?TSR2#S%8%EE0')WG`=TDG+$`/WD-#K@_4H,>>./Y%$=FRI281J'PZF\XO M-6/(K+>0--]I`4/E'TJ(#LQ]^5.:X60^\J2M(G3#5@Z_V/_6'[0D!KC MR@I[$#9L&T*2GL%AJE(N9),VY$+0T,F2$4OXFN-A]X+K:"GZ8+>>0CH^MK?" MQ;K^78!Q"%IEMBF+BYSUF^>+#B'5X;DR4#%,A-C"8Q@O\\70?I=6''L\TH+? M431RAP3')"(C$&',.7C,2C*5A)([F&0*/=/(&`9.5"F,ZJ@+\`C;Y*I6?!N1 M4]-*`UVCH!``R2)?0M*3C+235X.@9U$-7,V(XH"6&(^1^H-<"(?S[S#7(V8N M&XFY"*<:$)_)0B4P,H^8L_39.6$9QX=EJ3TAB1>83/DDNDO*O&AC6[ZQ?U!WCWPAA,ZMR-&;_!2R(^Z!2.-O$?;+X>K MD8L/I!$[0*5P95Z(SG$J#PM>'R<87Y'AR312-B<)8'LD$+RHH#@D7D+#C94A&[`5RIX+;9'.!0PR2TI]803Q`PS#I221+2H"`- M#M8$**Z(A@3_V$DH`RVU#C@TC[DA8/A@U$&R)O[%S)D_M\3(7-F)@&/Z- M9>@H4M.T;BB4JA0C#\G:&^DZDY8*(UG?Q<0/A3L=)F%$FD^V/*3W6$U'^3., M#1`H.Z"6(_&P:#QU0KZ("6;$L0J2UY$N502J6(;WH)V1/T4Q0KIP[7IBTQWF M5H>80A>PZE9W<:6F^:_$PZSRU@7*ACLR._%\4`7Q2*O#6TB7H`E%)/4;FP2J M^2FH*;+7(_%WPMI:GNK>DYN20:IWUI2QX9O3;BZ,+5T;>"?-X09')K4I9"MA MS"XB9B$O@*&D@\`T>ZL,[C1Z)Y\JKD-ITTQ)CH3CV8AWUOH@V&BM%);G5'>V MC#!>1Y%['K9\R>D8P/$Q6(YIEAH=,9&BDLM[0=XBNIND:*/TQIM*JP)>3E%` MV).YOP@+_H9=9V6KU#$)N'3LE]KJHL"CH2CQ"E9#Z.*L5L*YDG"86X*9IR2] M..C\!0]XV[V>NCY31#<9\O)KAA?X!I1-XD:WZO)-NU5H`0V2#TLEZQESG?/= MG??OD&.SC*#T2E`I6:9G`RNABR/$8\49'9\;URJ5.T0C$Q7Q")3<"Y6["^;= MB"M/HUE,(0&@E(IUAP:V/9"@]9;N,`F5?9U7VFL_*LD;2 MY<2OK.TAVH2C^0M1%6^]L+4\LC^0QX1/1N@'V_7`7,OED]W++`+*`LA@G-D< M[,>\>5":E/]$39SQ9A#%_P-?G)*I*0]R<=&Y;+]FOIKU3ZDG.P&1.V%?'?`` MDM73K==2QN!C:/0%>.6LPK'KL&R2[DO)[9*;A5N)6V&5K+YI?0)7C=+6`*L_ MW&DRU2[@I*=#;I39]N553[732^D2#8E&\)8.HP2>4!D6"Y)]6\U.J9]]8,S[ M(5!G2*5HSRB-SM@+Y#:5?DHEO5'5=T_+&M@SM0DZ[NRV0(D@L67B9142I#`. M+94N:@%EA+8ZG8MN@Q#'8@&CSKN5XAOS`$AS3D+U\=65W?1L5SI7J6G9D'N33RDH7`3\ M+L1,DFC("8;D>:YC*:EG<83A%.\S:OG5U`Z`@N.@L_=#.^D;L!SZ7[/5 M:K6S@T(^.>S,YNH$S1\\\HECWE4K'F;FCB.;::V@W^5UZ8(7ESM`6^S2U6,= M&L(7%&;:="7Z^2F>AKCCA\A/?09)[6+C0?CV= M)G[P/[;CX-&X.C;(B@@DF5?V3LR"?-CXZQ^6'B^^DZ.`IQKCZ7"#SENYY@`9 MN2"L0_N'I9Y+L.;4OU'>Y!/%,)0X'6*T)$ZS:BAZ'+L3$!C:>5CX63\.:Q96 M@Q%HRP%%3V4`([R-D,ZMET)P9+38"QSE@O\G[./8_M&P/@9WMG7C8&6!9EEB M+,>'T-_%Q>;45P<<`Z"-O`J#ATI1[H8H7(.0)9>$CD/3;J2@+MRKS0]42'_T M,=:LVS)YV%KSL,F+]EFX.,N?5!%@YQ9C_6D00F;%`2VCRO$+=HV*N>''RKB? MC2XIFFR1'!V?3F^PR[W[19ZI!C)9'S9LBA$#-$G2N27X>1#99XHQ6(?AD,MT M<7@&N@A_5A@\V%Y,!\L\2.&\13)&&5/H/+%BJD']I,JZS:CJ(>&UCD*'K)T. M7B?IAW#4,8I;A\FN42K9/>=>Y871*9Y4`X_6&'#QY)*+[=S0ZBAV&A]*AOKLL6/U6X8'&/1B_LZ;]9KP?1O'AO-7MY M&IJ[!4F)]WR[EH-0\G2#Z[$$&$='`#",A=TL2/+I46+]H"+5#S[*T27=TVHH M$!]CAN^3P6:P@TBP%3=9.5LU99ZT.=J#]<(7:6PB90`\S[?Q7@=PEWA)3G,Q MACBT/0HR1+>";LG)(E>@?>6YKN.$"1VNEU!6E.$9\Z8IEA.]JA\U;%4]8O4Y M@N[-"3>6.G47#Z,([=4S<,[NE\+OUF M[(:8[@G?/HBH4'/[3N**:W47>\BE:;&^X/\CT51HQ:.*>E,%BNCR&U96F5X M8DMT[-'_V@C8/"YW;F%M&U$98Z^')[T+FB'C7>W.9ZGR%K2*,^2]=?*NZ+!0 M$/+M@C"7RJ?;_ZF2(R0A=_O-UD]Z9X97UG]<7;U__^%#GK[U_QWV/EPNMI36 MH6")YLY2+'>>&Y(WEN6JP^M2E+:?'4K_L1$FNZWE,J#U6%S*XVU8D=S?3Q[;<]'VP1N!7>D6[!8(5JGEH=U#\L; M[JUOWCT;M&ZL`H\'<0N:R#[A^H];.;7/>XU6^WP>P\^/W/:B@1;W8UK^J3Q, MB;_HA;=*!\BW`%J]GT>^%\CO011E;SR\CV+*"/LT_BSOS>(#60N07FE3D_9I M:Z`U-?EV\R[7=1+ZG!:X_#2^5`F@GU7^YR6=VWT1(S'ED&L*]/FJS85^`[$W M^WH;"C'73NDS\)&^C.[)KR!VVBUN,;0>9-F*L!M-]-E^0!DR_]X7(;-!>(!L M01=;6%#)MG3DIJP-V6.W"`3$6BOZ$"1AG7>HVUJYGU7U>G:S05_X#NZ7]%;N MAS"8JAH(7`(A742G=!&]W")ZN(BW;C`56"_=NQS=X6GE"%O0X85V4$KOLJPO MV5HM?EAEL?US;;7+PJ3+P7, MND@!O348G.^JV5G98._EO3<"/OTQ':&=X:7_%'@!P@?11./IR.F<_-IM7@R6 M(&;96G9$,.5V"B'FG:";D]1@%(,*R/5J((F)57%7*A0KR&BN#VB-R&B^#^J3 M8:N:N-K-\XMZ$M=\(]6=H`L&696X+EK=BXNS>A+7@D:KN\;6(N(ZZ]:2N-H+ M.JQN$5TW[H]5::L[:/&K$5*L;],S.^)M*I[OJZ.BJQ_[;IV M5.^L?]ZK)QEUGP8Q"\71LG:ZJ]%,I>&N^FN_HTZ8:N&]57W`W9@!O^(M>7;7 M%O@<.NC9*N4SY'?03/F55078=KJR3`?AR@8\'Z^L%-R55W,VMQH`OC5(5\.? MNFV:5SI_*\V[!JU4Q=5VB=%,\N+"8*ZS=4DE;2(NZT.#;,DN=T?O_T[`U<%/G"O:J](D6JV? MJO*?Z;H_WCJ4IWM\KE4X\U^0D9G+]TRK"V/&)V>+YHH89T=BF)"=RT3U@_O0 MGKTYX7^O3AT?T_KX>*H3^!;K^CE2T8Z'EH[)[9@\Z@^EN!!OM@3CQPT[GP(Z M3]&%X\9YKBS9]CG$5B!SIX,_BH_+`2NCMV7`/H8>-UT9RGB1+0]%_=-N[!'@ M?ANR0!FDV6I);Q_\7M06L$-AT,S67(=+*]+F*C2FEH:HKD3\A^,(,1XO5Z9X M>6DYYO+(>*)ME=D^:\%F5:&H4'T?-W&=A6AY/&C3-`:#\Y(8NY'L-64$(]B$?608>UE,NS15@^G MOQJ;9_MRH<^UD)Z3S=-Y:;WH;F3W/$(*+$FQ/F(ID38D*2.RH\5S+=GA2&T; MS*$QMLUQ\<_3RRG5";VBC(*)XAR(-+AH=1L7%V?/RZ(QULP320G9FL08,WOG MA*,U9LZZQI@Y+O[9@YA2G6I,<.:`94%WT&[T.GL2!\:4.789D?@"!43;F#+& ME-G-F5-_3X%E8\HS1?R%$*F=];HG_?V(69(X%OR M?]M=J\G5J9,$2L^Y.R97Q]A-3Q("*K/)GZ_==!2+J(<,ZRR38?4*!U78'IWF M.=X,&P78O^/0#:D5%_,DDJ=QT>DT!N=[$3_,E(][8Q2Z0D26HP$5)<\5\T>;-^5*'>]VJ%'DOK]7L MJW+=CR8?(QE6D@R#3D<)>2,;ELB_?=RX;W@K'UKJQ<_-/ASYC.\\HK56- M/=/OW`@[LU+KVPTERBBM[I-V#G5%U+2P\^C8=L-#5`:3Q\@3N\>%P3?X?GV>8^_5S:F[<65O1J*DFCEKJ$KM=11C=%Z6;\C$&W%%38[ MJ(TT2[J>;25P+'5(.Z9_BO+3^HO_6:@DJYK''1*.-,E@KK7+95N[UF:6=ED^F.8J<[BJ]BU7UL9_EFE4/9`L;Y7FYK8B MJJ*%ZB.G?(6L^PY?J"LX[:[L9HJMYX,DMH;"I8987(MGQ'HXU>OW8E7]O4`E MK>:!/[X#358`<^-B?86:?Z4OES2=R6K\K=JVXK!K_.$NXA]DBO6M4TO'U,\6 MXXJV9KA4J.S3`U3K*'@+.P9Z/0#);OT]`)/GJPBGUK6/I9N0^SY[MI]9MK7% M\6I>]A,A]-JGPC#DOV`)0C32?XY87$KRM>P9.CJ"37XJ(U.&?;WN*&V%]0*? ME\OM#5[3F[1'\JOSUR\QE.K MW258!0B@[7D/C0RSA#B;6Z;\&^8L(F/!\FF&JC5I$(U`!8+RDR#!#TC)L'5( MSN2()1X>"9=IL#TP?`VYY;QA!4E8P2,V.*XC=EX!M;E];2`IHS6%>SD.@VG. MCNDV"^4TTY6#HO.0E*51`\/J[_6:9WG;I_@X@#"U?[C39&KY:;51^6-*:2-B M/5=6^P4.@55Q^(,($@B%S5CXDX("DU`(/PN`H&F&K\8('?,TOKSI?/=!XHT4 MM@2^!3M(L3-@/+"`A0T3/`@[;("Y!KOH(V0N;\^=`NMC#`?GAQ]D@"+=HR873Z4OL0EJI,)`)8MFMK5]'_@Q!5::B(`&-'M< M/X&_;\,@F5!67Q]D5#+\%_!?P[H-[G'0!CZ+.%;]G!A(EEZ!7X['^-9&7D4L M#44E5O5-B1+G-@,2K5HW*I_SWL8`CHT6(\ZOKG>UR4[NP0("GOXQ&SQR49+' M:S[_$V``F.T[U+!3=0+5#7OQ+?X1U#$@<1 M9T\X+CD22+JNC\1X&\!F.@)T5B1U`9,M?":=@C$X-],?1.K2]P%*!]75M#Y) M_3*U'ZQ;&_5P*E!P'@1-7W4L_+Q`0D8UVF2!,:N\KP,P7A7(!4SN&.C5`5PH M)4@RIZY\D'5>JPPNI$EJ%7RUP_E=!K]`6![D#>$5@CFI%>0 MSQ\;S*D\WGWNFY=#G,XZ-NU,&=.!3M>T9)@J%E1R#4:^C2Z?YP7WT:N%B]S> M$?E^C\/UTR#3N,$T;C"-&QX]^*/X^+#KPIO&#:9Q0VVR8H^92$SCAKK>>T!?]M M__.72FA77DQ[U<6L"NDG7\BUR=\TN`>GK>ZJ<%\AW7T:RZ=DDXUK65XXOX;. M'C;D`PRBK:QUVAJD*UL*^LJ[T]W'RH(DU%;6/\7%;876>MNFM1LPV?TJ:NMT M=D-M_2==13NWBC4H:XT5G3VA#&@--ES/'UP^F_P[V9*''@350"4@Z9M/XS$P M`A:V5VL;Y-=V#:OI(@2=_E^L#=0K$D1J=$&/?KMY=P+ZSG&GMA>].3GMG_P* M_B;]P\"O!=&C%W(^OY#>::M_VNG^=:GZ)WP-KN"1$%MNC/:T.JSLZ488)_AT M+T9?@QO;$]'E1!#K@9D"M',9?09[`[ZQ@5+&EZJ>_F]A$`$-!8X0H^A#&$S? MV\XMO@ZSLX63XN)BXTW]#!I?7W?WY%>P_[IRS3L$/L/0%S&U7>R^L"8%=%OS MJU:,N?YF=_6]7A.D?(.K=V(89TKG"E@9(Q^7TR`!:S<%OCT//$DV`/[WP/:C MS_8#3K8*Z)V^!'T5"/*P_N[ZL+PK,(O=^(/MH/GZ(`G];1""RP_O7=D8CH@? M,M@["V#7!EP%]I3%-H%H3M%&5,T4"/6S=!:XKBYOGP^RP!?4[>!K@#B^Q%X< M%,M+5[:R?;%PCYC"]:5>?_QP\FOOK'_>RVG?#>'-[V&ISE#E1$D'I3^FO=G: MV9)[U5RTC!"!\VFI^DH[(#>;9^UL0S<"+[]"#&02)VIAS#_!8_OF!T-P:N\0 MOFM_EL31%P%K0:(A10R?DA`9%%2T&_TN_;,'DF(9`E:V7U(P>*[?P4SQNJ5Z MO4#R/R+WE>]ZX.&'"2#KEZ=<78DMT\NMKO?8U65[WP(:[W0'W8ML]W>QN!7( M_Y-67#Y%18GIL\KB,U?B]\S#7Y7GVX-!O]>^6,(.&KCYQ5V.5(>O#ZX/-J!K M>]<^-14CDWU!T\3N^1$T31SB'W3"<::?<$AK]V\OX*G9F!PS\!:2"(K M2F8S/J1L6'RHE@<+HZG8:D9[A1_CFB,#>JK=L`+5KZK=MCZGSS9*^K3="]E( MC-9"0$;"\QK5RQ[BLSUB*,.HMA:\E M,QS_'WIDN-UOYL/"&:W(QEFF04LY!0,)=%6?MCGZ];/FA#J!]*S+[&O9LW!= M2L=W2F?80&RO5(8/I5IY"]&]@-AE7FX@FVSKH\YSJ.F M;IB<@,T)_0>)K#0U0(.JX@1$(87Y_$QM,DZ%`H#^2++V(8`(%YQ([NB7GLM; M+SX`[-;'H&F!OW3:'O2[%[V7ZG2EB;U&;&PAFG@QP^9&_".-TR@7*;:^?#ZC M*<@LW.T\;2(E^('E!?X$J&$H$#6CM/LK(D?K*5A$1=:.;W4R)3")_'&=9;P" M=E^0;BTFHX!Y>"?"B+9$>.,547IQUCGKOR3(.`P!,P/H$YD``2CU)X@TC7KR MS*BC5B,:G6"JT)%G9MGCL0+L>SH`T;K#]KFP+ MJ`A!@3%/"IXG`7WL'C4HWT8>Z1%T\'YAI=G,1AW,0?/MT1N0BE_B5I36BB&' M#R3#IB*^#:A5\M2-<7_@>\^^)W8?X8C471C[D_IZM^3X%$8^A35]%['Z^OQU M!A01YMCU.0OI2P+Q\X1P@[XFIU1=.B2TVA?=;GXA0,%>,LK6 M.[5'0G9!!ED*Y/SQ?V_>6W_\]U=B1&K:3+PJ?KC<(Q.XAUYGF(DKY]00LG#` MC,R"VE:/3^WO(@1&XKZO2C]P))[*\)*)9?PKK"/#*3:?U8AG3N%;0SR$`0V- M@B7!'#&,?K)?V+3^Y.:NV"PV&'HN[[\:DC0I#YN1!'GGW`DU?3WWZ@S(.4.K M3?CD2'FQE6FW8!/\I"1?9FI,,%B.Q$G1HEMRXKVPE* M1*YF[_UCT3:F+;)#.BM`C9\VWWV\(R6_A"6Y;#]-8("WBV\BBYTJ7 M>"_2SLA%^BXS?16LV,E9)ZIT0[_FU?:(<26UN11N*YHY,`>93!<$ZZ`AUT:] M?2U['&-R)^;@.("'S)[@))Q--1!)/#9.52?L"(?'=30`<'@UPWL=B+=>K)2& MB;Y2-^C4=,.C`>LR[\#]]MZZLF=N;'M/$3DZ5(Q^\BO@T9A9XV5,*8@HVPP3 MK1-LAPHL'*H#2J652($R+^/O6B61Q3O%S%5\!MTQ[-V>>*SM8KGYQ$(9G)*1 M^Z6#4'[\2'ID-L@BWX4_(K2U!-IV0S""Y/F>9EW9>:G;:1;:3,YU/Z?NX1Y. M3:8'8.8N\$BZXZ4/\OOH++$B3+0T2B0M"VE7Z$UK_TYL3^8!.@X>K4:R2SKJ M@.8.J"M/-EL=FZX;N!@Z`,.&MF\L!-$!K"U,!&?]RXQ[P,:=U&^J=WL\M_\@ M6R.EPC+7D.X*B2B6=G]3"^4[011C5WH\]V%J=]+S3Q4@1B*.JM5R7X;8$(KS.@>?3 MR#69R`!@9$9L95HNU\JJRLK%N:[X2LC/4>&"3(Q&FM#;;G@2XU0G`GK7THT!;&GZP"AL MY%<@##+H43WDLM4CBSW=&IZY\ZVV>;ZJ M@;.IWP4.90-]IDM<<_.NFO8L4V#I;YZZ=.!LWJ\<++AYF`X#+YMOU13EDU\_ M7W_FB7(C91.\!U:*'S"`&E[!S),@S#*5>JOF\YS\>NDX(+M#\N]I,)ZT9/3B MU%^DL^/'']&Q2.=>-;L7EOB?EU_^N/SZG^\_OF]8UQ^O]*GSHQ?GO@+$ATCB M(_'COX6V\%636DY^Q>LDW&[>+$^)$Q_*$BYZ9V6I16T`HK<\ M<>*LU^NWN]U>#J@%L\Y3>L8,'^";+"6F-UB+UO-47ABT:E9FAL*\JV=D_+]N MV:S:H//S?GV8:;2WNM!JMT[_7WXR'"F?A:+G<:9YXZRBL^7U5Q9=:V5'?<(P MJI9X\Q4U[GRZ2W]U`;:+=!<<3[X%*G#FV0^OK"$"F+LMN>&5T;.+N1NC\-7" M*^ELWLO2(ZUF&^N1R.]DB1+^\K%71/-W0=4-."X8EL(LX4QO^?N"_X\N_1:J ME:GB;D//!N05?E/796=Q_IID/O%(`L$]O5,@RMI]'\S=.NN=B)S0G9&UN-&E MQ,*6S-U+;"-@=;J*NR&BM)NZ:^$)R`XXT.GE75-HL"/EV^<7^;O^G2HY0I4KZ5+T@J]#YROJ/JZOW[S]\J,UM]BWO MPZ4,BJ%OBL>,?%HCPV/16A2L:@,LQ7+GN2%Y8UFN*FTL16G[V:'T'QMALMM: M+@-:C\6E')[,TU)U)\M!'@ZRO&*O!X$+>@\<(3KO^XE5/[O-=HM<_G,?S\ MR&TO&FB=LC[94=?BR&CA'B'+YR]X'9R/BK+(:ZF)U@T8-!H)V]S M4U2"\#'@4WX=BNYF4`#I`N660I'-D@?DBZZCKNA45(MBKUR315U.O_*":,4: M`[W"7?>$CZ].2],1 M^M2%G103VP/T:>@I+^_U>(C.VAW-'DHG7L/Z.%LU->&O]].9%SP(JI468A+6 M2H6"VKLQ0,Y*:W&5JM,\=0W.^ZV+34R0TB$J4SRKPG+<&9X-E\#`@GNM_ M?S4.@M@/8OC5_V[]H*_BAQFX%#`Q72@XD=^&`3H:MW$\>_7++_?W]\T?P]!K M!N'DETZKU?T%?_X%'SRAP=7P8,;G1H7/=AR$:E"0U0+L$DKX:ZLO;T-\'S+`_:WCVT\8+=L MP,?@$%.CMCMB*8B/06+9@.W6EG>EW2D.J*19;E10JD$2.N#Y_)AZ,"AF)@G_ M]-M-81[U.OGUFBZ`R+1_.[KE2ZWX!V8\PR*X(4!)0X&*-@)#VT.M MB/?1,!'^G[_DEEBZ[LLPCU`[=-1B,)N_R#)Q4+)J>&?)PN43OXQM!V-+$@&6 M3`IK[V13.IMMRJ/[Y&P/ZYTRK'>VA?7=L$)W,ZP?;`>2__B!A3I>6Q5M1XZD MV`L``00E M#@``!#D!``#M7=USXC@2?[^J^Q^X[.L1DIF;W9VIG=LBA$RH)2$%9';O:4NQ M1="MD5C9D.3^^I,-QE_ZM#$6S+[D`[I;W:V?6BVI+?_T\^O":ZTA]1'!G\\N MSR_.6A`[Q$7X^?/9RF\#WT'HK.4'`+O`(QA^/GN#_MG/__[[WW[Z1[O=HQ`$ MT&T]O;6F<]CZBG``GF'K"R6KY3];#^0%TLVW@_%@TNH!^D1PNQTR>PC_\2G\ M\01\V&):8#_Z]_/9/`B6GSJ=EY>7\]0 M)O[0V7R9)D42T0B'%CJ):$]"_-N0*9)0YI5^>1^17G[\^+$3?;LC]5T>(9-Y MV?GM;CAQYG`!$F*D)FZG]/;1)S_Z<$@<$$3=J?1D2T@1_M>.R=KA1^W+=^WW ME^?,B#/6?ZW6I@`8SEKA[\?Q(-/F<@[H`@1SB.&Y0Q:=D*8S"1A@%A`' M[=[H_KI_/^E?LS\FH^'@NCOM7T^F[.==_WXZ&=WT1G%LR'/IHL?1@_-F8Z52P-=9D%RR4) M/+>$YEGVZIJL%S[Q%F"V+JU,6D(E?0PZ9?30'W>G`_9MO9V?;N=0MO6ZD]N; MX>C7NG&=-%.G95?=8?>^UY_<]OO3&BS*B4];X@#/67E1S`LC&`3>(+>`^#T6P*7N/F//`$O6A>U^4(4!`Z M3(NCTY3E(]9]E*/:D/C^#:$0/>/>BE*6V+Q-*<`^<$*L=+$;_;=!3M?][\H/ MPCY7.*W>QG+^KJNQ;%>E!E"79GL-4"=6C?U9&#W9I&%+T?%7BT4DK8W8,(KY M9Y0LS+!'#NSU7N*'UJ>6AJ:M@+3JUI!0%U*6FI^U7IB,>1#]V=A08WHE9@E& M")]_\Z.[M\'R,?0\8#OHQER=R!8410@Z(_A$KR%N/%'LP>*L(.6P!O# M!4"LM^AH=L,4!]Y_(*""(+POL;G(65UL<^%.'S6D-C]F(Y12HW1\JJZ)77FL M@3T#'!HP?2'5P5X051[@*5&G"VJ1OPX#Y%3KQ1GQLND9,+4;V]0@NH84K9EA M:]CU?1B(UH,BLASXBV2-18$)>%&"40X-#*QP?&5J[[-PL4O(I MLPF+CM4[%IN&!Z\'22G;52,D)2`]3.0M',$@N2?8,<=/D4L'0FFN8T>1T`/[ M!%*Z$;O2H7+'O">]@W[07&FW3\4@W2,X0'C%DN_1$M*HE_TK."-TNY\U!:_0 MOT.8L+S[;8`#2-G,WL5N5DK_SQ7[^@X&<^*F)G]AXG5P#0I9W`$U:#Y:\>%) M;.@1?L3+*)S-+`^HJ%TS,(OG9&,E?MX8T']=0NR+EC=*^GQ\$M,WC^`F`$K, M?VQ%9HD(`T]Q,CXE7AV)UEF:$ M*",?5`"4JIUX;Z0RGKB%"E'K^RP-D9:$<"H?FE$@54IQ:`6.9!@TWCI*-MX;>>($!Y2-3G\, MUQ"O1-F)B*SP;$F>K'G(RC!#M"WDXXHC.]W_19EV+8%WZF\#NC)LY>E$02NA M.YK^5]E8"@`68913+Y4T>+)04/!8Q%,"OU/ MREFN`$S<3!HN"O%V!8]KN*300;Q%AHRD<+"?)CD2&$CL*M'K66EVI0=?(&:: M>PR077>!,/(#&FVZR`.$)E<."DJN(T&'F?4E`*-LH+C)VO`4$]"5$];IXN?> M'-!G8:(A(RU.*!S2(X&(AIWEI@^.5,LV1W=+K*T%5PS,,R2J%E-0LHT>8K[S`665$Y)QE M)J+Y:%$*'V0O+A,\`FN@4#H`F2EBUP*'1=50PP=*PGH&]^KMT8?,V!N$`7;8 M#-MU6-*U*=#F;"B*RT+W(+181UI)Z/$#?J]NW>\0J*J:70M"9H8#H1OM@*>? MN(O.@-(/Y@GP;\R?@[H!?_.HWA,J277W"?/&"OJE06Z@EUU!/JWXP/=7X4V, MHUF/+!8$3P+B_*&!8RF?!+\"OE/'K8Z[#HE7@3['$7?9`@RR7ST*7>$BVHA7 M,][F>$\=L[IN:RK.YG2R:P,PK?2O@%(0GFE`ZB#QB:,.BP2I1993!ZC"28?$ M95&5+1S_90D<=Z-F9VB/^,+M!Q5Y'H9"\I.$H)YS:H>?4(TM]#Y82267UL7V\]4+@$ MR(W'US:;B!-@Z?7FU80I$:TG[-N`>0G''A[[>DIN!\3WEFS+%XF[):5+FJI?PVC"ZAD8W4)@+D-V_ MHQ!PBM@L[<"Z@6NB6(SJRF=/?UUT_==%UWL>:(UW8%T#M<$KLR]M.;Q;+`&B MH=ZC67@[P)"E:N[F6.46>BYSQZ/XC2PFO/G]7CW>4QI&5=Q6^XZOGDXQ>+_G M@->^R\JNNL/N?:\_N>WWI\U=4B8][I8>7S?^YNZ-`O*W$'-IN(98])YA\;P!V'Q#=LY&?&@.;_@#1MKKLWKLEA"Z1L+$=$KP07=;<2K=5%>@=<6>.1! M0*IY08:>;5.9&^OUFDC`94GI^%5TP!W?MZ^N=U#2YT`DH3\"X.A::P@6B=@$ M()94;\`83,/6`():T&$DA94E0M?+:7K:6$6%*S%.\PD+#8@AX^;+2-U4V' MY2(3A/Q@!T)2,+XGV)&&&2DM[PV115J;P:!CGBX*!+*2[O_1CN[_0HC[PN9( M465%[NM\[<3N:YO[56"$;E-KH_4FAXQYB\\AZ_-?RS8*NN2,D@S:,NN6QQR3[4J3IFD MQ/GC)@'QL&[=AU74+ZW1:*C%=,F4]Y>92VHT7?S#(QA"O5K@L)-J\ZT5W_**AY MNWC6KX0DJ-`SMPPRA))E54,6P$-OEU?*H`")7?N]BA6SMK5&*V>95+OR4M[2 M30D1/2:-=?110<7(:B.XJ"3;=:-8>DY40D5.+$E`C@H:6E::[;T))-J5A2;+ M<9,91I-+N'-RK'.-F=U&<%&*MBMGU3ZJTCZ<4A]''?+N'P6@V!:_B/?RZ6BH>`.R_I:-!>NUN+C4TZM`J&4N6G*6. M80`0AFX?4,P6KG[*ZFLX0X[PZGQ]QL(>@IKQ6)!K[(0R0-1I),$5+T@+'W3< M?A'^>`(^9)_\'U!+`P04````"`#B@V9'/&HY6?$H``!GE@(`%``<`'!I<"TR M,#$U,#DS,%]D968N>&UL550)``,7'#U6%QP]5G5X"P`!!"4.```$.0$``.U= M6W/DN'5^3U7^@S)^C4:C&:^=WJP&S@T?#@\.@(/__.]OB^1D!3."029,\X/3UEG1.4_O,G]I]G M0.`)E2(EY?_]^=U+GB]_.CM[?7U]_^TY2][C;'[V\<.'3V>[UN^VS=FO<;[O M4&W\P]GFQVI3I""-4J9A=""=*!K_[8X*/T0M<@$-CI&]\6I&;H)](^<<['(&\'$ZM)4^D+=C_.]TU.V5_ M.CW_>/KI_#U5XAT=OY.3S0B"+,IP`A_@[&3[SZ\/M_R04%RUN3+LE[4'>%RI7%A7/\'1/WJ/(0NH>I`9)XE'* MDEI5JIU(37D8J>4+R!8@?X$I?!_AQ5DISQ(M3PDF8$G_$\%8+QOK\/'#^0\? M?OSTH92!H]!>'I@Z"U)V;2W!+(\@=I5AU[F]%*L%P,`*P:_N:-ET;B7%%2)1@DF1P=-+O%B@G+J+G-"XYQ*G.8V':%R$ M(+F".4`)<1#4DKZ/47:>?MN^ONQY41"40D+NT&\%BE&^IEI/LSE(T>]EJ.+% MJ,9,>D#)':1A4^=8:7#Q\_UP=]F[WAZ\=@)>YY&[W]YUKTI"@T&4(@8$%K[7 M*,-O.?W<'#Z:3!#[+V[):\<;4 M.H-)3G9_*14]_7"^C<+_L/WSWV_I>FT!'W.Z$&,HV87_DV]HC[P$/,.D7,^9 M]LA1SFQ@U.,L,,VO:F&OF>[U/F;:7]5B8!YGDVQGB6W0V&)=-,OPPFX`L9O. M5WOQ3WXZ,>!WDF-=LRO!,H0J_.X$9S',?GYW3G\JX^&?F,^#=)$\`PE;Y@\& MK`=(()7P99+&5W`%$[QD^EQ_6]+!@9]K2\`&O"QZ-D!FU-,GU$0+6B.8-<83 MM]'>!FX;OE7`V?`;`>RNZ0<.KR%\A-D*1?"1?G7@!?W$TZ_^@JFTF71)LK7' M=/8`(SRG\0V,[V&&,&U'L7NGS*0$(_UI-X0R#W^GO!H`[XB7QPFAV..I3XMNS:;WWX(< MB'`2=2*G@=>OR<=-N1]^,)MSK<:RLO/5>V#8QZSJ.X[L5B<^[/SP@0-)GA7P M\$>,$D@.R/NXS\B?"5+RG>?JV9;R4!"^02E((P22VY39 MD=E:D:#7M&Z`5]IZL`G[E(&4S&!&:.RX<684--.90%#R1&4AXI^4B\XN6#3L MZI=%[PM:'8AP+\84>AV):%5_TXE((\@!7R:`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`IK1,PCX]K>"`Z-,V7D,\8]X>#N6KI\9K2'EYP_,0K*@GN'G+ULKAT.(^=1VL;3TQS=3E`>8E6W5F!GF1*-^A.1P,3_:*.6B`,O@=XGJ M'EYZ9%753/J-['>PM=\KX1=2/[PRNN)OI*X1PTUSM1N@6'J54VI]C\5 M-_$W)/YP@L7_.;SB;S>0;G((>_9)B0^PQ'$,;DAEKU&D0O MK/MNFUET9J![;M63!5UR"PZG_=G6%O!]2-;_J:[[#*X0+FKB[2ZS3V>5^^\/ M,()H)?22SC0J*'>@$1QVV]K!%I'N_'BPZMQ,>!IV#A*=3IJ[X-"24?\'=QX@LRD5S#F?X$BA\MVV MIA`4IMK;P/:;[IZF'-)E>>`!ZMH#5!63LL)7 M&D_3!W9+ITPTI_$7G&:[_WL!"-(^5=8)CV;U;+\\!@N0?.BA>M#$._T.QJ&' M(V7=0A-W;V]Q06Z?VM0NI'K78LBCI=`/.>LMFE MZCF\142R*4\\6?246435L_^*.C9#+/(6QG90^P$Y=^'L-N`Z@B-3%>WW__P+ M@AF5^F5]QQZ8-9N;!IWETU/9>7C35$::\*):SU4M#8-9JZ`QZ/PU@8%F"IN: M1S>9%:+HYK->A#'-[*IB^Z!#>3;2IJL)6+FN_9Z\A0)^HQ/-CT_D0$.ZWVQFB3\A?B3L%W!'"KK+7V M&ETAPL2CUI@\D_)FN`1Y=IT;(#3M/)AIKF"&5N5SMA51+ZE?@=+J9B9=&F90 M=^EW,EJ.)W927#@-S3A7YY\1QQ%,P$W6PW[N&?=KX,V@WX!/RZ\@R>LN^""@ MQ!!FG;BGY=6=^IUWYF.)'?463CHMV_IKPT;LPKS\T%VN412)&*?>.DNT\E7_ M+&0;@=/L-!LH+:8]8#Y0]8AG9^E`LV+>]S'#:9=K+ M&K3])K[ZN+YBL^SN:F_2-CSM=\_17+HQN:!*)N*C=<;HHW7&Z.,198S$VG>? M,6KR'0'K\B%3]+E,D`J:C`MW&=6M15F\FA=6N MV0C6^QK=VJ_PI0S"O(/;]YK>?,M^D&6]B7@CF.BBC^0GZV#FDW4P\^F(@AFQ M]MT',TV^(WA*0OB)M`EA;`*7D8(").SR\>,+A'GY1"H=D/T#/H\YR$N'?0DVUS8Y0$G/'[8C*SV9 MZ$IV^&CC8BT2WNBR@T%7^5%.1==>KRBT180X9#8UC"9%ZR:;)$[6RW14UP?> M3BF_G5(.>+]U8_W-7%J](B@MO5@VCYE("4SF+&8]1%F*Q117SV= M"00EK``:$?^DG,I=L&C8U2^+_AV!!D2X%V.*'8-8M*HGZ$2D,3B*MS3:\:;1 MSM]_""]QNWTN1XDQ89L&JAIM^L51)^X"FQE`""R?`E5Q)Q9$A+2WG.TPGLSC MBMPYF^MS"6Z9YPUSB]$D?=#M[J%"@N/>&/R:9A`DZ'<8_T+GT!TF9)H>,"6; M_X:]&IY`VVO\/L'.,)U[!U-Q!MD/ZMY/&"W4_3@&#:L1[-F*@FWV%N/7%#\3 M&B,QE3?A]`.,,%4V08!9[:&QI;7Y"JW+NL,6F3Y?K`P2@NU9C=]1]3`$_6T_ M=*%#_S6N;YFQ0'+PSWO]&M/(K'&E5J&J\7BA;&6&SL!H*`4')TTAZT&VZ0DD M^'6X_?FR9"V=DS"^Q(LEC0C*V;HI9#LI\A>CH!<;%_FD`-]4NUKQRJK,!_3!M#EW'3/LXC]`Q MUO%`0R1^.K`376L%M_O1<_'ER.:W>$`8S]V[#ZFK3_4X"YO"(A^ M>L6M$K/[K M,27HW9(_ON_B7*R_@)S5?9%O?JL;2V_CU!M_'UO01J8:>!=9(V.@./T"%NJO MA:JI%*/5IOU[:\U("'$E54Z(*C$',1H$E(,Z%-`2"])/?Y]H4.RLMP.#V>?3 M-QP\[E\<&!]NN.RB8^F2RKQ3905ETJG?!9/2Z-A150T`#IQV*Q0+#D%](R:O M((O9+6I%""-LTWQAJ=[F^PA85(89.$X1BR:ZZ!;86GC"YLQ\4TSB8GUH?G@0**I@; M^@@4\2?FT M6WZ]HO_1!->:UDT/*6O]?03<9L8:^J*)1DA/A[TZ`ZLZ'M"UUP-VN.L7FH%1 M`\WB(H28CP8C00><=7&5WTYE6S4Z!OJ6:L="#@R+#Z.,BP(6VJ_XY MY,N!OGV'IY)H-^H00=3ON<-_)JJ;8FJKGB_9V(@:U]!.*_:5@`T[#0E9WJ"S0>`F2 M!,87ZUW^?MM0%L%[HMIP?JVI'MO4Z,;<`U6I\*5$4`E]D5(D9^[@AF+EKR\H M>FDJLC67HJR,'Z(&D\N&Z/:;O^TNFC_^QSJ1AQK"H6JF]:YNEU?HMF[J^ML29:4BDI2$ MLETE#2%I=VS8-S7)`.D&M5A=7EX3?A:G14YRD,8HG>^7;*6FI8"'TJZZ])-3:J<%RLL/`%7B$J]Q6U:8*DWF:`W5TCVV,SK<11A8I##09" MRF$=![$==OD6?Q\#KSH2U&K<#??S/8^\QYW\>Q;83""GQ,_/]Q]^''"*LM?$:I^;W9W%Z>SPY[7B6V]/H#&U M;0B,(`IPMD>;D,"!:5`[PG7YM[(K/QL&/90X:_3H/Y)P&#(IRE3J"YV6.7,Y MRL1,@XH_O,)*&IL,`"Q%I-(9KLR"F!Z1Y3&^*5\+4Q?ME36I1#=\DWZ#&Q,K M8B-M#(:V1GX7]TC)"L*><]_CIRQ,*VG1'+WA2LK:#IY=W5?3L3,ISDJ'+K33 M8[DB0-6V-SFK,IKPTU3;-M&FGD?XAZ*448!!#Q/0#!=)I@W169$2ZQ MOR[I8*;Y]KJ(=*&M:E99;HN;]1P:>+4]-M;?-[+JM6>T0G0)DL\H@23'*=RR MEE>KUK2L0$7:\@C08F:%[@&CDZ/+W-UC7L0T]IAF3QF[6B!_,DK5KOHHE+C= M$:#%Q`+=8T4MA:?S2D*D7""VZX5 M/)EW/0*(.=JI>]19"Q;4WF;P*PUY&B[DM88R#QOT8L,P;SBRY4;[;"6!T?LY M7IW%$+'9]4?V#S:I_EB95/1/?[^#6O]+O=Z7<9W8TX0J\G^[DRKO6?>\MRJ(R)M8+7AD]`:C=<0A*^*HG*HJX% MC.G'-IG$*U80,)9XD/+C((HI?- MK466N"I`4@F2F"!41(1%<+#M6EU_&G<-&R:.)F@%&6N>76XI[3'[`'/*GFK$ MJDH_@@22"SC#&;Q"),_0-J`D MM>6*;.=F;R`4U\@3-ZE5CVLV"1LF&I5:5HJ3T/9T/^+X2]NZCJIUD5K;H;4L M-^NQ='$U.IK,YQF<4\[W&:)R+D$R6>`BI6XFAHNRY*@F8C4G((EA30B$#956 MYO`6YUIPYI-LX919N28Y6E`MIK-[^@-Z3B!K(%DT6_55%UZ1]0T7>FV,X(PZ M-Z872O[K.LNL?+I+:&J/="LJ)<5A)Y3NJ M_'Q3*![F^:;,,PT@V=%#F<_2]V@Z*U6/<+%EKW![]V3`BL?/H"7M-L=4+S&1 MOC,I:L(AI-ID#)"0JN0!`P+:_*#[O)A0/"<;IC<0;A<`@H^.JEGU6H*P6;AC M:JA:JR^%DCX_MD.6,_M,;9O#E)V@4DUJ63/N2GRS6;A`,%2M]027TN>!X#&3 M*OJTW%(Y,DCRPZ)?,.WM.E8<@6G'-Q\3M`US!M(`/,,+S ME#T?Q/8(=CL`DR)&H@^%>:<*6DPZA8T4:[5;H<2"&X\0CZG?29H6(-D&+=M; ME0),J)I54"!N%O:X&ZC6:J25]/FQ]?B*W+;8RV8!.YT]0+1X+C(")6-LTKQZ MWUG9/.PQMU"UU=@;\>$Q,-SK:@Q'L]4BC7V]G'8#4%8FYCY#P!YM*^W&C4L% MA68=*CC4=?`UFX1\9$^DZ1OK-.CI831# MR8OU_I]_03!CEUW6=^RJB^+J@5WGQG+.M'/?%Q,,AAVW-($9(+G;"9:\@JJ+ M)]20UT)Y"-F)A@QU9C3Z/ZIL.<@B*#J81WB6V4P4(4*M1`BJ$&?O0)6>H`\" MJHHK.3TAU>S<_6!8#<*IWJ;+@D8P3,U/ROL]!CUD*!3UZ/>NC]N(B7"GU5Z- M,1/^0J@I^`K*GGX8\G+A#6)99022VY30&+;ZQDIZ1K< M:8A[.M#O!QQ/&4C)#&8LZ?`(LQ6*4#J?S@0ZE"50B/@GY3>T"Q8-&/IE,4"H MJ($,[L6:8E&,E&&C&.WEPV4 MD:NP30.HC3;]1J>=#!,V,X`06CX%JN)1+(@H?AVR3GEE07B'P#-*4+XN'_4Q MRV?*^\C3F*(^@4>T%@JW3UHJ6`15>'(O\DY@!,E6QWB:/L"HR#(ZE2X`0>1K MBI\)G5Q,[7)UQS;1Z1Q*4'GJHJFT6=JH:[XR"'?'=]`\J@)WHKG0D_5U:2Q> M:N&TZES:H$+JHYV:^BSPV":G6>8XD+EIG60.=G9Z/,M]!3.THD*LZFI("E4: MM*X<,U"V'BBMW/E@85M+J5'8E;R[`Q`F1)X6.3 M-VYKW?H[>F9^>,91:8=C--:.)K;;,@]ICN<\P7>_GZ\?B^1^0%9>?9I,50`ESY:S`//T1 ML-.>=]0B\`ML'J)M2Z;AZ>S)A(A03T9IX0F=.0>5(;E=+*G&3,OI[`Y3:6F, M$$\(@3GY"TQBJLA7Z9U?J[X-%!KV#1EZ+NJWP)L=.WG=IMX/?U\APH[04N5. M+PI"52-4P=\*%--8E7KS:38'*?I]4YH(YNQ1)5^GQ*ND+W%*<(+BS:,Y:7Q/ MOQOLSA3[OY5\^2/]B_XTN5_"E2C"%V%?D58K>0X#+SO/W@5Y7];DR'=]9MXS MJ'#G)N:;5)DL!LOJ98OTUG='F#<,%`S=8R\L1Q*SK5 M0E1N=/I--NN'#/NSBA!24@GVI:A:<>X2<6^O:G6/NPZ>V3)&GO=WMX8\U.;M M2RC=&N[]6Z@Z;]'R8VBV`>O]5Q64$+$7RZ^!@9QWU,76!F;R2\?RDWS^NI71">HX63)]1QFBROXK'NQ4=64J\TL:GIL[M[` M(+UY?J4LODIG=@,Y97BI;JR!W6`I%N5H*!!DGF$1<5#A(>BG'EDV?#J[S.@B M2GV;1MZ0JZ;+-^SW$Z,9`&RAE!$`^`LO"KJ!#7][AR!=;/;K$E0KS78^P6RA MZ=LK>'W`,<,1A#%A11IOF>0@N2E$AQO-&E&B4[A@44NZ>3B2*]V^VIR&GY?-+R@.O MNJ;571AIT[%#Q-`('4-%*X6G@X+B`KV[ETFV+FM32Y0\X0M6/!BRLV5?ESC= M"36=7;-G'F4/M7F@5BWWVX;:V+'ISY0=P]>'H/)3BF\EJ'L!FT.1:L\HLBIC M[?-QRDKT-HECM-DI-PN_I>TE$;B@_=B18V..'N-PN2@S,3=/A]S##2J=LA;N2L.:"X/13IZ9;/[J$8@)J+ M0E63YIV=6I-C0(Q"Z1Y`(^0>6AX:I.7WE1#Z,:4`EZ:@)>VXW#/7[AAPI%._ M#P\D%8%'U)"[ZRS/?BA*=@\SA&,4;2/_)Y@MR`5($HS3W9_H>E+AMMJ2:^#3 MG=PQP-B3,7M`>VM)P]K_?WS!62GV!6%*=!\8:H\_^]^^];364C()G24%ZSH#7L$DXX..S:>L;(U MXLNX+EV;IR>-N@YW0+0F'AWBN72YIVJJ5'K7M.<3AS9CAJW4%)](-.!7.W>J MXA/4B<7'Z`7&10)9TJ(B5N"B^H M MY.-@ZW*VCTPP`4M_;R(_HGF*9B@":3Z)(K:)22UPCQ,D?+.ZLA]MU[&R,VW: MT=<^NY*?K,:4>2=3S7JJ!V4Y+-A172Y99L9WMVMNP6_\M9>.^6J@Q4"VO/"G MY]3B&E]`Z'B[Q1?"+;ZW2WS?\R6^<;N#MSM\W=SA&[K@QSAKQ;A%",858.S" M@K>Z+F]U7=[JNKS5=>EH2DJ_O#U,2F4&SG!6&F;7G.?ED+[U$A!61I#]S_5O M!5J!A)UI47Q3]1V:KP$I.HSCJVNL?/6XTHXAM9PHE%_]5[34\ MD!1M43N3[#U4,`!!: MA7I#>L4A@\7C?"[#+2BT?P3#+ABT>=IBR$?/WIZV:"(CL* MFM8-Q$A;!WSTW$Q#]\/G.OI!@>/M1H*-=KW=2!@RW_%V(^$X;B2T7_DVDW2` M29"O-\4R!,M?H_:5-;"F?7^E)MP.RMNHV_*,O!FKH-S(\94=<$.*A9(M0&+$ MQ=,^NM!7/-!H)RU8X5Y,9?X=QJR8YBZ9,REB)*IC:=ZIXC5,.H4,""?%6_H/ M"W[R//L@5]QF>0)>YY'+';;:R(@O-U< M&]'--9"2>[!F#DT]^M*&@KJ_S8;!CKY.*=?1E],-:NE?_ZI=@BQ;[Y]W,8HF MQ5V4866S2[_8<(XTE9KZ"3DE+`)&S"TA!=LXN0(Y/#<"C+"'$B^-'B.!BTI/ M/V@1'MO7TKT$2_I+OC8(.DQ)*,(1/8E@\=7"$JZ`+^/S"&;'E M4.GVZICD0JJ!4/CBW?M2J).KPXY"OTU?1:+[0_Q6A;M(:]@<4R8-[5DCZ#7B\2C/IP7 MW7:/&C[0P*E\0RG>:@CF9F<13`BHX(Q*ED:P*N)-@G$F198O MSKJO-$4T/C_FJGO[-)&;APHG\UR5_WHV@U&.5K!%O*:@81RR"6D$ASL?MO`? MN*EX\CATRVQW@<-JMM4(=*(.2H35.XP$3@HM_6!'R(`'RI\]YE1P.G_:'I.Z MS^!RLP5#_[5`Q6*_%K[/4!JA)1"F3-PH5#,BMA2"@TM[.SCE,QPY\H!RVROQ M`:C-G;NG5]P>61PI=XA52!T#UF26Z0%T/&L>?1[W1/X*6)G'G+!S5S!^PO=% M%KT``ME;VSA]S''TSUOVXGC*/LLX?<+L$.ADGD&XN?G!8=`/P0H2VQ(,$H]> MK>2"2D\"^*IZ),0F>\H^V9YQN(%P.F/3B,EQ`1)V1G`[>00@M.Q909MQSR!A MY::W"WYL.?%`&3+C?YD`0J:S[2289@]H_I)??Z,R(P*I*X[@_D>R_97(-@HU[+3WOKR`IJ---5S#+T7,"O^`\AB]1*?'%Y!!XAG8 MED3-D&U,=&S0=K.69VS;"L&#.YQ]DHKD!X7*(,AL*]>@O_IZI*I_L.ATM8&G MBY,&_'C,#;DG%K*'X3=95K+&'M[3UVV:#?KU5R>ZWH%BRH[?9V7W(9<>`0->?>DKMC7 M%"PPU>%W&@P@$AG7#%#T4WX9A?V"Q9&MSGZ^A"H^/);<=D=\?0$W9QFV/I.I M(?W625MR7S5!RV`1HM?+_4LEI\P7"-CO0\C*!F[_SO[S#`BD?_E_4$L#!!0` M```(`.*#9D>W*BEQ9Y\``'M:"@`4`!P`<&EP+3(P,34P.3,P7VQA8BYX;6Q5 M5`D``Q<W>W5A32LINW:HRM"E5]\VEG8U1#(3$;@:I)AG*5/_Z`T`R@B]X M<9`.$A&2V4Q7*@AW1P2>YW$'"(+_[7]\W\3DF69YE";__7?O?__S[PA-PG05 M)0___7?;_%V0AU'T.Y(70;(*XC2A__UW+S3_W?]8_.__VW_[/]Z].\]H4-`5 MN7\A=X^4_"5*BN"!DC]EZ?;IA-RDWVA67KWZO>/&<93\_8_\ M?^Z#G!+6BR07?_[WWST6Q=,??_KIV[=OO_]^G\6_3[.'GTY__OG#3W7KWU7- M^=5(TSY*>+?#??N>_V\?1.OW?_C#'WX25W=-\TC6D+E]_]/_\^OU;?A(-\&[ M1H`\^F,N/KQ.PZ`0/Z;Q>Q!E"_[7N[K9._[1N_>G[SZ\__WW?/4[]NL14OY^ M61K3+W1-^']_^W*EC/F'GWB+GQ+ZP$?K.KBG,>NS<%&\/+$QS:/-4TSKSQXS MNI;[BK.LY8KW[0^\;^__C??M/[4C_#2ZJW<,F=1]?YMAFIV.^4?7[%^MX/1[ M09,57=7A>0#-<(OX`ES"\\YW&K:\QAPX:=;^3D_1$^OR^W_]^0\??A8=9A_\ MQUD89ENZNOS^1).%DP:LQ4!#E)UX0U)O=!S"6&Y(^4%F3%T,JO MI/=Q]""^1DZB).0.5X1)-'D*7H+[F)Z0)YH5091PET5*PC0OG/"VA8BX+:H?\??DMYSY9-^6 M42>F82%^O[#\L-[\GQ#[#PQ+YEP'IO$+645Y&*=\0*LA:/U0\X[U?_MI M+UI]H3O+VL(>9&&M->R?!IVJ6OS$QB:D3\6[N)G[UEFZ&2KCZ2AUK412I$CR M1V+E@X_2H-#3)9'_>&^5RUOUR.#T(8(B)1#F:U$U)G5KPIH3T9Y4!J1A\7HP MO!_<&5#,@T^(XU,;'!?]XGHXF$\1P7RZ!S.MP2PRA@!S_"I!?#HGB$][(!X^ M>5FM(IZ<@_@\W6S2Y+9(P[^?U972G[(TSV^#6#YWL31M3EW`IN/):ME+Q(D+ M/+*!J5!'BWU+4C8EHBW9-2:B-1'-2?`<1#&O7LF6UX%ES<:+T#2..=?_L8V* M%U:UK6DFBN4L8WVD_(M[0'1;\*5C0"$C.=!%A^/^`1^UV+*)B0-Z46K9P/ZU M8%=?9SE%+TZ5!0V&7F39!$8"\>F;=J/C7UNBN<4_:H'VMVU>\)&^H/?%59(7 MF:@]OE`VM)3]SE?5&MP7UH5/<9IF-Y312MSXD19MX]VU"KDQ[A`T8ORWP2SX M1O7&)"4CG"_VUKLU6\)7]OAZ76DN_CPA_`[7BFR?R(=W#.#%([E.DQ73(N'] M/DC^3I9<4U@;'H?\<'WUR9-T1DCL@>P]DYX+4/DJN"2]D[^:-72KT>,LO MI,)X1`?PB^61G7%(LU-UWCOI);XR*J>#C+\4P:V\6=,4#WZ7G MN[G5I9A:+:N9U:]T6]`2@M2FY"OI='_YT,A:PVG=-0HR_@-]=$ALX]@1JTTK8(B`5G4D`.@_'J0 MK"\''6-94N@-SD(?(Q[E+%G]EMR7_PQ#OFTI_R*V]?`T^9D6DA1D9]C(/U## MT7RUZR%>Y@''U;,5Z&91?UQMQ"HWC)46Y9ZYRGQ^D9 M5#'SBD5$#)CRC%*V%#N5ZK9D!]Y]:\*:OP:L:E.(.[2BK!(`0V&O!UB$10'M MJ51=R0\2=?WQ54!6-T-W"%G$6??'C`;AXW)]OM\/S6^W107/ZV??@FS%9OM1 MNI)5/):FS9H';#J>FI:]1*Q[X)$-[(0Z6I0M^2VAYO[V<->8!+PU7WACSG[)[G[U8*IN M#<)T##AD-`>ZZ!#=/P*@5E,V,7'`+RJJ$O[+-6FT)OOF1+0GI<%KP:Z^KG** M7IS:"AH,O;JR"8P$8E9AW5[]Z8S<2X5\_Z!26\B-LOUJL*XMR-QB';$H.P_R M1[[0]+]=_%7O(BV7V)7IX M+*[R?,N?_[X("MDV8[!-LP0PVXSG#K1?B*4`(*2!0D8/"]&$SS*K1F29$='L MA-0-"6_IP?(('!KIH)&3LM)K`!AUE5\!6+G)]SM_Q&5W>I>'#J[(&E MT\OO3PRU.5V=Y?MMG\^]\"L7IRVEF#R#B,O=@[)^FW\NRDO'RRDPGI MNG&0U8-X(O2I"D2XW!"Q2EO?&,M%-!^JO@D(F$Z,K7*C&H=;'C M;LXF+Z(6WPL,]T_NTNK1<1&"[&*0L[SQ4!DOWKM/G->1"`]%>"SAB3?=9'(Z1\[,7WH3'#>Z/57BPYZ_E M'?=DQ>_$1PGK8QC1_([OB53-0"`SUBM8X'-2-^3=6-=10J\*NE$N8`/-I!6$S@R16.;> MN:@EM%&A#-,X:9"L//JXPS+>DHBF7E$-`!4%W\`@DU-.;:[BW>SP=%-T&.*- MAV:[_,AE*>`5@1-8CF#"$[DPT01R5YT8@B*@]/1-0F4C.1U*AU4PU>\H?L.< MAK]_2)]_6M&(_9;O?^'_X.7-+^]^?E^]"^T_L8_V9V1\BH.'#N*5UZL?0G)] M%+>4\<9IO,RMFB3]UHV36_C?\^)=/2:I\6?LX+?7;@]4YR-KE[\-\BCW;C'$ M[>-Y#G.0EHV04C?\JB84YU>!%-6 M[A@LQ"?E0WIT1=;4DVTABO%*(;^O-'VVFW93I?.QQYU'2'S;C7LY/^`C7WU( M^*>'.O"&^MYFZ)'J]HY3_!I=$L`2`?R(E&KLW__T@60TR--$K($%!1/>A+[\ M2R[T0)3E_`U/#"W?HB*A>?GY"7F*M_GN`-6#E0U#W6V%'L05P?89IW;'^5O; M-A*AA>UHHECW$R]UVH36,PON:<'?OMUY[67GI:/EI@;6Y!USLR'W:9:)Y^5S MDFX+\7YOT5;[8M+RQ9^!>&_8GI^$OW2T/-T_W][_3;R-,R7A(W\!2+FS0KP] ME)\9R?Y[0A[3;_299MZ>X6^/\704]"3B`/;15@TO&899H-@%16(7+VFZ9^;[ M?E+^5!C6%DBN48Q24L&C8==:=I&QP,RJL[\$620[HE[H<4N-7Q&0=;6:'/?>&H&CX:E4.2I&:KTH..G![!U5RKI0Z)`5E(FR4%[]JI` M:U$AX<+6076DCN6V-M+'Q4$OJXON^,0X3H-$Z&K,;Q#S_?\9747%R?Z@F)47 M#WA/@EUX482,7=2"*(N>67)_IOO`U2/GN?)M.G"C5AED-D)@)+1GF,4/(*:) MAD87BWV;YE2[;N71*T4LT)$.&SLIWTS&7:IY@4;LD8] MY`JZF#`B9TG/2D6/B4'E1I[E808#JB/(QP\IH/0.!Q72Y%#M'W]"J(\U'%NG MKPU;^DD=`K8P)V]5'F/SPLN$]??E*EFGV4:DM;/[7!Q'+LOH%F;-U`XR&\\; MB]XA)GM85`.1($X6=2NQCE*V(XV&Y&O=U`=JV4`E'3J,,JH!S#N<\P>>J&4# M--YX:(I"X@VU#/OD>R#=KJ1@W=ES4:32-U9#Q-E\;0TT1B MLNB]O)=_[`'\-8.7PGYJ";#[C=LPG@@,F`JJ\&X+!*Z.QP<%K@;@SD!H82X=<#>.RN0[( M3L'A3MD:_NV!(56W(X&&A<9!P>%.YZXUQXX86BK5[AKQ]`9#'UQIWC7X"!&5 M71_>USX]Y&X:6PW*54!0P_Q:_NSZY*AQ)X;7%B=[J"U?`68LQ-$.->XD4GFK M4M=,*8YH]Y%TT5W)(O!VI-2H#VYO5O2U`ZE!M?&6HZRY#LU.P>%._<"W%15F M1PL-"[6#@L.=SJF.KM6T4JH8+?IV(!J39PK/9#1`&J?U`24BB-VSS96:X84HK M(-(8J''!?:U@TVHR'MQ0]JH90F!O5P.$&X6ZTU>,.MW^-434(>YBDT92S7W, MC4UU`5;1:^Z)XWH`-B_2F*I)XDM-#!AM,S=,DR:U$8`1[M'D/-U#)U1:X]>$ M)?O,;H4F=QG=S7LU#*$&@TJ7Q8\05-:)VPY4F`D[2H+X)GCAWC]1NESS1\.O MTR#Y6)Z*5AW=(LO>=I;-5`ZU',\47((_%9M M^4FZ_!VXXI@*WIY4!O7)+8I(R,6-;(8!@KU31;E9]54 MH/K4`R*HARZ%_=`R,G)-BFBF*R#*.:E2Y23 MD/UW=>BHT"4I*U1,]S+$\VV6\=E?E(=!S$_2O$Q6_'#-#M@@31NO2%0W'?U. M/5,OQDF=(8+^!7M*PT5UA927Q&'&A%T4AQS/_]X]X\"F-@,@>1>?RJ3]6KX9 M0(/^3D9MH&'H$2](>P7XT;[-<1R",+?N"JE>)E1?[?<:=(O]1@.<_-^+B%SJ M-_T#DO^^>57UL0]\2^_]0>IG=]5`]E+[KJ$DL[L;;/02O^W99J#W!?ZA#[6Y MN@<--EYMOW?II+1ON[<:OX]V!*B!$B?"FH8 M]:C0:"HA@UNPH:>[KF\[H.U3GOC0MZ1G/?3FQ`<>?+SDUW3J)/UU`UABX'0O M-[]6PO%K0PX^57*SW(O)P($D`J1C(/ACKAC(H.AML_%35\FPST(TT=>!##4A0D,%& M3$X[EVY24\N]U9CW9F;_^;!'WIQS0"./F&^NHX0NU^?B;6^?@I`?:?_RL7Y+ M^GGPQ#XJ7JHM=,OU_]H&<;2.Z.IC%,=T=1:&_"7K^1<:TNA9\62?HPB-C(<> M832M''UGO)R+WT$]K['C+;A#OBV\=$EJGV3GE-1>ZWWBO/7.,2D]D]HUV?OV M8,[KBC+I!!B5*!MRI+8T'CWY,6LP%UV;E/B\"G1'_3?FCP/H@7,?I:+&[A-V M2>ZB?]-*P&DE`;NW%)-U+0'W.PD(*[\GY!\[XM^7Q`]JXF<[GQX]A'.0"J"; MUQR4`LP_L_HMN9=W#F]J90PQ?FZE"3&7PAJ_]>RS*UT/G4BL.N#H(JMV?5PS M+#-S,&06RD\$E56&0I'90U(!#Z99^KY-JP`8$RV-!KPIP%B4'KP&S#G;4G?* MD^F6OH,32\'@"=8IU]Q2X-9<4H$Z[_K&-6+]>SK*,<:0\*DNYFP+0 MNC49TK1&T#)C7S"G*+I@)H%1VRYV%TGSJD>W;2%#GEJ.BY2!2JLNF68"%6[% MJP\S&%!E'?J*(&6H\,:#"O,YHNLT>>#'[5S0^^+R>QAO5_Q->E$N]%TFMY#V M3<'5MQ_/#DA_$$77$,[`$JWU@E\N3TGC#,`3T/"GUB,D8XK.KL.5 M.4&&*L+&0",`)H3X]4%,+\=((,.9"FLCV,UKTR*(#?-:8[0Q6&,SSCO>AR/$ MDW;6AH4GS/E4(]!-1JMC#=F_-M%VLYOCW611$D9/@?0NU3`/BC(`Y`&53!9] M=E,JP#H`YQO$WV+?B#R5K4Y(M";?*/^372'%(VV<9LF?/N-_18EXH)U=R^AS M&C_S[!"W%X^>LB@5Y2IOE8>/=+7E:T2;H-AFO,A?,0\^W"(:"%NE%MAC7Z4- M`$]JM?"20*[*(&AH5/)(2J4&FRJSYBV3G>7K1#VXQG*->_0Z#!(3_8[#@/BX M\#^=.WOX=&]A#CY!:TSG?)JO#F6?1.GJ[ELZOB#MN1I>F39<3:TSO6\Q6ZW: M[`FJ\.P=J_3G*8A6U:D'7#[649:S>=6WE+S0(,NYRK1TR:=78XP&[1A%45%@ MA+#L7(Y2&!\(-6/MVNZ#&S(-KV9)Z8,_L/O&GRY6O&/0',7O/OC,57"[(XZ( MI*Z+A^:E-UIUX>,?K1!KX.IH%G$(_')]6Z3AWZ_R?,NW4_V6K&@F/JG?]RXI M?`?9-ZI=2_O1:C*HOWAUK6UXO6S8>5O<,<+79W@]B[=B\#EPNMFD"@]:%4Y?MA6)$I6I#:B`BKZL/:[O6A7%M=3H5SE#K2+B)V\6@? M'1/NIT[%_Q6R0E<<3L8*Q#+P,V5U9[J.BB^T8"/*2IA/[,>]#6*:?Z3K-*,7 M45YDT?U67$JSCQD-PL?E^IP#)`AE&_.P7#:*Q?$N1ZL(UK?"*RD1>J27FM$! M%LP#FYMR%_Q]E6?L1RZ>7[*[7\D/04Y6=!TE3&"BA,G--BO^)6>357[<[-^V MJU)??B3W(@Y9-0(1]@FY%Z%*)2N#>5"(H@$_=0$\B6"-==W6L",@*6:=B](7 MMP3EU3"G:.F$[+P0[H8(/Z1T1)J>"'-%2E_BD<[*VQL!3:#RGH(H]?;H3F"7 MX"@=YU[^\2FZUJ#^N;V?Z\\XJ_2BFX!]<\JXJ:?OVBZHF MQ0;Z2\[440:`A!=EQPL3[4O-A@(%\S'$SVE!\YO@A2^]G#T\9/2!!=C=BOM2 MWZP[VR@>2QQDWUSJL+,?7ZT-Z2_B(H9E>$,99N7M[:TX(Q";C@:1K-:R\=,I MK'SF#>JZ@G5@1,Z(%0-N0"H+LC-I[-7:&9'2ZO5A7#_GGPCE.+-YJXCH4W?K MZ)A@9Y/R/;R?=O`.RH%A$^N]]+]"B&LGS5-!'/%66+7Q*GB@RW4_CR3VLQWC5GW5\/;LMW2WV[3F9`RW5&?M8<5=$/.^H`MS=J#G[%F0KNC+4>ZKFBNJNWQR5PJK>N*G<)-'@[.P9=YC8 MO"$:E$WX7B+QQ+;8H,#:W-Z]._WEW\3ZG"C*6!-FLMJ&A6]5F!(F2B(:@*4B M7==,3;&)H>BJ5I+&&0[#?AW4V"A3M3DV:($+FN'@0B]6>@%3ZTLDVS1NBW M&4\755S$:D`2PL"+GL6B\9%'Y_&J1RT%_<@R^';;=C`[!090T[#4N>7XBX3+ M/R1'`P%]/K4$`4[F['E%3Y?2"+98.&VIP0$C0)O%;!&`F:\R^AREVYPEQ)#2 M5QW@2#.TW8KXB`$%&9EM?';(?`@]0:X9!P9$Y M(&J.-Q8,AH$'/,`IBZRCHI=-@WJ`30=QJ%#%`HZS\LEPSH+.(^,G8NF!?;AK M$*;Y[I53WXL??YN\>@N")/S'RKS_1N,CK3T1QV7AT MI/KX/\0JRQV+QB=X@;V&6_* M8]\!?7:S]2?.0(.5JG)OM=\&K>*;JL MET+W/5@(>W+/'9!FD.8+=LG]"VFVNZD?#^2A3@@/5M4=C7`GI`Q(]A')E]D? M@I^6HNDL#)`HN//8;I[NJ(0*2*Q$^<+6,=<"5B0T&<(L2>]"C5!R`L4N%Q^#+CQ;(*M)_S20S. M8HI!9*[>1,8UR(]69N9=,X%TT)OE$FAG9U2;4[X'9:<5Y7:LA[+-FS:XPN7Q M:H/S30!_%3L^BOR&]81^X5W^%#VK'_X>[L0X-]0[<:20D)Z[GL<9^C!$S+0N MU>50;4:$'1&&A%N2TM2#[:$C``@0)@L@F\5&YPPB(=X1POV,PQ@=FPS:V8&: M#OX\U#\?'P:4YBX9X;",UH:=IC@V=@&=&*R0??_[?_OP!G73^0SU`5-ON`Q/>]2]LTR"P/L"KL`W"8-*B`/$@8=LX& M"L.\A)BE*FQ'QR;#@*J0T^$`4R4Z'W"J0C1&3%L5[L/.5A6VNX!.#%$5_I<_ MO$$=K2K$@_H,5>%2_1,@$RP\,K!_O0 M&R0)*@0/T8.E_!2]@R#"')7@TN*PSB$^!]#@\'(C-@]0BD`L)DQ:`BZ=G4@Z MK`?8A&#UWX??_^$_OV$)2B#X2!]4.-YB#XTO`U3B-F),4=-V`V/3@K[NK"DQ>%E M31>\0*D.,9DQ:878C#M7C=CM`SY!RKO'[]\0CUH$QM=0.+[SJ-M,HR^'V"%V(/>,%50('B0(M2^!NK!G$28I2YL M!4ZBSE8'MGJ`30BQ5OBO/[]A'*G^P\+X M#+7?'?,Q_DZQQ,N`^J_E93*R2_H^?0W8[@0.WYL^+1.@,#V\2E`&PT'ZH,;S M$'UH>!NF$+,38XZ:L!L>G13V=6%)B\/+FBYX@5(=8C)CT@JQ&7>N&K';!WR" ML#KQ]##K1">(QZ@541$_1[WX+1U?+79]#*D5]SZF(WVWWS/4B8TN(/%]Y]$V M&7Y+#[!"[$%OF"HH$#Q($6I?`_5@3B+,4A>V@B.38$!-R&AP@/D1F0L_:*')%I'(0MU%H;\/451 M\G"3QE$8T?PZ2NA503?=-VS:&S:K/*#A>!9;]1"QGH/&-=`5YF;1:$?V#4G= MDGSE;8EH[`.![6"3#A]0&5%!#CKL]`NNJ%47/"(&5$5]]096Q7!."E=)E>0F M@]SQUZC99H^6$31S5$9N:=CJV409HXXY@H*E"S/Y1#O?>==&!YQS,E2!V2:, M+9@V'1HG2PC[:&.1"$H$QX_%X=H_"(VHFL^/QGQ,XQ6;R5Z*-Y9JIPKFUDV5 MU[4>3RAS7Q!U71O,0".-[:)YD917?2N=`&.>6@Z,C"9JJPX_YD(5JCX;P@Q& ME%#D5X4IO?@BH`IG(5+C'WW)T1!K.+A.7QVXM*N%&.#"7`'LA5%.VO0MM3D< MK2#6]\%E[@9.Q!1V+0K\RXX#WI2YAK$U0-\XN9);F`#ON,H_9:^W:?>?9QAV#E]#7ICF68MP(.=7J_8;\%FY,_TAHWEW3?V M[Y?_EV:IX;`..\MN^H58XC`$WD?D]`P*#"`0P$]))[)K27A3PGKMU:D[EHCI MD\P:;CW*F3U(*.@35M&+`F!(%)SNBH8N4LO6A#?W[]B+"6!K+C0<`1>O$`'$ MB>ITF#^2.9ILND%\9;(TECBO8HI=`>;ZE*_%6\?,T>:99 M$;%*ZW-:T/PL*=^U=<,X\!CDM-[ZI*R)AKOJ%4E#7"'1>?BWP"ZC!O4$POZRR=><>4L?I$%8;$-8CZ-4=6R^M;= M_S#021'J'D5A+.S($I M]#),$V8PGO;%U.M`E+G@&8DIO+)%X=])9:*)-1Q:K+ZH016PFF%%BN.#DS'G MCX438N86)<-R714%91EQEU[39$6SJX0%3F@HGLJ+BL?K-$@DZ7RHBT:.MWXU7#0SH@9YWU@X7Y2R9U?AU^5Z7_1R*PHY$"9\`5);D&S,E,;.=G[*# M89=BP$!";5M7;;X?``4PBY=!L7'AS\N?G^*,E&_7`2% M;$^TMEVCM%.T&TU<;7R\(DT51L]`N=6B^OB$["\0?F5^"NE',P7_\!(J2-NW M\3XI1C"K&'6``?C@]4A=AAP=0+1UPU"(H%0`S6A>ZRLC@,K'UQ@Y0-Z%977M5M]\^T\ MW6S2I-J*MB_D6'''RKBSAXQ27I*HRZV1#OMUV6"'6*P:^8W0*[WA_0&1=*C[ MFLMY8X5BMX.E]$'J_<_2!0NR\^7!/C$D-,N$`HU\YB> MN&13L.V\+NER?Q3'-'E[.DM55LA8= MV.8744Y9_W+EPZFC_#3J[X%^1FO1J/[C5=M#NZ$7GF%>%U_H$_O=J-";9)UF MFW*N_$2S(H@2?CP;`W7MF^R<\]LEE7NQ)78?@-01R`^_^WQU=G7QNQ\]J+K' M03=%0Y%$W@$'9.)E\S"F^/-\X]P\T9;&%AF[ M_AW>"Q>$8=6N2!%ON-=6I;/A'K$&_1BE&[J*PB`^6ST';"Q67UC9P4;GD77@ M@C[3.'WBI=/9MGA,LZAX45:A(STUZM#!GD:+P+#N^(7@^&^H75HWOO MI'9/:O\BR38BD%T(#\K0L=A-$4$D$9J!'MM2N\6@RFWN"5T!J8^D9J3%MEH'%(R7! MAK_=0#R1'^2/O#*,TV^$,X+]6UB2=6E*@IP7BZ651[?]`>A([<90PCNU49M: M,Z$/L]`R1!F*/%XNU5=+?%772=7@F)"D+6G&8PFE,-&XQZX]#*$&0XI5$&>E M?F4TI-$SJ[YURK53K1/R[3$*N=J%\7;%SQXA89IS+]'F?LN^CJC7PW3SE";\ M7[R2#\@Z^LX#4-JX\A2\B'-PM^QO$H2/$PI@+:CFS)ILHIGG!VA-^()P/ M1P(A`EU7K"``'?^A9-U^2%63_D/%F+NG5%'1'PJ&[ROL&73+AN?ZR2[?J@'E M$,H>RX)LU.LVE3Y4Y1(.#AZ0M=GP)C'9/]?GT6:T80,/>?(4./283XZZVZ8E M#6")`)9V[]*"Y5>Y"IRP?)MO-R+QQC%9-9;`=JF0I=R,D@VMVO\ MM:_]@ECIK:+Y;O%,K&)QBYKX7!HHVW!PLW3`K MJ+'=<$8U7H?MS.L;&>2LQ:[:!^%.=C4:9Q;W4Q5O;\228\=3:J%4CV/B8Q>8 M8_OBCF&G38:-S%]O+).#R%>6(9;4R^PA2*)_BH+NG-7M:1RMQ!]GR>JF+);$ MG\OUIR@)DC`*XEOVB5AYXYNWPSC-MQE5O&4Y"8-2UZB5*"=FF+:4'K$*8,X6T/LUG0+P^433'SGO4?RFP^R=4[+W M2AHZXLT[J@^+X-HIR&%07#))F:=\NHX2>L7^+7L%):YCK)*IX7A>F>Q]PYGE ML=D?A[*X#X,BAU^Y/R(<'KH0]B&/)X$J.J%)WRX`HNCY1U6[6@:P.(/8K2DX MVRMB.$\_;G-V/?=@\ZO_]'-7>S@E(&:]<1X'>;X[K'Z9?8D>'HOEMF"S5[&* M5-^%O7T,6/]T^Y=&>FI4%(,]C=:ED=\!;VEE>$?TPC/4KWIK57V>FS#8;V0@ M6_ZZ@_B%+R(K7C;JP5K(6,RFB."12-!`CVW-.3@V82Y1C.F"$R;QG"U,.7?J M$[[3C`ASTK`G^SU#I0N?=IWYP!MM\IZ3.2CW+(?&QKY?.:8?;@C4VDXW//N\ MDDK3MPE.4H52X+3\CZMO*S^2:TNK_?+5MW0U<.2F]PNM:T?XX MJ]HV3D?)B@SR8R2E_-5'"- M>^P9DB'48$CQN0[]1JZCX#Z*62OJP<0%$42Z*0@"B'#?61"G#U%X'84TR>G9 MTU,6.DZ>G+&5Y1O>2`BO3]EL)@*88ISY;]1+UO0/0R,9CG6&.%G5+4C4E MC;:D;DS*UAX4`-8(ZI[J/`1_32Y"7?1.;?8-O-+*IQ1!(R*"P:&-_+JH"J-'N=QJ47U,EADI+_@CB?KA M3,&_O`39TO9M7$\*$DPA5`<8`!`N@GV(^*.!8S&BU;^A*$'5ONU]7):BGRB] MH0Q9TB/A=/8D"US&BQ_Y2PCTGUN0^:IQO'%/J;R[`L M:=Z!\G380)4[E7][7`BQDR+CT(&AE[E!T,`4N=^>V!=-BJJ"5-9WNF8-D9,W M&PUD770\D5-$T8-9:K2H/JVG+OX4=MIQ3*&_N03)LN9M)$^(#4R14_JWQP47 MN2XR_*GGQD%#*W/#P(%R3U+J&/MNI#+(`(R<'C%&=+!%3S:/,4T[W^9D'Q.K"J*W`<8A6Q"!)/AWP,,8N**$NS*6EA!7 MCN0!_BU<%YN@G@S1"X#C1=T&5(!65>8VD=6/9%WZE=6GWM:6%E@&"(TU,\QZ M8W8)$1ZO>>:^$`7VP0W'=*7I"=GQCSL@PD/UWCG2\/%&GRY4O".0PTH6$'R: MDA;8$4<\TA2Y)R2K><0AVTI,=5YZXY$,+_[Q:+)2^#.5[BJ%VH"+6V'C6!H: M_9JJ7"U#CN$Z]R!N'2>TV!,X,"^(5G5HL/K;-B^J%Z8=7,G9A)(%J?L(A'.7 MV=J0="+@3E?_U<%&@A96T9T0UO1X03BB%+.'X03%%8\R;1551QR+1G%T1D-` M:^74+`8>,2R'5S8#8(E8J_PI96X3GLS.TZ3(@E"])]S4M%&9J)N.II.I%WAU MB":2GCM*P\7^"JDO[79[>E`Y&$S&)`&V,8[CP(.2RY7.L5.X-M!`#)W*,71V?"C2)>.1*)KN_-S+A/7^Y5,4T^P\ M*.A#FKUT<&EHU3A+5]IJ]+FKFMCCS]65.]_Q16W<"E MP%]9#8]0E1HS^D=@@O,YT[Y]"79TB\T3!^2 MZ)]TQ9=B:VT]VZXBV:(HW*@Q]X`8C2X$X#W#FX^`8NIK`X"+1=6&3>SK1I*- MG^4$)5C%G/\!H8W'*-;Q& MZKY9>3M[7]KREL<,1>U\"1^,*',H0!CLV10PY&A,LAF6^`<#XL>S+Q=G8G$T M\>%@:H<0U$VV'$"P/P%S`L$/-A!D<\7[%`&$'S!`^.$U@O##M"#\@%<8+UE5 ME5TE8;JAUVF>?THS&CTDY_R)FR1\N_/:7);1#3978=_6-;O;Y=4F3/TX%&P3YU!T;+QSR_&-Y$8O+^ MZS5MXNXLRE`D9[]2^:1UM'GBU6+UW%K6\=O8[\'W=)%BWP7R$$0)^2%FO?Z1 MV951R9:%%9YR%IN_:I#?"HUI(?Z=;^_Y"[KXB?KQR_Y*O.^@F$DE)!*[G4^GVFK+-Q7C&^*-2?N7[=B8:R43=QE MV*K;'TK%2N@#F\&MO-(L\PK>Y!UZTZQ#T"S=`N8KTJQA"ZO#MU=]H0]1SFE0 M?`XV71DT->MML.HV0]I6(X^.M<6JYQVRGZ9C5&^GV7],^.>^[*=1#)]D0XUV MH/O[:=K-91MJ)H&$HZU6DB#VV&ALMCHR=`#V6]GB`W/'U5F2;(.X>KE>=8BR MY/:/KEGC)HV\V>CZ4A<=[X:'(HJ^4),:+^BL\; M\]U0P4-&?3E=6#O"*70T)'6)K'F[>I@0-9C+O$K_]HCA\E=AIGZ?:'7ET(&A M71@\_#NG_*Y^?,48_/U_4O7^>D6[7@'8:X>4[A7QL4K`OGM(GN]: MU6F^^IR("X1=\271JT91DNGU`]Y/])WVLDP_$38'59K--TN<@#*.$*A_TU;1J5(325J-3NR8V7CTH#Z)/[C*;1>M#GY[D MU0UA"OR])6E=TKJ=U2<#!6:YIW)O#0BN;G)('#8BM*7>$$Q@:MI-EH:4KG*^ M2_-LQ9]&29,@_L1F96PB)E$W4/N&SAG:CP8WJ#]XVF<*IP>]WGKQA3ZQ[TOY MR4A\/KP_4RD,\D<2)>LX_58>E1;LC,FZM!:OZJDFTCY-GV%X2:V'5$(EK5V; M5+.B$E-\S8%&()(+65LJWGTB*`V6;1D$@:3.: M",JX>(E?%D*/][[%HOJ(P9KE]2J][]>_4Y:_`_$T<$R#G'J0O-7CF8)^?@FT M>VW;<)X$'9@)6.[<$AD\T=;8X)^2\N/#!8`VA]I"`"57]KUBYT=Y!%LDG$I5 MXH"1H,MSUDA`S&>?(I8G(4E-W["1V50-1V-7WP.\'*>,HP>QPDR:[>Y?RK>; M):OZ@3'_LIYAP%/XT$@@+S=HXWYB(&&F0TV$(2#BB5%<(5ZFQ_%(T2;*X5A! M29D*U]AY4Q-F$&1.:\AL?,RC")#19=01D)GZ;+[S=,-&2+Q/0)S9FR^W!7^X M5[+P;&?4WU>@-<*ZD0SH&=J.`WTLT)UEG8O=36;1J'K!3=F,--IY<\L9`@K9 M_6%0,N/*3Y#-^]`?75(.DO@*LZJ:SSK"* M\70W+!+^0]GPN!AH_?"[Q?4.IZ\/G;HGBYVA$_&`Q,N\B#8"4SQ$]:2("'Z[ MO8]91-H%N*55H^X&68VFG47?\&IN6%`]WR`^%KM&%=>J1^4J_N5U0P]*;1N, MI`,'4$(Z@'6;II M2!SL:AH:>1@U!7-3L"(N//B\OL3#5DTX;PX#_+'LBJ2U2&&ILWB M0]ET/(D,O4`L,]21#&Q1&2[J*V7M4-3/$O"+/A01I@%.;09"1@:%28BS(T6?U4=C!R=\JY^A)6Q=H((1.M>IS-!#2 MYN)Q$$+,NC?EHV5_">(M7:[%`N1^,4*2>D'M6P_Z:=LC/.P"Z`_F@W[Z<*9G M7736B^HR>>;7^4;(![$>'#7OM7F0G&$02*U'2?K$B\:N^\3+C$##?7;/%&@$ MR,IG]TJ8_:6&67G;H76O[/A09GA^#P=G2,_OZ2+@/[]GBC8&;J=*5>-J=H0H MTS^_AX0RC-M4^@CXMZ?,\<;@[,-KPYGN!A0:SOHWG+!Q]LL`G-V-%;5?1H+M ME^K>9Y00UJ[(MF%1OLN5LH*='T97O[7H"''WRQ2X^P7Q^>3@>[39;LK-[,OU M%QIM[K<,/XJ#.R'-FT\M:YN/?SH1T!O$9YGUT0R/+.J,%]75QMDE6;,!Q\8] M7Z2/5A[,;T`82&W'2?:7/&FCL&@_7C,Y5M"?[=+%&00:GK:/'3;:1[3&`&?"D[W;/;BA692N M8.(I::N4SU9;9%)(^H$MH>T0-GQH6O;X4%[TDQ&RT=5P0@T&-2<:-CI63(0= MQY+:C3001#)9/4X868BK/9`F%-AK^A#$E^+YV[/OD4Q6%2T:8MIK,9H&BICC MA;/O6(_T;ON%^("4GY"O_+.9CX/6#5$*^$TE\.VT;(/6--BN*X$[YE:3_)N7 M)?F^O(PFT\UH>%F]\@K38-%X+[K\S_D!*1T-J;!*QDNFI+R97#P=C*BS7+MS M#A_:5D8]Q,$%)4K]\"*DPW60WXLONLW?/03!$Y>:?_V)QD5>?R)NX30TI_KX M/\["D*\>1P>QL';E#]$!"#4;B&]VB<=H'BJ"$/,%_< M;C>;('OA"Y^WT4,B7D7*3U[;F9#:AB7ERFKFQ&R!A]1^Q#ID,AONZ34`=Y/3 M+;\)7H+[F);OIC503=%83K->8TR**7J"2J]^##"UNJ:+^G-272#5%:^8HQI> M%6OT<%`PIF.D9,N4\$&M0P"AAN)(O!:Q1M)3>>F8$*0L87`P-'=YDVWIBA^\ M:-1:1<.^SO8:8I%$T0,T?>W[!W&B:[:H/A/'PYYX)ZJJ<93103_F$B)T#*0D MF`H?K@14%F8(4"KA%%"1[NB;><$4!S,0^1R`&E]D\S/[_:#*V6^K%L]F6VQ^ M]/N!+J&M$%;D:%AVA'1_Q3M>2$961PTE$#39X0&4CN=:PFEMXMYMMS/?C+XM'FIVGFZ>,/K*QC)YIXSBK-*/1 M0U*FBO#E+@N2/!;;D,]6?]OF!5]:_$R+Y?HN^*Z6;5>1^J*/'PF+^JY^`[2$ MXZ"#(+5!C[MH."7"*VFYK9^4%$\U5)Y)[9HT?).]<\*\\PW)S+\WZN:,53)M M=$QAB:YB1Y2J\NO1"U>%AI-^SB(<59&SDXY42$?8DH[YGT8\%@&`E%8'*0'S MEG6[=X7>!-'J*CD/GJ(BB,_WKP1056E@PV[1!3#$T41P#Y%*(D@\@%"9W31? MDJ)@="#AN#\(=9.$86$QH"I2Y!ZL_('/ M=U'R+BP;O@9\FM.6$X1ZDE3X.\:2,`KBJV2=9AN1`2^B/&1ET3:C=_1[\3&& MY!A+/\J4`_:#S&_+_F,G)'AX&])#O3858&=#&D9D;T6^FDQ'-N.$Z%-KUP0)+Z#:>L:?)0KBD%(6_KR^QQ1A)8I-#I:#!S M@JTGD?E=^H7R\8MBRB:4^QGH7F;? MV+RKUF&H7IIV$0I)K=S]"EC)WDD/(5+G(/"BX97#BJAAQU=!X5*1(GOQX!UEM^=H$GY-K'+LN1);VFXS40*O?P>QEN69?GKIGB/ MM^7AIKG?'3=:K,7/KS1+U0\=\7-P?TZBD?1@R),!X;>]T4 M"&@]FXC&8H[/'+W;,3G?,YG63!8OS0T;3$[7A-9,9M.YLC9YH[`]]@Z0Q/,6 M/WE.B_Q3$&7B*/S]C273;1BH7;=H,=OA2!JT?TC%!B`<0(&,7A9EDQ/"&U4O M4&IN5O#M7@(8)7U=L`18C_$F>PF;?<&FFU0*BHH`4I$"1:/C!Z$Y\3B`H0<) M`Y0=0*G`";=_*MZ6#E0*;<.YT_!T*Z2#5;$GD[>WEW>TACS]0 M_*`(\$#6M'*FE3%4^+J0+0N4^IB^39@$(5&%0-3!L]0$,+5D;J:X@GXPDBXNI,E;G9;4LZM+(KS.RI..D`"WP9*QF M6Q6`'8ZZ0WFR/`6K8U.)57T$B7^B90<#H(3!@."/H($F?HJV.H%S,@U0],.! MX`V8%'8M.P+HZ1Q1-;1Z,EC-&#LV!FI,`1R'TTA9I($(XAIZWE)/7[:((B#' M3DXML3.KO'X,\BA?KJL7$I=G,B2KQN'F_>.Y3<^I8KCLB/4XERC4Q/A6.-(_ MLB=F?H\*L!#6?'-(TYXP!^8C\[U[V!4%RCV)021(5X?&N.[+U8'3SDGB'-TA MM_SC:;AD8-IFX!NA3"#QGE+S%@I1'//=LXFH6;[0D$;/_/1XU:JUL7TWQ:O; MXPB)J3](R5D3!L!\I?6BO$3J:Z1QT1-J&P>\SUL@1GJ45-E)^#87K.R2SU.: M1WP;%R#_:`..@!C/',MMD1=!LN)EV7T)N*!^HT:V:WI\>#,G`03$2>0;&W.G M+@H>;;0Q@#O=J=KK`-GI%"`[=0ZR#S8@>Z;9?3H.9A]&PNS##F9[=)'[@/D+ MCQ%E'Z9`V8<9*U'^%#*KF?E_+O^Q93V*^5/+HEI^,:U-6=EV*E2@+0K[K/J) M4[E"0YJI"/.T$`>5\'4A\8]&RW)%Z,7#]2`[^/1(.P1]7?J"?/2I[!UXG2S. MP",CH5C<]>#P#20X?CV8-=;/+E$[Z[*(O(>2=]C##4!I!^$-]_`>N4PP59RA M?!3F:@J2K[R!U]FC-?1`^DG@`F,<-X323`JQV9E5G`=9]A(E#^+Q!#N2R6UA M?.O:NJ2>O)].6=@+.9B0'4^:,N^L('7;\F$RKVFJ``^4L5KL`M0D^Y0]WZL;`@M0FI;7S6`0/,H.MR$+`"%^>DKL!K=+Y` MWLD31]8=P,4^GXS\4/_Q(XEJG$=)F?H.+0>ZQ/[0I6D'Z)]WH3H.\GRY_BM+ MV$%2++,OT<-C>.LWAO2AX"%'\)86!T6W6FH$;[(;WA=7/#G= M\830-YH8L.`C3?IKE3/7M!?I)H@2F\JU;0&I3VL+=P+1[I/#6G,7:"##*WMU MW4B^EDU\V80!0`",MU+8@+A96@(9.!76IBO,&O%&@>X_=-.5(X?=L-II`/"\ M6[3(BXN@H/QTZ[\^1N%C-R-5"8MO4[?(`?9.`6G"QJDS=MM_,W?)QJHOPZ3! M(H1NJ8,[*<_)_\;=2!8Z2,.5OQ(S`-<@%1K,%XA,P9W#E.S`>#A9(K;LDFM" M\G3>'%MN]\8L"$X.@EO>%1*%;I>^J3UDEHBY1]_4'X[[*#EB<3X&MZ6:$NV@C0&:8#1XIS(;-`RV!YI]T?]YN[FFV7.]? M>W0>\&>5/[YT,Y"-P-M[A:0!&Z_N"&W_W1RF%*O.#-0$BQB5;BSWNK&L=:/T MPB\UWHE8.B(?7_;SPN4!W``?`&^8$`WF#4BLX-Z!DG9HA)PN#UOVR3DS>4ZO M&,B2^GFZV:0)$2^OR\EOR8IFL7AXK#9[XQX,1@?"/K>WX"WZ,>'->,M>N6?@ M_@9]3J(\W[*\Q\;YB?WFCWQ#9%Z2D;$S+-F9%VGX]S?%#7+2S2F63G#X/*CG2/G&-C:`XG8N%XWVY3."38O62ZO].V1N M&.;Z@C`&NSUQL'(FD0K_.>`FP]EW`9L,XL9(@PY!EPZO&?;FK#@I\/W/F(97 ML`WR,21?(K]Y:U"_)\R65J]XL_.H%P?OW@0W#&'#9`+XYC@K7P,E0HGW:?4A M36[Y9$E[^)ZBF83E[69H1)9%Q^-JQSN,CBVC17TG@W_DU=%WJJ&3TD;T@]KBH"[5Z1>*$_)\___[GGW]^3YZ"C#SS)O^5O/_YYY.? MR_^O%]^#;?&89M$_Z>J_DG_[Y>3#O_Z7D__RX13??OYP\N'G#W7C M:@V?7TP;<_N@(+<,'%3<:_OP\PGA&B!:7="P^O2]^/27$\+\/-&0OZ\D?CET MX((*0#OHSE[$59TI;Y1>B0$W:[6LM5JRVZVQJ2KK"[J`=X)8\;5EVY;SZO9T M>>CE5>U0GZVF]E#YV]]"],).E6NG5EMA,-/417?DU M`:T(J?33S@2L&=_66C8L;]WPX\;+#.$=0XV(T3$5"#<-7U4>M+R='ZNNLXS*=`< M2RBL>HN6.Z%106H`<[9HM21ETQ-2-B-?J__Z^%B@':!DHC`$DA(E`+F1"H"/ MH':5].#!\=!=I;@&OJ_3O'RLYRP,MYMM+!:NE\4CS8B,"*\-[)#$YQCNOJ6Y MS[18KN^"[_#,UK4P)[.]A2NJ=_OD+&4U`@WB\FIC(#YS`/YX0UHP?L\0: MGI"SHLBB^VU1[W^Y86544GA+W1X$&Q58`I`S]H2Q,CI@.CF3;2&>*,0V4\F M,\PXA2<=H ML?N$5!_Y0@O%R$FXH!WC/OS;S668GP0-=C+ZE.81?U`1HJ22./;(*#6S_(QD MU6^5T3#-5M5CEU'RG$8A^T.\7X85XN0A?:99LO$HA0\%$4!%;6&$=PIHU['5 ML9[@:9\DR``4G?91=/#8,!Y[:8^-_L&42-CX8(,-BX<%)6$&H./#[Q9'DG7V M/S0>*#[,6V`Q-!01FYA=I\G#'BHW5<<\S1 MF*R*QATJ$W:-/-6@#(/\D?T5>7.;T@TF(;4C*BIGGHGG17Z6YVD8\17YOT;% MX^7WJ%AF%U'.)BU!?,8/6!''Q1NW6CX/X( MC7V1Q`HDT].C9;RCV@&U>U-2GU M%U<)[QU?)[V.$GI5T(WJ]7Z&UIU*1MD:1:0,?<&I,=1!S*JALEWP"V1_A7SE MUXBXZ$GJ-HUSC]0P8'3YJ;#JDPV*I+EXL/FFB!BV;O3,L_&G0-JVG\;%]RUZH4MN2V<=]E_0FIC4C4EPOR$5`YV M'S-6W%-RX\V"Q6C,&E1D,`OT,@-W:]*A@^&5DRI\5&?<$8Q7V()B[&MLHB3@ M!Q'Q-3]_;@/[PQMC`3T_:F[.:EMIJ]@[Q MSI>F#RYJT#OPS5:9W>(V?*2K;4SY?F5^X^4=3W&D4T\RPHCF'K%%-W[<['= M4Y:\@8\,DH^^@4DZR.@9U;(T,4N/L[D8]C'(H_SV*:/!:IG$<@BSO\O8+J9 MS;7W)U\\Y2\`3@8R@P&I9[;: MC8GFWD#:T:LGK,+CH9LO7%RG0;+?H!0EK,"C>4$R=IWDPNBU8=IRB<(%JF=? M@MAW\CS(LA^4B-_4BV3*VXZ!W]ZZ^3LH& M/A)4@0$#*;7(T=.P;6JBWN1XFV`]7!)P'/!VZ]I1H_P):^P%1XT]RR0P!GT^ MB?U^FVWYSSQ*DYLL"H$S%X"]/@WH[%UPU-Q?)PE"&]::M!IO_>E+HW7]!V]/ MA(&7;`9@RD1M,"P-+%?[,5+>'V1/D8H,T1$AODM2X>[""7GBE\@3SY38?DM8N<)Z^4^ZXO>NP%,9C9TVD4GM'-!SI;-,B_] M1-5H1>IF/A)9!Q$#@.$WET#90F:@31-M`P(I4.O(%P M&K#H>=8T-!%L4H!-(/"]<&.05CX956W4)*LCQ9:EB@]%%]KA/IH05L?\#+SY MU@LX"F&GDA743:UF1XLXT_%`2(CK'QDTVY:JZK8IOWEWN5Y3_AP>?Y%4R*X% M#[#B`>A#O^W*Y,/%1BQ8OYULS3*&MMZL9?`HV;Y5WS'G)B=D9T3V5CYR'(HV MTS8O*]#J=<#@R[@5S#_L3[);!-('9!KPPNDJ"3/*VP8QN4^S+/W&;PJ*;2/; MO'RA:QC$H3BEW.LY\S1,L*S"W'+!HSEV\W$<4)J4&>@?16T9N'@H3M(C)X^3 MMN-8/\_6-.]M*6D]".HC3:7C;GHL38T5/?V:AL8'RZ;$UR09I1=P#-1XKN#_ M('$:\#MS]9/%QXHSVP<_-` M5CWE-5@A<0O4-RQ%-@6#4$WO8U$WJ%]?QU^/5;4A52-?*`:#A81N-GCJ$T]K M+2.A!T!T)/CFF*,16>[`JS`9E9@L@N_4FV4D-R@$)`!<''J1&+ZP:4"9U`VY MH-]0(?_-AJA$Z_<`5^1;_N$L:ICM:<,_K(HEOU@C&48E491#KF+&WD!-A@G@ MX51Z.V&&X*0EL/S-.22.@OLHCHJ78P`+6$CMX#*S7#YEE!\'SF9&2J'L-^E) M9+,)$OK[4;%DL>49`O2&P:+YER^HE@R0!,_*8>SC>-]4AF"G@^U(Y#H![$:] M%+;&CT)]>@."_?@#E`R*`,1MNPVGKC;J=D)8HN#T.-@/V%X+'OUYM]!FT7/` M=R:=Y3DMU-M_Y,UZ.:S;#`G6\NA8N:SG'8+ICM%B_PD1'_F";,7`2="M'>(^ MOMO-91B?!`R6N2XM@ABBLF2L@F3>@+V039WVE! MUMMDYJES`29+NI>8>NH M-)(->R0.FOI:7WXY(><^O5X6A``-E8RX49.J;ZHCV"QHRSN'RKS3L.Q0&BA[6-AB#@3T@1Q-3,RA!P)Q5,+*)*,QF)C M(/OU\X+?C7YB/]ECD%/R+O8],L_?9(V5 M54F[,3(Q93W!KD0Z,6P8V#)M5!\GY/Z%E)?(5W[1FUU3VB'6<$@#"35WFD8Z MUF@A-',];U/(VU3P+G/8!#7[\%0EK])]XX=L5&$I9DAF`:84EYBQJ[R?Q$NZ M+I/5P))G3-G-ZVT6F>\J_!C$_*42QP.>864T$#YN"V>[BKD$T&T19,50"(TH MEWF=_)$^1$ERG"@:5-Y"4=0O:#%1]&&J!0`1:2A^/C2SF,_3)%OD?'")G`]. MD?.+TS7^;J2AR/FE7NT_QDFY+=I^<8FV7WR;2GQFOZK]W8&^%61ZT;1RQ[E^ MWQQ..5K!!M*OX4,V#>'HVC?QF&@24,`HIT03B'I[:R`)IX;A=/HFS6Q/YZ%[Z..PP8 M,!XT$1L#8S_N-GP.-O0BW021>J^SNJFRO&DV1>9JOQ?8A4PK@@T5&X:M.PS\ M<_*UO.+=[07)J&JXH\2`FBY[$QU'-(B9@Q;[$Q7RLV3U9[IZH+G-K0:@O9)` M1GMD5@'[BTTUAK!TLUIPU^=$3W M#-F.IR&0Z(@0/^@-3N[Q;3%7<8?P>3?"1OE3F@?QG[)T^W25A/&6WYT3+PI) MBBC9TM7RB69!(5XXE;)_%B\W#)P%^R*7_]A&3QO-DABBZVY>1'&-(RR(WQ(I MF^+T"*!"&($6M1%R\=5,K8'5L&@+S"J-ZY.//-%Z]6Z?9.^:2S7*9DSS*"\YD5G+$ MG*7\_^^W4,]4N%UATDAHA M,4>#DB>TCT$>A2);743QEM\&^4P+-RB-20<;EEZE"C'^+)%5HP], M%0HK0ZKH63FAIZ)O;E)%/Y@]*[L^9*FBI.G9GJ9^VWF>EP=9/L#U^4?#T*8 M+;$T3(2!:/)*<.TJN%ELEYD#^R0IW_ MA]\">`YBON=!I=4#7'0%W,H%#AD']!I)ZNTB`]AJXW!1MB;+-:G;BU?4D65" M>%NQ"B/^T;#RA-%#@-:G^7"X]IAOX4HB!WZ#WDU:LNT`+OK%L06B?R3A(2L_6L%NSG130;W>5/BYBE.7RB]I=ES%-)Z_D17Y^F&GX0M[I2? MQ:('[%_+]1<:I@])]$_Q2KXH9>WR(K^.$GI54.6+NAU%Z296["@X,N3FNR.E M9_3.`30,.>:B=D@JC_O[+*PP;3HE>Z^\)-C[):5C(CR3K]PW$.)PTU2%]4P?WZF"NP0Y, M'_ROY#ZGXLAWNCK[%F2K7!P,T[S.O\_GM/AW6G2_Z:5G\CP2/D=.=:%-R7T@4=O6EC]',_TLT]S8R5H[2ULN[K MM$8656E?L&NN;A`;'6O;-NN=Z@KY6E[S[B:5?)@U`J##A9J\+2L=]?1`FHXV MGX)0O)GH/$[S*'G0DD;;MD,915L4PFC[@4,750@S6>26B_IC4GWN&5'T0]NC M"00)79)(;?H4@0%G2H)$V5^">$L_ONQ>XW4>!WFN><<@R*9'&*T-$G$`_<(B MD#X4A$@Z#PM^F8CKY./+_@UK1#3QZG6$,#1(.`8'49]K&EL9YV;&GI/IGSGB M2!#R:=AK`YYQ(H,)O5DG%+N>_4J#G,V*^2%=?XV*Q]^2]#YG4Z?@/J97R=.V MR/D,*.%92\R,V%_;+&.IBS\1NCN\].4VB)5G7[L,I4HSJ*%P%<+!KX"@W*9A,"DQOW#I@*9CS MW5Z[+U3V6IS@O$T*_B"M:>JFME#-P&06N"*H[A/R?$@:R$*')/;-!;[R\@FI M&XCC%#S3$LWXJR7!"!HEK_N6&GK.@32WY;,BWBC(E6?O5`C+CA9A\#)R),;\ M6+TK7[APEJP:KQ&JTM5JN<]$K,'GE&^I:22F.YZ_3+J/Y5^5)<;[QV4ZUO=% MSD`(W;(0C]'1FMFM43SES34U?E1NTYQ\%;:^W5Q`(X!:Q)`YIA2\L7$T\HA. MX\.2TFO#62U.8CB0U&OD4QFXI#;?1%@[Y0=3 M:817>/;P#`8WK'&BPRIRNM#B:_79"VXU8-Z;T_FNUX9=?'!3P,WCOJFSA5Q5 M+]W=W)5$'+:ZVG.DNOG:J@!]VR-H`1S0,J@!=I!%S:X+V"+EC*"=[+:B-#`. M>OE*R>M%Z:#[<#@X]6-)A2_RQ"GO8WYVGQ=9$*K>:PPQ4>48J0DN336]0LXI M\D@6;)0Y4"TBD*]U$]\XJ8.!FHMF\"@9*#'5,`\"N5EVGC=&]U-&_[&E2?@" MVW]NLE3O0E=;8N\'-O41?4>Z)J#5EF"EGT5S.]WNDJ^;@XT8T6T1!@),R5"U M!^UF83`Z9^'K[I]_CFC&!N7QY9H^L[$%419@K&:MUAB;N(">HG-7'].*OCI7 MK?G9[KJO#(9`1D=B..0T/-8XT5+9%\BZ?@C%%!H+NWQV]H;>[IC.@E\_YFOE MK?G&0N?_V@8)^SV"(GIF%]=IMA';LL2-)M-+WY&\ZC=%V7MUL9UEZ'=SLKEJ M0&>L=\-8QY!MTFHX.2%--Z3AI[J73;Q[%%Z1#+C1V';N(L,7DS3V0`V2#B;=^OZY6Z+Q,!% M+*F'IB(U&I"O_BX]:<$`VB9AO6PDLX5ME)@4>F[SLS+B2`QV\J+'*RN(R(,G M(`3L^2'\R_6G*`E8D@KBJR0OLJT8XILTCL(74P*`V*H2@=X6EY60?B(G!D-( M"W)J/34IFJ[)KB5I-#TA96/RM?JOOTD$!"@UI2WPJ"2VSH>&X+[`V6VR,49& MPK5(/C(LOQZ\PE.1`\3ZD9J:-4=_OP)LX=S&!^3!(;4/=P]CF/KM\%$B3>B! M3V4H/6H>+FHDN<:^(#^79:P`!WN4`XA;I4!`?`$?[?`)_M,]E*3M`3(/NAOA MWIA@!04/N.!=\MSM-;=.F0I+0*+L63K3!T4?W27%?L!A$M#UHSS:N/$LAO=, M5R$&Q&\]W""<[GB`,=F$U5F>QO@8Q/Q=.[>/E!9_RM+M4Y0\@,YV`IBJG\30 MF&)O:C?V$OTI#%U$JWWL:D&'YPU MTJTRCPUUBZP6X[X==OX;W!L;<1D8I"4[DXQX_HE'N*=FN#-Y(Z)JE%S>$+3?VH5:KG2_C301]@A\JI M+0Q/?+8LG#P\)NF3FR$8O>(9?6XEJ+/EJP"9]<-[0V'FG:"_MQ;T]]:"_MXYQ=Y/)>CO M1PKZ>[.@OS\`KG4Q`.*:'#@0IKVW8=ID:)M,T-^/%O3W74$_=I`-$O0A,/-. MT$^M!?W46M!/G5/L="I!/QTIZ*=F03\]`*YU,0#BFAPX$*:=VC!M,K1-)NBG MHP7]M"OHQPZR08(^!&9^"/KX9R/!#QTZ".7N\`MGSYDY^!6\.^)BX`.5F(%; M:=+\#I;JA?+FHRR\/TC,!PH8DBGSXP?@H+X?@#%X.=B<4,O;K>; M39"]\`?USA]9%YB.1$ES2S>[4"]@-D*_20,V3(].'.:M`ON/D>G.#->W[M9B MJM8X8JCO"U)%I`P"4"*%K?3A2+].2C8,DG.61O@S#7=9D.1!*#9JG"4K\6K8[X.4%D9T`T#SP=X7E2FI;4G3F#!KTC3?G2WAWUQV-&[[ M>H)$A9[>#/4K4:1#99>;7#FJ-PYI)O*ME&AE^S<*J?'A,8EF3?Q_"J+D.LWS M97(1Y4]I'O$>+M?E2X,5R1UDTTG@!AL4&0'U"R<1FT*954#O8<$ODQ]X@Q_Y M>DS1ECC@2A#S="!@RS!6/E.1! M^8:%H/R9'VF\(NLT$Y\?+Q2-*003C)ZD@ELVHLOU398^T:QXN6$@*B[_L8V> M^%35F!,@QLKDH#=&9BJDI]CIPA#3AK):5R5S>4-^;CYO2I9K4C- MOB`,:7AL@4$UG75.=+SV!L/`M/.'$L4)?0@*NK))/,;@6'#NIJ*5D,X@YNGH MJ<9TD*P(?8V(MDA1+C`];]*B"=>P*T MZJ8IDQ4.MV%]0TI,QF``"AM\+*H&8AFPW814;3QA*Q`5?9I:P:G'3KVUA)8^ MX-#-G`80[0RW`X\MB4&/)(!\6--Y>NC.D6>L'EV`^M+DG%>(WK&):!1^ MYTU*:;KZ%L6Q*N]T+G=3R^XR#@4[T9`2Q-XK@#]UXT7]+T]8T!V(/M#E0]5# M)04;K^@^IN6-AOJ2]I4] MUO8*K0+8H^(?W%]'>:$$8'O;TJ9`K[@I.02P+.FM:O-4Q!E_,[#=-2$J8;NCL-_9I'BM)$<_8! MP**;@G06..0U]PDIW6@#`?BIL5^4%QNO'*@O>_4`.V3\^RP$@Z;'/+6EA&]S M(LU-)>C,@H\$.Y_$_>R>[SX(58_,&%KK17W?V@7-NGUQ(N:- M(-:LVMDNSI>?+RX_WUY>$/:OV^7UU<79'?OC]H[]Y]?+SW>W9/F)+&\NOYS= M7;$&C&65J9],ZZ'`Q#(%;`S\JJV,W%+B;&I6\><0/K%?[CQ-BBC91LG#DI70 MY0/5'RF;`-*RW5WPG>:_1DF:1<7+5<)DG^:%N*'1],(?7BA>?J7%8\JN/+,F M_,OJ2[!)>R!E_T0]0%2427\S3)6:JN-0Y9NF/W5U(IX;Y`W)/A[9!R1E1%*U M%C%)'9344<5VW9[#,C0I8Y-&<)_D>%JJ*R1^#KV1IXU)>J)*16^B)^VQY>PG M+8(8.ON9KO]>J1^?G7VF!8FY5MV7"A>5\E5POV\"-2_.7[E$^32SK6?<%^DF MB!*[A MLO0YRKTYBQ8-4J>N(77J0V:'G>UN:J[*[6[.CC;U!CF[#SE776G'HEN M'&XUB>P.-%>9:4@T+:3R"U"W*5D,I)Z_65_':N\$-VCOQ[XQP:P&5*A$D=B5Z-]3Y&<!V6L5`0ZVGFN0E>!J6=CATXY^SL M'/.WTS_7V68?;@Q=:R^&/%,U\YVT78A8,%:.+CA9*WL;IDX,S.EF8+VH"`BM MYE`E')]>"QQ'9(_A@/0L;US0-<-A9TQ;_3L'-%3T3]7>:,? M;@@KNU[V>>.'NM&/)$I(W8Y4#7VEJ@HD`*KJ\64F:L<>0M29H#E1YI!%1<`H MSQP[.&:O!8X#,L=X0'J6.7;+<>?!4U0$L?E);DL'QERB=N"(N:8>N\HNFKA# M**QT)Y^G[.]D5>U]?#[<%EL`S@/Q:::^RA%$`[S!^$1I2AL>$^P\<9T_,F\T MYR55N@-Y]>I>?@>I<>_HCZ\1Z0/2G`NL>Y;X?DONQ<+K?BT0OI-$8VM,=U); M1RJ@Z:>K)"R&SZJ MV$@8YAEK!]@#NNF##]P!>0D/NIYEHYN,/@71JIXK5EOFZST3Y;F.X/1DX\R8 MKV#.'.F`S3=QE=&`?1@B#R#7\IQ7F>X7$>NGYO9[%TM[7_7$"J0`@1D`>K/> M0)Q"!,A[$DV67<&=<<4GGG]K\D@V&H9;9ID4U?SQC3PRB'A)GYD3^FH;TM5Y MFCS3C#\4N%R7_R[X.P0NZ'W1>9UU+X=;VO?2-M@>260L^XN5G.%A(?H!];:H MFI)]6WZV>:,UX(IL1RNI-M$1(W)^>E`#4AX[F$]I9D(3Z\DJ4 M@;@`:*4=,KS0/3;#N(B>HQ6M#R[_B`9`BI)[8)2IR*AVH.:G!PAU5'J#PF)`M94#(G'M M-8`2G"-P8>E%)BG[5.6VSU2]O4[?7)$U^LU1F:CJ#6Z&D$2!DZUGO"=8>8F_ MQUA<_/&$?/:MVE(.MY)E!H"HF-4U4_-I8D@YE71IL.'8DLAW^79#;ZOY\?@" M:_=PA'FATU5W^`(,;+6CV5*_XE&V=#'?;?;!RBL@)V*QW"^& MR$;3-.>5#+UAUBMN$IAFOFYQXE1HNW$&`4:V0D(R&O-%&O[CA8V[+DE:^+/5 M;QR2;%=0P%CR0E=O@FAE$-1F$X62EDU0J=&,BJN=E6750T4`6,[,&$`\ MA+KA%';R=(4"EG#N4VL<0(^;;IGL3D&K$2`P<;`P,!\G#8;!O`='[]Y.]"F( MLK\$\99>1'D8I_DV4]\8A1CU"(D)D)YAY4-#+`A%M"X6C>LGA+<@H@G9 MM_&%/R!`2!AE`:0^PW3&,L[-#D!'*=H83-;<8%$0-+'Q.*L,YOK-'E@R-OP*=8="]9\87PG#^B:=M1?WA2% MX"B](H*955+#!?_T'?]8K!>=$'Z%?.77/'E@73NN/>H`4-"EB\RD3Q(09N8C MAO;-B?K&!G*@OK%.WQ,W!+%X.Z+"5$$2KUY&9QAC(U%`[T"4&YG)HL#0A'3A MCSC`7D>C:]JEBK0I#E$TO4"BB3P"@"0RPX7X]&3WVIGJO]Z]?48[NGV2F+'0 MHXC$1$*0:9'CI-17!AH&(5[6B\\]*=['(\58J`_'RKQ%.7T(XD]4>91'[WI/ M-G?7D1#?B8SPAAL@4>8!GU>,]N=.G9=/%:M42=FP*T^2 MACB(5O8`2;!D_@'0[ILMFB\BJ3[T!-SJ4>RCW#3B/;#W#"2HGPX=EL*7%D$, M$#YYF"$PX5)XQZ/NGN?W[@5"X^!B5L=!@$&[U2IQ[>:&JR+0(-"Q]C+WG[FXO.,!33J-C*F'7=?A.HL6=T6:?CW MQS1>L81X^8]M5+S`BTZ0N5KB#.;8U`#U%ET<35&MN*1WUBI=^:F9S;:D;.QS M*0N#DXZ@-H#4<%?K1DMLGR#MNB`V!\?#MK@3<'7V\>KZZN[J\I:67VW\AE__KMZN[?W]MF+;)2(Y0[4LNDVRGA&+[C$*PV.W<":6N!,V5O".M'AO61>3(TM&^ M9)P(CZ[7P-1!QP-3NEHF#N/)&VW_A=!7@=#1TQM[C,Z;[>9CFF7I MM_+EF>R*I@2V=]'3/1L72$RQ[S66;EI%AA#,PN&"MR;+-2G;D]J`5!9D9T)J M&U\X.@!F$@X/!FN?X7!7,@7P&O*.DH=E!W"Q7R8?AOYT3<(2_>O*Y(1L*OC? M[^`?OG+X`U+<5`3P)D7^2C?W-`,DPG9#3;JK&Z(SO-T#_-2U\V]'TLIL1\0J M#7TM/_?FWH!R)+64DHZZCC:E@9X<"H3,6R/V*'I!\S"+GHHH59ZO,-`-H%;4 MNW&6/"&]=UH#FG)Q2W*!Z5$-SA'?/S:(JBK![,MNX",]=,WK.O&>GZLS_OL>!$]!+SZ MO*4%^R'X";/ZEQP#+'I%G<8"B>7&/F&5;+I`$.*J[1?[BV1_]<2OUR5#1E]" M3"AD^BQ46LI(-R/.')5)^GBC`"?>=,_^F17D6U0D-,_%<5G'B3-`;8.#M)F/ MX@Z2FRP-V5BR!/.)*C5@A?QGH/U,>## M+)4#$#*[+.8WP4MP'U/]/71E0XDP=ANB44#>`SQI[/F'8;]C)L0Q)]6'OMU" M5P^DE`#:09?AOVT@)X`!(-.^B."N.NK]UZ#89F(;^Q=:R5:^7-]D41)&3T'\ MA?)3X%B]A MV'LY(7L__*[#SA._4/GBGY?>"'?GBY0@H5SZ>@=$_O1E:IQ[^2LCCH"9CJI* MA$ZYIRBO67F6>.,6%",'PZ[97P)6=]YPQK>ZI:800#['6=T'_'1M=N(XQXGSY&%YXK?4=?[%I-/MIH]0*W>]HZ[^K\W M;$ZIEHTI%;E*Q`2*,'/_J&^-S#'%G0KG(\JYG M?WOC07?,O6."-VGX,QM(\!RFWUB32IN-T6G?[PE^.FS%L&-LP[2;TO:7_*.I M9'RU1%3B04>TO9&>2A/AQWEBZ(0:"B3QU,MNR7DEEIQCOI&E_C&?V#3(GX== M4%!E)>#VN)I9A//\/$V**'F@2?AR$6R"!YJ??0NR%5V)<_N4@@PU[(FSV1") M:-`>8HDV(!Z$=T8W"]Z&-!J=D*H9J=J=E.>Q^L)",%0DC+2$69^;)@0-8-M';ZA.*RM8%8?7]=))6E"&MV:KP)$DN=4NQBZ!J2W@S+ZEL`(^)S2#L M&>@L]V%D]/S0G2+=:"(C8;B==!B"RF.JZ?PY`1QH,U0>@<.N`[IL8M<98AK2W:MNU[6(F5+ M\I5?]F:/K#60#&2W`*.>[SI')M)[!>@),I@Q/":RRP6W-VRK1GE6='N4UZHN M7J1\GQILEB6ST,^MVA8NRE)9GYS,HSJ!K"O/EKUDSE13M&SA)4GE`#"5EQK4 M&$K*IJ6QD)P6:E/,>WKQ1F%.EA=>">ILIS*#<3>KO/_*.E#0)&`_K^XM$ZIF M'2'O-T.AE"HZCF1+O)LYTS-:-#[QZ>T3RI'K<<$PQEWX=YOW,6]$PY0P_UN: MG6_S(MTP5;U)XRA\*?_WCGXO/K+(?U@=5)G02-BX):L5<_ M>DBB=10&2;%'KWAUUUD8\F5COL\WI-$S?Y;X=2#76%.YPN[,-5:S?YHE8'5# M;6I!7`%3]\!%X@`OT4K,%O6?7JU/:4;0P!?`6FK?P,0%*3*F!+YX\8;V:`YI MFQ[<6VV0D"Z)BP7RMFL(OIL6B_JE27Z=O2$?*0FLU0/:1W2CK0S,CL?=4:'1 MC6`)`%X\5!\<[L@#4CU\[-&.C6U[=7,N;#^&[?B?'I,$&$]DM0+"G&>J?@XV M=+EN95CMC1!C^TZ:T[1'`;^Q/SCI3Q?&S`2U=:/B\VKAV3S,/8)`D=&EBM*N M3QLXF"8D$"W.@_SQ)DN?HQ5=?7SY+:>KJX2?M9>$4?)P%A;1<_DJYOM<[*92 M,6NPHR[E!CC"X>+@;X!$TB'Q`>RU=[M@-H0;D=J*?'PAW(X_[KRS)'M3-N.K MC'U1@.%P[$O#6&CW-,/:H41,#H?I9I,FMT4:_OTQC5>,!Q=1O"WH2IUR MA_GI9UQ;/UA*,JS_:/G6.CQ(/BR]BFQ;VI`?N-6/9&?'L5Y:DJ;I":F,O9&8 M@4"4*`);AASB=_%YNZ$9+U_(FOW_JAJS MBCE/-"/Y8Y!Y:9YT2JERZV36_;9\HF#+4H3 MU4UT'*>P=2*P4Y>38QLG1" M]J[(WIQAA@#-NH'/P[/N0B&A9.8,K@K%=W)0W9 M_]4L/)"EK)GI-G2):R;"S;WT)>MZU3O<\L+2*:R\`#MUJ6J6W\QI>0'ORV`Q M@X8PE1<[/P=>7M@"&ZIWPP@#5#N@<[#:'1(1IRPO;+KDFI'2\B+=L?!`RHN9 MZ3:TO)B)<'.7%_NU%LA=,\@=,1?+E`[O9-FO*K;N0/ESNI=\H/2+?C;+>8:E M.A?#;I<(GM*S9]B;-D!LP[9LKASO^=G,A%\PD?"+?RMFDL6^81NT`8X&WWB;9NGR90;M$W=<,$7/KNY.H*[6BZ8@'CW M"I,+= MEW,U#LDG*(SU=/0;J92XQOU3&?K$_L"R3LGR$5[\BV M.7YXJ)M>&6'K!DFOAO4>JU2PC@Z1(DNG3'J^D;T):=OX?YKQ8`1*Q&<4EOMB M8^=.)B\'P0I'L_6"AOG%]^ M?Z))KGJ)N+%]-UFJV^/PW]0?I/2G"0,@LM)ZT;Q4[^2L+GI"5>.`]SD)Q$B/ M>BH["9\VV@A\\8QPQ_M`TN*19KM-0K2\[,L^(42(F?4=`61^*K;I MEB;4#JK@V'=BH/USK.AVMR.-7G0*[]]]1C!&X(R$WD4TV5OP/RJ'YXL1N)PW?VSYX=_+]>Y^XBU]$),35=XPM>_F"W5['#:: M^H.4'S1A`*136B_*2V2Y;FP]J:]ZPC?CB/=Y!@1)CUTJ.PFKYL*5&W771AL! M,'&#IH18NFX\LYN7UX\/868%1\#8K(J]ZTV51DR;%XWM.XJM:8_"+&-_^IY^#"Q%TL`4/P01^-1+YJ6*H%$/_]#TP=DD;0\`D9FUQ!*[XZ#T0VF MF@;@HV$D%AHB3`$3MZII?5Z,W'(A?B@^4K5Z>K-'>BQ@X,II"9EYU3-[")+H MGV*@SME8I7&T$G^<):L;!E6:%.+/Y;K:TAG$M^R3WTB"FP4J%YV<7B!XN(Z%P:-A^^$6:*9;.IB^,4LQ[!5]S._I0=%E=PL*)1)(._V[@84* M<%SMA-X8PXB!K)%*>DXHBWQKV7FZ>B337Z!?I=HSL>U8N??*^G9"Z=V3[Q-_7R_I' MTHPT>GA"^#/OZ9JP7GJ2+ST:-G76];"3BMSM3T\E%8`_G3L^]7>S$N/9]SNH M-%`^QLP;EIK-9#?<;K8\!DL'14/>@[V:1TD8;U?EBVH2K\Y#]^B7/0BE-B]+ M^=-7K[4:[2T8/GTGV#LX_E"J=4(?V$1X=5AZ#7L'B%\]?M/K5ZS7IE>W>-17 MO_5ZSM?'B]_A.@KNHUB<`78GWG5OVBL",I*M96F,\%*6L6>(*SZZ6$`U5[NH MUD4:#LL]3;6-GE:[7+(UNKU1#-27%H)+:+ M*J\?U$W!=F!"XNT2I:*K;\RC#)BMU\VC#OIC+^ ME<[RG!;Y9X8GT7OE)C%=6UD]UF^+IX*J?B!60Y(00.GI65:U2/DYV5_P2":4 M`RMGN0$'4HIV;10,FQ(V[G*?--)`_.R/T(K3Y.$=Z\:&!"66^):$%5U3UFY% MPC3W*O6,Q!1,^`>B:G[95622.B_=$<6TRPH8Z= MU\!VW]#]Q!G.'A@E)Y^" M6G1K"F[N$WS88F=]8J9XZ[HO)_9XS<-1D\7YF#A_-=*X7W%NG@:J6QMNQYWC MU_3JOKBY`7=N.QV4V/9ON9U4Z]`^S0DUHVR\PR:'A>G6VKFVAI\:1^[2DB+6 M8$#M$TC^F&9%.46,]\V."U0PD1\!*Z_D&+8PIS4PB+*;M19MC]Q(\Y#%.KFY M9$^$E\MV^F$W$LIN`4]J:";5A/":1+&'+>JI'/16]KR7[7%`LQ;O85";7\)M MWWT%,Y))N>O7%<%ZABCIX]Z'97!1$<[[5V,!\2"GWM"79.F-%02<%W_N-'_L MB[.,3A0O1CEF_,'D'PV!LZ:!FR!:727_,TK8_S+UA"%8NH> MX,BZU+^901*S!?^,"3;AGY+Z8S\HHQG''DV,8]XE1M^@3X8)\>%$=A5AA@!% MO*DD3=Z)5\E']2]&?W% M_NN=A2]LM8:6A,4#X=GG-M21C//>0AR85&P?P+7L`";:>1JZ8;_08\"/T$_7 MY*D&.M^Z15\SQ`$);`J0>Y'P=L>K)0_G?!>?(;VIFBN26;\Y*J]5O<%-5)(H M<*+VC/=):'\&=/)`SOW90FD<:R7U#.A0T:QKIB;5Q'ARG!6DX89#BRO^1;TE M=[U#ED>;<_&0!9;PX=B:5YX9!CX'&WKV/5)*LJ1)5X9;37"H(HF*)+=MSP`> M-`T6_"_"_R1?^0>>;!Z5#E(?Y>JA[.&ZT52"9;<#[F;II1O`;N1%G7LD8V]6 M-?#H>Z%>%^DFB!*#?K4;*12L;H0*Z79D7!7;^8:CN3)IHKG\R#,\=P9,B6CI MP*H073968]HA`)RJ6B.$+1(ZRG8$6`#K&PP-\VI<1I^":%7=[F/S^L;37OJ- MS!:6736$6.(P!-Y')-T$!010".!G436JMUV(1=_6D[)>;8FVP4N?@-9@ZW'2 M[$%"5)^0ZD;@@7%1("M2007:^E6P8ATW+1_>J8:A?#;W=:#6G$L MKZZ370-?R`C`@(2%8.3TR:K2ZWH*?)PQW--A?T7CW=L+37)`.#/3I30?W% M3Q.FL';4U7OK))`?]JT9B7^LIB77NX]5^AV MGI3,T1%A7K[\HFK`L]/J5>+8*F>Y0K*7V>R:O]MQN3[/Z"JRS6126V`6Z]@Z MY;BTGVZS5S?D<$JW/>VS%F]'&DEKN2:B*?]'V=AOFLO!`Z:X#GM0UMG_XR4@5SH[$(EK40>.GX*K77JH"!`M[]LT01HU0!J6(,UYRY/JU5$\ M]317\<1%DC[Q,YSS$_%.*?9INE[3S+?-G0X!;I62L"#N32H2KU9:6S^19N]! MDYZ,'M#E`-AG_)1E#FRG#"9_G;F4>$\SFSP=P(-I`Q"FY;X=3'4:8/"D5P/O ML.X\"4+BHX*^GQB+1TIR\8IRSQ]5FQCT5JG/)>SG3H?R7K$9O#K_&4WZ"4]C M@L5Z8Z_04IHN$HC.:@<+77KBQWE[PU8S"&3TA$)'PD:EJ91^%X(_>WV_F\T+.[297;V'$0Q?Y7EIS1;UHM&[+A,I MQ-,/>O$0!0I\T,6^=8U4CTXYZ(^('*6`LRUV[13X=#&N[@3)XCR+9OL#'V*8 M#!D&>5X)HCEE/\[C6;*ZH,\T3L6ZB/X(?9!-5ZKT-C@PA_0+2=(,H0`LT'I8 MU)?%4G.C@5^'Y\.0T.>/!8!ZC-+92E@V-^[<2*XQXD@`ED\P5!`LWWZ\:W*\ MT#/+.2+X/)3],_X@X(/8`'R>)N*5B7?I#6.]4Y7M6+Z M!J41:]\.:3_P>[I,2_9=&JH>MI':&M-,2O7PX6_$\+]^55# MHE(`*&+C&`:3.LL84$D\8`)/F-^']&PB)O?JA3]Y/_A>_.?@YAU-)=_:LI#HUWV$]0(EUAR,/I;H:6T M,3T!Z<;P``O^L9`2\8]&`__*Z/$PE0D-%O@E^C/8M528\"@UL5YMPV++#Z,X M?PRR!^4QU+JF,GWI-<73#44O$/6@'P'(\Z[AHO4IJ3[VB+*J$95343_^4HIU M3!34F0XMKJI,>:!AL*GJR`9PO'K]^'C@0*K#@="9O_ZK.\2+U>R9?F8_J/9] M,C`CG<9*C/#YH^R9`]V5Q;*D4M]%AU)5@Q.R;^(AO=1XT!/-A",MX7K&!NK- M@S_W2BX/.1:(7-W/PC#;TA7)9"J?DW^2N!+>=<,O-Y>6X?TMSIH$'%5GP:;#4$%9N302PR:IVVR5A MM8,.UNYI0M>1A\O`B%@;5-;;H\T?':]2C/Y]D0`+0'&/^]8]0)_J_>_@@9?5#9!'O;H\825BY-AK/)RG>[MSGJ/1@*]^.$W*`R?0CH_!'V MLV3UA<8!7\]/1KS?%Y">BM@V2@CVI)5)VS3IK@-].J MMH0W."%U<_&GAQ2&H$G/9S@>M=36N#'PW!]$NT\[IN!XT.8):0?>G#[33!Q- M'[Y"&-OE*"=`EF0OQU`^M8$R0\=]B@KF4UPPGS;`W"ZO7B6@3^<']*DOY5A5 M)M[0+$I75TF8\4/9+FCY7XMIM]X!8!:N$#ZC>3P\5N,**$!&]H5X[YO&CWIK#C=::H M0$5O]4?P0*RTM\0E5@YN6RK[YN+FN"R8[7W+OH].6>;C`18@,!AN79I0I+][ MV;,VW<(TP\\+$EY'";TJZ&8`$WNF<#HV3%USLM=+Y\1L1AS%SKVC[DX6UJQ: MV18-R5?>E(BV_I.VCQL;YJI09T'?G0LK#JLQ.R61BX!U8W499`GK8,YF&-O- M5JSG7-!U%$;J70E0PQZ)S89(%(;V$(O`@'@0^AK=+.HVI&Y$&JU(U/R(!U0T^)F?=W7D;/M+5EK\@F[]V[R_\ MK7MGXE5[;#I_'07W4]2KQO:]$31)3N[\HD:JR^U1R\"3LH*_!Y.K`:\7&GJ@4D#@J(A M&6]<'P_&(V"[)T78!;TO+&LJM8FR1)*9((N=NE?8!8PTDHT"21RTY(1?/X`B M08,#C0X8T:,F==]4Q]%9,.O]KP&^@\S2U7%^GR0,?^`$YP,Z-,B]`W2#SUJ[WV/D# M'-V&UD"GK3RSM^%_<:MW_*"C0\D_EAC4",,@-*NE`N9.)Q]>\\)QCK/H!#Y! M>"Z\815[&#T%,;D)7C;BB-\T(<4C)T.5)5\[%2SRYE1D\"2_UK=L;VAV^QAD ME,_\0GY*>A1O"[JR3+.#O"FSK:4W9'$9]%VP1A>-7(TA@!J3;+RJI.F`V*4XZQMWQ=GU.JNSO:)U*?; M&Y$&IO=YJ.1+LM\\Q>D+I;XY"6O>;/[6_X<_6!?SF^UDL^L+^M5Q7]^3_ M25?E\V!\&WNY+FPN!?!CJ0L%S%C8HH?_.Z`7&:A=M-))Q,A[#5VR`J5R3"K/ MI6H2X9LTG9.]=VZW]U\?)2`B5*6,?_6+`Y+I1-D9IS6"C1=3*^>O0T)<5U7( M/9U)2[H5F5Q-WMWWU.2D*2?IFYQ,)B#!"ZFSVY^ M#T^KR:&+6LC1'5>5'B^-.6*?^WQ@O[R&&W>"K'`H&G,8Y>;P93[T^*VR4U5E MUN^Q?I,,=W@]8M'PI)S4'"8*7&($>U"6?``/R`(+[C-V608);*-]9G\M+6N? M.M,]2MW;&3$<8AJ1LL6I6G2,GG0R8@_V.61!KF[BT_QL6SRF&=>UWY(5S6X+ MIF;+)_'$(,-M_O'E\CO-PBBG-QG3R2\,RA2F)"Z#*L7'35!DO7+YRV!+G*.^ MVJBBDRZ`BL*3\DI.]F'(EL-_(:4YX?8GI/9`THR4/@Y@W]M0 M!.ND+9T-ZXY!P8O%KN]D$V0MGW(Y6RVV1%VR^R.8L M;RQ20\1C'LV[WD0?^",1%^DFB!)59I>UZ6;K=AL<99#%1I=C[L;E>]%L`2`4..C@8!9)BU`,*^/05).X_+/:?),\X*N M/F^;;_'N2N74\;LR/%U\'*I/_7LAI8\)NPU0ILEZLU#>([WC5=Y^_6H_T3XA25H06B[I\K6L-VV:#^BO6)T\++6MZF*K(M:I M%$]1'H[0MJKPDNRD]5EY;&5B$*.A]',*GPG3[J@<*98M&J5YV/PAJ5>[)E$0 M-3!+0#'EH?X"LDR52_XDRIJKI-P"B;V>H0V"M6BA"#)OR:[]YC,O/ZCZYK#F MEH?$6$C8+164OOF+<4OONS,//Z79FD;%-O/EI;B.Z(17AD-HBU9I2X,AEM.' M(P]^3=O579Q:)T2](K;GI>5E\L"OT]4;G3'`=A2$/LPBK)S`5YL*\[/G((KY M0A++6.+;89=CP'!8A9DQW+P:#/PU9B[6S+UT*,>FX,H%B58!]_&E]0APJX"K M;NOPYW_KG=EU%%ZXE57=@>L\E'9XBF]'=#3E-X1%S`&'+2U^%7J0SLZG,;O% MJIP$.V58,V5X>%,&E\@\6FTXBDIQ]Z")XQ*Q%\=1;=B(XY5R][Z_7]5@LWO3 M2?0^JI/Z;^?^N,2]3R5GJJYBK2LQWS]+Z4S%O1<(KVNZ=B]G4(IF%??TE*7/ M#"N\B(OR?!LP"KY1'0]_1T1V#VNU,.T M2NL1JD:>DV>\ZZM/FC11M#'A&"P_3<+=2`!^X>6X\8<+U=-\L3_W+'^L2S#O]WG8$/U)PXX#&6[CCTHU#0K52-^A8E6LX?U M$&&9:DC@1;DNS2_Z]E"_2S[8KU"-9Y_U$M6`D`-6J3"X/K<@@])+/[E<1PF] M*NC&08D,"(97)6N#S5TH`WZ)V6ME?1^=ELNZT,HG!NP.]I37W3P,$7&\%GPT MMF$6X'!V(];@FJ"H9;B-FARH\`\HQ%$BN93\"AEEM]'U'1CXKH6-D]J.?3K+BCV>9CFF7I-_[V9*4L*UOV9%72$DD6E7W` MDC59`(@L]>T6XD/"/R7[CWT1`O5@2HAL&OD^$7L6,B)-"!-'=SSE<0;AI;QC MR3Y^5W#$K.B]-_O-QV$%<*-Q&%HD-PKQ\')J@Y=GFMVG0Q%S.A@QI[];-(YB M)D]9E(314Q"3^R#V:9_;2/R-;1>T@U"?J$`CVF`MR M(B&S?Q!V4V#`0V-AN7/FOP'8KPG+YCK&*9KGW195!(6X6[5=%%H3*=@\7Y\O/%Y>?;RPO"_G6[O+ZZ M.+MC?]S>L?_\>OGY[I8L/Y'SL]L_DT_7R[_>DJ^UJ2_Y!P*//E/AH.JQ4V,J MX:0-%&?AX542IAM^;Y@O0V7TD29Y]$RK3\'4M/&B9BO,"S:!;?J.SFE@<"N: M@WP"F;_\]>;+Y9]9NZN_7)+KY:W7"F"%0ITH#("S1B<@WK32,8@7,ZC)QVT> M)33/JY=JY+IMRQ`;E5+(;7!U0=?SR_)[9\O+^^\+O3,X-%5 M=U#H:4HZI0MM'0<'[I1L3L._7^7YEJXNMAE?,1)'4_XEB+?TG+^S(_T?Y1!(&A.^%I1CCN@*1DC$1JK-O2WM2.MB= M<2U\G)"]%[Y$W/!#]HY\D1X,0$LT"8\G?;$:X5NF8@=./T>U]-@>.>8AK\7; M-/N_M_$+85_T#RW"7?BS3<1#J@%J>W_(-O/<0-KS( MI\R;LM!8:.:9L#JVD67!O-R0GZ>Q+P7C)?P#AKV"?;^8-:/EZXO3]9KR]J\* M^,;-GVZ!/^L645T7D9=X+)W:U'`SSS(MO]D$-9_391YH"%"->/`+/;:PME,I M1TL]0.>6FG88-)R^:G6\W`,/`E[O(3]$254(__C&/OS5GYGX-__ZSR.;5;$N MEJ\$_YP6]"+*PSC-MQDU/I%B:R^K(&#V>"IETU_$N@`8%B@Y(&^+9E-2MB6\ M,=FW]O$A%6M4R25D`#"E6@'QHY`%'['M+MF"HR."?/?BSJKQOU0X?WU0AB4^ MQV#V+)T9-SB9#(P)"WTSDZE'KE*2Y<8EI;DTZ?BW.37# M./?)`@)&CR]R*PEI@$B:C3>_4KY7!L::=EL]9^JV+AC3[H<3ONQ"6+.ELNQS MY6MYQ4^B=(;61!,I$@PD*6V,%'$/'#>++.,ET^F/KC;"W&Y@4L2FO5>HQ?;T`Q MCCED30;V-A*5'6A=9OXW@VR?GF)Q_DD0UT=@7B7K--L$D`.#[*Q[3`-:(_'. MJJ]8+(0&A7`2YFO1;$AX2\*;DD9;#U.?'9`D]!V"Q#Z905YDU/80RHZF./#8 M:)@NIS\-5*_V^YG3-0DYQM<]G4!&S!S<@OM66=5=UF0Y&L&X+-D=4NS MYRB,DH?&@5Y7">OD5IS/Q[-N+K^D+2-=A.CD0]P0*$KCXEOC9%;DGIFE"C7@ M0C3AVK5K1!JM/"NGG6"_IW0.&=850\Q0?<4\1\I,_4&J+S1A`-JBM!8RP56B M==$W=3".>9_J0)CT6*NRDU`0C*SIV/1;Z>P7]46RNTKVE_T@%F3P>]2"(Z9++HUEGUZS MPLQ)46F*-PIOO.3;(2XHW^B6D^S(`6>LPK`@-VN-]%N2T2#F;WC_$TLOUVF> M+Y,+FK&>%=&S\M`MH%5/W0U62-0#]0U+Y4W!(,S3^UCL&Q#>@OS`V_Q(TH0T MFOE"0A@P)$2T052?BEIK&1T]@**C3&"..1J3XG2G1^:"$H;'=1!EY)F?"-SP!N0(7H&@'F)KBN#FY%!)U/$A/6]+Y`V_DRP%CSH!H.EX4 M'8C]`T7=`/$#"(A_*(&8T(>@H*OQ0/R``L0/;VHI'\NI0/IA(I#^,@"D=SAY M_1<4I/XBDTS"VQU[A;D?NZE`^7>1%M&`25LSQIH^ZDKM,(AV?2 MR$A3MJYO`&O:)@OV-UFNR>X33Y@A'ZX^$73#VD-]J[$$Y.Z'W\TTJ1_"%@=B M62P76?PHD&">Q%AA8=9EK;\&6188'K^6MNFH6Z<-"KJE<7&TK>O:#.FVQ:+Z MT[.GJ>4CU8.S;D"[6&ZU[4/9^;@[$;5^!$L`<$FK/LB/``-&1;-!P;QZ1J.' M1S99.'NF6?!`RU>P+-?E2=S+;9$70;**DH>/01Z%*KT;XJ.KAW8^<'@SI-]( M>FH9&D`W*X^+NCFIVI/]RW=*$]*P.2'"RA.^#D);G\\C0-MCNXTOB1KXCGTW M.<6Z!\@D$#FIID%0T:!Z;=HV9Y]%"0F#.-S&Y0,_C!KW8@`36I"8S;KYJZA* M@]?+#',FG)`;:#&UL550)``,7'#U6%QP]5G5X"P`!!"4. M```$.0$``.U]6W/C.);F^T;L?\C->=V\54U/=W9,[88LRUF.45H>2]DULR\= M-`G)Z*8(%4$J[?KU"U"D1(*X$Q0)I5^R7/;!N?$[N!X<_/O_?=[&;_8@Q1`E MO[S]]/[CVS<@"5$$D\TO;W/\+L`AA&_?X"Q(HB!&"?CE[0O`;__O__F?_^/? M_]>[=],4!!F(WCR^O%D]@3=_@TD6;,";+RG*=__[S3WZ#M+#7V\?;I=OID'Z MB))W[VCC&";__"O]YS'`X`W1(L'%__[R]BG+=G_]\.'[]^_OGQ_3^#U*-Q]^ M^OCQYP\5]=N2G/XURHX-ZL1_^G#X8YT42EC#A%H8GEC'$N+_FA-%3I2LTM]_ M+D@_??[\^4/QUR,ICGB$A.>G#__U=;X,G\`V.!%#-?&[FMX8_A47OYRC,,B* MSZGTY!LA!?V_=Q79._JK=Y]^>O?SI_?$B+?D^[UY<_B"*8K!`UB_H?_]]G#; MD+E["M)MD#V!!+P/T?8#I?EP#7$8(YRGX-T4;;;N#.Z+=IS]]_/SS1ZK;OQCR_]#% M%BH\"@"T4//4M+,&ZRP$*++4H6K<78O]-K%6XM"VLPX88/3=5HFJ<7+N>G:WG%V3 M'Y:+^>WU9#6[7J[(OU]G=ZOEXF8Z6?YZ,U_\MK10UTZ,BSX>HW@;K/<=>OH3 MASX]?3693^ZFL^6OL]FJ!P\S[%WUE)(9RQR0B5CO\R)&2F?$A$%HB92BY1G\ MN@H>8]"?0ROV#F9Y@B;4.3J3;BWP5H]@^1)H\SC4C6=S/'B:K6_+7 M?JVR+.]NL[3Y(">$3R&`8 MQ#U/X1A9#M;>UDLSX&1=!JS%.Y'^R5K\)WWY]1W+SP?I"=C0_>AY\`@T(,/C M%:=I@Q7=^_Q,]SX__5NA95-"7=5="C`!4=$AT!WBAGCPG($D.JV2J0C7FZ6% M+I4V,0H;"L1T5QBEZF_P]Y.D"6\R6W&(J0<*%KHM,IA1H[5:?'!N#&8ED6\$ M;DD/@:46J9MQS9(U:]I6A\TD;=H9I,?E$_FQA9GFEGU)\6%7]&7OPB=XFH"L M4[0U^U;(VA'W-8/>_/6-AM`W&7JC+PRE$4A_>?OIIX]OWQ#GK4&:EO$H<4[A MF0RD�BUPA@]7,F#,+W&[3_$`%(!'SZ5_H#1=^_OOOXJ3PF^1?RJ[_/27<1 MSX@AV)2__OLT#C!>K'\+TC1(LD7Z`#=/&0EVL-*04H+L3__V_D\#=C[V6)LCC!O&7[WBI[!@P:31CX M!D]KYW3#JXG8JI?\V4OX/@3$%@DZ6W]GP%?[NV_8$IG6#3HUKA4R/@XYK>H` M#>(&XOPG8O(UV(,8[0H'T"Y\4^P"4$>D09BMT#U(URC=WJ!T0=9;*0F7%=%. M!BN7O%E(NN'M'9Q[<&G'4'"CT7$:ZF<8'3?-JBW/)=@<%F3B\-!JP\!>T<8W M.)NXH!M,%9*.O;B?Z,L?,?@])^;,]N0?1;>LH&81)Z+V#FM:9G=$F4C&50J"\.DPP:6=V9-JWM[^DW'0FH-#;M M4">O2&$FEE[M^.E+K8!W[G6W8%@&`+:#DI$T=HM9$N]0H["R(SK: MW$L4?!X#".Y`=I^B-
0$;,(2;>$%\N@Y@LP`&9'X)KB+,4/N;%GU#*8IT# M&EF!/U?1@%ZE`%\'[S0"<-DLTF+T]#[%!+;=T'\ M`';!2]%U;U&>C)0#9=V#&K`-&7@'3([>:@C-$UE#[4*5F+S.!B4LQH%$D7D`MRU MR;U&F<)ZAYAJ2RH1].?S#MP:%C;$1M\"6/9 M()O##&X*TY8@(^92FVX3TCT!G)VZ/@Y,S!K6@*/;T#LH67FD([AT958)*6,8 MIQ[`'B0Y>``AVB3P#Q#1A6ZUC)WD$>3U2OJ-:E#3:>0=S(P]T1%B.O*JWNQ? MQX"O29+D03P_]+GWA]4H!U$RLAJ&^&3>H4;#VHXXX4NHD&$\0W8\SGT-GN$V MWQ[6@(OU`X#;QYQ@3P`.'?(:2.3DWH'%P/J.H)%+JL!C/($>Q2EU&0I3A#-A MFB2'A$V$;)!X!24-*SO`A\^]@HRGB&G/YLB:DIHG!)"R10M/DA:>PDO7!T[0 M)A%6@N_4H%;6]!*!J^<4]5D5B2[@:;Y&- M`JY?`YAD(*%5%V4S0!$9`\(VF9=X4UCK`%IM"=976=Q<^-.]`3HK[BA>HRTQ M@,&*Z,^UNY_-/SO+GH1H"R):ZV`2[:E+(T'V>YX]H90H\!5L'T'*J.^`4SVW MTI;38`$C_'S(I6^8V&&%'C,I;87U<%9^YF\@NF*,E!'&\2W#K+INW&1B[;-1 MWC7F]DT&+73N&[ONP8H*TXL$"#LF/D&MOV$)!H.PB:>1AG$,J#785WT(R[:" M^7N725YC\2S;59@#WL3155^B)<7KO2[)Q.Y4SF;RB'DYT)UXL-V0&8_A06IE M:K20[T,T6PP.2XN:!N)]"(DW M!)C4%R_9AVB*'0B0XFG,# MYC+GWB45?_@5(5#,8#DD[*=OD'CW[<4&=OSX#<:GK^_GIF-1IX.+%`D%K_@) M'R=GW3XM$@.DMG!I6ANG#9K!<<_S/](S20#T&L?F1FB#TPG97B_1VN5MV-HW MQJYC)P4-+E[/2CN4*J$W^:7S5Z>\W=6ZJ?,>'JQ.B]>XJ8HC=+XH1%S8X*A^ M3EWW,+X>%M-?)CBO9!+#L7,6K:/`C1;.IS('#PBCJY MSCW.3RK6#EDT5;/-&'*='0MC@#.45'F[6`A8!64])U9$>9EPU'/,.=`GU,0V MG\(QV)99'D&`%^DJI?7(A5"3TM5OHO'I+A-F.DXY!\@$>MAFF#F&V+<=^11) M5@:`$&$RLAK`^&27B2\-EYP#7GPUO%Z-E07XI*LJ+@U;H*Y)XZS\`'U88E(\ M+"&,%R%-O=!`FV;P2.&[%>D9)8![@^>Q6$";UW'CY:/#:E1#^%"K="72P[+( MIS(9C;J#3=Y^]POM&HKR/D)%KRYH.9H=$E6-2GDY2R-H\24IBEEZG\C%V"3= M3I?2RD$UGIY>B1(QI(QZ?Y$<":`Z9U(VP/3O'UH^GI-?]/O0U*YZCM[1I.,: MA7F9$S(K,B=O$SHQ/""&G_MCVJPV-=%K=J9\[PG1)*+:W,3!AK%1^/=:QC?S M]T&O`QA]#Z2VCW,/0$=$E83+L![!K3Q=4$SSE/KY!N(PB/^;+*=F9#'5KN*D M0UJ#BIC4.]1H6MT10&(I0U4SM`%39?&A-+(825*Z&HP$=-YA2,?>C@`2B!BH M"H\->%9I$,%DLWS9/J*8`QKNWVM@8?[N'4AD]G4$!\-ZH+*]]G?4;F`,TBD! M]`:E+QQH2*A:-]88*N]@HK:U(UBX`JR+QPV&F0>PH>6K@R2["[:\04A&UD(- M2^8I;*36.L$-*V&@NOCVN)D">F80WY*EZO-_`'%O(Z!K(:=%YRETY/8ZP4Y+ MQ!C>##)$#]IN4;+,4/C/Y1/Y$GB19S@+$CK\BJ&DT:B-*VDC7T&F[PDWB)/* M&\.3E*9+K],*\H;\AO>LLX*2L_QJ47J'+CV;'2W!6D)LBS(/#J/#8E(/2!Q: M(90:M)Z#26RW4S@UQ`Q4`[X+H.AYA01#]3]S8'/XL[=(X5CG"!P'SNZJ;`UV MQK/.0H`B5Z<\L]]SXK_%FOB"C.2PL,]$N0??53??,X6PA-^]A:E\,O7 M*-V]4;K=0HR)^Q??0;1"Q8N#DPTHRMJ2CX-!-,';U*&U'TM0&$SNUN91S/V=+OO>HV4.E0;H3=Y+3T M0%&"]U`SFO>D0\P5!IGCAX>RV.J]2B>N2DOX!@;696EQ6\J^SB(L&I?OW]GUMX'''5QB3G$#*6-Z48R,78/4=[H)`O=D["H MB'3<9W\`(8![_@.3MCSJET',>?B`PZZN,<>BA<0J[7$$#H--X8IIU?VC) MH89&8PX^8+&;6\R1:"QO!-OCW:I4UH\D:4I_F,)'$%WEV;>$S%]S$)6_+!X5 MQH<`K%=3Y!2M[,J24\/2GN784=Z#X\Q@[T:!$21_=KA'5$4YB*YSZJ##"=AA MN74'OA=_$KUQ8-:8O6FDV=@7%%LYPPZONJ(&.A'7V$-;,^U:[7)B!D$BXL'O%RNLX/9`!J75^>SY MG5#'NNE#@^>U[($_90\\Q]9KU8,153WP.2MNOTV<)<7=!#`MMM"^@H!V]D6= MF]9DM7Y"J-6@?EJH:.`L@X#W1DTM=?\NIPBHSF9GSR`-(>8>.73D5#_YM^4T MZ!15\Q,CE][BS&3E:AS/[VW%>UVM266U:--7LQF[L:MLY@E>+?U@!4Y]65X_ M,'N[W1%74/,7ZSFBFQ)[FCY_!7%T@])OPF?CC=HRF-1LZQDP;3S2"9V: M`KU^LOL^13N09B]D2O@/0`M_+M+)/H`Q7;G2XI_DCP%]H&5.G`7N@&CKP)8- M`UQS-IYAN*.?.L'97/9`99GT)^.BPPYC!XA#&]ZTPG)Y(==ZTV3`>G:.,!W&RL-T:&JK0210!AGM*S MLZL`0_PM08\8I$5ZUFVRRS/R9T1\$L/"G>RH(#V=.IM<46?;G]S!3S?T)@.\ M[OI,'T-P6B+5F]OA]Z>OUWNN1_^-3C,1Z`ZDV2>?VUA;?4?:]$&6XGK*?$F&Y[ M78,4[HD']LT!1%!R0(.Z7C-?1CT>S/4^TB-3YZF`V9?&5?\LU?3T*-&05?$= M]-&%6W`1T#]+TWPT6HCZ7UZ+\2#?J,_D=;I*AZB0K*,!MZ?E23XA<\@"??;( M7*5!@HG2>))$2Q*[,"31O%ASEMO%JW>8_R?IY*(/$0SVW8H8/E@4>RGH+,X5 MQ1%?N7K$N%7*Z]EYFNY-`S"&9K!(=H+[I">3P3`=*E2'W\'5 MR,%R0S'`Z+M-F'BM%B\>KD+:&4E23\B)V[=Y.(3C\!49<\@(Q6:.:K(5'PJ9&2K M\,X:3T8]UOB\1U*T\:3<:=)2SE!T]M!4C;A;:>)&(T(,!P>M33!-ZY7(.?:$4O@'B&I5=8JR(G34(<-3=:7B/H4A M>*#C%B]C\;Q"V0E/ST('#Y17IS>)%U_9Z5;+>TS/*V2:O#UUH8KBOJS6W M&OPSB[3TMD-VZR]9(8W^)&FM-3M*^@$CLO\O-G@X]V*BKTOA#LYHNV(NN,]] M'F'N>@2IL-=.H9_OYG._(+72MA+BX%W##U4S:\#HLBG!-4!X*"IZ&:?6#(YO ME_%N<>;B1%*?@]YH]G7[G)3V-L3@.LAX=^VUVZAJ/S7;C!2L^<=3`L_")`KI:NA54#W@R!4QTN#H%*@V)A*I9L68".6.*FZU^#3 MH>9>R><'0;H++X^G?U8K[O>S+SR;&[XZ_A&7?\6?!'/G3KQTZ@&J>?T`(>;2 MVVD;9[\]P?")-;GTB.R-)2=,-8+/A.D/'H76_A]5 M.)I8X77M1FY?=!SKZ3W5XD;I-*!OL5^]L(XP&0S-N>H,BR9GA"I7<]:9$\@73T%R>$3X#N4[`'.0'3PI>V=&=?R32_2 MN)/_`W4-0WW5P3J1,QH\T.N/W(TCOME5%WGRV0W<`^$5"'LFM2TC&R:7%9#\ M&Q:=G7N.D&I>V+!1>4R[J=KZHSSM'A0M)C9!46/R&A0:SAUQ4-14]G&D6"3= M!XH6#XN0J/%XC0BU:\<;$#6-QU1I35?])=B#I'-$<+A8Q$2#RVM4Z+AWO''1 MT+F,C+]X%1GPN7M84+MVQ!%QTMCKAQ\+_SRA MF)B`#QO1=RAKO47/GMAH-6*/612-AH\'/:OJ9QSG+(,BB@6IUHT#BIZU]?7. MBO+!<_5=3/FM,3']\)A7W(Z47Z0TNH7%EZ2X`\G>AS)^LV]DX))>C)+2RD$U MGDF%$B5B2!E-`41R)(!B-P&[@6FXZK`(![O$ICPL?PH--PE_TJ+#)%Q\AZD$''O M,.C0U^\JR.D'?2?.\",A0'[KBIJ%5J,.$QQ18 MC;?,=27:YCX-O3JB0_\DB9@9@*0.DKH!F\TO:>`1_(SMMX:=CB2GI5C/"+@T=5P2T9*0,Q/JF'X-*PN3.L^#)\W3K\&OP#I=,<9VA+G[81PTE, MR(")1^@AE)3V=@823X*OM=(>%(5^6W]G)^LC**IKCQ61=9TA4F/L:S'IYHH" MX8P,R>1W(-U+\:+72KKDX[3R$5M&GNB..)4X7ZN5MFU7'!&K&["/A4D:])LM MHG%%Z_C*Z`3C?'NXE35)DCR(;U"Z!I!6K7_@EVXZFTQE-HI3F8,?-&D`3)J$ MTM\7$+T>)E18GGOB5-'Q9_EJF%OTLC#,0%1D)WQ+8(:_T/P<$-TFPE.=FY*#LDR0KL;^A1XJGY4I?]Q*J'K-V@]J"UNX!F$ MM6WOA$N9E*K#/G>A'4=@@WB'R-CS)47Y[C:A@49\07X;(NJ5'$2+'3@4:;]/ M$?DQ>Z'W7NA&/DV#V%%_B&#ID#4+8">L?8.Z>W]V"PHG^E3A<^X%H)OPF6UW M,7H!9+!*]S`$_/G=L5Y=L46&5R@+XOK?Z<'8'!:\@WZC3F%^;LVK#N'<9S(C[Q#.'?OG#O/7B!9X?IS!>XI3 M/V^)?`E@,D<8+Y+#-`8>5I03C(&POKI6&R9>%&T\P[R)!SKA5B&HPMZYZSBZ MP=[M=A?`E$Y_%^M;XJ%D`Q]C<+#M-HG`&I+!$,1P#Z+#U@=QUA>$HN\PC@70 M=,&206XWEIX!VZ'_.N&^FQY56/CY+A190J(M6`7/LV,XSI M6MX)91(A7M>/*MXJH)/G%#S1E(<].,03GI5\ZA86^3*]?C+5.1RX?#"HR MD+$@%[Y?(:[>UA((\2Q&>O5QITARK5FU%/=S%GM*X^>7/>#_5EK,SP5+WE!B MS7+PT-&H7<$.+V[\)P@4L3ZM(<=:#U\+&[!E&J0%4>7$BFH9HRF%*JU^(:F2 M85($E2=#5AV#+7_J'8Q@`A;K*5$7RDN?B@E9^'`(1P<=<<53I9V:P&G7.N5Q M]A4V=\&6V-*H\"'M@)3T[-ZEF'YP+$DJIR!SBP5P:@MI[%6*F0]0AYE[[^,+ MVH,TH9/2JI2C\'D'%6GMEH>8='!8J#\X,C)7``RAF.I&AYC]4/>"');@D4_H MVQ2\,CQ\Q)RU)M4SW.9;J2UG@^A0 M?A.NLH2@EOFLM4:JO#3C;,7FI[&OP5NR9U;9R04@__P5VLG)&I7T1X MZ:!,->9(E?!UCDMG\8MU8T-;.L=5TC/=MX1^'`C5J,J%S,V7P5`LL=Z9223Y MBK535BR9O`5)*)_H**B%"=(,]>`H4T.&F]TL,UJ`+J$D?FHR(\%75-T$(8Q) MKSR-$2862S$EI640):#U"T\Z!G=!DX"_DSJ7P[UL`QP^:]-Z%VTN>\M&35VO M!B&C=E;:XE1_`U=K[3R(5R#=B@R04[,&B*B'+?.I\2&0J8IR#:(7F-`C3VX2HGH`B/>@WF#W-4<#.,+NPJ&'*G(4O M0.OH'#OTF0L=4V6I*M):2O4XJ MY-K<>,SW^$=<_A6+J$P(F7+T/!FL7.@X+$SULWW(82X"@[18EA;.FP0YF M07P8[2!GJP<^/9$ M<]8WV0HK$FYT<,0Y&;AX^_FF8#W=/7/-T2/MXLIY2>:HWBF6:%_LCT`$\+ M4\U7F&6\O7X[GKL&DCV_K*+76=B.X3%!-:A,33:#E09WK^?@-S`A*PD8Q*W MQ>R/=Y48MM6(^O[<8ZKXDZ^^(_DG;Q&PG[Q&X-TG%QG7\9/7V%:]VWN7[PN- MQ;.B7'G]/L[$T6R>O%2*UY/7HH;6FEZ,3:)#(6F8;!9KSM0*TUQ=S/^3_#9' M#R+8"R!.10P>`:I),SJ+QUO'G\P)@0[T_>)B$Q!^X!U73UG?S\\O]`BN@%F$0XZS%LR>Y?ZK0< M#4KX4R,[#RC`TYPF:8OPNI]IKX7O4`;8>FWLR9%6(_882-%H<,1I6B7<3#=X MM5LN2KRGWO&Y[E$@KIP,2Z_"<6D8/#$T@\.GEQD5TO.)Z):<0Y7JHRJCRG'/ MX*.#G=-!+M;1!^IBA/,4O+O*,4P`QL<+]4$2+=)-D,`_"HG7(`M@C%U=P:NS MGJ($H[@L+4P^6?VKUC[-DOSF<+__I+;H9+,/]K7IA%OVKB96G;2:2VY`NF7L MRH]ST;W*,^_7]X(UU*/G.4<#+FVHAG%7NE?=K)_'4[+2D8I:F9+C*C[I18:! M@7?.`&RY-KZ6:Q`7%FP5!Q-6(&0KA+4)+QJ>2L^<$9P\79Q4?QBJ^)X$D>T2 M9IS">S\`_D1^."/L:BK89I0X+O1VGZ(0@`C31TUNZ:NZ07R3%[NY,DW&M,M=UFB8;%(`ZJ_-MPMKM$C:A3-J)!<( M+H4?>H=46_Z8TKE/K\-1BZ3U,%2D-6")22\08)I^Z1UH8CT&RL#D`FZR(8%` M7^$=(+EBP<^@N$G(F'SKIPX2AC6S_(,0C+`O>'SIE6&H7;QYST MH8).3H>\!D$Y^04BT,`_O0-0KHMMQ9)1'++07?C3R?WAW4$8EAT\+'8O[U&3'==;8MDC2*B;A.B!L"9)$IX M)`SRFR07BF:)'\Z"T*9\Z\=61U)Z:D[6B/$-`,)#\7BC>1!\X" MMIIPW_,R@J28DF-:(Y]8)$S*$-"U,C):=)>*/X5'SH/#MA(#U;AV5?P(I<5T MX@JE*?I.;!)U@!+*5@$B#N6%@E+ME;/`DJM&U5$:GTN.94A^??!YC`\^G_&= MU=<7GR_HQ6?O>-/Z+CALIM-]&ICE&4WFB&.0;E[(0'Z;K(O7 M4'*:N@8"#,0O?7;B4T^NL.,S.-BT'Y)VX2@!%I6O3%O*'E-NV!4D9D4P#.)) MM*=5E8OW)LEWHL^=7H,]B-&NJ!-PJ#"9O0@1VY%3#;/6G/Q!K1MGV>+66KK7 M5;@Z+;$4U[&=\F;F!(YX.\LY.1X8URJV'S-JOJ0(XV40MS9-;9K6 M";C%`NKD.D$/X43%8R:+MFK5P'?N#S^&89$&=D@!HS<* M[@`OT<"L86-<3\'`-RJ7^5/&W=R0^]M M3`-,YW_T/[34R9[TV=19V31(TQ>8;(J["8+YCU%;MG*I7MO+"YTNSNL[+@QU M\[IL\QP&C_25+GX5;KE7&#E*>+Y\V=T?WU5[J\K MP"FFY!QUM2@O&)Y*QYP-GSQ-JCT5/Y/S'@#-1PRS/*7W:)+H`<3$`]$4X6SV MO`-A^;/HA5;3YNR->NWFEPMO2Q>>"_/ZZGE=4N^!UB1+0#0+TH2F6I`U9+[- M"U.OP1J&4-1MZS=L85_=\))1;^BV\^%=K9CM-OI(YB1%<0UIU@2'@E<+A7]N M<]9B0\4]%*DM7)I6B:$&S>!AQ_,_TC-)$"<=DK6?XJQ.W8") M;EF#P;JNJP!#O%C7,4=+S,)-`LDH$R196^L5^<971*5_"ASC@B7CNFXL!^\( M-*"">O&?H"L1ZU/O6[KIX?4TG+]=65CYHH*_45NM/>Q66\\`;>.13LC5%.CU M!6'ZT&\*R#"*X1[<)F0H!0<#-5%JV)P%JG9SW[!JYY=N<-66Z??SNPB3M2[& MB*Q^R3+V-Y@]S9YAMDBO(=Z1R5\\"3.X+[;=%VECOT>WYW4NH(5Z=P*\BXN> M?-LQJ#1;,0!3MO(,;&9>Z`0\I:BJ._-S=GL3P+0L8LI[R.9@K0"+1FW9U];U MVGJ&2QN/=$*GID#K:\3CP"A*`=PDAQ-X$GOTB::`7M5)Z"M-Q?_&A?LTIZ^= M^;%8MN?G&[X=>:X;YNV5\#KM[0M"T7<8Q\5=M2Q(-O`Q!F1.#C)<_4G:71NW M9V!NT-XS6-MZIA.,#81Z79[DL,^R"I[U.F<5>:M,F(C<,PQJVMT)!IF9)`Y.]?H.6TC>O+F.' MW]P;G9"H)<[KPIIWX'O-%2E*R(\AJ"WT]%!JRX8M?6+,QC/\=O13)S";RZY& M<#\W0Q_HZ_`Y?EK7;M9)QE>T\0ZNI)SK!4T.8=3'94>"QV.J] M(E.;B)X9@P0?DHIW96X.F4@3W\$]N(^#1+Y)VH%3JR:C!2?/4-S=6YUP;27> M[V*VWXKW3&CDZVW#SK)MQXK=LH9:M"CHEH M5(QF04Q['UA4"_OE[4??CPAK+MGN8O0"P!*D>Q@"_H@^B0M=BGMBY23V#Q`= M7N@H4IT,8J>+H=/)!_0M+X=0;A=S]9+P'5 M=Q_)*3?5LZP?O6_4+_`U4+_8*.'EY]3%C2?F[`L7;-YH/U+8/%/74@;[*J62 M(.+;0$MA)%C4\YDU9L<-S<:#]TU]00IU=*2@AW*L;KU;TU6SZJ?>?_0SS^*0 M/W*LIS$O756_><_-YI&VX";T"%J,S7+I6Q):;?2L'\V;$CK?LY74I.<"0=A* M)+93FX22O)XA?"$KJ#2@B8*3:`L32.=5]!2B[%>DU5",VK()GWIMQPI*\>,Y M-DXQ@V?[61U-F5Y7[.>_2J`#4X.6[9)RZI;^0=3<(5T!JB71ZWZT<2]U2J9J M&\&#/OH-9/4-F09>8E#/?`?0$PK2.;-PV%L.\%WZW;5!Y]H#$("@%^L:%S1= M6W6\G^[P@OHEPTI_C3<41*0:5L5I'-S?'?9$Y?4LYKY>)F.EG^ M>C-?_+8)_I'CK$AU7R':ORR(`XR+""K^ M>C3R`00Q'96_[5!"'Q-;I'/X>UZ6:F:^QG`*U-[Z.K<"PW?-?6(?C>"KB@:& M'NP^/DQU9GN]WHVY+C4^7DHNMYJNR-"U%I;?UVS5*K"E:'7QX6CGOS/'D+:2 M7A<4O09$:5I'KST4RDA:D*Z3_$#X%7IF,+#6-?*Z<.B7`";4'XO#8+,F'B$^ MR%[H=:>,%O@MC@1$)XU&C=FC1LW&/PS.K;PY4`3HZFI\^?[S(3:2XF'B:.CH MN-WN`IA24Q9K^C+8'.Y!="C8\RN((S+;^R;,"#-JR^:$Z+7]84+#QI<#18:F MJEZ72R&N2FD1F&MP^&_-.=-@![,@5NS"F#-H)TUI,_AQHL36JT.%BH&^7M=# MNP\@\-0G#-">*G1YCGR11<91Q=%GM;]J3>#NVRJF]*=O!H\MB M(BZ=QG?RJSA34U-'^93=5+?J`.M25KYE$@DF_1(@/8;X;K1)4YV0:#6]1-C+ M_=,_M%ORS?.//1@+"BOO@QQN.5[YDR@/0KW^[&:MH'527%9 MD%(;KX)V2KRVVET<7N6>Z1FO+>$57OTLV-PV\%M")C\Q-;`:1?0GU)*V2MQR MVUX<=M4>ZAF_7`7,ZX..?99`O+@+8%1%:YF=4TWU#^=;VK`V8:;$N1ZSBP.^ MA0][C@0]C'"XBL1X1A(,Y`]F-4P4#SV%O[2NG4#?1 MPN^:_'<@X^VCEN\,&ERSL&?4>G+"G)$'[ILB>N\H)[\K`8@2T?#IAJFU6_E, M!^]7.@`,]>1;09]CKFGS59!N&EJ?/R/2&0[='=T'+\6IS_&E4])-T]N^PNP) M.7DKAT)$?B'HUO1'+[@5RS;.?!O7_(_X(P0@PC?D@_T6I"G-=WT&:0BQ<%VO MTX3%IK3)I>!3WR_]8%0JW^N'8^NF/9!E616,Q5*,IJ6N0+J]!H_"1#33]A+\ M*MI?()A-/-8[LA7*>'VA4&3G'":`_&=*C!%>*S1JJPEOINV%0UOFJ;/"FE'$ MZSRUNHVW&.?$+X"8AK9;E"PS<741[782*`O:72",=3S4.X0%2GA]GU#@G=MD M#[!1H0Y[1GI;'5)&'KBO^PZ2(5-KM_JU@Z0#,/4.DIUOS7H*#"\ZW.& MTGIFX:)Y_:0*R@XG_!Y\GT.[XI70VIOW,:U[FNUU<>":(*\_<)FM$'T"B,%%L M?)BU9O=`=%M[!V,[OW3$KK;0"K"^%C`YE`*EQ4$%L.21M*Z]UTF&!Y@A8)"6 ML2)`Z0EK7DZO"ZD`Y.!.[F#//:[W6XSB;;#>1\,]TU9'R8>+3JX9)+4 MZWI^!0$U,5K0U^ORE!;#(`1W*$FK_[T*,&P^<`USE_!N,.^7O]#>;L@^T] M?(>6C!Z^14W&X-V3>^RB\WP00:_GS)YZ[^C8CM->Q?#A>/52ZD_[_IL4_)[3 M%S[K3]Z+@DS=4A0ZLI8_2$!H.V\0F,NT.\T$Q@#>XX^_0I"2C_ST,@=[$.OA M5Z.Q&,+2QC\,BO5=.!"0I0J>UE@7\<':0R6RWZ[H\7L=]6SDJZOU\WH14G.3 M^5Z366.FT])M?/DQ8.7&
"KI)>7\7@6*;*[]5I(AJNN4W&@W>918Z74[Q] M!A7".>JY7AVMFE7]QX!,WA3X&FT#*'HJSJ"E"*>REN.!J\;BA8=:;;>H\"B6 MSX6E3.Y(`8?;TU9CZ"EY:(!0PF-,<-19A2@0J>LM-38ERJC@*5%B3$"]379Y MA@NK?OX*MH\@5<%2W$($0EZ+\4#."#@\Y"D=HL*9C@9YT\Q;/LDS$L M/QG#\M-EPY+OD'/`\A,#2S_7^SS+?C*&Y4_&L/SILF')=\@Y8/D3`TO/%]YU MEQR79GKXU&BJ,[=L-1TE8D5+%=5\4NX8`\`R"BCGD"W!7G>CI\2HVJ;"E!@( MA-6>=)H(,]5X30;'I>&^)3=U3>D+`23U9/-SV7@R;=&X!^DC&BD>38!H@L#+ M@]Y9,==A83.&)$JN37Z1>2=;&V\TA>3SA(!O_Q M3LR[Z>+N>G:WG%V3'Y:+^>WU9#6[OIK,)W?3V?+7V6RU'#B]7RN77RMQ?P19 M^M+(`G`YN-827G[?4.=&.8 MU9G%Z,Q>1@,8T9Q$-'DQ`0K#6SAW\?Q]U"LR^(*(ULNE5CZ`$)!U]&,LW&93 MTC/`D=#[`R)=HVT!)>'O=>_S6EO5$0`=%E55@M&L.J6?*S7BFUT`H]GS#B08 M$&MK,TOY8&G0LC4%TVCI#R3-'6$+2"U)7B\?OR6/C1$`GX8``0PU6C#PD[;P M!W;ZAMO"32K!ZZ5F^X18_R:4WB:GK(&%V;1J$;7EX^>?/Q:6D%_\?1*&:0ZJ M[@!7_4$I3WQ0;-6VM,^P[>#AI/'A4#>/J$_N."%F*-#KN2^Q$^6T&'+P0KL. MQ1)<2LRNQ07$GJ#.R&8KF*DD>#UU/9UTWR;$Y+Q(0R-1]"N(-@";Y,EHMAP9(6\]TPJB!T`JV?LYQM3,*M?,(QYX]J`$Y!WF"$FS),@+]/)R?HV2S M`NGV&CQF"A2)*5D8\2A]PY'2VFY`XK&O9F?O_^QG5=UBVJG=*RFH>>>V%]`_ MZ5G="5M"$55/Y>=:^P'0T3S,*-8!&"P9ETA:>(4W?^DYHDXHY M]FA^=F@U#Y`)Y#)#X3^?4$Q,PG0?/WO1W^S1:BZ>C2F:CV#I])KC;?&]>\SR MEBI@D^?M,((]^S3:>[8.OXI,IM>;+>KM%/6&R6BW1+I`ZRQ8\CRU1F6]Y3AL M.?Y>#O9TO-(/(`622Y3^Q4^4UM;VRKF0G%BRL7(Q,Q\M#[A$GT">U_D.[)I? M+V?>9/HM:^`U_K0]X1"#,IE>)T3P=@.46-1KI+%5M3(.F+6SJ-!T< MI486MFZE6#^**935OJ72YT:,1PZWW-QV]"GTI7L]9$W",-_F,?%-F=.'ML2* M)Y#@(KTE1%LP1QC?H!3`37+8*0Q?5FF0X/@`HN@?^>%AM#M`?+L*GL7Y1%'1'9&.*8#1;3(-=I`^ M?HNV6Y04?A6%EG9#-E(T&OH&?%-?=,.QAK3C$?5'/U?<-6.DE_\$9.P]OQ:9 M9P!3V-D)3FW>U0SP_4<_YQ'@<.DB*2X@D;LB$E:P=YR#``%_3D(KQ8#7^:@I.&`6UGUBSXL$9_`UXN+I^ M^)4(>HI?'FB2RY9>+V),E-+4KA-R:`:/VHX%\?1B!]*`FE9T_E.`<>$( M#I:,VM6@I=G.;Z39.,#D]Z M$`.6.:U.A`&[?C=L54.A5BN_,6CN&)<(U)(^T%*,C[[G'0B)OH5Z&2U'=`@B M'N04I'6<"4D]!Y>>"YPB2BC2?1*^/8Q*BXLML,7Z2TJZX%-GS,&2%GT-4`IZ MOU%EX@R7T%+(-4ZH<#5,.CLGI250Z`14619$0-@^I6P1^HL\;?-=04XFL%I7 M?O1R>[)FD3*Q44HK!MRHTAA=8LXTA=$%[#CIBY_\O#IU76I0'$`.D4XPRM)D4\+#NQ9H@D'_V%L M[S#7L#;2I!KHC;>?X\$3,FJV48L*^XI[&)-G*+HRK=E*=H.&UVHP+ZR(`.8[ M-Y^O9>Q7TC.62^@'#UG=;XG,S1>$I$)B/0@EDFQ/"T<<<7.8@-L,;"W"KM54 M/_9J34?BE*<@W0C+-4=)EW']Q&*" M(?P&JI%/E"2EKX/XJW!D.^T2+^K;B+K'LWV@F@*VF0I##UPW04AO0+U,R9R9 MV/<5;!]!*NBDI;2MA3F7=G`TJFD+@_`U M![+W',@S^FM%L'`5BV\FV3&Q\5B-R>`=2>=-D4YN<[TO8JJ,NUGCB/.Z5X>W MWD8=G*^=F;!Z4?'Y5)V77B-%%2.VD?^=DY%;7'=&*N&GSF?@JCBNO=]-LV13W0`87@!-PF9+@@,VAZZ'03 M(Y3>@S2DGW'#2S9TP:[^K%0G=H/W`*IOC9P[3=`+"!0Y/CO528&A:M%S\=PT MP`R\QFUK2#5HZPLL;=UAAT$#:=9'@OT##G\-Z#Y#]G)-%"_NTI!1][]!P.[F M6+04@DW2TD^HZ;K"!=`DL@:J3":^-%?>2[@!8+&F94_G*$BN@C@@'709'AR4 M&;9DK]7IM/0%97:NL$.9MJQJS_K<*;1NW!1BN@>+Q(1%QXPNLX]:\1(E!HH?YD?,K6*[??TZ?IB@"0_;6&^ M/5IUG\(DA+N`&Q%V'.J`-^7@#9X[N<82KJ8RJ\7;.'IP,^W);R"*5M]1=URV M6-D#M,;J0I$JGI%N,<1,4=@2E*]B#-()DFW:'L5$SW M/D_#IP"#WX(T#;%)0%);F(-@-PQJ.NS+T!'Z:XJ5,CV\V'2 M:1Q@O%B73EBD#W#SE,V>R3`$,2"#4`B.?\3E7_$G4:)!%UYLPH$=+Q]P[])= MYI#O*+U"N_&]/S)./*(1X/TT8E43L6+DN@]>)+?]-%NUDF84K;Q"JY$+.N!2 M):>JP^5GG63FG)&,.70[GI[^B'I5C1;2K`VFA4^8TS?='F]2&;Y>16L:=15@ MB)?$@B!:)'\+4D@#Z4$;RN%59C5I(H4EV\1?*$J-=P4_5HC7CR$QIIUF'((,HS*)U;31SUIA34._)<$6$4/_`%%5E$4+J9)V4H1RV_F+3+4; M7"&2*ZD:K?U\<[)I8#U]30N"O`92[#4;^`LZB>&NT-844<',UYT:<4;N;+VF M>[%[T,X!EJ^=]7C(5],J'OXBU,P]SE;<*JD5CHWWUT>)XS(GDVYKZ5W1X360 M(K39P%\X2@QWA;VF"-O*V*/$63VLBB=QHPZ=I8B!=D_99N`O+@TP"U_.SKHM[@ MX?9`+5>[-3%?@I!N&D-A65XG/'GO:-OS]`GU+MUG'P8=M:A.^\]]:ZK7J%@^ MD>^,'8>%(5.]N-!F>@&!8>=`YY&AK485&GZ^ST,=I%U(4$[,V0P>56G`)A9D M;[M(**4[WF-YJT7QG80[VP:/K_!%B'>PF==4?*UC+O.7T*WM7M"@SVJ5(A?R MMMU/&#I7F6;Y9^5]6%HQ6_(ZC8R4749Q27T!D(:A=NCA,_8US9VU1OJTCYQ8 M`9_1/.HC188$02;/^/!DR$#D^\,]]3T"Z>,'8D+))LYHGCU00$*P4V/RX`%? M@F@[AGGJP+MG,^@]X.I:FAPV0L)6K],F]`DV*COM8MLMT-9/&S9 MZ-&O_)158+HG'UKO M;W37HQK`WOM9.<3``;<)M;A=N,P%*_M8J+&Z3/R+?'4.S-=DN[LJ.N!L[76> MUK^IDXBL"LF'"V):OIK@B,)HC>@G(;_5?XS,F@_C(`L^'G4D7;UDW8M8"+Z( M+N2U#SG'6?_Q@==B-T'G^2^=)NPYO;2)1YV`@>W6\2Z7X74AB9-II^G08EV? M)ADBT(R-$)6Z;+Q$JI6/'*!75Z[G[V(6@]5^B]'O9&`F/PRW17D3P+3(4#M] M(:P8O'2:M%ZIEC49,%TEA?N`7H:NO8(H'+(EM*T1FTL[>$^@]>60F) M:J9:<$5<1GP/-QO]H*.IBE?3UX^`9!]25&^(R./[":925.1,Z1-_>T< M]#WBJH^02G3750R+T../OT*0DL_X]#('>Q!++E69-1:C5-IX>->4<\8B3ZFM MJO3FD!4/D:/T>(PGKO50P8MP"V^I0EVJ##?H]92XC.@O]PFI/WZ67DC1:*'8 M"FZT&`]8C2`GV?<5.T2%4!T-9)N\#M'ASM&PW8FZD&?/UG0'YK4?8A0 M!\&T02K;NF30N/H.GD^.Z7E%S=G#*S!%H2\\9Z^T"^<4W=@*9QNV;"\@%)QX MU'F0V&IU#!]/X^>4P5K=N9=-M>74+-I%U/Z"6,M^5]@4"1NJ7C;W,N-M`C.B MXRG5Y&@F@R$]XMHU1AGQB!#4L3M#AIY1@LM.G^I2I$R/$G=_^>AI7_?#9J0Y MP*C+K+4.$-7+;#-^1G)7E$R;)9'W$/V[^,F^'QRD+<\,#E/C\?L`4R(ZS88& M*F^_X#>8/;5227`SEZ1YWEUYY649Q$*<]RE*8Y.SNZB+C+$S?)4S!&@_5ACG M+7X^Q'<"-O1MG*%C^UN2@B"F;SY^"6`R1Q@ODE-/)@I3S59,Q"E;763PF/GJ M#'&@5,@V\6\D=<57:9!@HC;-PUJ2N(8A\1&M9M%:8F-:P`GS_R0]9.M#!!,L M;D4,'UF*W11T%N>*HHNO7#UHW"KE]1'>;T%*G"$O/LBE81#.T`P.T5YPA_1\ M(@"F2Y7J:&94.1W=.;A^,4CVV7'D>S==W%W/[I:S:_+#`=A^H#(6TC!=V`0$`]HMN,O1YC9D&:D*X.WX.T>-R`+KU" MT@E>PSC/3IT#`R'-5@RBE*U\`IB9"^SQII3C=ZH!USP3U)E@[0(0UB^N?'\V MF#7*K!E9->#.=\^D M@4\Q-=RGL8_3L^IJ!\9_J*+(?74+Z$%%)S0XI#[1_\529W MA2J'?PFK/WMZ('0'LE/\3/8!C(M[RFB*MEN4%`_0/:&8F(CELQAK/@P8+?CX M!-.N;K('L(7D$MI^OA[8L%<'M#J`]!AL_0#IE#GHY;!ZAQ)TF&LDFX-19?>N MV*/5;L>"2=W.*X`9NJ$#Z-22;!,$1]%;+2KC2K-4-]B5]`SP)/0^`4[7;'N@ M221X72!IT8P>R:`HH12!RM7.BS7,K'FPB@1D/GP#9Q3WV4#646FVB^EF[468L M:ZOR!+(;,P-E-XQL6E:IUM,51^05_/V"[X%$HP MWNT8)XB*6=P>1J`Z)SZNRQ6X4C<40$W6T&_T:;O$)2!E0KW.>:T,;'CB#HC/ M].7D`C2VR?W&H,)\E\AKBZKP9OYP^!@`)W2"Z2&7Z>&6KYC3=8`+T$EDV6\^ MC&'7N)C\FD)/KQ%['*%HY"<(C5SA`HDJ@4/M';Q>@!\)(IW<<#>"I.X5=D^/ M)*X!43J$O.TI&4FK"E"=9'!HJ8_JD99Y`OP(V3=K]-39VB:(C*3.P1>0$)-C MLAZ:1%N80&HNA;]\)-5LQ6!)V)DYH0OBE)(N(XFDB"_(=WBB.SJT1C7:T;UL>?>EU89!E:*-7P@S<4`7M"GD M>+W31FS+TCRD+Z0GF^E3D&Z$/9>,M`TS#JEWZ%*9VQ%4'/;5\92W+]^='O5Y M=Y5CF`",#^=O,'L)DFB1;H($_G&8=0XV5->4F*($H[@\'B0!7O^DM1(RQQ0# M9?*Q2][LE,`-[^&F2%WT/P%+]99?7V)AU]HGB^FM-.VG M\I'%=QM(0P,`G%W#X8K`_>(/9R?*284UIR82+3F,N`%5);6BFZ.(T6K;JIDA:#=S:V7QS9N$30 M/1CJT*R^*I'M=9VI2ZV:X@!P%M54.D",7V7%87Z+GQ_!^?:#^R_G0D5WM4S& MN&5V-9E/[J:SY:^SV6IY7\#F"61D/14/ME]6^][';4I5&NQPA_06XUQX%UY!W9Z?\*G'U$NIOR.JT:'LT[3N#I' MYUZ35Y?#P?W"0>;]M+P'!MF`L_A3%=M#'?`[E*EW'W4:M6;N\D;#[8?JZC<7LMQXPS.]&BB['T3O'-D550)``,7'#U6%QP]5G5X"P`!!"4.```$.0$``.U=W7/; M-A)_OYG['WA^N7:FBNPX22>>N!U9EE/-R*8K*6WO7CH0"4JXDH`"@+)]?_TM M0%($*7Y)=A)JCB\>"M@%L/O#+A:?_O#S8^!;&\P%8?3RY.S5Z8F%J<-<0I>7 M)Z'H(>$0\`\RAU/QS-KB/B"T5Y/,3\*]T(X*QP@"YI`Q<6C3^A?ER/!-?90Z`/,(?T<(I]X M1*D#^SC`5&8(C&R)^!++.Q1@L48.;B896(AE:1M!E#*)))BG3DM2UVM"/18G M0:+JD!=)KYQBS](&X9"V!IS2;`P+*K_4E(YR-]7*F!Q0K_-0KG8 MVUR"1#*11C&2^)&(NI? MVW*3DE-`?H)1R.I9U\P)E0\Q/V'`M494$@F#)YBZJ@T8/O3S)>0+#P5V;?J3 M_LX;:R7T6@^B[#9BZ,:O]<`VK8X^-X6:)DE6G&15E1F!^,S8;Q' M'`A76!(0<7],L^S5`)\?`K#U7::*[SO`]P=\-H>_MZ.[^]'T\%\#+F- MP"YAK0;Z33.@T[(M^\9*2^\@?A[$0_OV?CKZ!6C&OXTF]FQ_I'=+J`;\[2&` M9RJQ5"T=\,\$?C#[Y69B_WX`X%O.:J#?'00T%&[ITCN`"P"^)L+QF0@Y[EV% M@E`LQ(1\#HD+$2O$KC9?(DK^JX6)<-V'H0K.LRADWI8&/Y+R?K"V)>KXV2RS M`[%DQB*80.MTRA+]K`;@=1Z`61@$B#]9S+-F9$F)!T$/6-K`<5@([HF':]O,K98,/3X!J=O]UQ,Y(Y?ZV8[V(N_FF- MP-7+IT[590Y%&OY$UJCZW8X[(11!5P;//>>("N0HPJY?E_?K,[-CG]6H^\?= M`70A\.=0A:>C3>>WZ\*5?+Q2';"\?D[`8GVGOYZZ)9Q*1&0.D6J'<_X\1.9H MX6/1(5(12\I,,%F'1M-HLE-]_4!@6@*N4WRC$*?3>GVLDPEVZK3>,-KI]/Y" M"T#76"+BB[W7@1*^*C3?G!ZX(&1]%Q??P5LYLE,W-[1#0C4@KW5E9';A-PO3,L(9KS>QMP9A6&*IW-K87#((] M9(#0O^N@V%T\*(3"-*G?%2R=<32<33F8F2XO^EV-RKM=`RF;5:FM$JC,AT`A MALKV/,R!L$.G"3H^>E@Z&7SBE#J$=NRF#*$)0]0:+#F.3DP\$+FR/HZL(5K# MJ.1W*#5!:;UFTL^@%*?4H;0;SY6@=`\FXY`U\JU[]!2%$1`C0&.L.>:!I4#L MH&H8Z/D!\C;Y,"].K`OR=AU?DR!O(`2.]XXG!"V(3]2!](3!M9`TRNEP;(BC M0[P-#"UY)+?)=5CNNLA2+--Y\G"%Z!*P(]0DAXPD4C<`[I!LO*QH'+$`*\D< ML"A;46S`4MT#WNQ:<^5)CP[-%T`S6F;?!\R8HWJ9?[\S.]UJ__.!G("'/,@X MLXQU)KKCI&N`C4K___"\'_KY"Z)Q2O8BJ;Y&2H(UX]*BA9=3RVX\1[>V)\S1 MA56PJ%^]A*^GDGIGKWOG9Z^@ZN2Z774SBN]1-VQ`PJ!J?MN\SI([V0TKU=2J MQG>]T]>]US\>6&_Q_>XF;3`Y[R)&U9SW2O5G[Y[=G,.:\E+M*+B,WJ0A/N<9 MKA=IB'G#?3^32/@.,HG2N_/-V^`?;HME-^M+*B_D41^]E+EY"RHOZE>UH)"Q MCWTIDI1>6M1.>^+[_;I!ER<#Q^$A=N,]+3&@K@TC)1^&7%WW,^+\[03DSSU8 MH@O3^FF%BX!1&*WXTUCB0/EWD#%<"$EDJ"343VPDI`1(3BQ*?%]%,)8@\#M`X> M4PD?0DY!PAN?,7Z/N8/U&RFF8IY32J0L\+"J[2KUI35EJL0->7RAIUPG\.VJ MWW.6+O-&J[S)(N\M#A:8&PIHSA)+JU]&N7!9@`A]`7FCWP>)>T548\&D/]%% M]!EMDXLI=C#9J/KNC!-A?S:E_ZHVX.+%H29PQ3%R5K:G@8,JPLB\HUA\\("X M>Z_+,S30F,/400+%-^[=0R16JF=NP%,!:+=(AARZ:5[&&K(V"N8C(6POWB6S M^90L5W(L1*AZR#4X'D.X>M*,@)#RK853_4NH)Z[L!^S.F1YG!C`[E#`F@V>% M:=5`I$[5]K+#TCUG#L:NN.$L&$'?5>RVIX^[&./;%ZWDJWKY>JLW#+9H72:G ME"I"LZ=`PR"[5C)77JR>E!K"A>Y87\BS&TL*^;9#P*UKSJ-?2WV`M%]T]!JR MD$<^%[LW.-N;\SDMBN%!M\.O]??,T0$$/JZ-K M6T.AVE#D==1>%F'-T98C9E:-OBVTT(P1S6 M",VPE+YQ)^3/HKSCB>EU_3.WJ/76_-0$6?J(NY3DGF M6JD"]F0[&J.XPX`B\XB<8@FIT""UOZ*W9JZPQS@&0X_^P8/*8CR_.9EJZ/DE MM41I#3K1'9-8P/Q'5;C=I=KV_FEB'X,@ZTGW9&O'%G<#=11NVFWEBL298A<' MZZB@1!_[\K7-EYCMWW;_>$^H6,I=JM;)I,XV#_39YGQT4Y#5NI@&AJ0-86%F MMSC9>E>^9GNP*@HU,SCMSWHT%CK%"AH8FO8=]_9F;(D3KQ_Y],F!*_48A_D6 MAQ&X7SVE)/%:E[;:[1K?`-00N28Q``-`/HQJ'B9J%6F:.1#R%:IJFQLY6.0I M5E&"([&K.]8G2J3XJ'8DL3NF^6-$7[:6S(*M/F?22J4F.[8P<#K0&T#R&_!. M>>=]"&_KO'MC(0K600_A/5H%%*RF'L!ZM.+/\`;30Q6083Y>%9#'@Q60LAZM M^(6K\@-'&@>=D/*:$E\^>F6K*C M2:EQ5T5M$^04449DRMJ2:Q[Q,D>,1X3@G$VP6ND84Y"`8OVXT.]$KM2!EU32 M_3F/9O4HEFGTN"81;?:^2TEV!MUO?\%.$R!?G0%7=:O%>-_'?/D$7FI,/2U'**Z)T(]$Y-W\@>RM<_I7A`7@ M#1WD#]R-LAFU2(01@`MR7*MGBMA:KQ^%S,%Q%/.B.'B$R!-LS5DW+*4P9"95X M"4/7MW5.VVW!N'-%FX)BSJYPL@WS:^-]WEL+WXM$?G;__@ITK>"=-5WO3(_HB#K=-"GA>,;):ADSKSTU(#T>N3\R M:#95",*$`"/$9$FCQPB=)^,?#,!43O_RXT[KJ(A>;\/J7/UJG2IWBI&OM*+6 M&/2K13RZ)X2RJQ1?N]ZC\;K1B<LOL#%G M:43<#I.M1UX]+*S/>JNF2_7V9`2N(6XI14OPK1RO2DFP2+D(K>-5TW51F&C_T40/=8-/_\'4$L!`AX#%`````@` MXH-F1WEP-OBVN```"4P(`!``&````````0```*2!`````'!I<"TR,#$U,#DS M,"YX;6Q55`4``Q<`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9' M%&Y'[3\.```2S@``%``8```````!````I($`N0``<&EP+3(P,34P.3,P7V-A M;"YX;6Q55`4``Q<`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9' M/&HY6?$H``!GE@(`%``8```````!````I(&-QP``<&EP+3(P,34P.3,P7V1E M9BYX;6Q55`4``Q<`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9' MMRHI<6>?``![6@H`%``8```````!````I(',\```<&EP+3(P,34P.3,P7VQA M8BYX;6Q55`4``Q<`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9' M(;M#RIU(``!YQ00`%``8```````!````I(&!D`$`<&EP+3(P,34P.3,P7W!R M92YX;6Q55`4``Q<`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9' M7'G`K\L/``"`G@``$``8```````!````I(%LV0$`<&EP+3(P,34P.3,P+GAS M9%54!0`#%QP]5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``"!Z0$` "```` ` end XML 40 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ 2,355 $ 178,509

Non-current portion of derivative instruments related to stock purchase warrants 227,898 629,170

Total derivative instruments related to stock purchase warrants 230,253 807,679

Recurring [Member]

Assets

Investment in money market funds ^[1] 6,430,038 6,429,104

Total investment in money market funds 6,430,038 6,429,104

Liabilities

Current portion of derivative instruments related to stock purchase warrants 2,355 178,509

Non-current portion of derivative instruments related to stock purchase warrants 227,898 629,170

Total derivative instruments related to stock purchase warrants 230,253 807,679

Recurring [Member] | Level 1 [Member]

Assets

Investment in money market funds ^[1] 6,430,038 6,429,104

Total investment in money market funds $ 6,430,038 $ 6,429,104

Liabilities

Current portion of derivative instruments related to stock purchase warrants

Non-current portion of derivative instruments related to stock purchase warrants

Total derivative instruments related to stock purchase warrants

Recurring [Member] | Level 2 [Member]

Assets

Investment in money market funds ^[1]

Total investment in money market funds

Liabilities

Current portion of derivative instruments related to stock purchase warrants

Non-current portion of derivative instruments related to stock purchase warrants

Total derivative instruments related to stock purchase warrants

Recurring [Member] | Level 3 [Member]

Assets

Investment in money market funds ^[1]

Total investment in money market funds

Liabilities

Current portion of derivative instruments related to stock purchase warrants $ 2,355 $ 178,509

Non-current portion of derivative instruments related to stock purchase warrants 227,898 629,170

Total derivative instruments related to stock purchase warrants $ 230,253 $ 807,679

[1] Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313

+ Details

Name: us-gaap_DerivativeAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Trading Securities

-URI http://asc.fasb.org/extlink&oid=6526789

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 35

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Available-for-Sale Securities

-URI http://asc.fasb.org/extlink&oid=6505594

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a, f, g

-Article 7

+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Leases) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Commitments and Contingencies [Abstract]

Accrued restructuring expenses $ 244,769 $ 244,769

Accrued restructuring expenses - long term 184,018 184,018

Restructuring Cost and Reserve [Line Items]

Restructuring expense $ 422,482 2,519,273

Facility Closing [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expense $ 400,000

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedRentCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedRentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]

Net loss $ (1,324,768) $ (4,628,435) $ (2,202,305) $ (7,325,995)

Other comprehensive income (loss):

Foreign currency translation adjustments $ (5,869) 336 $ (7,162)

Realization of cumulative translation adjustment included in net loss 229,192

Comprehensive loss $ (1,324,768) $ (4,634,304) $ (1,972,777) $ (7,333,157)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to license, development and marketing rights for SIGA's drug candidate, Arestvyr™ (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.

In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery's finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court's opinion.

On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company's lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company's reasonable attorneys' and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.

On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with BARDA. SIGA's petition for bankruptcy initiated a process whereby its assets are protected from creditors, including us.

On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015.

On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company's lost profits for Tecovirimat, also known as ST-246^® (formerly referred to as “Arestvyr^™” and referred to by SIGA in its recent SEC filings as “Tecovirimat”), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company's reasonable attorneys' and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene's entitlement to interest from and after SIGA's bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.

SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply brief on cross-appeal on May 11, 2015.

On October 7, 2015, oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene's favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.

While we believe that we may have a right to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future.

PharmAthene's ability to collect the Judgment depends upon a number of factors, including SIGA's financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA's filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company's ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. The Company has not recognized any potential proceeds from these actions in its financial statements to date.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (“DCAA”) and other government agencies such as BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies.

We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA in the amount of $5.8 million in connection with these costs, all of which was collected in April 2015.

BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax^® contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.

Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company's financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company's financial condition and/or results of operations.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $0.2 million for each month until the failure, if it occurs, is cured.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

License Agreements



On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVax^TMvaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (“rPA”). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax^TM.

Leases

The Company leases its office under a 10-year operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized a loss of $0.4 million in restructuring expense our condensed consolidated statements of operations for the nine months ended September 30, 2015.

The present value of the Company's remaining lease liability (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses as follows:

Description

Present Value at September 30, 2015

Accrued restructuring expenses

$

244,769

Accrued restructuring expenses - long term

$

184,018

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholders' Equity (Narrative) (Details) - shares
9 Months Ended

Jan. 28, 2015

Sep. 30, 2015

Dec. 31, 2008

Dec. 31, 2007

Stockholders Equity [Line Items]

Warrants issued to purchase shares of common stock 1,922,781

Warrants [Member]

Stockholders Equity [Line Items]

Number of common shares expired underlying stock purchase warrants 2,572,775

2007 Long Term Incentive Plan [Member]

Stockholders Equity [Line Items]

Common stock reserved 4,600,000 3,500,000

Shares approved for issuance 10,300,000

Shares available for grant 4,400,000

Options award term 10 years

X

- Definition
Represents the number of common shares expired underlying stock purchase warrants.
+ References
No definition available.
+ Details

Name: pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired

Namespace Prefix: pip_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock Options Contractual Term
+ References
No definition available.
+ Details

Name: pip_StockOptionsContractualTerm

Namespace Prefix: pip_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Stockholders Equity [Line Items]
+ References
No definition available.
+ Details

Name: pip_StockholdersEquityLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=pip_StockIncentivePlanTwentyZeroSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 70 160 1 true 27 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.pharmathene.com/role/pip-daei Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 101 - Disclosure - Business, Liquidity and Organization Sheet http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization Business, Liquidity and Organization Notes 7 false false R8.htm 102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmathene.com/role/pip-sosap Summary of Significant Accounting Policies Notes 8 false false R9.htm 103 - Disclosure - Fair Value Measurements Sheet http://www.pharmathene.com/role/pip-fvm Fair Value Measurements Notes 9 false false R10.htm 104 - Disclosure - Commitments and Contingencies Sheet http://www.pharmathene.com/role/pip-cac Commitments and Contingencies Notes 10 false false R11.htm 105 - Disclosure - Stockholders' Equity Sheet http://www.pharmathene.com/role/pip-se Stockholders' Equity Notes 11 false false R12.htm 106 - Disclosure - Financing Transactions Sheet http://www.pharmathene.com/role/pip-ft Financing Transactions Notes 12 false false R13.htm 202 - Disclosure - Summary of Significant Accounting Policies (Policy) Sheet http://www.pharmathene.com/role/pip-sosapp Summary of Significant Accounting Policies (Policy) Policies http://www.pharmathene.com/role/pip-sosap 13 false false R14.htm 302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.pharmathene.com/role/pip-sosapt Summary of Significant Accounting Policies (Tables) Tables http://www.pharmathene.com/role/pip-sosap 14 false false R15.htm 303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pharmathene.com/role/pip-fvmt Fair Value Measurements (Tables) Tables http://www.pharmathene.com/role/pip-fvm 15 false false R16.htm 304 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.pharmathene.com/role/pip-cac 16 false false R17.htm 305 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.pharmathene.com/role/pip-set Stockholders' Equity (Tables) Tables http://www.pharmathene.com/role/pip-se 17 false false R18.htm 40101 - Disclosure - Business, Liquidity and Organization (Details) Sheet http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails Business, Liquidity and Organization (Details) Details http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization 18 false false R19.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.pharmathene.com/role/pip-sosapnd Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.pharmathene.com/role/pip-sosapt 19 false false R20.htm 40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) Sheet http://www.pharmathene.com/role/pip-sosapsosced Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) Details http://www.pharmathene.com/role/pip-sosapt 20 false false R21.htm 40301 - Disclosure - Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) Sheet http://www.pharmathene.com/role/pip-fvmsolmafvd Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) Details http://www.pharmathene.com/role/pip-fvmt 21 false false R22.htm 40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details) Sheet http://www.pharmathene.com/role/pip-fvmsocifvolld Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details) Details http://www.pharmathene.com/role/pip-fvmt 22 false false R23.htm 40303 - Disclosure - Fair Value Measurements (Narrative) (Details) Sheet http://www.pharmathene.com/role/pip-fvmnd Fair Value Measurements (Narrative) (Details) Details http://www.pharmathene.com/role/pip-fvmt 23 false false R24.htm 40304 - Disclosure - Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) Sheet http://www.pharmathene.com/role/pip-fvmsoqialfvmd Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) Details http://www.pharmathene.com/role/pip-fvmt 24 false false R25.htm 40401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables 25 false false R26.htm 40402 - Disclosure - Commitments and Contingencies (Leases) (Details) Sheet http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails Commitments and Contingencies (Leases) (Details) Details http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables 26 false false R27.htm 40501 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.pharmathene.com/role/pip-send Stockholders' Equity (Narrative) (Details) Details http://www.pharmathene.com/role/pip-set 27 false false R28.htm 40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details) Sheet http://www.pharmathene.com/role/pip-sesowd Stockholders' Equity (Schedule of Warrants) (Details) Details http://www.pharmathene.com/role/pip-set 28 false false R29.htm 40601 - Disclosure - Financing Transactions (Controlled Equity Offering) (Details) Sheet http://www.pharmathene.com/role/pip-ftceod Financing Transactions (Controlled Equity Offering) (Details) Details http://www.pharmathene.com/role/pip-ft 29 false false R30.htm 40602 - Disclosure - Financing Transactions (Loan Agreement with GE Capital) (Details) Sheet http://www.pharmathene.com/role/pip-ftlawgcd Financing Transactions (Loan Agreement with GE Capital) (Details) Details http://www.pharmathene.com/role/pip-ft 30 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. pip-20150930.xml pip-20150930_cal.xml pip-20150930_def.xml pip-20150930_lab.xml pip-20150930_pre.xml pip-20150930.xsd true true XML 46 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 93,757 $ 280,720 $ 426,988 $ 1,172,703

Research and development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense 12,034 52,434 85,259 329,655

General and administrative [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 81,723 $ 228,286 395,470 $ 843,048

Restructuring benefit [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense $ (53,741)

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Commitments and Contingencies (Details) - USD ($)		1 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Jan. 15, 2015	Apr. 30, 2015	Jul. 31, 2009	Sep. 30, 2015	Jan. 07, 2015
Commitments and Contingencies [Line Items]
Amount of contract expectation damages	$ 113,100,000				$ 113,000,000
Amount of award	194,600,000
Expert witness fees	$ 81,500,000
Warrant expiration date			Jan. 28, 2015
Maximum amount of reimbursement				$ 210,000
Annual License Payment				$ 200,000
Initial Maximum Maintenance Failure Obligation [Member]
Commitments and Contingencies [Line Items]
Percentage of aggregate principal amount of convertible Notes				1.00%
Aggregate principal amount of obligation				$ 200,000
Every 30 days until failure is cured [Member]
Commitments and Contingencies [Line Items]
Percentage of aggregate principal amount of convertible Notes				1.00%
Aggregate principal amount of obligation				$ 200,000
BARDA [Member]
Commitments and Contingencies [Line Items]
Audited BARDA revenue		$ 5,800,000

Financing Transactions (Controlled Equity Offering) (Details) - USD ($) $ in Millions	Sep. 30, 2015	May. 23, 2014	Mar. 25, 2013
Equity Offering [Member]
Equity Offering [Line Items]
The maximum value of common stock issuable under the controlled equity offering arrangement			$ 15.0
Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock			3.00%
Amount remaining available under controlled equity offering sale arrangement	$ 3.0
Amendment to the Controlled Equity Offering [Member]
Equity Offering [Line Items]
The maximum value of common stock issuable under the controlled equity offering arrangement		$ 15.0

Financing Transactions (Loan Agreement with GE Capital) (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2015	Mar. 30, 2012
Loans Payable [Member]
Debt Instrument [Line Items]
Debt instrument, carrying amount		$ 2.5
Warrants issued to purchase common stock, in connection with loan agreement	46,584
Warrant exercise price	$ 1.61
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 5.0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 17,389,409	$ 18,643,351
Billed accounts receivable		110,656
Unbilled accounts receivable	$ 659,663	297,431
Prepaid expenses and other current assets	196,478	199,194
Total current assets	18,245,550	19,250,632
Property and equipment, net	248,270	325,772
Other long-term assets and deferred costs	53,384	53,384
Goodwill	2,348,453	2,348,453
Total assets	20,895,657	21,978,241
Current liabilities:
Accounts payable	306,172	391,396
Accrued expenses and other liabilities	1,453,123	$ 1,195,412
Accrued restructuring expenses	$ 619,119
Short-term debt		$ 746,146
Other short-term liabilities		70,326
Current portion of derivative instruments	$ 2,355	178,509
Total current liabilities	2,380,769	$ 2,581,789
Accrued restructuring expenses - long term	184,018
Other long-term liabilities	431,015	$ 493,137
Derivative instruments, less current portion	227,898	629,170
Total liabilities	3,223,700	3,704,096
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	6,436	6,360
Additional paid-in-capital	$ 240,151,146	238,780,633
Accumulated other comprehensive loss		(229,528)
Accumulated deficit	$ (222,485,625)	(220,283,320)
Total stockholders' equity	17,671,957	18,274,145
Total liabilities and stockholders' equity	$ 20,895,657	$ 21,978,241

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (2,202,305)	$ (7,325,995)
Adjustments to reconcile net loss to net cash used in operating activities:
Realization of cumulative translation adjustment	229,192
Share-based compensation expense	426,988	$ 1,172,703
Change in fair value of derivative instruments	(577,426)	(464,703)
Depreciation expense	108,798	113,272
Deferred income taxes	46,310	48,105
Non-cash interest expense	(51,820)	$ 68,130
Impairment of property and equipment	36,981
Gain on the disposal of property and equipment	(7,600)	$ (5,393)
Changes in operating assets and liabilities:
Billed accounts receivable	110,656	1,427,113
Unbilled accounts receivable	(362,232)	1,895,858
Prepaid expenses and other current assets	(9,602)	23,869
Accounts payable	(85,175)	$ (846,090)
Accrued restructuring expenses	800,769
Accrued expenses and other liabilities	$ 149,438	$ (773,517)
Deferred revenue		(284,937)
Net cash used in operating activities	$ (1,387,028)	(4,951,585)
Investing activities
Purchases of property and equipment	(68,277)	(92,269)
Proceeds from the sale of property and equipment	7,600	8,000
Net cash used in investing activities	(60,677)	(84,269)
Financing activities
Repayment of debt	$ (750,007)	(749,997)
Net repayment of revolving credit agreement		(1,091,740)
Net proceeds from exercise of warrants		683,325
Proceeds from issuance of common stock, including exercise of stock options, net of offering costs	$ 943,601	15,341,264
Net cash provided by financing activities	193,594	14,182,852
Effects of exchange rates on cash	169	(7,585)
(Decrease) increase in cash and cash equivalents	(1,253,942)	9,139,413
Cash and cash equivalents, at beginning of period	18,643,351	10,480,979
Cash and cash equivalents, at end of period	17,389,409	19,620,392
Supplemental disclosure of cash flow information
Cash paid for interest	$ 108,134	$ 105,916

Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value Measurements [Abstract]
Derivatives	$ 230,253	$ 807,679

Business, Liquidity and Organization	9 Months Ended
Business, Liquidity and Organization	Sep. 30, 2015
Business, Liquidity and Organization [Abstract]
Business, Liquidity and Organization	Note 1 – Business, Liquidity and Organization Since 2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning. On March 9, 2015, our Board of Directors approved our realignment plan (the “Realignment Plan”) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (“SIGA”) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA's appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (“NIAID”). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $2 million (all of which was expensed as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company's product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5 million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations. As of September 30, 2015, our cash balance was $17.4 million, our unbilled accounts receivable balance was $0.7 million, and our current liabilities were $2.4 million. As of September 30, 2015, we had approximately $3.0 million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 – Financing Transactions – Controlled Equity Offering). We believe, based on the operating cash requirements and capital expenditures expected for 2015, the Company's cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016. On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (“GE Capital”), as discussed further in Note 6- Financing Transactions. On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (“rPA”). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 - Commitments and Contingencies - Leases. On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016. We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, in connection with the Realignment Plan, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr. Richman's continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA's appeal has been adjudicated and we have received SIGA's payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA's appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected. In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	64,358,834	63,603,303
Common stock, shares outstanding	64,358,834	63,603,303

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 04, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	PIP
Entity Registrant Name	PHARMATHENE, INC
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		64,451,334

Business, Liquidity and Organization (Details) - USD ($)		3 Months Ended	9 Months Ended
	Sep. 03, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Mar. 09, 2015	Dec. 31, 2014	Dec. 31, 2013
Business, Liquidity and Organization [Abstract]
Expected severance cost					$ 2,000,000
Accumulated deficit		$ (222,485,625)	$ (222,485,625)			$ (220,283,320)
Cash and cash equivalents		17,389,409	17,389,409	$ 19,620,392		18,643,351	$ 10,480,979
Accounts receivable (billed and unbilled)		700,000	700,000
Liabilities current		2,380,769	2,380,769			2,581,789
Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement		$ 3,000,000	$ 3,000,000
Short-term debt						$ 746,146
Organization and Business
Maximum amount of reimbursement		$ 210,000	$ 210,000
Annual License Payment		200,000	200,000
Proceeds from Additional Funding		$ 2,300,000
Accrued interest paid			$ 108,134	$ 105,916
Line of Credit [Member]
Organization and Business
Debt termination payment	$ 81,347
Final payment fee	75,000
Outstanding principal balance	10
Accrued interest paid	208
Legal fees of the lender	$ 6,129

Financing Transactions	9 Months Ended
Financing Transactions	Sep. 30, 2015
Financing Transactions [Abstract]
Financing Transactions	Note 6 – Financing Transactions Controlled Equity Offering On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $15.0 million. On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus. Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement. As of September 30, 2015, shares having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement. The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended. Termination of Loan Agreement with GE Capital On September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5.0 million based on our outstanding qualified accounts receivable. The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method. The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets. In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase 46,584 shares of the Company's common stock at an exercise price of $1.61 per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method.

Fair Value Measurements (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Fair Value Measurements [Line Items]
Impairment of property and equipment	$ 36,981	$ 36,981
Fair value of leased assets	$ 0	$ 0
Level 3 [Member] \| Derivative Liabilities [Member]
Fair Value Measurements [Line Items]
Warrants to purchase common stock	1,775,419	1,775,419	1,775,419

Summary of Significant Accounting Policies (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015 USD ($) shares	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) shares	Sep. 30, 2014 USD ($) shares	Mar. 09, 2015 USD ($)
Significant Accounting Policies [Line Items]
Restructuring expense	$ 422,482		$ 2,519,273
Number of operating segment			1
Realization of cumulative translation adjustment included in net loss			$ 229,192
Expected severance cost					$ 2,000,000
Share-based compensation expense, extension of exercise period			75,000
Share-based compensation, reversal from stock option forfeitures			129,000
Net reversal of share-based compensation expense			$ 53,741
Stock options granted \| shares	100,000		112,000	1,357,755
Restricted stock granted \| shares			117,500
Unrecognized share-based compensation expense related to unvested awards, net of forfeitures	$ 800,000		$ 800,000
Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period			2 years 2 months 12 days
Income tax expense	$ 15,437	$ 25,068	$ 46,310	$ 48,105
Anti-dilutive securities excluded from computation of earnings per share \| shares			6,000,000	10,900,000
Employee Severance [Member]
Significant Accounting Policies [Line Items]
Restructuring expense			$ 2,100,000
Facility Closing [Member]
Significant Accounting Policies [Line Items]
Restructuring expense			$ 400,000

Stockholders' Equity (Narrative) (Details) - shares		9 Months Ended
Stockholders' Equity (Narrative) (Details) - shares	Jan. 28, 2015	Sep. 30, 2015	Dec. 31, 2008	Dec. 31, 2007
Stockholders Equity [Line Items]
Warrants issued to purchase shares of common stock		1,922,781
Warrants [Member]
Stockholders Equity [Line Items]
Number of common shares expired underlying stock purchase warrants	2,572,775
2007 Long Term Incentive Plan [Member]
Stockholders Equity [Line Items]
Common stock reserved			4,600,000	3,500,000
Shares approved for issuance		10,300,000
Shares available for grant		4,400,000
Options award term		10 years

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at September 30, 2015

Valuation Technique

Unobservable Inputs

Black-Scholes option pricing model

Expected term

Expected dividends

Anticipated volatility